amlodipine profile

Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	2162
CHEMBL ID	1491
CHEMBL ID	3304444
CHEMBL ID	3211346
CHEBI ID	2668
SCHEMBL ID	26478
MeSH ID	M0026284

Synonym
BIDD:GT0810
HMS3394N03
STL356053
AB01274726-02
BRD-A22032524-074-03-2
BRD-A22032524-074-02-4
CHEMBL1491
hgp0904
ckd-330 component amlodipine
hgp-0904
AKOS015843475
istin
uk-4834011
3-ethyl 5-methyl 2-{[(2-aminoethyl)oxy]methyl}-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
norvasc
hsdb 7079
caduet
amlocard
amlodipino [spanish]
amlodis
lipinox
3,5-pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester
amlodipinum [latin]
coroval
amlodipine [inn:ban]
amlodipine (usp/inn)
D07450
SPECTRUM5_001550
BSPBIO_002727
amlodipine base
smr000469198
MLS001401409
C06825
amlodipine
88150-42-9
NCGC00165957-01
amlodipine free base
(rs)-3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
DB00381
3-ethyl 5-methylester, (+/-)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
norvasc (tn)
KBIOGR_001643
KBIO3_001947
SPECTRUM4_001132
SPECTRUM3_001004
SPBIO_000351
SPECTRUM2_000486
NCGC00165957-03
NCGC00165957-02
HMS2052N03
HMS2089H07
AC-4535
morphine sulfate pentahydrate usp
FT-0662111
FT-0657130
FT-0662112
amlodipino
3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
3-ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
amlodipinum
CHEBI:2668 ,
3-o-ethyl 5-o-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
3-ethyl 5-methyl ester 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid
A842481
NCGC00165957-05
NCGC00165957-04
3-ethyl-5-methyl (+-)-2-((2-aminoethoxy)methyl)-4-(2-chlorphenyl)-1,4-dihydro-6-methyl-3,5-pyridindicarboxylat
3-ethyl 5-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
ec 425-820-1
unii-1j444qc288
1j444qc288 ,
3-ethyl-5-methyl (+-)-2-((2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
BCP9000295
HMS2231K08
CCG-101157
BCPP000403
FT-0602653
S1905
copalia (amlodipine + valsartan)
gtpl6981
o3-ethyl o5-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
HMS3370G17
katerzia® (amlodipine oral suspension, 1 mg/ml)
CHEMBL3304444
amlodipine [inn]
3-ethyl 5-methyl (+/-)-2-((2-aminoethoxy)methyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
amlodipine [ema epar]
amlodipine [vandf]
3,5-pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester, (+/-)-
amlodipine [mart.]
amlodipine [who-dd]
amlodipine [mi]
amlodipine [orange book]
CCG-220414
CPD000469198
HY-B0317
AB01209618-01
2-(2-aminoethoxy)methyl-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine
2-[2-aminoethoxymethyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine
2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine
2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid 3-ethyl 5-methylester
2-[2-aminoethoxymethyl]-3-ethoxycarbonyl-4-(2-chlorophenyl)-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine
NC00407
SCHEMBL26478
AB01274726-01
NCGC00165957-07
racemic amlodipine
3-ethyl-5-methyl (.+/-.)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
3-ethyl 5-methyl 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
bdbm50088383
CHEMBL3211346
AB01274726_03
AB01274726_05
AB01274726_04
DTXSID7022596 ,
mfcd00864687
3,5-pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester
uk-48340
SR-05000001461-5
sr-05000001461
HMS3651I04
SR-05000001461-4
SR-05000001461-3
HMS3713C10
SW220228-1
Q411347
amlodipine (norvasc)
AS-13747
BCP02420
BRD-A22032524-074-04-0
3-o-ethyl 5-o-methyl 4-(2-chlorophenyl)-1-deuterio-2-[2-(dideuterioamino)ethoxymethyl]-6-methyl-4h-pyridine-3,5-dicarboxylate
SY104813
88150-42-9 (free base)
amlodipine 100 microg/ml in acetonitrile
BA164164
3-ethyl5-methyl2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
PD003146
EN300-708796
c08ca01
(rs)-3-ethyl 5-methyl 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
dtxcid302596
3-ethyl 5-methylester, (+-)-2-((2-aminoethoxy)methyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
katerzia (amlodipine oral suspension, 1 mg/ml)
3-ethyl-5-methyl (+-)-2-((2-aminoethoxy)methyl)-4-(2-chlorphenyl)-1,4-dihydro-6-methyl-3,5-pyridindicarboxylate
amlodipinum (latin)
amlodipina
amlodipine (mart.)
PD033068

Excerpt	Reference	Relevance
"Amlodipine is a long-acting dihydropyridine and inappropriate dosage poses a great threat for profound vasodilation, hypotension, and refractory vasopressor-resistant shock."	( Refractory Shock from Amlodipine Overdose Overcomed with Hyperinsulinemia. Kakava, K; Koliastasis, L; Lampadakis, I; Milkas, A; Papaioannou, S; Sourides, V; Strempelas, P; Tsioufis, P, 2022)	1.76
"Amlodipine is a comparatively newer calcium channel blocker that with a longer duration of action and lesser side effects as compared to nifedipine."	( Amlodipine Induced Gum Hypertrophy: A Rare Case Report. Bohra, GK; Chhabra, V; Kumar, D; Midha, N; Reddy, SC, 2022)	2.89
"Amlodipine besylate is an antihypertensive agent recommended for the management of hypertension in children and adolescents. "	( Physicochemical Stability of Compounded Amlodipine Besylate Suspensions in PCCA Base, SuspendIt. Bostanian, LA; Graves, RA; Mandal, TK; Morris, TC; Nguyen, AT; Pramar, YV; Swopes, D, )	1.84
"Amlodipine is a dihydropyridine calcium channel blocker widely used in the treatment of high blood pressure and coronary heart disease. "	( Postmortem fatal and non-fatal concentrations of amlodipine. Alvarez, JC; Cappy, J; Knapp-Gisclon, A; Lorin de la Grandamison, G; Mayer-Duverneuil, C, 2020)	2.26
"Amlodipine is a commonly prescribed antihypertensive drug metabolized by CYP3A4, thus predisposed to a risk of DDIs."	( Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs. Alves Saldanha, S; Buclin, T; Cavassini, M; Courlet, P; Csajka, C; Decosterd, LA; Guidi, M; Marzolini, C; Stoeckle, M, 2021)	1.56
"Amlodipine is a calcium channel blocker shown to be effective in lowering blood pressure with minimal adverse effects in mammals. "	( Use of Amlodipine in Psittacine Birds: 5 Cases (2010-2018). Fink, DM; Mans, C, 2021)	2.52
"Amlodipine is a general antihypertensive drug used in combination with various other antihypertensive agents."	( Effect of Co-Administration of Curcumin with Amlodipine in Hypertension. Choi, HY; Jo, C; Lee, K; Lee, S, 2021)	1.6
"Amlodipine is a mixture of two enantiomers, one of which (S- enantiomer) has L-type channel blocking activity, while the other (R+ enantiomer) shows ~1000-fold weaker channel blocking activity than S- enantiomer and has other unknown effects."	( Amlodipine Inhibits Vascular Cell Senescence and Protects Against Atherogenesis Through the Mechanism Independent of Calcium Channel Blockade. Hayashi, Y; Ikegami, R; Katsuumi, G; Kayamori, H; Minamino, T; Shimizu, I; Suda, M; Wakasugi, T; Yoshida, Y, 2018)	2.64
"Amlodipine is a classical drug with varied properties extending from control of blood pressure to as an antianginal and anti atherosclerotic agent. "	( Amlodipine in the Era of New Generation Calcium Channel Blockers. Kashyap, R; Langote, A; Tiwaskar, M; Toppo, A, 2018)	3.37
"Amlodipine (AMLO) is a calcium channel blocker with vasodilating properties, in which the specific effects on the coronary circulation are not fully known. "	( Effects of amlodipine and adenosine on coronary haemodynamics: in vivo study and numerical simulation. De Lazzari, C; L'Abbate, A; Micalizzi, M; Neglia, D; Trivella, MG, 2014)	2.23
"Amlodipine is a dihydropyridine calcium channel blocker that is used in the management of both hypertension and angina. "	( Amlodipine-induced gingival hyperplasia in chronic renal failure: a case report. Aldemir, NM; Begenik, H; Emre, H; Erdur, FM; Soyoral, Y, 2012)	3.26
"Amlodipine is a racemic mixture of CCB; S-amlodipine has higher activity than R-form."	( Pharmacokinetics, tolerability, and safety of the single oral administration of AGSAV301 vs Exforge: a randomized crossover study of healthy male volunteers. Bae, KS; Choi, HY; Kim, MJ; Kim, YH; Lee, SH; Lim, HS; Noh, YH, 2014)	1.12
"Amlodipine is a commonly prescribed calcium channel blocker for the treatment of hypertension and ischemic heart disease. "	( Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation. Chen, W; Du, A; Li, Q; Tang, W; Wang, F; Zhu, M; Zhu, Y, 2014)	3.29
"Amlodipine is a commonly used agent in allogeneic stem cell transplant patients. "	( Possible amlodipine-induced hepatotoxicity after stem cell transplant. Hammerstrom, AE, 2015)	2.28
"Amlodipine is a representative calcium channel blocker that is frequently prescribed for the treatment of hypertension. "	( Effects of orally administered antibiotics on the bioavailability of amlodipine: gut microbiota-mediated drug interaction. Kim, DH; Kim, IS; Yoo, DH; Yoo, HH, 2016)	2.11
"Amlodipine is an antihypertensive agent recommended for the management of hypertension in children and adolescents. "	( Design and stability study of an oral solution of amlodipine besylate for pediatric patients. Hanff, LM; Koch, BC; Postma, DJ; Smeets, OS; van der Velde, I; van der Vossen, AC; Vermes, A; Vulto, AG, 2016)	2.13
"Amlodipine is a non-antibiotic compound with anti-inflammatory activity."	( The potential role of amlodipine on experimentally induced bacterial rhinosinusitis. Halici, Z; Korkmaz, M; Parlak, SN; Polat, E; Tatar, A; Uslu, H; Yayla, M, )	1.17
"Amlodipine is a racemic mixture, composed of the S(-)-enantiomer, which is the pharmacologically active isomer, and the R(+)-enantiomer, which is 1000-fold less active."	( Efficacy and safety profiles of a new S(-)-amlodipine nicotinate formulation versus racemic amlodipine besylate in adult Korean patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, double-dummy, parallel-group, ph Ahn, TH; Chung, N; Kim, SA; Lim, DS; Oh, BH; Park, S; Tahk, SJ; Yang, JY, 2008)	1.33
"Amlodipine is a racemic mixture composed of S- and R-form and metabolized stereoselectively. "	( Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects. Kim, KA; Park, JY; Park, PW, 2009)	2.02
"Amlodipine is a calcium-channel antagonist with neuropharmacological properties believed to be protective against cerebral hypoperfusion, microinfarcts, and excitoxic cell death. "	( Measures of cognitive functioning as predictors of treatment outcome for cocaine dependence. Herron, J; Horner, MD; LaRowe, S; Malcolm, R; Turner, TH, 2009)	1.8
"Amlodipine is a third-generation dihydropyridine calcium antagonist for the treatment of angina and hypertension. "	( Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. Jia, J; Li, S; Liu, G; Liu, Y; Lu, C; Yu, C, 2009)	2.03
"Amlodipine is a long-acting calcium channel blocker capable of producing hypotension and dysrhythmia in overdose. "	( Amlodipine toxicity in children less than 6 years of age: a dose-response analysis using national poison data system data. Bakhireva, LN; Benson, BE; Spyker, DA; Troutman, WG; Watson, WA, 2010)	3.25
"Amlodipine is a potent vasodilator with a long half-life and delayed onset of action that is particularly concerning after an overdose. "	( Methylene blue in the treatment of refractory shock from an amlodipine overdose. Hoffman, RS; Jang, DH; Nelson, LS, 2011)	2.05
"Amlodipine is a dihydropyridine calcium channel blocker used in the treatment of hypertension and angina pectoris. "	( Amlodipine fatality in an infant with postmortem blood levels. Bosse, GM; Milliner, BA; Spiller, HA, 2012)	3.26
"Amlodipine is a dihydropyridine calcium antagonist drug with distinctive pharmacokinetic characteristics that seem to be attributable to a high degree of ionization. "	( Amlodipine-induced delirium in a patient with ischemic stroke. Dikici, S; Kocaman, G; Kocer, A; Ozdem, S, 2012)	3.26
"Amlodipine poisoning is an uncommon presentation with potentially life threatening complications. "	( Amlodipine poisioning complicated with acute non-cardiogenic pulmonary oedema. Hasson, R; Mulcahy, V; Tahir, H, 2011)	3.25
"Amlodipine is a racemic mixture and the calcium channel blocking (CCB) effect is confined to S-amlodipine, whereas R-amlodipine has a 1000-fold lower activity and no racemization occurs in vivo in human plasma."	( Pharmacokinetic interaction of telmisartan with s-amlodipine: an open-label, two-period crossover study in healthy Korean male volunteers. Bae, KS; Choi, HY; Jin, SJ; Kim, MJ; Kim, YH; Lim, HS; Lim, J; Noh, YH; Sung, HR, 2012)	1.35
"Amlodipine is a well-known inhibitor of CYP 3A4, an isoenzyme of CYP3A that activates clopidogrel."	( Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention. Kang, HJ; Kang, J; Kim, HS; Koo, BK; Lee, HY; Oh, BH; Park, JJ; Park, KW; Park, YB; Yang, HM, 2012)	2.54
"Amlodipine is a dihydropyridine calcium channel antagonist extensively used for the treatment of arterial hypertension, with predominant effect on the peripheral vascular territory. "	( Cardiac rhythm disturbances associated with amlodipine acute intoxication. de Carvalho Borges, M; Fiorante, F; Galli, AM; Guimarães, EG; Miranda, CH; Misiara, GP; Pazin-Filho, A; Xavier, L, 2012)	2.08
"Amlodipine is a racemic mixture of (R)- and (S)-enantiomers. "	( Quantification of pedal edema during treatment with S(-)-amlodipine nicotinate versus amlodipine besylate in female Korean patients with mild to moderate hypertension: a 12-week, multicenter, randomized, double-blind, active-controlled, phase IV clinical Choi, DJ; Kang, HJ; Lee, HY; Oh, BH; Oh, GC; Zo, JH, 2012)	2.07
"Amlodipine is a dihydropyridine calcium channel antagonist that is useful in the treatment of hypertension and angina pectoris. "	( The physicochemical equivalence of eight brands of amlodipine tablets in Lagos, Nigeria. Akinleye, MO; Awodele, EO; Idris, O; Oladimeji-Salami, J; Olayemi, SO, )	1.83
"Amlodipine (AML) is an inhibitor of CYP3A2 in rats."	( Effect of amlodipine on the pharmacokinetics of tacrolimus in rats. Cheng, ZN; Li, J; Li, PJ; Liu, Z; Tan, HY; Wang, CJ; Yang, GP; Yang, M; Yuan, H; Zhang, BK; Zhou, LY; Zhou, YN; Zuo, XC, 2013)	1.51
"Amlodipine is an effective antianginal agent, whereas ARBs are not."	( Amlodipine versus Angiotensin-receptor blockers for nonhypertension indications. Kalus, JS; White, CM, 2002)	2.48
"Amlodipine is a dihydropyridine calcium antagonist and is widely used for the treatment of cardiovascular diseases. "	( Stereoselective pharmacokinetics of amlodipine in elderly hypertensive patients. Arakawa, M; Fujimura, A; Harada, K; Hifumi, S; Miyamori, I; Ohmori, M; Takasaki, H, )	1.85
"Amlodipine is a calcium antagonist of the dihydropyridine class. "	( Pharmacokinetics of amlodipine in hypertensive patients undergoing haemodialysis. Kungys, G; Naujoks, H; Wanner, C, 2003)	2.09
"Amlodipine besylate is a potent dihydropyridine calcium channel blocker also with dose-related antihypertensive efficacy, but with possible dose-limiting AEs, particularly peripheral edema."	( A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. Borgnino, C; Capuano, V; Malacco, E; Palatini, P; Spagnuolo, V; Varì, N, 2003)	1.26
"Amlodipine is a potent peripheral and coronary vasodilator with high selectivity for vascular smooth muscle, and is widely used in mild to moderate hypertension, chronic stable angina and vasospastic angina. "	( Amlodipine associated hyperpigmentation. Erbagci, Z, 2004)	3.21
"Amlodipine is an effective treatment for hypertension. "	( Hemodynamic effects of amlodipine, bisoprolol, and lisinopril in hypertensive patients after liver transplantation. Alexander, GJ; Brown, MJ; Byrne, CD; Neal, DA; Wilkinson, IB, 2004)	2.08
"Amlodipine is a long-acting dihydropyridine derivative that is suitable for use as a once-daily calcium antagonist."	( The calcium antagonists in vasospastic angina. Chahine, RA, 1991)	1
"Amlodipine is a dihydropyridine calcium channel blocker that is widely used for the treatment of hypertensive patients and has an antioxidant effect on vessels in vitro. "	( Amlodipine-induced reduction of oxidative stress in the brain is associated with sympatho-inhibitory effects in stroke-prone spontaneously hypertensive rats. Hirooka, Y; Ito, K; Kimura, Y; Nozoe, M; Sagara, Y; Sunagawa, K, 2006)	3.22
"Amlodipine is a calcium channel blocker (CCB) known to stimulate nitric oxide production from endothelial cells. "	( The calcium channel blocker amlodipine promotes the unclamping of eNOS from caveolin in endothelial cells. Balligand, JL; Batova, S; Dessy, C; DeWever, J; Feron, O; Godfraind, T, 2006)	2.07
"Amlodipine was shown to be a well tolerated and effective drug in one in three patients, and achieved the therapeutic goal in a higher proportion of patients at specialised-care centres compared with those in primary care, and in those receiving combined therapy compared with monotherapy."	( Efficacy and safety of amlodipine: a comparative study of hypertensive patients treated at primary- and specialised-care centres. Arístegui, R; Gil, A; Hernández, V; Jiménez, R; Valcárcel, Y, 2006)	2.09
"Amlodipine is a highly effective and safe antihypertensive dihydropyridine calcium channel blocker. "	( Combination therapy with renin-angiotensin system blockers: will amlodipine replace hydrochlorothiazide? Fornoni, A; Lenz, O; Materson, BJ; Tejada, T, 2007)	2.02
"Amlodipine camsylate is a newer formulation developed for generic use."	( Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension. Ahn, YK; Chung, WS; Kim, HS; Kim, IJ; Kim, JJ; Kim, SH; Kim, YD; Lee, JW; Lim, DS; On, YK; Park, JB; Seo, HS; Shin, EK; Yang, JY; Yoon, MH, 2007)	1.26
"Amlodipine is a dihydropyridine that blocks L-type channels, thereby preventing entry of Ca2+ into the muscle."	( Effect of chronic blood pressure reduction on soleus muscle contractile properties in spontaneously hypertensive rats. Atherley, R; Carlsen, RC; Gray, SD, 1994)	1.01
"Amlodipine is a potent peripheral and coronary vasodilator with high selectivity for vascular smooth muscle and minimal effect on myocardial contractility or cardiac conduction."	( Amlodipine: a new calcium antagonist. Clavijo, GA; de Clavijo, IV; Weart, CW, 1994)	2.45
"Amlodipine is a calcium channel blocker used in the management of angina and hypertension. "	( Amlodipine-induced gingival overgrowth. Ellis, JS; Idle, JR; Monkman, S; Seymour, RA; Thomason, JM, 1994)	3.17
"Amlodipine is a recently introduced, dihydropyridine with a long half life."	( Amlodipine in patients with angina uncontrolled by atenolol. A double blind placebo controlled cross over trial. Channer, KS; Morice, AH; Stewart, AG; Woodmansey, PA, 1993)	2.45
"Amlodipine is an intrinsically long-acting, vasoselective calcium antagonist structurally related to nifedipine, but with unique binding and pharmacologic properties that distinguish it from other agents of this class. "	( Unique pharmacologic properties of amlodipine. Burges, R; Moisey, D, 1994)	2.01
"Amlodipine is a long-acting calcium antagonist and effectively lowers BP in patients with essential hypertension."	( Double-blind comparison between nifedipine and amlodipine for the treatment of essential hypertension. Cappuccio, FP; Carney, C; Crane, M; MacGregor, GA; Markandu, ND; Singer, DR, 1993)	1.26
"Amlodipine is a novel, relatively well tolerated, calcium antagonist."	( Acute pulmonary vasodilatory properties of amlodipine in humans with pulmonary hypertension. Channer, KS; Morice, AH; O'Toole, L; Woodmansey, PA, 1996)	1.28
"Amlodipine is a dihydropyridine calcium antagonist with prolonged duration of action. "	( Hemodynamic and 24-h blood pressure profile of amlodipine monotherapy. el-Boghdadly, B; Ibrahim, MM; Zaghloul, SS, 1996)	1.99
"Amlodipine appears to be a safe and effective oral treatment for systemic hypertension in cats when used chronically once daily as a single agent."	( Treatment of systemic hypertension in cats with amlodipine besylate. Henik, RA; Snyder, PS; Volk, LM, )	1.11
"Amlodipine is a dihydropiridine with a pharmacologic profile different from other C.A.T.S."	( [Clinical pharmacokinetics of calcium antagonists]. Sesin, J; Tamargo, J, 1997)	1.02
"Amlodipine is a relatively new agent that has the longest half-life of all calcium channel blockers. "	( Amlodipine overdose causes prolonged calcium channel blocker toxicity. Adams, BD; Browne, WT, 1998)	3.19
"Amlodipine proved to be an effective, more safe and better-tolerated therapeutical alternative for hypertension management than nifedipine retard."	( Antihypertensive effect of amlodipine compared with nifedipine retard in patients with mild and moderate essential hypertension. Gross-Furek, V; Herman, ZS; Kalina, Z; Madej, A; Maślankiewicz, A; Okopień, B; Szwed, Z; Tokarz, D, )	1.87
"Amlodipine is a calcium antagonist with a long elimination half-life (35 to 50 h) allowing a once daily dosing in the treatment of hypertension. "	( Prolonged antihypertensive effect of amlodipine: a prospective double-blind randomized study. Biston, P; Clement, D; Degaute, JP; Mélot, C; Quoidbach, A, 1999)	2.02
"amlodipine, is a milestone in the effort to test whether newer compounds offer a better reduction of the cardiovascular consequences of hypertension, as well as good BP control."	( Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. Valsartan Antihypertensive Long-term Use Evaluation. Julius, S, 1999)	1.02
"Amlodipine is a calcium channel antagonist of the dihydropyridine group. "	( Enzyme linked immunosorbent assay for determination of amlodipine in plasma. Arafat, T; Badwan, A; El-Thaher, T; Jehanli, A; Matalka, K; Saleem, M, 2001)	2
"Amlodipine is a mixture of two enantiomers, one having L-type channel blocking activity (S-) and the other about 1,000-fold weaker activity and of little known other activity (R+). "	( Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R+ enantiomer of amlodipine. Chahwala, S; Hintze, TH; Loke, KE; Mital, S; Zhang, XP, 2002)	1.97
"Amlodipine is a dihydropyridine calcium antagonist with a long elimination half life making it suitable for once-daily dosing. "	( Intra-arterial monitoring of the antihypertensive effects of once-daily amlodipine. al-Khawaja, I; Brigden, G; Broadhurst, P; Heber, ME; Raftery, EB, 1992)	1.96
"Amlodipine is a new calcium antagonist of the 1.4-dihydropyridine group for treatment of hypertension and angina pectoris. "	( [Amlodipine: pharmacokinetic and pharmacodynamic profile of a calcium antagonist with prolonged effect]. Heynen, G, 1992)	2.64
"Amlodipine is a dihydropyridine calcium antagonist drug with distinctive pharmacokinetic characteristics which appear to be attributable to a high degree of ionisation. "	( Clinical pharmacokinetics of amlodipine. Elliott, HL; Meredith, PA, 1992)	2.02
"Amlodipine is a low-clearance, dihydropyridine calcium antagonist. "	( Pharmacokinetics and pharmacodynamics of amlodipine. Abernethy, DR, 1992)	1.99
"Amlodipine is a newly developed long-acting dihydropyridine-based calcium antagonist. "	( (-)[3H]amlodipine binding to rat cardiac membranes. Gu, XH; Nayler, WG, 1991)	2.18
"Amlodipine is a 1,4-dihydropyridine calcium antagonist which, although structurally related to nifedipine, has a number of important distinguishing properties. "	( Amlodipine: a once daily calcium antagonist. Burges, RA, 1991)	3.17
"Amlodipine is a dihydropyridine calcium antagonist which can be used once daily in hypertension. "	( Amlodipine: an effective once-daily antihypertensive agent. Tyler, HM, 1991)	3.17
"Amlodipine is a 'second generation', long-acting calcium antagonist. "	( The unique binding properties of amlodipine: a long-acting calcium antagonist. Gu, XH; Nayler, WG, 1991)	2.01
"Amlodipine is a dihydropyridine calcium antagonist that has unique pharmacokinetic properties. "	( The efficacy of amlodipine in the management of ischaemic heart disease. McGibney, D, 1991)	2.07
"Amlodipine is a novel dihydropyridine calcium antagonist with distinctive pharmacokinetic and pharmacodynamic properties, including slow onset and long duration of action, with minimal effects on cardiac electrophysiology and myocardial contractility. "	( The pharmacological profile of amlodipine in relation to ischaemic heart disease. Burges, RA, 1991)	2.01
"Amlodipine is a long-acting dihydropyridine calcium antagonist with vascular selectivity. "	( Vascular and myocardial effects of amlodipine: an overview. Gu, XH; Nayler, WG, 1991)	2
"Amlodipine is a dihydropyridine calcium antagonist with a unique pharmacokinetic profile providing advantages over other therapies of its kind. "	( A review of amlodipine in myocardial ischaemia. Taylor, SH, 1991)	2.1
"Amlodipine is a powerful arterial vasodilator with no negative inotropic effects."	( Haemodynamic and electrophysiological effects of amlodipine, a new long-acting calcium antagonist. Dailey, S; Epstein, A; Kay, G; Plumb, V; Vetrovec, GW, 1991)	1.26
"Amlodipine is a long acting dihydropyridine calcium antagonist recently introduced for the treatment of angina and hypertension. "	( Liquid chromatography assay for amlodipine: chemical stability and pharmacokinetics in rabbits. Mosher, SJ; Pollak, PT; Yeung, PK, 1991)	2.01
"Amlodipine is a very weak inhibitory of 5-HT-induced aggregation."	( How can we inhibit 5-HT-induced platelet aggregation and why should we bother? Bevan, J; Heptinstall, S, 1988)	1
"Amlodipine is a long-acting dihydropyridine-based calcium antagonist developed for use on a once-a-day basis. "	( The effect of amlodipine on hypertension-induced cardiac hypertrophy and reperfusion-induced calcium overload. Nayler, WG, 1988)	2.08
"Amlodipine is a new long-acting calcium antagonist that has a long half-life and appears to be suitable for once-daily administration. "	( A double-blind evaluation of the effect of amlodipine on ambulatory blood pressure in hypertensive patients. Allenby, KS; Burris, JF; Mroczek, WJ, 1988)	1.98
"Amlodipine is a useful new calcium antagonist for the treatment of hypertension producing smooth, dose-dependent blood pressure reductions with convenient once daily dosing."	( A dose-response study of amlodipine in mild to moderate hypertension. Frick, MH; McGibney, D; Tyler, HM, 1989)	1.3
"1. Amlodipine is a novel calcium antagonist which, although pharmacologically similar to other dihydropyridine calcium antagonists, has a long plasma half-life, permitting steady state blood levels to be achieved with a once-daily dose regimen. "	( 24 h blood pressure control with the once daily calcium antagonist, amlodipine. Al-Khawaja, I; Brigden, G; Heber, ME; Raftery, EB, 1989)	1.13
"Amlodipine is a dihydropyridine derivative belonging to the group of pharmacologic calcium entry blocking agents and is characterized as having a slow onset and relatively long duration of action with minimal effects on cardiac electrophysiology and myocardial contractility. "	( Cardioprotective effects of amlodipine in the ischemic-reperfused heart. Hoff, PT; Lucchesi, BR; Tamura, Y, 1989)	2.01
"Amlodipine is a light-insensitive and water soluble 1,4-dihydropyridine with prolonged vasodilatory action and plasma half-life. "	( Relaxation of potassium chloride-induced contractions by amlodipine and its interaction with the 1,4-dihydropyridine-binding site in pig coronary artery. Matlib, MA, 1989)	1.96
"Amlodipine is a long-acting dihydropyridine-based Ca2+ channel blocker, developed for use on a once-daily basis. "	( Amlodipine pretreatment and the ischemic heart. Nayler, WG, 1989)	3.16
"Amlodipine is a potent calcium antagonist, inhibiting Ca2+-induced contractions of depolarized rat aorta with an IC50 of 1.9 nM. "	( Pharmacologic profile of amlodipine. Burges, RA; Dodd, MG; Gardiner, DG, 1989)	2.02
"Amlodipine is an antihypertensive and antiischemic agent that has the combined advantages of a good safety profile with once-daily dosage and a smooth onset and long duration of action."	( The safety of amlodipine. Osterloh, I, 1989)	1.36

Excerpt	Reference	Relevance
"Amlodipine has an inherently long pharmacokinetic half-life, whereas, in contrast, nifedipine has an inherently short half-life but in the GITS formulation the sophisticated delivery system allows for once-daily dosing."	( Long-acting dihydropyridine calcium-channel blockers and sympathetic nervous system activity in hypertension: a literature review comparing amlodipine and nifedipine GITS. Elliott, HL; Meredith, PA; Toal, CB, 2012)	1.3
"Amlodipine has a beneficial effect on LVH and also is an effective and safe drug to treat mild to moderate hypertension."	( [Effect of the treatment with amlodipine on left ventricular hypertrophy in hypertensive patients]. Hoyos, M; Justo, E; Moreno, R; Oliván, J; Pérez Cano, R; Pizarro, JL; Ramos, E; Rodríguez, A, 1996)	2.03
"Amlodipine also has a long elimination half-life, which makes it suitable for use on a once-daily basis."	( The efficacy of amlodipine in the management of ischaemic heart disease. McGibney, D, 1991)	1.35
"Amlodipine has low renal clearance (7 mL/min/mg) and long half-life (35-50 h) and duration of action, which allows it to sustain its anti-hypertensive effect for more than 24 h following a single dose."	( Amlodipine in the current management of hypertension. Palmer, BF; Sever, P; Vogel Anderson, K; Wang, JG, 2023)	3.07
"Amlodipine has longer biological half life and lower potential to stimulate SNS."	( An Open Label Prospective Study on Evaluation of Safety and Efficacy of Cilnidipine Over Amlodipine in Stage 1 Hypertensive Patients. Das, K; Harlalka, S; Majumdar, G; Mandal, P; Roy, UK, )	1.07
"S-amlodipine has been broadly used to treat hypertension, but its protective effects and underlying mechanism remain controversial. "	( S-amlodipine improves endothelial dysfunction via the RANK/RANKL/OPG system by regulating microRNA-155 in hypertension. He, C; Si, D; Yang, J; Yang, P; Zhao, Y, 2019)	1.96
"Amlodipine has effects on hemorheology (HR), and its hemodilutory property may partly contribute to its antihypertensive action."	( Amlodipine alters hemorheological parameters: Increased efficacy at the cost of edema? Arunkumar, S; Lokhandwala, Y; Padgaonkar, K; Panicker, G; Puniyani, RR; Ravindra, RP; Sharma, R; Vadivelu, R, )	2.3
"Amlodipine has been shown to improve vascular endothelial function in hypertensive patients, but whether S(-)-amlodipine has a similar effect remains controversial. "	( The effects of amlodipine and S(-)-amlodipine on vascular endothelial function in patients with hypertension. Ding, M; He, Y; Li, B; Ni, L; Si, D; Yang, C; Yang, P, 2014)	2.2
"Amlodipine has greater potential for vascular endothelial protection than S(-)-amlodipine."	( The effects of amlodipine and S(-)-amlodipine on vascular endothelial function in patients with hypertension. Ding, M; He, Y; Li, B; Ni, L; Si, D; Yang, C; Yang, P, 2014)	1.48
"Amlodipine (Aml) has R- and S-isomers with different pharmacological effects. "	( Effects of (S)-amlodipine and (R)-amlodipine on L-type calcium channel current of rat ventricular myocytes and cytosolic calcium of aortic smooth muscle cells. Jiang, WP; Lai, LH; Li, XR; Wang, RX, 2008)	2.14
"Amlodipine, however, has been shown to be effective in reducing BP throughout the day and night, independent of dosing time."	( Chronotherapy with valsartan/amlodipine fixed combination: improved blood pressure control of essential hypertension with bedtime dosing. Ayala, DE; Fernández, JR; Fontao, MJ; Hermida, RC; Mojón, A, 2010)	1.37
"Amlodipine has an inherently long pharmacokinetic half-life, whereas, in contrast, nifedipine has an inherently short half-life but in the GITS formulation the sophisticated delivery system allows for once-daily dosing."	( Long-acting dihydropyridine calcium-channel blockers and sympathetic nervous system activity in hypertension: a literature review comparing amlodipine and nifedipine GITS. Elliott, HL; Meredith, PA; Toal, CB, 2012)	1.3
"Amlodipine has two stereoisomers [R(+), S(-)], and only the S(-) isomer exerts vasodilating action."	( Stereoselective pharmacokinetics of amlodipine in elderly hypertensive patients. Arakawa, M; Fujimura, A; Harada, K; Hifumi, S; Miyamori, I; Ohmori, M; Takasaki, H, )	1.13
"Amlodipine has antihypertensive and antioxidant activity in vivo, which effectively inhibits many of the oxidative stress-dependent mechanisms involved in Ang II-mediated cardiovascular injury."	( Inhibition of oxidative stress and improvement of endothelial function by amlodipine in angiotensin II-infused rats. Jaimes, EA; Raij, L; Zhou, MS, 2004)	2
"Amlodipine has been reported to improve endothelial function in patients with arterial hypertension and to significantly limit the progression of carotid atherosclerosis. "	( An in vitro study of the peroxyl and hydroxyl radical scavenging capacity of the calcium antagonist amlodipine. Carpi, A; Femia, FR; Franzoni, F; Galetta, F; Plantinga, Y; Regoli, F; Santoro, G, 2004)	1.98
"Amlodipine, therefore, has the potential to become the preferred calcium antagonist for this condition."	( The calcium antagonists in vasospastic angina. Chahine, RA, 1991)	1
"Amlodipine has been shown to prevent decrease in vascular responsiveness induced by injection of Salmonella typhosa lipopolysaccharide (LPS); however, there is no study reporting if this protection by amlodipine extends to ventricular contractility. "	( Protective action of amlodipine on cardiac negative inotropism induced by lipopolysaccharide in rats. Bravo, G; Hong, E; Huang, F; Kurtansky, A; López-Muñoz, FJ; Rojas, G; Villalón, CM, 2007)	2.1
"Amlodipine also has beneficial effects in patients with the metabolic syndrome but has no effect on MPV."	( Effects of doxazosin and amlodipine on mean platelet volume and serum serotonin level in patients with metabolic syndrome: a randomised, controlled study. Basar, M; Demirtunc, R; Duman, D, 2007)	1.36
"Amlodipine besylate has been used in Korea for the treatment of hypertension for >17 years, with well-established efficacy and tolerability. "	( Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension. Ahn, YK; Chung, WS; Kim, HS; Kim, IJ; Kim, JJ; Kim, SH; Kim, YD; Lee, JW; Lim, DS; On, YK; Park, JB; Seo, HS; Shin, EK; Yang, JY; Yoon, MH, 2007)	1.98
"Amlodipine has FDA-approved labeling for use in the treatment of hypertension, chronic stable angina, and vasospastic angina."	( Amlodipine: a new calcium antagonist. Clavijo, GA; de Clavijo, IV; Weart, CW, 1994)	2.45
"Amlodipine has slow receptor binding kinetics that result in a gradual onset of action and may allow for less dependence on instantaneous plasma levels."	( Unique pharmacologic properties of amlodipine. Burges, R; Moisey, D, 1994)	1.29
"Amlodipine has also been found to provide improved antianginal effects when combined to treatment with beta blockers and/or long-acting nitrates."	( Amlodipine once a day in stable angina: double-blind crossover comparison with placebo. Cheitlin, MD; Das, SK; Deedwania, PC; Pasternak, RC; Pool, PE; Singh, JB, 1993)	2.45
"Amlodipine has a beneficial effect on LVH and also is an effective and safe drug to treat mild to moderate hypertension."	( [Effect of the treatment with amlodipine on left ventricular hypertrophy in hypertensive patients]. Hoyos, M; Justo, E; Moreno, R; Oliván, J; Pérez Cano, R; Pizarro, JL; Ramos, E; Rodríguez, A, 1996)	2.03
"Amlodipine has demonstrated atheroprotection in both rabbit and subhuman primate models of this disease."	( Cholesterol, calcium and atherosclerosis: is there a role for calcium channel blockers in atheroprotection? Laury-Kleintop, L; Mason, RP; Tulenko, TN; Walter, MF, 1997)	1.02
"Amlodipine has sustained vasodilatory effects and relieves coronary spasm, which may reduce luminal loss and clinical complications after PTCA."	( Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES). Buller, C; Endresen, K; Erikssen, J; Forfang, K; Goulet, G; Hansen, J; Jørgensen, B; Simonsen, S; Thaulow, E; Vatne, K; Webb, J, 2000)	1.99
"Amlodipine has no demonstrable effect on angiographic progression of coronary atherosclerosis or the risk of major cardiovascular events but is associated with fewer hospitalizations for unstable angina and revascularization."	( Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Byington, RP; Furberg, CD; Hunninghake, DB; Mancini, GB; Miller, ME; Pitt, B; Riley, W, 2000)	2.15
"Amlodipine has potential advantages in children since it can be dissolved into a liquid preparation and has a long elimination half-life, allowing for once-daily administration. "	( A randomized prospective crossover trial of amlodipine in pediatric hypertension. Arbus, GS; Blowey, D; Khattak, S; Koren, G; Lyszkiewicz, DA; Rogan, JW, 2000)	2.01
"Amlodipine, which has membrane-remodeling properties, is emerging as an important atheroprotective drug."	( The smooth muscle cell membrane during atherogenesis: a potential target for amlodipine in atheroprotection. Chen, M; Ferdinand, FD; Huang, Y; Laury-Kleintop, L; Sumner, AE; Tulenko, TN, 2001)	1.26
"Amlodipine has significant anti-anginal efficacy."	( A double-blind dose-response study of amlodipine in patients with stable angina pectoris. Alfiero, R; Cocco, G, 1991)	1.27
"Amlodipine has also been shown to attenuate the cardiac hypertrophy associated with the development of hypertension in spontaneously hypertensive rats."	( Amlodipine: a once daily calcium antagonist. Burges, RA, 1991)	2.45
"Amlodipine also has a long elimination half-life, which makes it suitable for use on a once-daily basis."	( The efficacy of amlodipine in the management of ischaemic heart disease. McGibney, D, 1991)	1.35
"Amlodipine has also been found to be effective in reducing the anginal attack rate in patients with vasospastic angina."	( The efficacy of amlodipine in myocardial ischemia. Taylor, SH, 1989)	1.34

Excerpt	Reference	Relevance
"Amlodipine blunted the increase in diastolic BP that occurred during the second and third sets of exercise at 40% of 1RM (+75 ± 6 vs."	( Amlodipine reduces blood pressure during dynamic resistance exercise in hypertensive patients. Barros, S; Costa, LA; Forjaz, CL; Gomides, RS; Mion, D; Ortega, KC; Queiroz, AC; Souza, DR; Tinucci, T, 2015)	2.58
"Amlodipine could suppress Ang-II-induced endothelial dysfunction and apoptosis through diminishing ROCK1 expression."	( Amlodipine suppresses Ang-II-induced endothelium dysfunction by diminishing ROCK1 expression. Cai, A; Feng, Y; Li, L; Mai, W; Qiu, R; Xu, R; Zheng, D; Zhou, Y, 2016)	3.32
"Amlodipine promotes neovascularization by improving EPC mobilization from bone marrow in diabetic rats after AMI, and activation of VEGF/Akt/eNOS signaling may in part contribute to this."	( Amlodipine Ameliorates Ischemia-Induced Neovascularization in Diabetic Rats through Endothelial Progenitor Cell Mobilization. Dong, L; Ferro, A; Kang, L; Sun, J; Xie, J; Xu, B, 2016)	2.6
"Amlodipine and the ARBs lower blood pressure to a similar extent. "	( Amlodipine versus Angiotensin-receptor blockers for nonhypertension indications. Kalus, JS; White, CM, 2002)	3.2
"Amlodipine reduced the increase in oxidative stress by inhibiting excessive MDA production. "	( Amlodipine and glutathione cycle in hypercholesterolaemia. Bayindir, O; Habif, S; Mutaf, I; Ozmen, D; Parildar, Z; Turgan, N; Uysal, A, 2004)	3.21
"Amlodipine can inhibit the HKC apoptosis and protect the renal tubule cell from injury induced by meglumine diatrizoate."	( [Protective effect of amlodipine on the cytotoxicity induced by contrast media in human kidney cells]. Duan, SB; Li, GY; Liu, FY; Liu, RH; Peng, YM; Ye, Y; Zhou, XR, 2007)	2.1
"Amlodipine can increase CsA levels"	( Amlodipine increases cyclosporine levels in hypertensive renal transplant patients: results of a prospective study. Curtis, JJ; Jones, PA; Julian, BA; Pesavento, TE, 1996)	2.46
"Amlodipine did not increase cardiovascular morbidity or mortality in patients with severe heart failure. "	( Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. Belkin, RN; Carson, PE; Cropp, AB; DeMets, DL; Frid, D; Ghali, JK; Miller, AB; Neuberg, GW; O'Connor, CM; Packer, M; Pressler, ML; Wertheimer, JH, 1996)	2.14
"Amlodipine was found to inhibit growth and bFGF-induced DNA synthesis in a concentration-dependent manner."	( Amlodipine and vascular hypertrophy. Herembert, T; Iouzalen, L; Marche, P; Stepien, O; Zhu, DL, 1997)	2.46
"Amlodipine prevented an increase of the weight of right ventricle (0.62 +/- 0.03 g/kg, P < 0.01) and LVDd (7.9 +/- 0.2 mm, P < 0.01 to MI)."	( Long acting calcium antagonist amlodipine prevents left ventricular remodeling after myocardial infarction in rats. Iwao, H; Kim, S; Omura, T; Shimada, T; Takemoto, Y; Takeuchi, K; Yoshikawa, J; Yoshiyama, M, 1998)	1.31
"3) Amlodipine (10 nM) could inhibit both short-term and long-term p42/p44 MAPKs activation by bFGF."	( The inhibitory mechanisms of amlodipine in human vascular smooth muscle cell proliferation. Gao, PJ; Marche, P; Stepien, O; Wang, XY; Zhang, YZ; Zhang, ZL; Zhu, DL, 2000)	1.11
"Amlodipine did not cause significant change in oxygen uptake at the anaerobic threshold or at maximum exercise and there was also no change in heart rate or catecholamine responses."	( Effect of amlodipine on cardiopulmonary performance in volunteers. Bjorksten, AR; Blake, DW; Lay, L; Stainsby, GV, )	1.26
"Amlodipine was found to inhibit hyperplasia and hypertrophy in mesangial cells."	( Effect of amlodipine on mesangial cell proliferation and protein synthesis. Raij, L; Shultz, PJ, 1992)	1.41
"Amlodipine was found to increase exercise capacity significantly and reduce electrocardiographic evidence of myocardial ischaemia after treadmill exercise testing 24 h after administration compared with placebo in patients suffering from angina pectoris."	( A review of amlodipine in myocardial ischaemia. Taylor, SH, 1991)	1.38

Excerpt	Reference	Relevance
"Amlodipine treatment led to a significant reduction in SBP (-24.9 mmHg; 95% CI: -28.3 to -21.6; P<0.0001) and DBP (-14.8; 95% CI: -16.4 to -13.3; P<0.0001), without affecting the heart rate."	( Effect of amlodipine on ventricular hypertrophy in hypertension patients: a systematic review and meta-analysis. Gao, Y; Yang, P; Zhou, D, 2021)	1.75
"Amlodipine treatment in patients with hypertension significantly reduced the LV mass index and LV posterior wall thickness, without notably affecting the LV end-diastolic diameter. "	( Effect of amlodipine on ventricular hypertrophy in hypertension patients: a systematic review and meta-analysis. Gao, Y; Yang, P; Zhou, D, 2021)	2.47
"Amlodipine treatment reduced LPK rat blood pressure (untreated vs. "	( Amlodipine Improves Vessel Function and Remodeling in the Lewis Polycystic Kidney Rat Mesenteric Artery. Ameer, OZ; Phillips, JK; Quek, KJ, 2020)	3.44
"Amlodipine treatment also resulted in decreased parthenogenetic activation and arrested early embryonic development."	( The role of L-type calcium channels in mouse oocyte maturation, activation and early embryonic development. Ge, ZJ; He, GF; Luo, SM; Ma, JY; Shen, W; Sun, QY; Yang, LL; Yin, S, 2017)	1.18
"Amlodipine treatment at 25 nM prevented apoptosis and restored cellular calcium levels and oxidative damage in cardiomyocytes. "	( Amlodipine protects rat ventricular cardiomyoblast H9c2 From hypoxia-induced apoptosis and restores oxidative balance by Akt-1-dependent manner. Bhardwaj, V; Nehra, S; Saraswat, D, 2014)	3.29
"Amlodipine treatment did not significantly affect any test score, but VAL treatment significantly increased the word-list memory and word-list recall test scores."	( Comparison of effects of valsartan and amlodipine on cognitive functions and auditory p300 event-related potentials in elderly hypertensive patients. Katada, E; Matsukawa, N; Takuma, Y; Uematsu, N, )	1.12
"Amlodipine treatment also increased cardiac SDF-1/CXCR4 expression and gave rise to activation of VEGF/Akt/eNOS signaling in bone marrow."	( Amlodipine Ameliorates Ischemia-Induced Neovascularization in Diabetic Rats through Endothelial Progenitor Cell Mobilization. Dong, L; Ferro, A; Kang, L; Sun, J; Xie, J; Xu, B, 2016)	2.6
"Amlodipine treatment did not cause any serious adverse events."	( A randomized trial of amlodipine in addition to standard chelation therapy in patients with thalassemia major. Baldanzi, GR; Coelho, OR; Costa, FF; Fernandes, JL; Fertrin, KY; Fioravante, LA; Higa, T; Loggetto, SR; Mashima, DA; Piga, A; Saad, ST; Tan, DM; Veríssimo, MP, 2016)	1.47
"Amlodipine treated group showed significantly increased superoxide dismutase and glutathione levels and decreased malondialdehyde levels compared to all treatment groups."	( The potential role of amlodipine on experimentally induced bacterial rhinosinusitis. Halici, Z; Korkmaz, M; Parlak, SN; Polat, E; Tatar, A; Uslu, H; Yayla, M, )	1.17
"Amlodipine-based treatment was associated with a smaller arteriolar length:diameter ratio than atenolol-based treatment (13.32 [10.75 to 16.04] versus 14.12 [11.27 to 17.81], median [interquartile range]; P<0.01)."	( Differential effects of antihypertensive treatment on the retinal microcirculation: an anglo-scandinavian cardiac outcomes trial substudy. Allemann, S; Chaturvedi, N; Hughes, A; Mayet, J; O'Brien, E; Poulter, N; Sever, P; Stanton, A; Stettler, C; Tapp, R; Thom, S; Witt, N, 2009)	1.07
"Amlodipine-treated patients had a higher incidence of peripheral edema (22.4% vs 2.2%) and associated discontinuations (7.3% vs <1%)."	( Randomized study to compare valsartan +/- HCTZ versus amlodipine +/- HCTZ strategies to maximize blood pressure control. Ferber, P; Papst, CC; Zappe, D, 2009)	1.32
"Amlodipine treatment reduced the contractions and improved relaxation to ACh."	( Amlodipine ameliorates endothelial dysfunction in mesenteric arteries from spontaneously hypertensive rats. Cheng, G; He, X; Jiang, HK; Li, DL; Sun, L; Yang, JL; Yu, XJ; Zang, WJ; Zhang, HL; Zhao, M; Zhao, Q, 2011)	2.53
"Amlodipine treatment did not modify HDL3c AOX in the whole study population; changes in AOX were, however, positively correlated with SBP (r = 0.37, p = 0.05 for maximal diene concentration; r = 0.34, p = 0.08 for LDL oxidation rate)."	( Blood pressure-lowering response to amlodipine as a determinant of the antioxidative activity of small, dense HDL3. Bittar, R; Bonnefont-Rousselot, D; Bruckert, E; Chantepie, S; Chapman, MJ; Girerd, X; Hansel, B; Kontush, A; Orsoni, A, 2011)	1.37
"Amlodipine-treated patients experienced a mean decrease in SBP of 26.7 mm Hg, compared with 18.8 mm Hg in patients receiving an ARB and 15.8 mm Hg for patients receiving an ACE inhibitor (P = 0.008, amlodipine vs ACE inhibitor)."	( A retrospective electronic chart review of blood pressure changes in elderly patients treated with amlodipine or an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker. Arocho, R; Brown, C; Dollar, A; McLaughlin, T; Okamoto, L; Putnam, D, 2002)	1.25
"In amlodipine treated patients these figures were 103.4, 113.1 and 147.1%, respectively."	( [Postoperative spasm of mammary-coronary grafts and possibilities of its correction by dihydropyridine calcium antagonists nifedipine and amlodipine]. Dzhavadova, GK; Mamchur, SE; Nemik, BM; Tepliakov, AT; Vecherskiĭ, IuIu, 2002)	1.03
"Amlodipine treatment significantly reduced calcification in the lesions, whereas atorvastatin alone had no effect."	( Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE*3-Leiden transgenic mice. Delsing, DJ; Emeis, JJ; Havekes, LM; Jukema, JW; Princen, HM; van de Wiel, MA; van der Laarse, A, 2003)	1.35
"Amlodipine treatment reduced left ventricle, aortic and mesenteric artery weight."	( Comparative study of the antihypertensive activity of Marrubium vulgare and of the dihydropyridine calcium antagonist amlodipine in spontaneously hypertensive rat. El Bardai, S; Lyoussi, B; Morel, N; Wibo, M, 2004)	1.25
"Amlodipine treatment produced a slight decrease of systolic blood pressure and an increased in heart rate, which were more pronounced in women."	( Assessment of sex differences in pharmacokinetics and pharmacodynamics of amlodipine in a bioequivalence study. Abad-Santos, F; Almeida, S; Gallego-Sandín, S; Gálvez-Múgica, MA; García, AG; Novalbos, J; Vallée, F, 2005)	1.28
"Amlodipine treatment significantly reduced ambulatory blood pressure without altering the normal circadian variation throughout the monitoring period."	( Effect of amlodipine on 24-hour ambulatory blood pressure in hypertensive patients. Allenby, KS; Burris, JF; Mroczek, WJ, 1991)	1.41
"Amlodipine treatment had no significant effect on heart rate."	( Open evaluation of amlodipine in the monotherapeutic treatment of systolic hypertension in the elderly. Lambert, M; Vandewoude, MF; Vryens, R, 1991)	1.33
"Amlodipine treatment produced significant falls in blood pressure (-23.7/-17.3 mm Hg; p < 0.05) with no effect on heart rate."	( The efficacy and safety of amlodipine in the treatment of mild and moderate essential hypertension in general practice. Varrone, J, 1991)	1.3
"No amlodipine-treated patients withdrew due to side effects."	( An 8-week double-blind study of amlodipine and diltiazem in patients with stable exertional angina pectoris. Barth, J; Bernink, PJ; de Weerd, P; Enthoven, R; Haagen, FD; Holwerda, NJ; Klomps, HC; Remme, WJ; ten, CF, 1991)	1.08
"Amlodipine treatment significantly decreased the serum creatinine, more than 12 per cent lower than the FC group (from 70.4 +/- 6.2 to 61.4 +/- 5.2 micromol/L, p<0.05)."	( Amlodipine preserves the glomerular number in spontaneously hypertensive rats. Bezerra, DG; Mandarim-de-Lacerda, CA; Pires, KM, )	2.3
"Amlodipine treatment in parallel with HCD feeding reduced the ischemic lesion size in ApoE KO mice."	( Amlodipine treatment reduces stroke size in apolipoprotein E-deficient mice. Chen, R; Horiuchi, M; Ide, A; Iwai, M; Iwanami, J; Mogi, M; Tsukuda, K; Yoshii, T, 2006)	2.5
"Amlodipine treatment at doses of 1 and 3 mg/kg significantly increased the calcium (P<0.01) and phosphor concentrations (P<0.01) in the femurs of ovariectomized rats, compared to those of control (ovariectomized) group."	( Protective effects of amlodipine and lacidipine on ovariectomy-induced bone loss in rats. Borekci, B; Cadirci, E; Halici, Z; Ozdemir, Y; Suleyman, H, 2008)	1.38
"Amlodipine treatment was associated with significantly fewer reports of headache and flushing than nifedipine retard (p < 0.05)."	( Side effects of dihydropyridine therapy: comparison of amlodipine and nifedipine retard. Bremner, AD; Fell, PJ; Hosie, J; James, GV; Saul, PA; Taylor, SH, 1993)	1.25
"Amlodipine treatment (10 mg/kg/day orally) significantly reduced the increase in blood pressure (BP) in SHR, but did not change BP in WKY."	( Selective interaction of the calcium antagonist amlodipine with calcium channels in arteries of spontaneously hypertensive rats. Godfraind, T; Morel, N, 1994)	1.27
"Amlodipine treatment induced corresponding increases in oxygen delivery (1302 vs."	( Amlodipine improves hepatic hemodynamic and metabolic function in the isolated perfused rat liver after sequential cold and warm ischemia. Dunne, JB; Piratvisuth, T; Tredger, JM; Williams, R, 1995)	2.46
"Amlodipine treatment did not appear to produce clinically significant changes in blood lipids; HCTZ, however, produced an increase in total plasma cholesterol (delta 22.9 +/- 8.6 mg/dl)."	( Double-blind comparison of amlodipine and hydrochlorothiazide in patients with mild to moderate hypertension. Ames, RP; Applegate, WB; Burris, JF; Davidov, ME; Mroczek, WJ; Ram, CV, 1994)	1.31
"Amlodipine-treated mice made significantly more avoidances on the test session than control animals."	( Effect of the calcium channel blocker amlodipine on memory in mice. Ermita, B; Hawxhurst, A; Puente, J; Quartermain, D, 1993)	1.28
"Amlodipine treatment 1) lowered fasting serum insulin (from 273 +/- 19 to 200 +/- 17 pmol/L; P < 0.0005) and glucose (from 5.4 +/- 0.1 to 5.1 +/- 0.1 mmol/L; P < 0.02), 2) reduced the area under the curve for glucose (from 1342 +/- 25 to 1198 +/- 23 mmol/L.min; P = 0.0001) and the area under the curve for insulin (from 155.5 +/- 7.8 to 103.9 +/- 4.3 nmol/L.min; P = 0.0001) during the oral glucose tolerance test, 3) increased fasting serum DHEA-S (from 5.19 +/- 0.37 to 7.95 +/- 0.58 mumol/L; P = 0.0001) and androstenedione (from 5.65 +/- 0.65 to 6.83 +/- 0.53 nmol/L; P < 0.01), and 4) decreased fasting serum cortisol (from 538 +/- 35 to 494 +/- 26 nmol/L; P < 0.05)."	( The calcium channel blocker amlodipine raises serum dehydroepiandrosterone sulfate and androstenedione, but lowers serum cortisol, in insulin-resistant obese and hypertensive men. Beer, NA; Beer, RM; Jakubowicz, DJ; Nestler, JE, 1993)	1.3
"Amlodipine treatment did not cause any significant change in the total and HDL cholesterol levels in both the obese and non-obese patients."	( Relationship between body mass index (BMI) and changes in plasma total and HDL-cholesterol levels during treatment of hypertension in African patients. Agbedana, OE; Ahaneku, JE; Taylor, OG, 1995)	1.01
"Amlodipine treatment resulted in significant increase in total exercise time, increase the exercise time to angina onset, increase time to ST segment depression, decrease in ST segment depression, decrease in total duration of ST segment depression and decrease in duration of pain."	( [Comparative study to assess the efficacy and adverse effects of amlodipine and nifedipine retard in patients with stable exertional angina and hypertension]. Hlawaty, M; Kubler, G; Negrusz-Kawecka, M; Olszowska, M; Salamon, P; Tracz, W; Witkowska, M, 1997)	1.26
"Amlodipine-lovastatin cotreatment increased sialic acid and decreased the susceptibility of LDL to oxidation more effectively than amlodipine alone."	( Antiatherosclerotic and antiatherogenic effects of a calcium antagonist plus statin combination: amlodipine and lovastatin. Akhmedzhanov, NM; Orekhov, AN; Pivovarova, EM; Sobenin, IA; Tertov, VV, 1997)	1.24
"In amlodipine-pretreated rats (15 mg kg(-1) day(-1), orally, for one week), the effect of LPS was lower than in untreated ones and it was completely reversed by L-NNA."	( A therapeutic dosage of amlodipine prevents vascular hyporeactivity induced in rats by lipopolysaccharide. Godfraind, T; Morel, N; Salomone, S, 1998)	1.12
"Amlodipine treatment effectively reversed the infarct size augmentation in cholesterol-fed rabbits (46.3 +/- 6.3%, n = 9, P < 0.05), but did not affect infarct size in normal-fed rabbits (51.0 +/- 4.7%, n = 8)."	( Reduction in infarct size by chronic amlodipine treatment in cholesterol-fed rabbits. Hori, M; Hoshida, S; Kuzuya, T; Yamashita, N, 1998)	1.29
"In amlodipine treated patients the increase in AUC of capillary blood cell velocity did not reach the level of statistical significance (1.59 +/- 1.36 to 2.14 +/- 1.05 mm)."	( Effects of losartan titrated to losartan/hydrochlorothiazide and amlodipine on blood pressure and peripheral capillary microcirculation in patients with mild-to-moderate hypertension. Drewe, J; Gasser, P; Martina, B; Weinbacher, M, 1998)	1.05
"Amlodipine treatment resulted in a greater relative reduction in sudden deaths (21%) than in pump failure deaths (6.6%) overall."	( Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation. Anderson, S; Belkin, RN; Carson, PE; Cropp, AB; DeMets, DL; Frid, DJ; Miller, AB; Neuberg, GW; O'Connor, CM; Pressler, ML; Wertheimer, JH, 1998)	1.42
"Amlodipine treatment caused a significant decrease in IMT compared with control (-0.052 +/- 0.017 vs."	( Effect of calcium channel blocker amlodipine on the intimal-medial thickness of carotid arterial wall in type 2 diabetes. Koshiyama, H; Minamikawa, J; Tanaka, S, 1999)	1.3
"Amlodipine treatment slightly but significantly inhibited the enhanced responses in aorta but did not alter the responses in mesenteric arteries."	( Effect of prolonged treatment with amlodipine on enhanced vascular contractility in cardiomyopathic hamsters. Fukao, M; Hattori, Y; Kanno, M; Kitabatake, A; Okamoto, H; Sakuma, I; Sato, A; Tomioka, H; Watanabe, M, 1999)	1.3
"Amlodipine treatment had no effect on alpha-tocopherol levels in plasma or cardiac tissue in SHR rats."	( Effects of lisinopril and amlodipine on antioxidant status in experimental hypertension. Ahmed, S; MacNee, W; Mantle, D; Patel, VB; Preedy, VR; Rahman, I; Richardson, PJ; Wassif, WS; Why, HJ, 2000)	1.33
"Amlodipine treatment (0.04 mg amlodipine besylate/rat/day for 30 days) decreased plasma follicle-stimulating hormone and testosterone but not luteinizing hormone or prolactin concentrations (measured by double-antibody radioimmuno-assay)."	( Antireproductive effect of the calcium channel blocker amlodipine in male rats. Almeida, SA; Anselmo Franci, JA; Brentegani, LG; Lamano-Carvalho, TL; Teófilo, JM, 2000)	1.28
"Amlodipine besilate treatment 1) lowered the fasting serum insulin level and total serum insulin level during 75 g-OGTT and 2) increased serum DHEA and DHEA-S levels."	( Effects of amlodipine on serum levels of adrenal androgens and insulin in hypertensive men with obesity. Miyachi, Y; Tsuboi, K; Ueshiba, H, 2001)	1.42
"Amlodipine treatment reduced the level of adrenocortical angiotensin II type 2 receptor (AT2R) mRNA in SHR from 8 weeks of age."	( Chronic treatment with amlodipine modulates adrenocortical angiotensin II receptors in spontaneously hypertensive rats. Kataoka, H; Kishida, M; Makino, H; Mimura, Y; Nakamura, Y; Ogura, T; Otsuka, F; Takahashi, M; Yamauchi, T; Yokota, K, 2001)	1.34
"Amlodipine treatment of hyperlipemic hamster was assessed."	( The hyperlipemic hamster - a model for testing the anti-atherogenic effect of amlodipine. Constantinescu, E; Ologeanu, L; Sima, A; Simionescu, M; Stancu, C, )	1.08
"Amlodipine pretreatment attenuated this increase in a time- and dose-dependent manner."	( Effect of amlodipine pretreatment on ischaemia-reperfusion-induced increase in cardiac endothelin-1 binding site density. Casley, DJ; Gu, XH; Nayler, WG; Ou, RC, 1992)	1.41
"Amlodipine treatment caused a rapid concentration-dependent decrease of intracellular calcium concentration in the HT-39 cell line."	( Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse. Simpson, RU; Taylor, JM, 1992)	1
"Amlodipine-treated patients reported fewer adverse events (26%) than did the nitrendipine-treated group (47%), with two patients from the nitrendipine group discontinuing treatment due to treatment-related adverse events."	( Amlodipine compared to nitrendipine for the treatment of mild-to-moderate hypertension. Beressem, P; Englert, R; Kramar, M; Stafunsky, M; von Manteuffel, E, 1991)	2.45
"Amlodipine treated patients had lower arterial pressures in both the supine and upright positions (P less than .001), higher HDL levels (P less than .05) and lower CHOL:HDL and LDL:HDL ratios (P less than .01), than placebo-treated patients."	( Antihypertensive effectiveness of amlodipine in combination with hydrochlorothiazide. Chrysant, C; Chrysant, SG; Hitchcock, A; Trus, J, 1989)	1.28
"Amlodipine treatment was associated with a slightly higher incidence of side effects compared with placebo, but most of this difference was the result of edema, which was usually well tolerated."	( The safety of amlodipine. Osterloh, I, 1989)	1.36
"Treatment with amlodipine appears to be effective in lowering SABP in cats with DM and SH."	( Concurrent disorders of cats with diabetes mellitus and arterial systolic hypertension. Hess, RS; Williams, JG, 2023)	1.25
"Treatment with amlodipine appeared to improve ophthalmic lesions over time."	( Ocular fundus abnormalities in cats affected by systemic hypertension: Prevalence, characterization, and outcome of treatment. Andreani, V; Barsotti, G; Cirla, A; Drigo, M, 2021)	0.96
"Treatment with amlodipine can be used to control portal hypertension in leukemic children having HCV-induced portal hypertension."	( Treatment for hepatitis C virus-induced portal hypertension in leukemic children. Al-Tonbary, Y; Darwish, A; El-Ashry, R; El-Gendy, AA; Ghayaty, EA; Malek, HA, 2013)	0.73
"Treatment with amlodipine or atorvastatin alone significantly decreased left ventricular mass index, cardiomyocyte cross-sectional area and interstitial fibrosis in SHR (each P < 0.05)."	( Amlodipine and atorvastatin improved hypertensive cardiac hypertrophy through regulation of receptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa B/osteoprotegerin system in spontaneous hypertension rats. Cui, W; Du, H; Hao, J; Liu, D; Liu, F; Lu, J; Yang, X, 2016)	2.22
"Treatment with amlodipine, candesartan, or indapamide did not significantly affect plasma visfatin levels."	( Effects of antihypertensive treatment on plasma apelin, resistin, and visfatin concentrations. Piecha, G; Skoczylas, A; Więcek, A, 2016)	0.77
"Rats treated with amlodipine showed improved postischemia neovascularization and cardiac function, together with reduced cardiac remodeling, decreased interstitial fibrosis, and cardiomyocyte apoptosis."	( Amlodipine Ameliorates Ischemia-Induced Neovascularization in Diabetic Rats through Endothelial Progenitor Cell Mobilization. Dong, L; Ferro, A; Kang, L; Sun, J; Xie, J; Xu, B, 2016)	2.2
"Treatment with Amlodipine alone or combination with atorvastatin significantly decreased blood pressure, left ventricle mass index in SHR rats (P < 0.05 for both). "	( Amlodipine and Atorvastatin Improved Hypertensive Cardiac Remodeling through Regulation of MMPs/TIMPs in SHR Rats. Cui, W; Du, H; Hao, J; Li, Y; Lu, J; Xiao, B; Yang, X, 2016)	2.23
"Treatment with amlodipine, however, was not associated with a significant difference in conduction outcome events (HR, 0.94; 95% CI, 0.81-1.09; P = .42)."	( Effect of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) on Conduction System Disease. Albert, CM; Alonso, A; Davis, BR; Dewland, TA; Haywood, LJ; Magnani, JW; Marcus, GM; Piller, LB; Soliman, EZ; Yamal, JM, 2016)	0.77
"Pretreatment with amlodipine effectively counteracted the alteration in mitochondrial enzymes induced by ischemia-reperfusion liver damage."	( Protective role of the calcium channel blocker amlodipine against mitochondrial injury in ischemia and reperfusion injury of rat liver. Dagagi, AV; Kumar, WA; Pallab, C; Pronobesh, C, 2008)	0.93
"Treatment with amlodipine + valsartan + HCTZ for up to 8 weeks was generally well tolerated in the large, phase III trial, with most adverse events being transient and of mild to moderate severity."	( Amlodipine/valsartan/hydrochlorothiazide: fixed-dose combination in hypertension. Deeks, ED, 2009)	2.14
"Treatment with amlodipine/valsartan/hydrochlorothiazide maintained full 24-h effectiveness, including during the morning hours; all hourly mean ambulatory SBP and mean ambulatory DBP measurements were ≤130/85 mm Hg at end point."	( 24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension. Calhoun, DA; Crikelair, N; Glazer, RD; Lacourcière, Y; Yen, J, 2011)	0.95
"Pretreatment with amlodipine resulted in a dose-dependent suppression of Ang II-induced HUVEC apoptosis. "	( Amlodipine treatment prevents angiotensin II-induced human umbilical vein endothelial cell apoptosis. Bian, YF; Gao, F; Xiao, CS; Yang, HY; Yang, ZM; Zhang, NN, 2011)	2.15
"Treatment with amlodipine is associated with increased clopidogrel OPR and increased risk of thrombotic events after PCI, which is dependent on the CYP3A5 genetic status."	( Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention. Kang, HJ; Kang, J; Kim, HS; Koo, BK; Lee, HY; Oh, BH; Park, JJ; Park, KW; Park, YB; Yang, HM, 2012)	2.17
"Oral treatment with amlodipine (n=7), initiated at day 0, reduced systolic blood pressure, reversed cerebral edema and restored blood-brain barrier integrity."	( Reduction of cerebral injury in stroke-prone spontaneously hypertensive rats by amlodipine. Blezer, E; Goldschmeding, R; Joles, J; Koomans, H; Nicolay, K, 2002)	0.86
"Treatment with amlodipine had no significant effect on atherosclerotic lesion area, whereas atorvastatin markedly reduced atherosclerosis by 77% compared with the control group."	( Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE*3-Leiden transgenic mice. Delsing, DJ; Emeis, JJ; Havekes, LM; Jukema, JW; Princen, HM; van de Wiel, MA; van der Laarse, A, 2003)	0.97
"Treatment with amlodipine may be an additional way of therapy in CHF."	( [Influence of amlodipine on serum level of some cytokines in patients with congestive heart failure]. Halawa, B; Karolko, B; Salomon, P, 2003)	1.02
"Treatment with amlodipine markedly inhibited the L-NAME-induced increase in vascular inflammation, oxidative stress, and local ACE and Rho activity and prevented arteriosclerosis."	( Novel anti-inflammatory actions of amlodipine in a rat model of arteriosclerosis induced by long-term inhibition of nitric oxide synthesis. Egashira, K; Hiasa, K; Inoue, S; Ishibashi, M; Kataoka, C; Kitamoto, S; Ni, W; Takeshita, A; Usui, M, 2004)	0.94
"Pretreatment with amlodipine created no difference in both variables (p > 0.05)."	( Radiocontrast-induced nephrotoxicity and urinary alpha-glutathione S-transferase levels: effect of amlodipine administration. Altun, B; Arici, M; Cağlar, S; Erdem, Y; Kes, S; Turgan, C; Usalan, C; Yasavul, U, 2003)	0.86
"Treatment with amlodipine and diltiazem resulted in an improvement in total exercise time, time to angina and total work, mean ST-segment deviation at maximum common load, median number of angina attacks/week, and NTG tablet consumption/week."	( An 8-week double-blind study of amlodipine and diltiazem in patients with stable exertional angina pectoris. Barth, J; Bernink, PJ; de Weerd, P; Enthoven, R; Haagen, FD; Holwerda, NJ; Klomps, HC; Remme, WJ; ten, CF, 1991)	0.9
"Treatment with amlodipine did not significantly lower blood pressure, but resulted in a 43% reduction (P < 0.03) of lesion area as compared with the untreated group."	( Anti-atherosclerotic effect of amlodipine, alone and in combination with atorvastatin, in APOE*3-Leiden/hCRP transgenic mice. de Maat, M; Emeis, J; Havekes, L; Jukema, W; Maas, A; Offerman, E; Princen, H; Szalai, A; Trion, A; van der Laarse, A, 2006)	0.96
"The treatment with amlodipine (AMLO group) or Tempol (TEMP group) significantly inhibited the development of LV hypertrophy and cardiac dysfunction."	( Amelioration of hypertensive heart failure by amlodipine may occur via antioxidative effects. Aburatani, H; Hasegawa, H; Kohro, T; Komuro, I; Niitsuma, Y; Takano, H; Ueda, K, 2006)	0.91
"Treatment with amlodipine/benazepril 10/40 mg/day and 10/20 mg/day resulted in a decrease of mean sitting systolic and mean sitting diastolic BP by 13.3/12.7 mmHg and 12.1/11.6 mmHg, respectively, compared with monotherapy (6.6/8.5 mmHg) (p < 0.0001). "	( The effects of high-dose amlodipine/benazepril combination therapies on blood pressure reduction in patients not adequately controlled with amlodipine monotherapy. Arora, V; Chrysant, SG; Khan, M; Lefkowitz, M; Salko, T; Shi, V; Sugimoto, DH, 2007)	1
"The treatment with amlodipine reduced SBP but failed to ameliorate the ADMA-induced histological changes."	( Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginie dimethylaminohydrolase 2. Hasegawa, K; Hayashi, K; Homma, K; Itoh, H; Kimoto, M; Sugano, N; Tatematsu, S; Wakino, S; Yoshioka, K, 2007)	0.66
"Treatment with amlodipine either as monotherapy or combined with other antianginal therapy for up to 26 weeks shows that efficacy is maintained, with no evidence of tolerance.(ABSTRACT TRUNCATED AT 250 WORDS)"	( Amlodipine once a day in stable angina: double-blind crossover comparison with placebo. Cheitlin, MD; Das, SK; Deedwania, PC; Pasternak, RC; Pool, PE; Singh, JB, 1993)	2.07
"Treatment with amlodipine was well tolerated and the incidence of side effects was low.(ABSTRACT TRUNCATED AT 250 WORDS)"	( Double-blind evaluation of the dose-response relationship of amlodipine in essential hypertension. Garland, WT; Gradman, AH; Lopez, LM; Mehta, JL; Nash, DT; O'Connell, MT; Pickering, BI; Vlachakis, ND, 1993)	0.87
"Treatment with amlodipine in a concentration of 15 mg kg-1 also increased renin immunoreactive areas in the kidney cortex by retrograde recruitment of renin expressing cells in the afferent arterioles."	( Effect of amlodipine on renin secretion and renin gene expression in rats. Hamann, M; Kaissling, B; Krämer, BK; Kurtz, A; Macher, A; Schricker, K, 1996)	1.04
"Pretreatment with amlodipine did not further modulate the cardiovascular reactivity."	( A calcium-channel blocker, amlodipine, attenuates insulin antinatriuresis but does not modulate insulin-mediated attenuation of cardiovascular reactivity in healthy man. Alvestrand, A; de Potocki, K; Ottosson-Seeberger, A; Stenvinkel, P, 1997)	0.92
"Treatment with amlodipine alone and the amlodipine-lovastatin combination ameliorated the atherogenic effect of LDL."	( Antiatherosclerotic and antiatherogenic effects of a calcium antagonist plus statin combination: amlodipine and lovastatin. Akhmedzhanov, NM; Orekhov, AN; Pivovarova, EM; Sobenin, IA; Tertov, VV, 1997)	0.85
"Treatment with amlodipine reduced the elevated fasting- and fed-glucose levels significantly."	( Effect of chronic treatment with amlodipine in non-insulin-dependent diabetic rats. Gokhale, MS; Goyal, RK; Hakim, Z; Santani, DD; Shah, DH, 1998)	0.92
"The treatment with amlodipine normalized [Ca2+]i of PMNLs as well as the calcium transient in response to 3G8 monoclonal antibody and reversed the defect in their phagocytosis."	( Effect of amlodipine therapy on the monoclonal antibody 3G8-induced calcium signal in polymorphonuclear leukocytes of hemodialysis patients. Ahmed, A; Krol, E; Massry, SG; Smogorzewski, M, 1999)	1.02
"Treatment with amlodipine versus placebo significantly delayed the mean (+/- SD) time to first hospitalization (447 +/- 26 d vs 315 +/- 18 d, respectively; P = 0.0139)."	( Hospital use and costs among patients with nonischemic cardiomyopathy in the first prospective randomized amlodipine survival evaluation study. Martin, BC; O'Connor, CM; Radensky, PW; Unger, AN, 1999)	0.86
"Treatment with amlodipine resulted in an average cost per success of $609 per patient compared with $772 per enalapril-treated patient."	( A retrospective analysis comparing the costs and cost effectiveness of amlodipine and enalapril in the treatment of hypertension. Arikian, S; Arocho, R; Casciano, J; Casciano, R; Doyle, J; Gonzalez, MA; Omvik, P, 2001)	0.88
"Treatment with amlodipine was found to reduce myocardial oxygen demand, improve recovery of peak developed tension, have a favourable effect on Ca2+ fluxes, improve retention of tissue adenosine triphosphate and creatine phosphate, and reduce acidosis in the ischaemic/reperfused myocardium."	( The pharmacological profile of amlodipine in relation to ischaemic heart disease. Burges, RA, 1991)	0.91

Excerpt	Reference	Relevance
"The frequency and severity of adverse effects during the first 14 days of treatment with amlodipine (5 mg once daily), nifedipine retard (20 mg twice daily) or placebo were compared in a multicentre, three-way, cross-over study involving 97 patients with mild-to-moderate hypertension."	( Comparison of early side effects with amlodipine and nifedipine retard in hypertension. Bremner, AD; Fell, PJ; Hosie, J; James, IG; Saul, PA; Taylor, SH, 1992)	0.78
" Most adverse events were mild or moderate and the investigators' overall evaluation of tolerability was excellent or good for 91% of patients."	( A study of the efficacy and safety of amlodipine for the treatment of hypertension in general practice. Varrone, J, 1991)	0.55
" Thus amlodipine administered once daily is an effective and safe agent for second-step therapy in mild to moderate essential hypertension."	( Safety and efficacy of amlodipine added to hydrochlorothiazide therapy in essential hypertension. Chrysant, SG; Glasser, SP; Graves, J; Koehn, DK; Rofman, B, 1989)	1.07
" No patient withdrawals resulted from adverse events directly related to amlodipine."	( Clinical safety and efficacy of once-a-day amlodipine for chronic stable angina pectoris. Glasser, SP; West, TW, 1988)	0.77
" Apart from class-typical effects, such as edema for calcium antagonists, and cough for angiotensin-converting enzyme inhibitors, both drugs were equally well tolerated, with few adverse effects of clinical significance."	( A double-blind, long-term, comparative study on quality of life, safety, and efficacy during treatment with amlodipine or enalapril in mild or moderate hypertensive patients: a multicenter study. Eide, I; Herland, OB; Midha, R; Omvik, P; Thaulow, E; Turner, RR, 1993)	0.5
" Adverse events were reported in 28% of patients treated with lacidipine and in 48% of patients receiving amlodipine."	( Efficacy and safety evaluation of lacidipine compared with amlodipine in mild-to-moderate hypertensive patients. Lombardo, D; Raimondi, F, 1994)	0.75
"3% of amlodipine patients recording adverse events, compared with 13."	( Amlodipine and the total ischemic burden: circadian anti-ischemia program in Europe (CAPE) trial-methodology, safety and toleration. The Steering Committee members and all of the investigators. Detry, JM, 1994)	2.21
" A side effect of mild headache was reported by one patient (2."	( Efficacy and safety of amlodipine in hypertensive patients with renal dysfunction. Abe, K; Iimura, I; Ishii, M; Saruta, T, 1994)	0.6
" Adverse experiences possibly related to amlodipine were reported by 19."	( A multicentre study of the safety and efficacy of amlodipine in mild to moderate hypertension. Cross, BW; Kirby, MG; Miller, S; Shah, S; Sheldon, DM; Sweeney, MT, )	0.65
" Therefore, the new once-daily calcium antagonist amlodipine is safe and efficacious in non-hypertensive patients with coronary artery disease."	( Safety and efficacy of amlodipine. A new once-daily calcium antagonist in non-hypertensive patients with coronary artery disease. Ogawa, T; Sugishita, Y; Tomizawa, T; Yasui, K, 1993)	0.85
" The overall incidence of adverse effects were temporary and extremely limited (2%)."	( Middle term evaluation of amlodipine vs nitrendipine: efficacy, safety and metabolic effects in elderly hypertensive patients. Feraco, E; Grandinetti, O, 1993)	0.59
" Nineteen patients in the amlodipine group experienced at least one adverse event compared with 12 in the nifedipine coat-core group."	( Comparison of the efficacy and safety of nifedipine coat-core versus amlodipine in the treatment of patients with mild-to-moderate essential hypertension. Hypertension Study Group. Breuer, HW; Knaup, G; Spiecker, C; Steindl, L; Zidek, W, )	0.67
" Nor have previous studies compared commonly used quality of life instruments for consistency, or investigated whether improvement or worsening of quality of life correlates with adverse events or blood pressure reduction."	( Antihypertensive therapy and quality of life. Influence of blood pressure reduction, adverse events, and prior antihypertensive therapy. Adegbile, IA; Alemayehu, D; Lefkowitz, MP; Papademetriou, V; Prisant, LM; Weber, MA; Weir, MR, 1996)	0.29
" With the 50-mg dose of mibefradil, the incidence of each adverse event was similar to, or lower than, that observed in the placebo-treated patients."	( Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist. Charlon, V; Kobrin, I; Lindberg, E; Pordy, R, 1997)	0.3
" No serious adverse events occurred in any patients during therapy with amlodipine as well as with nifedipine."	( [Comparative study to assess the efficacy and adverse effects of amlodipine and nifedipine retard in patients with stable exertional angina and hypertension]. Hlawaty, M; Kubler, G; Negrusz-Kawecka, M; Olszowska, M; Salamon, P; Tracz, W; Witkowska, M, 1997)	0.77
" Outcome measures included cardiovascular and noncardiovascular deaths, and adverse cardiovascular events including new/worsened angina, myocardial infarction (MI), serious arrhythmia, stroke, congestive heart failure, and bleeding."	( Safety of long-acting dihydropyridine calcium channel blockers in hypertensive patients. Kloner, RA; Levenstein, M; Materson, BJ; Vetrovec, GW, 1998)	0.3
"The primary aim of this double-blind, parallel group trial was to compare incidence of newly occurring vasodilatory adverse events in elderly patients treated with recommended once-daily doses of felodipine extended release (ER) or amlodipine."	( Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: a randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events. The International Study Group. Aldons, PM; Burgess, ED; Girerd, X; Morgan, TO; Rehn, L; Schaefer, RM; Singh, GP; Tilvis, R, 1998)	0.74
" Angiotensin II receptor antagonists provide adequate 24-hour blood pressure control, as measured by ambulatory blood pressure monitoring, and have a side-effect profile similar to placebo."	( Safety and efficacy of angiotensin II receptor antagonists. Neutel, JM, 1999)	0.3
" Telmisartan, a new angiotensin receptor blocker, is a safe and effective drug to use in combination for the treatment of patients with severe hypertension and proved at least as effective as the enalapril combination."	( The efficacy and safety of telmisartan compared to enalapril in patients with severe hypertension. Neutel, JM; Reilly, PA; Smith, DH, )	0.13
" Overall adverse events for bisoprolol and amlodipine were 39% and 40%, respectively."	( Efficacy, safety, and effects on quality of life of bisoprolol/hydrochlorothiazide versus amlodipine in elderly patients with systolic hypertension. Benetos, A; Consoli, S; Dubanchet, A; Safar, M; Safavian, A, 2000)	0.79
"The HOCM, diatrizoate, was more toxic to rat kidneys than the LOCM iohexol; PLA2, LPO and calcium load played a role in producing renal function impairment induced by diatrizoate meglumine; amlodipine protected the renal tissue from nephrotoxicity induced by diatrizoate."	( Nephrotoxicity of high- and low-osmolar contrast media. The protective role of amlodipine in a rat model. Duan, SB; Liu, FY; Liu, RH; Luo, JA; Peng, YM; Wu, HW; Yang, XL, 2000)	0.72
" The incidence of adverse events was lower in the amlodipine relative to the nifedipine group (11."	( [Amlodipine versus nifedipine retard. A randomized double-blind comparative study on long-term efficacy and safety of amlodipine and nifedipine retard in the monotherapy of chronic stable angina pectoris]. Kupper, W; Sauerbrey-Wullkopf, N, 2001)	1.47
" Given the lower incidence of adverse events with amlodipine and its convenient once daily dosing regimen, however, amlodipine may help to enhance patient compliance."	( [Amlodipine versus nifedipine retard. A randomized double-blind comparative study on long-term efficacy and safety of amlodipine and nifedipine retard in the monotherapy of chronic stable angina pectoris]. Kupper, W; Sauerbrey-Wullkopf, N, 2001)	1.47
" Details of any adverse event reported or noted during the treatment with the combination were recorded in the appropriate section of the case record form, whether considered treatment related or not, as reported by the patients."	( Efficacy and safety of losartan-amplodipine combination--an Indian postmarketing surveillance experience. Gokhale, N; Pawar, D; Shahani, S, 2002)	0.31
" Adverse events were mild and infrequent (headache, edema, and dizziness at rates of 4% to 15%), and similar for both agents."	( Comparative efficacy and safety of nisoldipine extended-release (ER) and amlodipine (CESNA-III study) in African American patients with hypertension. Ferdinand, K; Noveck, RJ; Saunders, E; White, WB, 2003)	0.55
"Nisoldipine ER was as effective as amlodipine in reducing 24-h BP in African-American patients with hypertension, with a similar adverse effect profile."	( Comparative efficacy and safety of nisoldipine extended-release (ER) and amlodipine (CESNA-III study) in African American patients with hypertension. Ferdinand, K; Noveck, RJ; Saunders, E; White, WB, 2003)	0.83
"The observation study confirmsthat Amlodipine besylate is an effective and safe antihypertensive drug both in mono and combination therapy."	( [Safety and antihypertensive efficacy of the dihydropyridine calcium antagonist Amlodipine besylate--results from an observational study in 9,672 patients]. Clemens, A; Keck, M; Regourd, E; Sauerbrey-Wullkopf, N, 2004)	0.83
" No patient required discontinuation of amlodipine because of adverse effects."	( Efficacy and safety of prolonged amlodipine treatment in hypertensive children. Flynn, JT, 2005)	0.88
" The adverse events related with the treatment were significantly less frequent with E/N than with a (19."	( [Double blind study of the efficacy and safety of the fixed dose combination of enalapril 10 mg/nitrendipine 20 mg versus the increase of amlopidine dose in essential hypertensive patients not controlled with amlodipine 5 mg]. de la Figuera-von Wichman, M; de la Sierra-Iserte, A; Delgadillo-Duarte, J; Luque-Otero, M; Marín-Iranzo, R; Oliván-Martínez, J; Pontes-García, C; Redón-Mas, J; Roca-Cusachs, A, 2005)	0.52
" Evaluation of safety of the trial was based on the evaluation of a physician, standard laboratory evaluation, adverse effects."	( Clinical study on safety and efficacy of the administration of amlodipine in a combination with lisinopril in hypertensive patients. Arslanagic, A; Bajraktarevic, A; Zulic, I, 2005)	0.57
" Minor adverse effects have been reported, which were not a reason for interruption of the treatment, with the exception of 3 cases (lower leg oedema, dry cough)."	( Clinical study on safety and efficacy of the administration of amlodipine in a combination with lisinopril in hypertensive patients. Arslanagic, A; Bajraktarevic, A; Zulic, I, 2005)	0.57
" Amlodipine was well tolerated, with most adverse events being mild or moderate."	( The efficacy and safety of amlodipine in the treatment of mild and moderate essential hypertension in general practice. Varrone, J, 1991)	1.49
" Twenty-seven patients experienced adverse events reported as drug related."	( An open multicenter efficacy and safety evaluation of amlodipine in the treatment of symptomatic myocardial ischemia. Beckerman, B, 1991)	0.53
" Amlodipine was not associated with adverse effects on hematologic or biochemical safety parameters nor on serum cholesterol or triglyceride levels."	( An update on the safety of amlodipine. Osterloh, IH, 1991)	1.49
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
" Following coadministered treatment, the adverse events reported were similar to either agent alone."	( Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. Bakris, GL; Ferrera, D; Flack, JM; Houston, MC; Lee, E; Messerli, FH; Neutel, JM; Petrella, RJ; Sun, W, 2006)	0.6
" Effects on systolic blood pressure, heart rate, biochemical variables, adverse events and quality of life were studied as secondary efficacy parameters."	( Efficacy and safety of 24 weeks of therapy with bendroflumethiazide 1.25 mg/day or 2.5 mg/day and potassium chloride compared with enalapril 10 mg/day and amlodipine 5 mg/day in patients with mild to moderate primary hypertension : a multicentre, randomis Borrild, N; Rasmussen, S; Vang Andersen, J, 2006)	0.53
" The incidences of adverse events were similar in the low-dose bendroflumethiazide groups, with significantly higher incidences in the enalapril and amlodipine groups."	( Efficacy and safety of 24 weeks of therapy with bendroflumethiazide 1.25 mg/day or 2.5 mg/day and potassium chloride compared with enalapril 10 mg/day and amlodipine 5 mg/day in patients with mild to moderate primary hypertension : a multicentre, randomis Borrild, N; Rasmussen, S; Vang Andersen, J, 2006)	0.73
"2%) experienced adverse events related to the study drug, mostly mild to moderate in nature."	( Efficacy and safety of amlodipine: a comparative study of hypertensive patients treated at primary- and specialised-care centres. Arístegui, R; Gil, A; Hernández, V; Jiménez, R; Valcárcel, Y, 2006)	0.64
" The most frequent adverse events were visual symptoms and sinus bradycardia with ivabradine (0."	( Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Ford, I; Fox, KM; Ruzyllo, W; Tendera, M, 2007)	0.58
" Safety and tolerability evaluations were based on adverse events, ECG and laboratory tests, and clinically relevant reports of abnormalities."	( Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hypertension: MAISH study. Alberici, M; Lembo, G; Payeras, AC; Sladek, K, 2007)	0.58
" Overall, coadministered atorvastatin and amlodipine was well tolerated and without adverse pharmacodynamic interaction; combination treatment did not affect the low-density lipoprotein cholesterol-lowering efficacy and safety of atorvastatin, or the systolic blood pressure-lowering efficacy and safety of amlodipine."	( A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. Dykstra, G; Gillen, D; Harvey, P; Herfert, O; Jukema, JW; Preston, RA; Sun, F, 2007)	0.81
" However, valsartan/amlodipine offered some advantages in terms of less pronounced BP orthostatic changes and absence of metabolic adverse effects."	( Efficacy and safety of two treatment combinations of hypertension in very elderly patients. Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, )	0.45
"The addition of an angiotensin II receptor blocker to calcium channel blocker-based antihypertensive therapy may be associated with enhanced efficacy and reduced risk of adverse events."	( Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy. Ansari, A; Brachmann, J; Handrock, R; Klebs, S; Mahla, G, 2008)	0.58
" Adverse event rates were low in both treatment phases, and most were mild or moderate in severity."	( Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy. Ansari, A; Brachmann, J; Handrock, R; Klebs, S; Mahla, G, 2008)	0.58
" Also, the incidence and severity of adverse events (AEs) and adverse drug reactions (ADRs) were reported."	( Efficacy and safety profiles of a new S(-)-amlodipine nicotinate formulation versus racemic amlodipine besylate in adult Korean patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, double-dummy, parallel-group, ph Ahn, TH; Chung, N; Kim, SA; Lim, DS; Oh, BH; Park, S; Tahk, SJ; Yang, JY, 2008)	0.61
" The combination of A 10 + Val 160 was well tolerated, and the observed adverse events (15."	( Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination. Ansari, A; Braun, N; Handrock, R; Klebs, S; Ulmer, HJ, 2009)	0.6
" The most frequently reported adverse events (AEs) were peripheral edema, upper respiratory tract infection, headache and bronchitis."	( Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension. Hollanders, G; Liao, W; Littlejohn, TW; Trenkwalder, P; Zhao, Y, 2009)	0.58
" Between-group comparisons of adverse events and changes in laboratory parameters did not reach statistical significance, except for uric acid which showed a significant increase in the valsartan/hydrochlorothiazide group compared with the amlodipine group, but was still below the laboratory's upper limit of normal."	( Efficacy and safety of valsartan/hydrochlorothiazide fixed-dose combination compared with amlodipine monotherapy as first-line therapy for mild to moderate hypertension. Chao, CL; Chen, JC; Chiang, FT; Hwang, JJ; Lin, LC; Lin, LY; Lin, YH; Tsai, CT; Wang, YC, )	0.53
" The most common adverse events were peripheral oedema (11."	( International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme. Bauer, B; da Silva, PM; Feldman, RD; Genest, J; Gensini, G; Harvey, P; Jenssen, TG; John Mancini, GB; Manolis, AJ; Richard Hobbs, FD, 2009)	0.58
" Tolerability was assessed by treatment-emergent adverse events."	( Evaluation of safety and efficacy of telmisartan-amlodipine combination in treating hypertension. Faruqui, AA, 2008)	0.6
" After 8 weeks of treatment, the combination of amlodipine + OM is safe and efficacious, irrespective of baseline hypertension stage or prior antihypertensive medication use."	( Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use. Karki, S; Lee, J; Melino, M; Oparil, S, 2009)	0.83
" Study medication was safe and well tolerated."	( Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. Chrysant, SG; Heyrman, R; Karki, S; Lee, J; Melino, M; Oparil, S, 2009)	0.59
" Adverse effects (headache, excessive heartbeat, peripheral edema) were less in patients who have received S(-)AMLODIPINE besylate that contributed to more expressed positive clinical dynamic of the state of patients of this group."	( [Comparative estimation of efficiency and safety of racemic amlodipine and its S-enantiomer in hypertensive patients]. Alshantti, IS; Kuz'minova, NV; Sierkova, VK, )	0.59
" Incidence of adverse events was comparable in monotherapy and combination therapy groups."	( [Efficacy and safety of the single pill combination of valsartan 80 mg plus amlodipine 5 mg in mild to moderate essential hypertensive patients without adequate blood pressure control by monotherapy]. Huang, J; Ke, YN; Zhu, JR, 2009)	0.58
" Safety assessments included monitoring and recording of adverse events (AEs)."	( Efficacy and safety of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients inadequately controlled with amlodipine monotherapy. Cardenas, P; Hong, H; Ke, Y; Wang, R; Zhang, Y; Zhu, D; Zhu, J, 2010)	0.61
" These results suggest that olmesartan/amlodipine is effective and safe in a wide range of patients, regardless of age or hypertension severity."	( Efficacy and safety of olmesartan medoxomil plus amlodipine in age, gender and hypertension severity defined subgroups of hypertensive patients. Böhm, M; Schmieder, RE, 2011)	0.89
" Head-to-head randomized controlled trials (RCTs) of 12 months minimum duration reporting comparative efficacy (changes in systolic and diastolic blood pressure) and safety (total adverse events and ankle oedema), were included."	( Efficacy and safety profiles of manidipine compared with amlodipine: a meta-analysis of head-to-head trials. Laurent, S; Richy, FF, 2011)	0.61
"Two thousand seven hundred and eighty-five patients with arterial hypertension were enrolled, 52 discontinued (eight due to adverse events), and four patients' data were missing."	( Real-life safety and effectiveness of amlodipine/valsartan combination in the treatment of hypertension. Chazova, IE; Dongre, N; Vigdorchik, AV, 2011)	0.64
" Adverse event incidence was low and comparable between losartan and placebo/amlodipine groups."	( Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial. Gleim, GW; Lam, C; Le Bailly De Tilleghem, C; Shahinfar, S; Strehlau, J; Webb, NJ; Wells, TG, 2011)	0.8
" Adverse events were experienced by 34."	( Efficacy and safety of aliskiren-based dual and triple combination therapies in US minority patients with stage 2 hypertension. Ferdinand, KC; Israel, M; Jaimes, EA; Lee, J; Purkayastha, D; Weitzman, R, )	0.13
" Both treatment groups had similar adverse event rates (35."	( Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension. Black, HR; Hilkert, R; Israel, M; Izzo, J; Lee, J; Purkayastha, D; Sridharan, K; Weinberger, MH, 2011)	0.61
" Most treatment-emergent adverse events were mild to moderate in severity."	( Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study. Chrysant, SG; Fernandez, V; Heyrman, R; Izzo, JL; Kereiakes, DJ; Lee, J; Littlejohn, T; Melino, M; Oparil, S, )	0.37
" The observational period was 12 weeks, during which time surveys on outpatient blood pressure, adverse events, palatability, etc."	( Efficacy, safety, and palatability of RACTAB(®) formulation amlodipine orally disintegrating tablets. Fukui-Soubou, M; Kawashima, K; Terada, T; Terashima, H; Utsunomiya, O, 2011)	0.61
" Adverse events observed were not significantly different from those observed during drug use trials of amlodipine formulations reported in 2003."	( Efficacy, safety, and palatability of RACTAB(®) formulation amlodipine orally disintegrating tablets. Fukui-Soubou, M; Kawashima, K; Terada, T; Terashima, H; Utsunomiya, O, 2011)	0.83
" There were 38 adverse events in 20 patients (21."	( Comparative efficacy and safety profile of amlodipine 5 mg/losartan 50 mg fixed-dose combination and amlodipine 10 mg monotherapy in hypertensive patients who respond poorly to amlodipine 5 mg monotherapy: an 8-week, multicenter, randomized, double-blind Chae, SC; Cho, SY; Hong, TJ; Jeong, JW; Jung, JW; Kang, SM; Kim, CH; Kim, JJ; Kim, MH; Kwon, J; Park, CG; Park, SH; Shin, DG; Yang, JY; Yoon, JH; Youn, JC, 2011)	0.63
"Antihypertensive therapy is effective in reducing the risk of major adverse cardiovascular events."	( Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study. Deng, Q; Liu, L; Liu, M; Ma, L; Sun, H; Wang, J; Wang, W; Zhang, Y; Zhao, Y, 2012)	0.73
" Safety evaluations included monitoring of any adverse events (AEs)."	( Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study. Deng, Q; Liu, L; Liu, M; Ma, L; Sun, H; Wang, J; Wang, W; Zhang, Y; Zhao, Y, 2012)	0.73
" Adverse events occurred at 11."	( Efficacy and safety of aranidipine enteric-coated tablets compared with amlodipine in Chinese patients with mild to moderate essential hypertension: a multicenter, randomized, double-blind, parallel-controlled clinical trial. Chen, GL; Fan, CM; Li, HM; Li, YS; Lin, YZ; Pang, HM; Wang, L; Wu, SY; Yan, LR; Yu, J; Zhao, RP, 2012)	0.61
" There were no significant differences in adverse effects between groups, with the exception of more respiratory disorders in the amlodipine/benazepril group than in the valsartan/hydrochlorothiazide group (17 vs 5; P = 0 ."	( Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando Chen, JF; Hung, YJ; Lee, IT; Lee, WJ; Sheu, WH; Wang, CY, 2012)	0.8
" However, respiratory adverse events (particularly coughing) were more frequently reported in the amlodipine/benazepril group."	( Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando Chen, JF; Hung, YJ; Lee, IT; Lee, WJ; Sheu, WH; Wang, CY, 2012)	0.81
" Safety profile was assessed by recording adverse events reported by patients or observed by the investigator."	( I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospec Bobrie, G, 2012)	0.61
" Treatment-emergent adverse events were experienced by 10."	( I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospec Bobrie, G, 2012)	0.61
" Safety profile was assessed by recording adverse events reported by patients or observed by the investigator."	( I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prosp Bobrie, G, 2012)	0.61
" Treatment-emergent adverse events were experienced by 13."	( I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prosp Bobrie, G, 2012)	0.61
" Safety was assessed by recording all adverse events."	( Safety and efficacy of aliskiren/amlodipine/hydrochlorothiazide triple combination in patients with moderate to severe hypertension: a 54-week, open-label study. Garcia-Puig, J; Koenig, W; Murray, AV; Patel, S; Uddin, A; Zhang, J, 2012)	0.66
"Olme/Amlo single pill combination can be a safe and effective option to reduce blood pressure, improve insulin sensitivity and decrease inflammatory markers."	( Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies. Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Querci, F, 2013)	0.64
"7%) patients experienced a total of 174 adverse events (AEs)."	( Efficacy and safety of valsartan and amlodipine single-pill combination in hypertensive patients (PEAK study). Berktaş, M; Boyacı, B; Kızılırmak, P; Yalçın, MR, 2013)	0.66
" All adverse events (AEs) were resolved without sequelae; no serious AEs were reported."	( Pharmacokinetics, tolerability, and safety of the single oral administration of AGSAV301 vs Exforge: a randomized crossover study of healthy male volunteers. Bae, KS; Choi, HY; Kim, MJ; Kim, YH; Lee, SH; Lim, HS; Noh, YH, 2014)	0.4
" Incidence of adverse events (AEs) and serious AEs (SAEs) was recorded as safety variables."	( Real-life effectiveness, safety, and tolerability of amlodipine/valsartan or amlodipine/valsartan/hydrochlorothiazide single-pill combination in patients with hypertension from Pakistan. Abid, R; Afzal, J; Iktidar, S; Khan, W; Kumar, K; Maheshwary, N; Moin, N; Qadir, M; Sakrani, J; Siddiqi, A, 2014)	0.65
" The incidence of adverse events was similar across the treatment groups."	( Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension. Ammentorp, B; de la Sierra, A; Laeis, P; Volpe, M, 2014)	0.63
" Safety assessments consisted of recording all adverse events."	( Efficacy and safety of valsartan/amlodipine single-pill combination in patients with essential hypertension (PEAK LOW). Ar, I; Ilerigelen, B; Kızılırmak, P, 2014)	0.68
"2%) experienced a total of 12 adverse events; there were no serious adverse events."	( Efficacy and safety of valsartan/amlodipine single-pill combination in patients with essential hypertension (PEAK LOW). Ar, I; Ilerigelen, B; Kızılırmak, P, 2014)	0.68
" The incidence of drug-related adverse effects did not differ significantly between the groups."	( Efficacy and safety of olmesartan medoxomil/amlodipine fixed-dose combination for hypertensive patients uncontrolled with monotherapy. Gao, PJ; Zhang, SY; Zhu, JR, 2014)	0.66
" Tolerability was assessed by recording treatment-emergent adverse events (TEAEs)."	( Efficacy and safety of the dual L- and T-type calcium channel blocker, ACT-280778: a proof-of-concept study in patients with mild-to-moderate essential hypertension. Dingemanse, J; Klainman, E; Kracker, H; Mueller, MS; Otasevic, P; Putnikovic, B; Shakeri-Nejad, K; Zimlichman, R, 2015)	0.42
" Adverse events were assessed."	( Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension. Azuma, K; Fujita, KP; Nishida, C; Numaguchi, H; Rakugi, H; Shimada, K; Shirakawa, M; Tsuchihashi, T; Yamaguchi, H, 2015)	0.66
" Deaths and adverse reactions were absent barring clinically insignificant side effects in 28 of the 160 patients (17."	( [Effectiveness and safety of losartan and its combination with amlodipine in therapy of arterial hypertension]. Bazaeva, EV; Boitsov, SA; Drapkina, OM; Luk'ianov, MM; Panov, AV; Shchukina, GN; Terent'ev, BP; Tiurin, VP, 2013)	0.63
"Losartan and amlodipine are effective and safe agents for AH therapy."	( [Effectiveness and safety of losartan and its combination with amlodipine in therapy of arterial hypertension]. Bazaeva, EV; Boitsov, SA; Drapkina, OM; Luk'ianov, MM; Panov, AV; Shchukina, GN; Terent'ev, BP; Tiurin, VP, 2013)	1
" Efficacy was assessed in accordance with the Austrian hypertension guidelines while tolerability was evaluated on the basis of adverse events."	( Efficacy, safety, and tolerability of antihypertensive therapy with aliskiren/amlodipine in clinical practice in Austria. The RALLY (Rasilamlo long lasting efficacy) study. Ratzinger, M; Rosenkranz, AR, 2015)	0.65
" Overall, 44 adverse events were documented in 41 patients, and physicians reported that 94 % of patients were compliant in a final survey on evaluation of therapy."	( Efficacy, safety, and tolerability of antihypertensive therapy with aliskiren/amlodipine in clinical practice in Austria. The RALLY (Rasilamlo long lasting efficacy) study. Ratzinger, M; Rosenkranz, AR, 2015)	0.65
"0001), and a lower incidence of pedal edema and adverse events compared with amlodipine."	( Efficacy and safety of perindopril arginine + amlodipine in hypertension. Bakris, GL; Elliott, WJ; Feldstein, JD; Whitmore, J, 2015)	0.9
" Overall, the olmesartan/amlodipine FDC was well tolerated, and there were no serious adverse events associated with medication."	( A multicenter, non-comparative study to evaluate the efficacy and safety of fixed-dose olmesartan/amlodipine in Korean patients with hypertension who are naïve or non-responders to anti-hypertensive monotherapy (ACE-HY study). Ahn, Y; Bae, JH; Jung, HW; Kang, DH; Kim, CH; Kim, KI; Park, CG, 2015)	0.94
" Treatment-emergent adverse events (AEs) were also assessed."	( A Randomized, Multicenter, Double-blind, Placebo-controlled, 3 × 3 Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of the Combination of Fimasartan/Amlodipine in Patients With Essential Hypertension. Ahn, T; Ahn, Y; Bae Park, J; Cho, EJ; Choi, DJ; Chull Chae, S; Chun, KJ; Han, KR; Hyon, MS; Jeon, ES; Jeong, JO; Joo, SJ; Kim, DI; Kim, DS; Kim, JJ; Kim, KS; Kim, YJ; Kwan, J; Lee, HY; Oh, SK; Park, JS; Rhee, MY; Seog Seo, H; Shin, JH; Sung, KC; Yoo, BS; Youn, HJ, 2015)	0.61
" Adverse events (4."	( Safety and effectiveness of combined antihypertensive and cholesterol-lowering therapy in high-/very high-risk patients. Gaszner, B; Hild, G; Kónyi, A; Sárszegi, Z, 2016)	0.43
" Treatment-emergent adverse events were also assessed."	( A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Fimasartan/Amlodipine Combined Therapy Versus Fimasartan Monotherapy in Patients With Essential Hypertension Unresponsive to Fimasartan Monotherapy. Cha, KS; Chae, SC; Chun, KJ; Ihm, SH; Il Kim, D; Jeong, JO; Joo, SJ; Kim, CH; Kim, DS; Kim, JJ; Kim, KH; Kim, KI; Kim, MH; Kim, YJ; Nam, CW; Park, S; Park, SM; Rhee, MY; Seo, HS; Shin, ES; Shin, J; Shin, MS; Sung, KC; Yoo, BS; Youn, HJ, 2016)	0.65
" Adverse drug reactions were observed in 9 patients (6."	( A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Fimasartan/Amlodipine Combined Therapy Versus Fimasartan Monotherapy in Patients With Essential Hypertension Unresponsive to Fimasartan Monotherapy. Cha, KS; Chae, SC; Chun, KJ; Ihm, SH; Il Kim, D; Jeong, JO; Joo, SJ; Kim, CH; Kim, DS; Kim, JJ; Kim, KH; Kim, KI; Kim, MH; Kim, YJ; Nam, CW; Park, S; Park, SM; Rhee, MY; Seo, HS; Shin, ES; Shin, J; Shin, MS; Sung, KC; Yoo, BS; Youn, HJ, 2016)	0.65
"Fimasartan/amlodipine combination therapy exhibited superior efficacy in reducing blood pressure, with no increase in adverse drug reactions, compared with fimasartan monotherapy."	( A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Fimasartan/Amlodipine Combined Therapy Versus Fimasartan Monotherapy in Patients With Essential Hypertension Unresponsive to Fimasartan Monotherapy. Cha, KS; Chae, SC; Chun, KJ; Ihm, SH; Il Kim, D; Jeong, JO; Joo, SJ; Kim, CH; Kim, DS; Kim, JJ; Kim, KH; Kim, KI; Kim, MH; Kim, YJ; Nam, CW; Park, S; Park, SM; Rhee, MY; Seo, HS; Shin, ES; Shin, J; Shin, MS; Sung, KC; Yoo, BS; Youn, HJ, 2016)	1.04
" The adverse events (AEs) during both treatment periods were generally mild."	( The efficacy and long-term safety of a triple combination of 80 mg telmisartan, 5 mg amlodipine and 12.5 mg hydrochlorothiazide in Japanese patients with essential hypertension: a randomized, double-blind study with open-label extension. Higaki, J; Ikeda, H; Komuro, I; Kuroki, D; Nishimura, S; Ogihara, T; Shiki, K; Taniguchi, A; Ugai, H, 2017)	0.68
" Overall, the incidence of adverse events was 20."	( Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy. Hafeez, K; Jia, Y; Sibulo, A; Wang, JG; Yukisada, K; Zhang, J, 2017)	0.69
" Both treatment regimens were well tolerated regarding adverse events or laboratory testing."	( Blood pressure-lowering efficacy and safety of perindopril/indapamide/amlodipine single-pill combination in patients with uncontrolled essential hypertension: a multicenter, randomized, double-blind, controlled trial. Amodeo, C; Asmar, R; Brzozowska-Villatte, R; de Champvallins, M; Mourad, JJ, 2017)	0.69
" Adverse reactions were reported by only 13 (0."	( Adherence to Treatment, Safety, Tolerance, and Effectiveness of Perindopril/Amlodipine Fixed-Dose Combination in Greek Patients with Hypertension and Stable Coronary Artery Disease: A Pan-Hellenic Prospective Observational Study of Daily Clinical Practice Kotsis, VT; Liakos, CI; Papadopoulos, DP, 2017)	0.68
" A systematic review of the literature revealed its most common adverse effects as: peripheral edema (depending on the dose of amlodipine, but attenuated by perindopril), cough, dizziness and hypotension."	( Perindopril arginine and amlodipine besylate for hypertension: a safety evaluation. Bistrika, EA; Elliott, WJ, 2018)	0.99
" The number of patients with Adverse drug reactions (ADR) were found in 35."	( [Pharmacogenetic approaches to predicting the efficiency and safety of amlodipine in patients with arterial hypertension]. Kalle, EG; Morozova, TE; Ryzhikova, KA; Shih, NV; Sychev, DA, 2017)	0.69
"Most adverse events (AEs) were mild or moderate in intensity, and no deaths or treatment-related serious AEs were reported."	( A phase III, open-label, multicenter study to evaluate the safety and efficacy of long-term triple combination therapy with azilsartan, amlodipine, and hydrochlorothiazide in patients with essential hypertension. Nishiyama, Y; Rakugi, H; Sano, Y; Shimizu, K; Umeda, Y, 2018)	0.68
" For safety assessments, all adverse events and abnormal laboratory findings were recorded."	( Efficacy and Safety of S-Amlodipine 2.5 and 5 mg/d in Hypertensive Patients Who Were Treatment-Naive or Previously Received Antihypertensive Monotherapy. Demir, M; Şen, S; Üresin, AY; Yiğit, Z, 2018)	0.78
" Adverse events (AEs), clinical laboratory data, and vital signs were assessed in all patients."	( Efficacy and Safety of Triple Therapy With Telmisartan, Amlodipine, and Rosuvastatin in Patients With Dyslipidemia and Hypertension: The Jeil Telmisartan, Amlodipine, and Rosuvastatin Randomized Clinical Trial. Ahn, Y; Chang, K; Cho, JM; Hong, SJ; Hyon, MS; Jeong, HS; Kang, WC; Kim, HS; Lee, JH; Pyun, WB, 2019)	0.76
" No significant differences were found in the incidence of overall AEs and adverse drug reactions, and serious AEs were comparable among 3 groups."	( Efficacy and Safety of Triple Therapy With Telmisartan, Amlodipine, and Rosuvastatin in Patients With Dyslipidemia and Hypertension: The Jeil Telmisartan, Amlodipine, and Rosuvastatin Randomized Clinical Trial. Ahn, Y; Chang, K; Cho, JM; Hong, SJ; Hyon, MS; Jeong, HS; Kang, WC; Kim, HS; Lee, JH; Pyun, WB, 2019)	0.76
"Incremental uptitration with dosage-adapted perindopril/amlodipine SPC is a safe and effective strategy for managing hypertension."	( Efficacy and Safety of Incremental Dosing of a New Single-Pill Formulation of Perindopril and Amlodipine in the Management of Hypertension. Dolan, E; Gupta, AK; O'Brien, E; Poulter, NR; Sever, PS; Whitehouse, A, 2019)	0.98
"7%) patients due to adverse events."	( EFFICACY AND SAFETY OF A SINGLE-PILL COMBINATION OF ATORVASTATIN/AMLODIPINE IN PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA. Georgieva Torbova-Gigova, S; Ivanov Manov, E; Margaritov Runev, N; Naydenov Naydenov, S, 2018)	0.72
" We administered this solution to three animals in order to determine a toxic dose, capable of facilitating a two-arm study of amlodipine toxicity."	( Development and Feasibility of a Porcine Model of Amlodipine Toxicity. Boley, SP; Engebretsen, KM; LeRoy, JM; Mackenzie, RB; Stellpflug, SJ, 2020)	1.02
"This study demonstrates a potentially repeatable model of amlodipine-induced toxic shock using intravenous administration of amlodipine and several methodological considerations for researchers undertaking similar work."	( Development and Feasibility of a Porcine Model of Amlodipine Toxicity. Boley, SP; Engebretsen, KM; LeRoy, JM; Mackenzie, RB; Stellpflug, SJ, 2020)	1.06
" No serious adverse events or adverse drug reactions were observed in all groups."	( A randomized, double-blind clinical trial to evaluate the efficacy and safety of a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension. Ahn, JC; Ahn, YK; Chang, K; Cho, EJ; Cho, KI; Kang, DH; Kim, M; Kim, SJ; Kim, SY; Kim, U; Kim, W; Kim, YJ; Lee, CH; Lee, SH; Park, CG; Shin, JH; Yu, CW, 2020)	0.77
"Chronic hypertension is associated with adverse perinatal outcomes, although the optimal treatment is unclear."	( Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis. Bellos, I; Daskalakis, G; Loutradis, D; Papapanagiotou, A; Pergialiotis, V, 2020)	0.56
" Safety and tolerability were assessed by the incidence rate of adverse events (AEs) and discontinuation."	( Real-World Effectiveness and Safety of a Single-Pill Combination of Olmesartan/Amlodipine/Hydrochlorothiazide in Korean Patients with Essential Hypertension (RESOLVE): A Large, Observational, Retrospective, Cohort Study. Park, SJ; Rhee, SJ, 2020)	0.79
" The secondary efficacy variables were changes in MSSBP, mean sitting diastolic blood pressure (MSDBP), LDL cholesterol and other lipid levels at 4 weeks and 8 weeks, as well as observed adverse events during follow-up."	( Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia. Ahn, JC; Chae, IH; Cho, EJ; Cho, JM; Cho, Y; Choi, SY; Han, KH; Hong, SJ; Hong, SP; Hwang, J; Hyon, MS; Jin, X; Kim, H; Kim, HS; Kim, JH; Kim, MH; Kim, PJ; Kim, WS; Kwon, K; Lee, H; Lee, HC; Lee, JH; Lee, K; Lee, SH; Park, CG; Rhee, MY; Seo, JS; Shin, JH; Sung, JH; Sung, KC; Yoo, BS, 2020)	0.81
" These results suggest that lipid emulsion inhibits late apoptosis induced by amlodipine at toxic dose via the activation of phosphoinositide-3 kinase and ATP-sensitive potassium channels in the extrinsic apoptotic pathway."	( Lipid emulsion attenuates extrinsic apoptosis induced by amlodipine toxicity in rat cardiomyoblasts. Ahn, SH; Bae, SI; Hwang, Y; Kim, HJ; Lee, SH; Ok, SH; Park, KE; Shin, IW; Sohn, JT; Yoon, S, 2021)	1.09
" Adverse events, total adverse drug reactions, and serious adverse drug reactions were found in 808 patients (1."	( Telmisartan Plus S-Amlodipine Single-Pill Combination Therapy is Safe and Effective in Patients with Hypertension from Large-Scale Nationwide Surveillance Data in Korea (NOVEL) Study. Hong, GR; Jo, SH; Kim, SW; Park, CG; Park, SJ, 2021)	0.95
"Telmisartan plus S-amlodipine single-pill combination was safe and effective in patients with hypertension in a large real-world population."	( Telmisartan Plus S-Amlodipine Single-Pill Combination Therapy is Safe and Effective in Patients with Hypertension from Large-Scale Nationwide Surveillance Data in Korea (NOVEL) Study. Hong, GR; Jo, SH; Kim, SW; Park, CG; Park, SJ, 2021)	1.28
" Safety parameters with adverse events and compliance by traditional pill count method."	( An Open Label Prospective Study on Evaluation of Safety and Efficacy of Cilnidipine Over Amlodipine in Stage 1 Hypertensive Patients. Das, K; Harlalka, S; Majumdar, G; Mandal, P; Roy, UK, )	0.35
" The blood pressure, pulse rate and adverse effects were monitored in each patient over 12 weeks."	( A Randomized Open-Label Parallel-Group Study Comparing the Efficacy and Safety of Cilnidipine and Amlodipine in Hypertensive Adults. D, DC; Jj, NK; Kavitha, R, 2022)	0.94
" The patients in the cilnidipine group experienced significantly less adverse effects such as pedal edema and palpitations when compared to those in the amlodipine group (p<0."	( A Randomized Open-Label Parallel-Group Study Comparing the Efficacy and Safety of Cilnidipine and Amlodipine in Hypertensive Adults. D, DC; Jj, NK; Kavitha, R, 2022)	1.14
"Cilnidipine therapy is an effective and safe alternative in the treatment of essential hypertension."	( A Randomized Open-Label Parallel-Group Study Comparing the Efficacy and Safety of Cilnidipine and Amlodipine in Hypertensive Adults. D, DC; Jj, NK; Kavitha, R, 2022)	0.94
" Adverse events and laboratory test results will be monitored throughout the trial."	( Efficacy and safety of Tengfu Jiangya tablet combined with valsartan/amlodipine in the treatment of stage 2 hypertension: study protocol for a randomized controlled trial. Chen, W; Hua, Z; Li, Y; Wang, Y; Zhu, Y, 2022)	0.96
" In terms of safety, no special adverse events and clinically significant results were noted, and all dose groups of the triple combination are considered safe for use in essential hypertension patients."	( Efficacy and safety of low-dose antihypertensive combination of amlodipine, telmisartan, and chlorthalidone: A randomized, double-blind, parallel, phase II trial. Ahn, JC; Cho, EJ; Han, SH; Kang, SM; Kim, KH; Kim, KI; Kim, SY; Kim, W; Kim, YJ; Park, CG; Park, SJ; Park, SM; Shin, J; Shin, JH; Sohn, IS; Sung, JH; Sung, KC, 2022)	0.96
" As a rare and unique adverse effect of infliximab, hypertension should be paid enough attention in clinical work."	( Hypertension as a rare adverse effect caused by infliximab in the treatment of Crohn's disease: a case report. Mo, J; Tang, J; Zhang, B; Zhao, X, 2022)	0.72
"Hypertension, as one of the rare adverse reactions of infliximab in the treatment of Crohn's disease, should be paid enough attention."	( Hypertension as a rare adverse effect caused by infliximab in the treatment of Crohn's disease: a case report. Mo, J; Tang, J; Zhang, B; Zhao, X, 2022)	0.72
"50%) were the most frequent adverse events."	( Efficacy and safety of single pill combination of amlodipine and valsartan in hypertensive Saudi patients. Ahmad, A; Alama, MN; Alharthi, TS; Alkreathy, HM; Alluhabi, SI; Alqarni, F; Alrafiah, AR; Damanhouri, ZA, 2023)	1.16
" Third-standard-dose triple antihypertensive combination therapy demonstrated early effective BP control compared to third-standard-dose dual combination therapies, without increasing adverse drug reactions in patients with mild-to-moderate hypertension."	( Comparison of efficacy and safety between third-dose triple and third-dose dual antihypertensive combination therapies in patients with hypertension. Cho, DK; Cho, GY; Cho, JM; Heo, JH; Hong, SJ; Jeong, MH; Jung, JA; Kim, DH; Kim, SH; Kim, SY; Kim, W; Kwon, K; Lee, HY; Lee, JB; Lim, SW; Park, K; Park, S; Pyun, WB; Rha, SW; Rhee, MY; Shin, J; Sung, KC, 2023)	0.91
" The numbers of patients with adverse drug reactions (ADRs) were compared as safety variables."	( A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia. Ahn, Y; Chae, IH; Hong, SJ; Hong, TJ; Kang, DH; Kim, BK; Kim, H; Kim, HS; Kim, MC; Kim, MH; Kim, SH; Kim, SY; Kim, W; Rhee, MY, 2023)	1.11
" There was no significant difference in the adverse events rates between RSV 10 mg/AML 5 mg, RSV 20 mg/AML 5 mg, and ATV 20 mg/AML 5 mg."	( Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia. Bae, HJ; Cho, EJ; Choi, JY; Han, KR; Hong, BK; Hong, SP; Hyon, MS; Jin, HY; Jung, HW; Kim, CY; Kim, KS; Kim, SY; Kim, U; Lee, JB; Lee, KH; Lee, KJ; Lee, SR; Lee, SY; Nam, CW; Park, CG; Park, SJ; Park, TH; Rhee, MY; Ryu, JK; Seol, SH; Shin, JH; Yang, DH; Yu, GW, 2023)	1.12
" There are no serious adverse event and no one discontinued medication due to adverse event."	( Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double-blind, active-controlled, multicenter phase 3 trial. Ahn, Y; Cha, KS; Chang, K; Cho, EJ; Choi, DJ; Choi, SY; Doh, JH; Hong, SJ; Hong, SP; Hwang, JY; Hyon, MS; Ihm, SH; Kang, WC; Kim, HS; Kim, MH; Kim, SH; Kim, WS; Kim, YH; Kwon, K; Lee, JH; Lee, N; Lim, SW; Rhee, MY; Shin, J; Son, JW; Yoo, BS, 2023)	1.14
" The therapy was safe and well tolerated."	( Real-World Effectiveness and Safety of a Single-Pill Combination of Olmesartan/Amlodipine/Hydrochlorothiazide in Korean Patients with Hypertension and Cardiovascular Risk Factors. Hong, JH; Hyun, D; Kim, GH; Kim, HL; Kim, W; Lim, S; Min, KW; Oh, J; Park, SD; Shin, J, 2023)	1.14

Excerpt	Reference	Relevance
"This study characterizes the single dose pharmacokinetic characteristics of the dihydropyridine calcium antagonist drug amlodipine in a group of 16 elderly subjects, aged 65 to 86 years (8 M:8 F)."	( An assessment of the pharmacokinetics and pharmacodynamics of single doses of amlodipine in elderly normotensives. Elliott, HL; Green, ST; Meredith, PA; Vincent, J, )	0.57
" Amlodipine is distinct from other calcium antagonists by its pharmacokinetic profile: slower onset of action with less acute vasodilatation associated side effects and a sustained antihypertensive and anti-anginal efficacy over 24 hours."	( [Amlodipine: pharmacokinetic and pharmacodynamic profile of a calcium antagonist with prolonged effect]. Heynen, G, 1992)	2.1
"Amlodipine is a dihydropyridine calcium antagonist drug with distinctive pharmacokinetic characteristics which appear to be attributable to a high degree of ionisation."	( Clinical pharmacokinetics of amlodipine. Elliott, HL; Meredith, PA, 1992)	2.02
" The slow rate of elimination (elimination half-life of 40-60 h) confers several pharmacokinetic characteristics that are not seen with other calcium-antagonist drugs."	( Pharmacokinetics and pharmacodynamics of amlodipine. Abernethy, DR, 1992)	0.55
" Thus, amlodipine seems to provide a useful alternative to other agents currently available for the treatment of essential hypertension and chronic stable angina pectoris, with certain pharmacodynamic and tolerability properties that should be advantageous in many patients."	( Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Heel, RC; Murdoch, D, 1991)	2.18
" In order to document its stability in vitro and to develop a pharmacokinetic model in rabbits, a new reversed-phase liquid chromatography (LC) assay with UV detection was developed."	( Liquid chromatography assay for amlodipine: chemical stability and pharmacokinetics in rabbits. Mosher, SJ; Pollak, PT; Yeung, PK, 1991)	0.56
" Pharmacokinetic studies were conducted with nonlabeled drug using specific high-pressure liquid chromatography or gas chromatographic procedures."	( The metabolism and pharmacokinetics of amlodipine in humans and animals. Beresford, AP; Humphrey, MJ; Macrae, PV; Stopher, DA, 1988)	0.54
" The elimination half-life was of the order of 50 h, similar to previously observed values, and did not vary with differences in renal function."	( Pharmacokinetics of amlodipine in renal impairment. Carmody, M; Donohoe, JF; Doyle, GD; Greb, H; Kelly, JG; Laher, MS; Volz, M, 1988)	0.6
" amlodipine, clearance tended to be decreased in elderly as compared with young patients with resulting prolongation in elimination half-life (64 +/- 20 vs."	( Amlodipine in elderly hypertensive patients: pharmacokinetics and pharmacodynamics. Abernethy, DR; Gutkowska, J; Lambert, MD, 1988)	2.63
" The elimination half-life was of the order of 50 h, similar to previously reported values and did not vary with renal function."	( Pharmacokinetics of amlodipine in renal impairment. Carmody, M; Donohue, J; Doyle, GD; Greb, H; Laher, M; Volz, M, 1989)	0.6
"Amlodipine, a dihydropyridine calcium antagonist, was synthesized in an attempt to develop a compound with a pharmacokinetic profile characteristic of this class, which would also have an increased oral bioavailability and extended clearance time."	( The pharmacokinetic profile of amlodipine. Abernethy, DR, 1989)	2.01
"Intravenous administration of amlodipine (single dose, 10 mg) to 12 volunteers gave a mean plasma half-life of 34 h, mean clearance of 7 ml min-1 kg-1 and a mean apparent volume of distribution of 21 l kg-1."	( The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. Chasseaud, LF; Faulkner, JK; McGibney, D; Perry, JL; Taylor, IW, 1986)	0.87
" In studies with hypertensive patients in which pharmacokinetic and pharmacodynamic indices have been integrated, we have demonstrated that the intersubject variability in the pharmacokinetics of verapamil, nifedipine, enalapril, and amlodipine is directly related to the variability in blood pressure response at steady state."	( Amlodipine; clinical relevance of a unique pharmacokinetic profile. Elliott, HL; Meredith, PA, 1993)	1.91
" The mean values of AUC (0-4 h), Cmax and Tmax for benazepril given as combination versus given alone were 161 vs 140 ng."	( Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. Chan, K; Cipriano, A; John, VA; Sun, JX, 1994)	0.53
"Pharmacokinetic and pharmacodynamic data were compared between elderly and young patients with hypertension who received single intravenous doses of amlodipine, a dihydropyridine calcium antagonist, followed by oral administration of amlodipine up to 10 mg once daily for 12 weeks."	( An overview of the pharmacokinetics and pharmacodynamics of amlodipine in elderly persons with systemic hypertension. Abernethy, DR, 1994)	0.73
"The distinctive pharmacokinetic characteristics of amlodipine, particularly the long half-life, are presumed to translate directly to a prolonged duration of action, but the concentration-effect relationship for the antihypertensive response has not been clearly established."	( Pharmacodynamic modeling of the antihypertensive response to amlodipine. Donnelly, R; Elliott, HL; Howie, CA; Meredith, PA; Miller, SH, 1993)	0.78
" Cmax values were found to be similar in both groups although Tmax was shorter, and T1/2 was longer, in patients with hepatic insufficiency."	( Pharmacokinetics and safety of single oral doses of amlodipine in patients with and without hepatic impairment: an open study. Darnis, F; Poupon, R, 1993)	0.54
"When amlodipine was coadministered with grapefruit juice, Cmax was 115% and AUC(0-72 h) was 116% compared with water, but tmax was not significantly changed."	( Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers. Ahlner, J; Josefsson, M; Zackrisson, AL, 1996)	1.06
"Amlodipine, a third-generation dihydropyridine calcium antagonist, has a mode of action and pharmacodynamic profile which are comparable to those of conventional compounds in this series, such as nifedipine."	( Amlodipine: an overview of its pharmacodynamic and pharmacokinetic properties. van Zwieten, PA, 1994)	3.17
" Significant differences were found between all principal pharmacokinetic variables, when comparing the 2 treatments after both single and repeated dosing."	( Crossover comparison of the pharmacokinetics of amlodipine and felodipine ER in hypertensive patients. Jacobsen, IA; Videbaek, LM, 1997)	0.55
" The pharmacokinetic behaviour of R-(+)- and S-(-)-amlodipine after single enantiomer administration to healthy male human volunteers together with comparative administration of the racemic mixture of both enantiomers were studied."	( Pharmacokinetic behaviour of R-(+)- and S-(-)-amlodipine after single enantiomer administration. Josic, D; Kopitar, Z; Kremser, M; Luksa, J; Milutinovic, S, 1997)	0.81
" Pharmacokinetic analysis of drug accumulation showed one-compartment characteristics with an half-life of 76 min."	( Amlodipine dynamic effects and myocardial pharmacokinetics in the isolated and perfused guinea-pig heart. Bruun, J; Jeppesen, P; Nielsen-Kudsk, F, 1998)	1.74
" Neither AUC nor trough levels of FEL and AML were significantly influenced by transit times, nor was Cmax after any of the three treatments."	( The pharmacokinetics of extended-release formulations of calcium antagonists and of amlodipine in subjects with different gastrointestinal transit times. Laufen, H; Riedel, KD; Scharpf, F; Schumacher, T; Yeates, R; Zimmermann, T, 1999)	0.53
" Pharmacokinetic parameters of racemic amlodipine (AUC, Cmax, tmax, and kel) were not markedly changed with grapefruit juice coadministration."	( Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine. Dogolo, LC; Foulds, G; Friedman, HL; Harris, SI; Vincent, J; Willavize, S, 2000)	0.8
" The geometric means of the primary pharmacokinetic parameters at steady state (day 9) for amlodipine when given alone were the following: maximum plasma concentration (Cmax) 17."	( Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers. Stangier, J; Su, CA, 2000)	0.79
" Blood samples were collected after administration of amlodipine and AUC, Cmax, and tmax were determined."	( Comparative pharmacokinetics and pharmacodynamics of amlodipine in hypertensive patients with and without type II diabetes mellitus. Alonso, A; Baltodano, NM; Chung, M; Epstein, M; Gaffney, M; Preston, RA, 2001)	0.81
" These results suggest that the influence of aging on the pharmacokinetic profiles might differ between the R(+)- and S(-)-isomers of amlodipine."	( Stereoselective pharmacokinetics of amlodipine in elderly hypertensive patients. Arakawa, M; Fujimura, A; Harada, K; Hifumi, S; Miyamori, I; Ohmori, M; Takasaki, H, )	0.61
" The pharmacokinetic results indicated that the plasma half-life (t1/2) of amlodipine was 38."	( Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hirai, A; Ichikawa, S; Kanada, S; Kuramoto, K; Nakachi, T; Ogihara, T, 2003)	0.89
" Pharmacokinetic parameters [Cmax, tmax, kel and AUC(0-24)] were calculated for the single dose and for the dose on day 30 and the accumulation index calculated on the basis of AUC(0-24) and Cmax."	( Pharmacokinetics of amlodipine in hypertensive patients undergoing haemodialysis. Kungys, G; Naujoks, H; Wanner, C, 2003)	0.64
"This study was performed to compare the pharmacokinetic (PK) and pharmacodynamic (PD) properties and safety profiles of a newly developed amlodipine formulation with a conventional formulation in healthy male subjects."	( Randomized, open-label, two-period crossover comparison of the pharmacokinetic and pharmacodynamic properties of two amlodipine formulations in healthy adult male Korean subjects. Kim, KA; Kim, SL; Lee, GS; Lee, YS; Lee, YW; Park, JY; Park, PW; Shin, EK, 2004)	0.74
"All subjects completed the study and 90% confidence intervals for relevant pharmacokinetic parameters were within the ranges defined by European and US Regulatory Authorities: the geometric mean and the 90% confidence interval test/reference ratios calculated from log-transformed values were 104."	( Assessment of sex differences in pharmacokinetics and pharmacodynamics of amlodipine in a bioequivalence study. Abad-Santos, F; Almeida, S; Gallego-Sandín, S; Gálvez-Múgica, MA; García, AG; Novalbos, J; Vallée, F, 2005)	0.56
" Although there were no relevant gender-related differences in the pharmacokinetics of amlodipine, women reached higher amlodipine concentrations most likely because of their lower body weight, and therefore, the reported pharmacodynamic effects were higher within this gender group."	( Assessment of sex differences in pharmacokinetics and pharmacodynamics of amlodipine in a bioequivalence study. Abad-Santos, F; Almeida, S; Gallego-Sandín, S; Gálvez-Múgica, MA; García, AG; Novalbos, J; Vallée, F, 2005)	0.78
" We evaluated potential bidirectional pharmacokinetic interactions between calcium channel blockers and coadministered indinavir and ritonavir."	( Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Aberg, JA; Fichtenbaum, CJ; Gerber, JG; Glesby, MJ; Grosskopf, N; Hafner, R; Hall, S; Kendall, MA; Zolopa, AR, 2005)	0.33
" Twenty-four-hour pharmacokinetic collection was performed on days 7 and 26, with 12-hour collection on day 19."	( Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Aberg, JA; Fichtenbaum, CJ; Gerber, JG; Glesby, MJ; Grosskopf, N; Hafner, R; Hall, S; Kendall, MA; Zolopa, AR, 2005)	0.33
"Structural features of amlodipine give the molecule physicochemical and pharmacokinetic properties that are unique among calcium antagonists."	( Amlodipine: pharmacokinetic profile of a low-clearance calcium antagonist. Abernethy, DR, 1991)	2.03
" For example, in vagotomized dogs, the total area under the plasma concentration-time curve from time zero to the last measured time, 48 h, in plasma (AUC(0-48 h)) was significantly greater (725 versus 348 ng h/ml) and Tmax was significantly shorter (1."	( Pharmacokinetics of oral amlodipine orotate in vagotomized dogs. Choi, SM; Chung, HK; Kim, JH; Kim, JO; Kwak, HH; Kwon, JW; Lee, JH; Lee, MG; Yoo, M, 2006)	0.64
"A pharmacokinetic interaction between oral DA-8159 and amlodipine was evaluated in male Sprague-Dawley rats."	( Negligible pharmacokinetic interaction between oral DA-8159, a new erectogenic, and amlodipine in rats. Kim, EJ; Kwon, JW; Lee, JH; Lee, MG; Yoo, M, 2006)	0.81
" The present method provides an accurate, precise and sensitive tool for buspirone and was successfully applied to a pharmacokinetic study in eight subjects."	( Rapid and highly sensitive liquid chromatography/electrospray ionization tandem mass spectrometry method for the quantitation of buspirone in human plasma: application to a pharmacokinetic study. Cho, SH; Choi, YW; Im, HT; Lee, HW; Lee, KT; Park, WS; Rew, JH, 2006)	0.33
"A population pharmacokinetic study was conducted in 74 hypertensive children (mean age 10."	( Population pharmacokinetics of amlodipine in hypertensive children and adolescents. Flynn, JT; Mahan, JD; Nahata, MC; Portman, RJ, 2006)	0.62
" After a single-dose administration of 5 mg amlodipine, plasma concentrations of amlodipine were measured and its pharmacokinetic characteristics were compared according to ABCB1 genotype."	( Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. Kim, KA; Park, JY; Park, PW, 2007)	0.82
" Four open-label studies investigated the pharmacokinetic interactions between aliskiren 300 mg and the antihypertensive drugs amlodipine 10 mg (n = 18), valsartan 320 mg (n = 18), hydrochlorothiazide 25 mg (HCTZ, n = 22) and ramipril 10 mg (n = 17) in healthy subjects."	( Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Bizot, MN; Denouel, J; Dieterich, HA; Dole, WP; Kemp, C; Vaidyanathan, S; Valencia, J; Yeh, CM; Zhao, C, 2006)	0.74
"A novel, specific and sensitive ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method was developed for the determination and pharmacokinetic study of amlodipine in human plasma."	( Determination and pharmacokinetic study of amlodipine in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry. Li, F; Lu, X; Ma, Y; Qin, F; Sun, X, 2007)	0.79
" Blood pressure and pulse rate were also measured for pharmacodynamic analysis."	( Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. Choi, SH; Chun, BG; Kim, KA; Lee, OJ; Min, BH; Park, JY; Park, PW; Shin, JG; Shin, KH, 2006)	0.56
" Here, we evaluated the comparative pharmacokinetic and pharmacodynamic characteristics of the nicotinate and besylate forms of amlodipine."	( Comparative pharmacokinetic and pharmacodynamic characteristics of amlodipine besylate and amlodipine nicotinate in healthy subjects. Ha, MC; Kim, JS; Kim, KA; Lee, GH; Lee, OJ; O, MJ; Park, JH; Park, JY; Park, PW; Ryu, JH, 2006)	0.78
" Blood samples for the pharmacokinetic analysis of amlodipine were obtained over the 144-hour period after administration."	( Comparative pharmacokinetic and pharmacodynamic characteristics of amlodipine besylate and amlodipine nicotinate in healthy subjects. Ha, MC; Kim, JS; Kim, KA; Lee, GH; Lee, OJ; O, MJ; Park, JH; Park, JY; Park, PW; Ryu, JH, 2006)	0.82
" After administering a single dose of each formulation, mean AUC0-infinity and Cmax values were 190."	( Comparative pharmacokinetic and pharmacodynamic characteristics of amlodipine besylate and amlodipine nicotinate in healthy subjects. Ha, MC; Kim, JS; Kim, KA; Lee, GH; Lee, OJ; O, MJ; Park, JH; Park, JY; Park, PW; Ryu, JH, 2006)	0.57
"The two amlodipine formulations showed similar pharmacokinetic and pharmacodynamic characteristics and the new amlodipine formulation, amlodipine nicotinate, was found to be equivalent for pharmacokinetics to the currently available amlodipine besylate with respect to the rate and extent of amlodipine absorption."	( Comparative pharmacokinetic and pharmacodynamic characteristics of amlodipine besylate and amlodipine nicotinate in healthy subjects. Ha, MC; Kim, JS; Kim, KA; Lee, GH; Lee, OJ; O, MJ; Park, JH; Park, JY; Park, PW; Ryu, JH, 2006)	1
"The objective of this study was to compare the pharmacokinetic and pharmacodynamic properties and safety profiles of a newly developed amlodipine formulation, composed wholly of S-amlodipine, with those of the conventionally prescribed racemic formulation."	( Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study. Ha, MC; Kang, SW; Kim, JS; Kim, KA; Lee, GH; Lee, KR; Lee, OJ; Park, JY; Park, PW; Ryu, JH, 2006)	0.78
" Blood samples for pharmacokinetic analysis of S-amlodipine were collected at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours after drug administration."	( Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study. Ha, MC; Kang, SW; Kim, JS; Kim, KA; Lee, GH; Lee, KR; Lee, OJ; Park, JY; Park, PW; Ryu, JH, 2006)	0.83
" The mean (SD) values for Cmax AUC from time 0 to the last available measurement (AUC(last)), and AUC from 0 to infinity (AUC(0-infinity)) for the reference formulation (3."	( Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study. Ha, MC; Kang, SW; Kim, JS; Kim, KA; Lee, GH; Lee, KR; Lee, OJ; Park, JY; Park, PW; Ryu, JH, 2006)	0.57
" The newly developed formulation, comprised of only S-amlodipine, had pharmacodynamic profiles comparable to those of the conventional racemic amlodipine formulation in these healthy Korean male subjects."	( Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study. Ha, MC; Kang, SW; Kim, JS; Kim, KA; Lee, GH; Lee, KR; Lee, OJ; Park, JY; Park, PW; Ryu, JH, 2006)	0.82
" Blood samples for pharmacokinetic profiling were taken up to 144 h post-dose, and amlodipine plasma concentrations were determined with a validated LC-MS/MS method."	( Pharmacokinetics and bioequivalence study of a generic amlodipine tablet formulation in healthy male volunteers. Arnold, P; Erenmemişoğlu, A; Hincal, AA; Kanzik, I; Martin, W; Sailer, R; Tamur, U, 2007)	0.81
"We conducted 3 open-label, multiple-dose, 3-period, randomized, crossover studies in healthy subjects to assess the potential pharmacokinetic interaction between vildagliptin, a novel dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes, and representatives of 3 commonly prescribed antihypertensive drug classes: (1) the calcium channel blocker, amlodipine; (2) the angiotensin receptor blocker, valsartan; and (3) the angiotensin-converting enzyme inhibitor, ramipril."	( Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects. Campestrini, J; Dole, K; Dole, WP; He, YL; Howard, D; Ligueros-Saylan, M; Marion, A; Pommier, F; Sabo, R; Sunkara, G; Wang, Y; Zhao, C, 2008)	0.72
" Potential pharmacodynamic interaction between drugs should be investigated as part of developing single-pill combinations."	( A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. Dykstra, G; Gillen, D; Harvey, P; Herfert, O; Jukema, JW; Preston, RA; Sun, F, 2007)	0.55
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
"Population pharmacokinetic models for amlodipine and olmesartan were developed using data collected from 4 phase I studies in healthy volunteers and 1 phase III study in subjects with mild to severe hypertension."	( Evaluation of population pharmacokinetics and exposure-response relationship with coadministration of amlodipine besylate and olmesartan medoxomil. Carrothers, TJ; Khariton, T; Kshirsagar, S; Lee, J; Rohatagi, S; Salazar, D, 2008)	0.83
" The proposed ITP-CZE-DAD method was characterized by favorable performance parameters (sensitivity, linearity, precision, recovery, accuracy, robustness, selectivity) and successfully applied to an enantioselective pharmacokinetic study of AML."	( Direct quantitative determination of amlodipine enantiomers in urine samples for pharmacokinetic study using on-line coupled isotachophoresis-capillary zone electrophoresis separation method with diode array detection. Havránek, E; Marák, J; Maráková, K; Miks, P; Nemec, I; Valásková, Ia, 2008)	0.62
" Blood samples for pharmacokinetic analysis were collected over a period of 144 h after drug administration."	( Comparative pharmacokinetics of a single oral dose of two formulations of amlodipine. A randomized, single-blind, two-period, two-sequence, crossover study. Caubet, JC; Domínguez, G; Negri, AL; Pico, JC; Terragno, NA, 2008)	0.58
"194) and R-amlodipine also showed 21% higher Cmax in CYP3A51/3 carriers (3."	( Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects. Kim, KA; Park, JY; Park, PW, 2009)	0.97
" From a pharmacokinetic perspective, the 2 drugs are well suited to coadministration in a fixed-dose combination."	( Pharmacokinetics of amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed-dose combination. Allison, M; Bathala, MS; Haworth, S; Heyrman, R; Lee, J; Noveck, R; Rohatagi, S; Rubets, I; Salazar, DE; Shenouda, M, 2008)	0.67
" This novel method has been applied to human pharmacokinetic study."	( Development and validation of a highly sensitive and robust LC-ESI-MS/MS method for simultaneous quantitation of simvastatin acid, amlodipine and valsartan in human plasma: application to a clinical pharmacokinetic study. Mullangi, R; Ramani, AV; Sengupta, P, 2009)	0.56
"The aim of this study was to assess and compare the pharmacokinetic properties, bioavailability, and bioequivalence of a newly developed dispersible tablet formulation of amlodipine besylate with those of an established branded formulation in healthy Chinese adult male volunteers."	( Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. Jia, J; Li, S; Liu, G; Liu, Y; Lu, C; Yu, C, 2009)	0.78
" The amlodipine serum concentration-time curves were used to obtain pharmacokinetic parameters including AUC(0-t), AUC(0-infinity)), and C(max)."	( Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. Jia, J; Li, S; Liu, G; Liu, Y; Lu, C; Yu, C, 2009)	1.1
" On analysis of variance, no period or sequence effects were observed for any pharmacokinetic property; however, a significant formulation effect was observed for C(max), AUC(0-t), and AUC(0-infinity))."	( Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. Jia, J; Li, S; Liu, G; Liu, Y; Lu, C; Yu, C, 2009)	0.58
" Bioequivalence was established for all pharmacokinetic parameters."	( Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. Bolbrinker, J; Huber, M; Kreutz, R; Scholze, J, 2009)	0.58
" The method was successfully applied for a pharmacokinetic study and for the determination of commercial amlodipine tablet content."	( High-performance liquid chromatographic method for quantitative determination of amlodipine in human plasma and pharmaceutical dosage form and its application to pharmacokinetic studies. Alsarra, IA, )	0.57
"This study was conducted to compare the pharmacodynamic (PD) and pharmacokinetic (PK) characteristics of the S-amlodipine formulation (S-amlodipine gentisate) and amlodipine racemate (amlodipine besylate)."	( Pharmacodynamic (hemodynamic) and pharmacokinetic comparisons of S-amlodipine gentisate and racemate amlodipine besylate in healthy Korean male volunteers: two double-blind, randomized, two-period, two-treatment, two-sequence, double-dummy, single-dose cr Jang, IJ; Kim, BH; Kim, JR; Kim, KP; Kim, MG; Lee, BY; Shin, SG; Yu, KS, 2010)	0.81
" The developed assay method was successfully applied to a pharmacokinetic study in human male volunteers."	( Simultaneous determination of atorvastatin, amlodipine, ramipril and benazepril in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. Inamadugu, JK; Karra, VK; Mullangi, R; Pilli, NR; Rao, JV; Vaidya, JR, 2011)	0.63
"To explore if non-concurrent amlodipine dosing results in less drug interaction, the pharmacokinetic profiles, safety and efficacy endpoints were assessed following repeated doses of simvastatin, co-administered concurrently or non-concurrently with amlodipine in patients with coexisting hypertension and hyperlipidemia."	( Non-concurrent dosing attenuates the pharmacokinetic interaction between amlodipine and simvastatin. Choi, JW; Kim, SH; Lee, H; Lee, SJ; Lim, HE; Park, CG, 2010)	0.88
"The Cmax and AUClast and of simvastatin acid in the non-concurrent amlodipine dosing group were 63."	( Non-concurrent dosing attenuates the pharmacokinetic interaction between amlodipine and simvastatin. Choi, JW; Kim, SH; Lee, H; Lee, SJ; Lim, HE; Park, CG, 2010)	0.83
"The steady-state pharmacokinetic (PK) interaction potential between amlodipine (10 mg), valsartan (320 mg), and hydrochlorothiazide (HCTZ; 25 mg) was evaluated in patients with hypertension in a multicenter, multiple-dose, open-label, 4-cohort, parallel-group study."	( Evaluation of pharmacokinetic interactions between amlodipine, valsartan, and hydrochlorothiazide in patients with hypertension. Ayalasomayajula, S; Bhad, P; Jarugula, V; Karan, R; Leon, S; Riviere, GJ; Sunkara, G, 2011)	0.86
" In China, where the prevalence of hypertension is increasing the pharmacokinetic study of valsartan, amlodipine assumes significance."	( Pharmacokinetics of single and multiple oral doses of valsartan/amlodipine (80/5 mg) in healthy Chinese subjects. Chen, J; Duan, J; Karan, R; Meiser, K; Smith, HT; Sunkara, G; Yin, Q, 2012)	0.83
"Following the single-dose oral administration of valsartan/amlodipine 80/5 mg, valsartan and amlodipine plasma concentrations reached peak levels at median tmax of 3 and 6 h, respectively."	( Pharmacokinetics of single and multiple oral doses of valsartan/amlodipine (80/5 mg) in healthy Chinese subjects. Chen, J; Duan, J; Karan, R; Meiser, K; Smith, HT; Sunkara, G; Yin, Q, 2012)	0.86
"To investigate the effects of coadministration of telmisartan and S-amlodipine on the steady-state pharmacokinetic properties of each drug as a drug-drug interaction study required before developing the fixed-dose combination agent."	( Pharmacokinetic interaction of telmisartan with s-amlodipine: an open-label, two-period crossover study in healthy Korean male volunteers. Bae, KS; Choi, HY; Jin, SJ; Kim, MJ; Kim, YH; Lim, HS; Lim, J; Noh, YH; Sung, HR, 2012)	0.87
" The pharmacokinetic properties of each drug after coadministration of telmisartan and S-amlodipine were compared with those of each drug administered alone."	( Pharmacokinetic interaction of telmisartan with s-amlodipine: an open-label, two-period crossover study in healthy Korean male volunteers. Bae, KS; Choi, HY; Jin, SJ; Kim, MJ; Kim, YH; Lim, HS; Lim, J; Noh, YH; Sung, HR, 2012)	0.85
"Following multiple-dose coadministration of high doses of telmisartan and S-amlodipine, the steady-state pharmacokinetic properties of telmisartan were not significantly affected, and telmisartan had no significant effect on the pharmacokinetic properties of S-amlodipine at steady state in these selected groups of healthy volunteers."	( Pharmacokinetic interaction of telmisartan with s-amlodipine: an open-label, two-period crossover study in healthy Korean male volunteers. Bae, KS; Choi, HY; Jin, SJ; Kim, MJ; Kim, YH; Lim, HS; Lim, J; Noh, YH; Sung, HR, 2012)	0.86
" The method was successfully applied to pharmacokinetic studies of amlodipine and bisoprolol in Sprague-Dawley (SD) rats."	( Simultaneous determination of amlodipine and bisoprolol in rat plasma by a liquid chromatography/tandem mass spectrometry method and its application in pharmacokinetic study. Bi, K; Chang, H; Fan, G; Guan, X; Li, J; Qian, Z; Sun, F, 2012)	0.9
"Reasonable sampling scheme is the important basis for establishing reliable population pharmacokinetic model."	( [Modeling and simulation activities to design sampling scheme for population pharmacokinetic study on amlodipine]. Barrett, JS; Di, W; Guo, R; Huang, ZJ; Jing, NN; Ng, CM; Pei, Q; Yang, GP; Yuan, H; Zhang, BK; Zhou, YN; Zuo, XC, 2012)	0.59
" Meanwhile, blood pressure and heart rate were repeatedly taken to delineate the pharmacodynamic profiles."	( Pharmacokinetic and pharmacodynamic profiles of a fixed-dose combination of olmesartan medoxomil and amlodipine in healthy Chinese males and females. Chen, X; Hu, P; Jiang, J; Liu, H; Liu, T; Zhao, Q; Zhong, W, 2012)	0.59
" The elimination half-life of amlodipine is more than twice as long as that of olmesartan."	( Pharmacokinetic and pharmacodynamic profiles of a fixed-dose combination of olmesartan medoxomil and amlodipine in healthy Chinese males and females. Chen, X; Hu, P; Jiang, J; Liu, H; Liu, T; Zhao, Q; Zhong, W, 2012)	0.88
"After single and multiple doses of olmesartan medoxomil/amlodipine 20 mg/5 mg FDC tablets the pharmacokinetic profiles of olmesartan or amlodipine were comparable to those reported for monotherapy with olmesartan medoxomil or amlodipine, except that the elimination half-life of olmesartan was longer because of the longer time course over which pharmacokinetic blood sampling was carried out in this study."	( Pharmacokinetic and pharmacodynamic profiles of a fixed-dose combination of olmesartan medoxomil and amlodipine in healthy Chinese males and females. Chen, X; Hu, P; Jiang, J; Liu, H; Liu, T; Zhao, Q; Zhong, W, 2012)	0.84
" There are significant pharmacokinetic interactions between TAC and AML."	( Effect of amlodipine on the pharmacokinetics of tacrolimus in rats. Cheng, ZN; Li, J; Li, PJ; Liu, Z; Tan, HY; Wang, CJ; Yang, GP; Yang, M; Yuan, H; Zhang, BK; Zhou, LY; Zhou, YN; Zuo, XC, 2013)	0.79
" Pharmacokinetic drug interactions between tacrolimus and amlodipine were evaluated in a randomized, 3-period, 6-sequence crossover study in healthy Chinese volunteers according to CYP3A5 genotype."	( Effect of CYP3A5*3 polymorphism on pharmacokinetic drug interaction between tacrolimus and amlodipine. Barrett, JS; Cheng, ZN; Guo, R; Li, J; Li, PJ; Li, ZJ; Liu, SK; Liu, Z; Ouyang, DS; Tan, HY; Wang, CJ; Wang, JL; Xie, YL; Yang, GP; Yuan, H; Zhang, BK; Zhou, LY; Zhou, YN; Zuo, XC, 2013)	0.85
"The 90% confidence intervals for the test/reference ratio of the pharmacokinetic parameters in fasting state (mean Cmax, AUC0-t, and AUC0-∞) were within the acceptable range of 80."	( A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. Biswas, E; Choudhury, H; Ghosh, B; Gorain, B; Halder, D; Pal, TK; Sarkar, AK; Sarkar, P, 2013)	0.39
" The current assay was successfully applied to a pharmacokinetic study to quantitate AML enantiomers following oral administration of 10 mg AML tablet to humans."	( Rapid quantification of amlodipine enantiomers in human plasma by LC-MS/MS: application to a clinical pharmacokinetic study. Hotha, KK; Mullangi, R; Ravindranath, LK; Roychowdhury, S, 2013)	0.7
"The goal of this study was to compare the pharmacokinetic profiles of single administration of a newly developed FDC tablet containing amlodipine orotate 10 mg and valsartan 160 mg (test formulation) with the conventional FDC tablet of amlodipine besylate 10 mg and valsartan 160 mg (reference formulation) in healthy male Korean volunteers."	( Pharmacokinetic comparison of 2 fixed-dose combination tablets of amlodipine and valsartan in healthy male Korean volunteers: a randomized, open-label, 2-period, single-dose, crossover study. Bahng, MY; Chae, D; Kim, Y; Lee, D; Park, K; Roh, H; Son, H; Son, M, 2013)	0.83
" Blood samples were collected up to 144 hours after the dose, and pharmacokinetic parameters were determined for amlodipine and valsartan."	( Pharmacokinetic comparison of 2 fixed-dose combination tablets of amlodipine and valsartan in healthy male Korean volunteers: a randomized, open-label, 2-period, single-dose, crossover study. Bahng, MY; Chae, D; Kim, Y; Lee, D; Park, K; Roh, H; Son, H; Son, M, 2013)	0.84
" In conclusion, this study has quantitatively described the pharmacokinetic interaction between simvastatin and amlodipine using a modeling approach."	( Development of a pharmacokinetic interaction model for co-administration of simvastatin and amlodipine. Jang, SB; Lee, D; Lim, LA; Park, K; Roh, H; Son, H, 2014)	0.83
" The final population pharmacokinetic model shows that the elimination rate constant for simvastatin acid, the active form by hydrolysis of its lactone prodrug (i."	( Genetic algorithm guided population pharmacokinetic model development for simvastatin, concurrently or non-concurrently co-administered with amlodipine. Chaturvedula, A; Lee, H; Sale, ME, 2014)	0.6
" Meanwhile, the Cmax of amlodipine, losartan and EXP3174 were reduced by 11."	( The influence of food on the pharmacokinetics of amlodipine and losartan after single-dose of its compound tablets in healthy chinese subjects. Guo, R; Li, R; Lv, C; Wang, B; Wang, X; Wei, C; Yao, H, 2014)	0.96
" The objective of this study was to compare the pharmacokinetic (PK) characteristics of S-amlodipine and valsartan when administered as one tablet each of Exforge and AGSAV301 to healthy male subjects."	( Pharmacokinetics, tolerability, and safety of the single oral administration of AGSAV301 vs Exforge: a randomized crossover study of healthy male volunteers. Bae, KS; Choi, HY; Kim, MJ; Kim, YH; Lee, SH; Lim, HS; Noh, YH, 2014)	0.62
" Population pharmacokinetic analyses were performed on data which were collected prospectively from 60 Chinese patients with mild to moderate essential hypertension [age range 40-74 years, males (n = 31), females (n = 29)] receiving oral racemic amlodipine for 4 weeks."	( ABCB1 polymorphism and gender affect the pharmacokinetics of amlodipine in Chinese patients with essential hypertension: a population analysis. Barrett, JS; Guo, CX; Hua, Y; Huang, ZJ; Pei, Q; Wang, JL; Yang, GP; Yuan, H; Zhang, WL; Zhou, HH; Zuo, XC, 2014)	0.83
"The aim of this study was to compare pharmacokinetic characteristics of fixed-dose combination (FDC) of two different salt form of amlodipine, amlodipine adipate/valsartan and amlodipine besylate/ valsartan, in healthy Korean volunteers under fasting conditions."	( Pharmacokinetic comparison of amlodipine adipate/valsartan fixed-dose combination with amlodipine besylate/valsartan fixed-dose combination in healthy volunteers. Ghim, JL; Han, SK; Kim, EJ; Kim, EY; Kim, HJ; Kim, HS; Nam, JH; Oh, M; Shin, JG; Song, GS, 2015)	0.91
"This study aimed to quantify the pharmacokinetic drug-drug interaction between CsA and nicardipine, amlodipine, and lacidipine."	( Pharmacokinetic drug-drug interaction of calcium channel blockers with cyclosporine in hematopoietic stem cell transplant children. Bernard, E; Bertrand, Y; Bleyzac, N; Goutelle, S, 2014)	0.62
" This study was performed to determine the pharmacokinetic (PK) interaction between RG and amlodipine, an antihypertensive drug."	( Negligible pharmacokinetic interaction of red ginseng and antihypertensive agent amlodipine in Sprague-Dawley rats. Cho, YB; Jeong, WS; Kim, JW; Kim, KB; Kim, YG; Kim, YS; Lee, HK; Lee, SH; Ryu, SH, 2014)	0.85
" The aim of the ROMAN study was to compare the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in clopidogrel treated patients with CAD."	( Comparison of the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in stable patients with coronary artery disease treated with dual antiplatelet therapy : The ROMAN (RanOlazine vs. aMlodipine on platelet reactivity in stable Angiolillo, DJ; Gaudio, C; Greco, C; Marazzi, G; Pelliccia, F; Rollini, F; Rosano, G; Vitale, C, 2015)	0.88
"Volume of distribution is one of the most important pharmacokinetic properties of a drug candidate."	( Volume of Distribution in Drug Design. Beaumont, K; Di, L; Maurer, TS; Smith, DA, 2015)	0.42
" We evaluated the pharmacokinetic interactions between lobeglitazone and amlodipine in healthy male Korean subjects."	( Pharmacokinetic Interaction Between Amlodipine and Lobeglitazone, a Novel Peroxisome Proliferator-activated Receptor-γ Agonist, in Healthy Subjects. Kim, C; Kim, CO; Park, MS; Sil Oh, E, 2015)	0.92
" Thus, 21 participants completed the study schedule to compare the pharmacokinetic parameters of lobeglitazone, and 22 participants completed the study of amlodipine."	( Pharmacokinetic Interaction Between Amlodipine and Lobeglitazone, a Novel Peroxisome Proliferator-activated Receptor-γ Agonist, in Healthy Subjects. Kim, C; Kim, CO; Park, MS; Sil Oh, E, 2015)	0.89
"To determine whether a potential pharmacokinetic interaction exists between perindopril arginine 5 mg and amlodipine 5 mg, after administration as a fixed-combination of perindopril 5 mg/amlodipine 5 mg (S05985)."	( Investigation of a potential pharmacokinetic interaction between perindopril arginine and amlodipine when administered as a single perindopril/amlodipine fixed-dose combination tablet in healthy Chinese male volunteers. Chen, X; Hu, P; Jiang, J; Liu, T; Zheng, X, 2016)	0.87
" Serial blood samples were collected in each treatment period for determination of plasma amlodipine, perindopril, and perindoprilat concentrations and for calculation of the respective pharmacokinetic parameters (AUC(0-∞), AUC(0-t), C(max), and t(max))."	( Investigation of a potential pharmacokinetic interaction between perindopril arginine and amlodipine when administered as a single perindopril/amlodipine fixed-dose combination tablet in healthy Chinese male volunteers. Chen, X; Hu, P; Jiang, J; Liu, T; Zheng, X, 2016)	0.88
" The aim of this study was to study the pharmacokinetics of amlodipine after oral administration of amlodipine and GLT and to investigate the potential for pharmacokinetic herb-drug interactions between GLT and amlodipine in rats."	( Effect of Ginkgo Leaf Tablets on the Pharmacokinetics of Amlodipine in Rats. Chai, Y; Sun, S; Wang, R; Wang, Y; Yuan, Y; Zhang, H, 2016)	0.92
" Plasma concentrations of amlodipine were determined at the designated time points after oral administration by using the developed LC-MS/MS method, and the main pharmacokinetic parameters were calculated and compared."	( Effect of Ginkgo Leaf Tablets on the Pharmacokinetics of Amlodipine in Rats. Chai, Y; Sun, S; Wang, R; Wang, Y; Yuan, Y; Zhang, H, 2016)	0.98
" In 3 separate studies, pharmacokinetic drug-drug interactions (DDIs) potential was assessed when LCZ696 was coadministered with hydrochlorothiazide (HCTZ), amlodipine, or carvedilol."	( Pharmacokinetic drug-drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol. Greeley, M; Hsiao, HL; Langenickel, TH; Pal, P; Rajman, I; Rebello, S; Roberts, J; Sunkara, G; Zhou, W, 2015)	0.82
"Our data show a potential pharmacokinetic interaction, most likely via CYP3A4 between amlodipine and RIS, reflected in significantly different C/Ds for RIS, 9-OH-RIS and AM."	( Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions. Gründer, G; Haen, E; Lammertz, SE; Paulzen, M; Schoretsanitis, G; Schruers, KR; Stegmann, B; Walther, S, 2016)	0.66
" However, the pharmacokinetic interactions among these 3 substances are not well understood."	( Pharmacokinetic Interaction Between Rosuvastatin, Telmisartan, and Amlodipine in Healthy Male Korean Subjects: A Randomized, Open-label, Multiple-dose, 2-period Crossover Study. Guk, J; Heo, YA; Kim, Y; Park, K; Soh, D; Son, M; Woo Chae, D, 2016)	0.67
" Pharmacokinetic samples were collected up to 72 hours after the last dose in subjects who received rosuvastatin only, and up to 144 hours after the last dose in subjects who received telmisartan/amlodipine with or without rosuvastatin."	( Pharmacokinetic Interaction Between Rosuvastatin, Telmisartan, and Amlodipine in Healthy Male Korean Subjects: A Randomized, Open-label, Multiple-dose, 2-period Crossover Study. Guk, J; Heo, YA; Kim, Y; Park, K; Soh, D; Son, M; Woo Chae, D, 2016)	0.86
"These results demonstrate that when rosuvastatin, telmisartan, and amlodipine are coadministered to healthy male subjects, pharmacokinetic exposure increases with respect to rosuvastatin and telmisartan, whereas no change occurs with respect to amlodipine."	( Pharmacokinetic Interaction Between Rosuvastatin, Telmisartan, and Amlodipine in Healthy Male Korean Subjects: A Randomized, Open-label, Multiple-dose, 2-period Crossover Study. Guk, J; Heo, YA; Kim, Y; Park, K; Soh, D; Son, M; Woo Chae, D, 2016)	0.91
" Single oral dose of amlodipine was administered to the hypertensive/normotensive subjects either morning or evening to assess the pharmacokinetic profile after morning dosing or evening dosing, respectively."	( Evaluation of the effect of time dependent dosing on pharmacokinetic and pharmacodynamics of amlodipine in normotensive and hypertensive human subjects. Hs, S; Khodadoustan, S; Kumar, C; Nasri Ashrafi, I; S, C; Vanaja Satheesh, K, 2017)	0.99
" The aim of the present study was to evaluate in vivo pharmacokinetic (PK) interaction between allopathic drugs tolbutamide (TOLBU), amlodipine (AMLO), and phenacetin (PHENA) at low (L) and high (H) doses with ethanolic extract (EL) from GS."	( In vivo pharmacokinetic interaction by ethanolic extract of Gymnema sylvestre with CYP2C9 (Tolbutamide), CYP3A4 (Amlodipine) and CYP1A2 (Phenacetin) in rats. Kharkar, P; Pandita, N; Sahu, N; Vaghela, M, 2017)	0.87
"This study compared the pharmacokinetic (PK) and safety profiles of a fixed-dose combination (FDC) formulation of telmisartan and S-amlodipine with those of concomitant administration of the two drugs."	( Comparative pharmacokinetics of a fixed-dose combination vs concomitant administration of telmisartan and S-amlodipine in healthy adult volunteers. Choi, YK; Ghim, JL; Kim, EY; Oh, M; Park, SE; Shim, EJ; Shin, JG, 2017)	0.87
" Ritonavir (RTV) is a potent mechanism-based and reversible CYP3A inhibitor and moderate inducer that is used as a pharmacokinetic enhancer in several antiviral treatment regimens."	( Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model. Menon, RM; Mukherjee, D; Shebley, M; Zha, J, 2018)	0.78
"Amlodipine is rarely used in the treatment of pregnant hypertensive women due to limited pharmacokinetic data during pregnancy and the postpartum period."	( Pharmacokinetics of amlodipine besylate at delivery and during lactation. Kogutt, BK; McIntire, DD; Meek, C; Morgan, JL; Roberts, SW; Sheffield, JS; Stehel, EK, 2018)	2.25
" A one compartment, first-order model was used to calculate pharmacokinetic estimates for maternal plasma."	( Pharmacokinetics of amlodipine besylate at delivery and during lactation. Kogutt, BK; McIntire, DD; Meek, C; Morgan, JL; Roberts, SW; Sheffield, JS; Stehel, EK, 2018)	0.8
" In the immediate postpartum period, the amlodipine elimination half-life was 13."	( Pharmacokinetics of amlodipine besylate at delivery and during lactation. Kogutt, BK; McIntire, DD; Meek, C; Morgan, JL; Roberts, SW; Sheffield, JS; Stehel, EK, 2018)	1.07
" Although of special clinical relevance, data on pharmacokinetic interactions between AMLO, RAMI, and venlafaxine (VEN) are lacking."	( How to Treat Hypertension in Venlafaxine-Medicated Patients-Pharmacokinetic Considerations in Prescribing Amlodipine and Ramipril. Augustin, M; Gründer, G; Haen, E; Paulzen, M; Schoretsanitis, G, 2018)	0.69
" Pharmacokinetic assessments were performed over 48 hours for candesartan in part 1 and 72 hours for amlodipine in part 2 after drug administration on Day 10."	( No pharmacokinetic interactions between candesartan and amlodipine following multiple oral administrations in healthy subjects. Huh, W; Kim, JR; Kim, S; Ko, JW, 2018)	0.94
"This study was conducted to compare the pharmacokinetic profiles of the bisoprolol-amlodipine FDC tablet with the bisoprolol tablet and amlodipine tablet administered concomitantly under both fasting and fed conditions."	( Bioequivalence and Pharmacokinetics of Bisoprolol-Amlodipine 5 mg/5 mg Combination Tablet versus Bisoprolol 5 mg Tablet and Amlodipine 5 mg Tablet: An Open-Label, Randomized, Two-Sequence Crossover Study in Healthy Chinese Subjects. Chen, X; Gao, D; Hu, C; Hu, X; Huang, Y; Li, L; Wang, C; Zhang, L; Zhao, Z; Zhou, D, 2018)	0.96
"To build a physiologically based pharmacokinetic (PBPK) model for fimasartan, amlodipine, and hydrochlorothiazide, and to investigate the drug-drug interaction (DDI) potentials."	( Physiologically Based Pharmacokinetic Modeling of Fimasartan, Amlodipine, and Hydrochlorothiazide for the Investigation of Drug-Drug Interaction Potentials. Jeon, I; Kim, E; Lee, HA; Lee, S; Rhee, SJ; Song, IS; Yu, KS, 2018)	0.95
"The predicted-to-observed ratios of all the pharmacokinetic parameters met the acceptance criterion."	( Physiologically Based Pharmacokinetic Modeling of Fimasartan, Amlodipine, and Hydrochlorothiazide for the Investigation of Drug-Drug Interaction Potentials. Jeon, I; Kim, E; Lee, HA; Lee, S; Rhee, SJ; Song, IS; Yu, KS, 2018)	0.72
" The aim of this study was to investigate the possible pharmacokinetic drug-drug interactions between amlodipine, valsartan, and rosuvastatin in healthy Korean male volunteers."	( Pharmacokinetic Drug Interactions Between Amlodipine, Valsartan, and Rosuvastatin in Healthy Volunteers. Cho, S; Gwon, MR; Kang, WY; Kim, BK; Lee, HW; Ohk, B; Seong, SJ; Yang, DH; Yoon, YR, 2019)	0.99
"When amlodipine, valsartan, and rosuvastatin were coadministered to healthy volunteers, the pharmacokinetic exposure to valsartan was decreased, but no change in exposure to amlodipine and rosuvastatin occurred."	( Pharmacokinetic Drug Interactions Between Amlodipine, Valsartan, and Rosuvastatin in Healthy Volunteers. Cho, S; Gwon, MR; Kang, WY; Kim, BK; Lee, HW; Ohk, B; Seong, SJ; Yang, DH; Yoon, YR, 2019)	1.29
" The objective of this study was to evaluate the pharmacokinetic interaction between telmisartan/amlodipine fixed dose combination and rosuvastatin in healthy Korean male volunteers."	( Pharmacokinetic interactions between telmisartan/amlodipine and rosuvastatin after multiple oral administrations in healthy Korean male subjects. Jang, K; Jeon, JY; Kim, MG; Lim, Y; Moon, SJ; Yu, KS, 2019)	0.99
"The pharmacokinetic parameters of telmisartan/amlodipine, but not rosuvastatin, met the pharmacokinetic equivalent criteria."	( Pharmacokinetic interactions between telmisartan/amlodipine and rosuvastatin after multiple oral administrations in healthy Korean male subjects. Jang, K; Jeon, JY; Kim, MG; Lim, Y; Moon, SJ; Yu, KS, 2019)	1.03
"This study was performed to compare the single-dose pharmacokinetic properties and safety of DP-R212 (FDC of amlodipine and rosuvastatin) to those of each agent co-administered in healthy Korean subjects."	( Pharmacokinetic and bioequivalence study of a fixed-dose combination of amlodipine besylate and rosuvastatin calcium compared to co-administration of separate tablets in healthy Korean subjects . Jeon, JY; Kim, MG; Park, JS, 2019)	0.96
"Both drugs were safe and well tolerated, and the pharmacokinetic profiles were comparable between the treatments."	( Pharmacokinetic and bioequivalence study of a fixed-dose combination of amlodipine besylate and rosuvastatin calcium compared to co-administration of separate tablets in healthy Korean subjects . Jeon, JY; Kim, MG; Park, JS, 2019)	0.75
" The objective of this study was to evaluate the pharmacokinetic interaction among telmisartan, amlodipine, and hydrochlorothiazide."	( Pharmacokinetic Interaction Among Telmisartan, Amlodipine, and Hydrochlorothiazide After a Single Oral Administration in Healthy Male Subjects. Jeon, JY; Kim, MG; Moon, SJ; Yu, KS, 2019)	0.99
"The pharmacokinetic parameters of telmisartan, amlodipine, and hydrochlorothiazide when administered separately or co-administered were compared, and all the parameters met the criteria for pharmacokinetic equivalence."	( Pharmacokinetic Interaction Among Telmisartan, Amlodipine, and Hydrochlorothiazide After a Single Oral Administration in Healthy Male Subjects. Jeon, JY; Kim, MG; Moon, SJ; Yu, KS, 2019)	1.03
" The comparative pharmacokinetic study was performed to compare the profile of an FDC tablet formulation of amlodipine/losartan/rosuvastatin with that of concomitant administration of a currently marketed FDC tablet of amlodipine/losartan with a rosuvastatin tablet."	( Comparison of Pharmacokinetics of a Fixed-Dose Combination of Amlodipine/Losartan/Rosuvastatin with Concomitant Administration of Amlodipine/Losartan and Rosuvastatin in Healthy Volunteers. Chung, JY; Jang, IJ; Jung, JA; Kim, YI; Park, SI; Yoon, DY, 2020)	1.01
" Blood samples were collected for up to 144 h post dose for pharmacokinetic evaluations."	( Comparison of Pharmacokinetics of a Fixed-Dose Combination of Amlodipine/Losartan/Rosuvastatin with Concomitant Administration of Amlodipine/Losartan and Rosuvastatin in Healthy Volunteers. Chung, JY; Jang, IJ; Jung, JA; Kim, YI; Park, SI; Yoon, DY, 2020)	0.8
"We confirmed the pharmacokinetic equivalence of the FDC and LC treatments."	( Comparison of Pharmacokinetics of a Fixed-Dose Combination of Amlodipine/Losartan/Rosuvastatin with Concomitant Administration of Amlodipine/Losartan and Rosuvastatin in Healthy Volunteers. Chung, JY; Jang, IJ; Jung, JA; Kim, YI; Park, SI; Yoon, DY, 2020)	0.8
"The aim of this study was to investigate the effects of P450 oxidoreductase (POR) genetic polymorphisms on the pharmacokinetic parameters of amlodipine."	( Effects of cytochrome P450 oxidoreductase genotypes on the pharmacokinetics of amlodipine in healthy Korean subjects. Chung, JE; Gwak, HS; Han, JM; Lee, KE; Park, K; Yee, J, 2020)	0.99
"The performance of "trough sampling before reaching steady-state" and "serial sampling beyond the interval between steady-state" in a multiple-dose pharmacokinetic evaluation was compared."	( Contribution of Trough Concentration Data in the Evaluation of Multiple-Dose Pharmacokinetics for Drugs with Delayed Distributional Equilibrium and Long Half-Life. Choi, S; Han, S; Jeon, S; Yim, DS, 2020)	0.56
"Amlodipine pharmacokinetic data were collected from a human pharmacology study performed in Seoul St."	( Contribution of Trough Concentration Data in the Evaluation of Multiple-Dose Pharmacokinetics for Drugs with Delayed Distributional Equilibrium and Long Half-Life. Choi, S; Han, S; Jeon, S; Yim, DS, 2020)	2
" With informative trough samples, extended hospitalization for serial sampling (until 3-5 half-lives after the last dose), which is particularly problematic for long half-life drugs, may be avoided."	( Contribution of Trough Concentration Data in the Evaluation of Multiple-Dose Pharmacokinetics for Drugs with Delayed Distributional Equilibrium and Long Half-Life. Choi, S; Han, S; Jeon, S; Yim, DS, 2020)	0.56
" Repeat dose pharmacokinetic and pharmacodynamic study of the nano-fixed dose combination (FDC) was done in dexamethasone-induced animal model."	( Pharmacokinetic and pharmacodynamic evaluation of nano-fixed dose combination for hypertension. Bhandari, RK; Bhatia, A; Kaur, N; Malhotra, S; Pandey, AK; Rather, IIG; Shafiq, N; Sharma, S, 2020)	0.56
" In pharmacokinetic analysis a sustained-release for 7 days was observed in nano-FDC group."	( Pharmacokinetic and pharmacodynamic evaluation of nano-fixed dose combination for hypertension. Bhandari, RK; Bhatia, A; Kaur, N; Malhotra, S; Pandey, AK; Rather, IIG; Shafiq, N; Sharma, S, 2020)	0.56
" sativa with amlodipine improved the pharmacological response of amlodipine in hypertensive rats, though there was no remarkable change in pharmacokinetic parameters (Cmax, Kel, elimination t1/2, and AUC0-t)."	( Effect of Nigella sativa and Fenugreek on the Pharmacokinetics and Pharmacodynamics of Amlodipine in Hypertensive Rats. Ahad, A; Al-Jenoobi, FI; Al-Mohizea, AM; Alam, MA; Bin Jardan, YA; Raish, M, 2020)	1.15
"A population pharmacokinetic analysis was developed using non-linear mixed effect modelling (NONMEM) and included 163 amlodipine concentrations from 55 PLWH."	( Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs. Alves Saldanha, S; Buclin, T; Cavassini, M; Courlet, P; Csajka, C; Decosterd, LA; Guidi, M; Marzolini, C; Stoeckle, M, 2021)	1.05
" The objective of this study was to compare the pharmacokinetic (PK) profiles of HCP1401, a fixed-dose combination of amlodipine 5 mg, losartan 100 mg, and chlorthalidone 25 mg, with the separate components (loose combination) of amlodipine/losartan 5/100 mg and chlorthalidone 25 mg."	( Pharmacokinetics of a Fixed-Dose Combination of Amlodipine/Losartan and Chlorthalidone Compared to Concurrent Administration of the Separate Components. Choi, Y; Chung, JY; Jeon, I; Jung, J; Moon, SJ; Park, SI; Yu, KS, 2022)	1.19
" These herbs also influenced the Cmax, AUC0-t, and Tmax of amlodipine."	( Effect of Hibiscus sabdariffa and Zingiber officinale on pharmacokinetics and pharmacodynamics of amlodipine. Ahad, A; Al-Jenoobi, FI; Al-Mohizea, AM; Alam, MA; Alzenaidy, B; Bin Jardan, YA; Raish, M, 2021)	1.08
" sabdariffa with amlodipine, improves its pharmacodynamic response."	( Effect of Hibiscus sabdariffa and Zingiber officinale on pharmacokinetics and pharmacodynamics of amlodipine. Ahad, A; Al-Jenoobi, FI; Al-Mohizea, AM; Alam, MA; Alzenaidy, B; Bin Jardan, YA; Raish, M, 2021)	1.18
"This study aimed to evaluate the bioequivalence of 2 amlodipine besylate tablet formulations, a generic formulation and an original formulation, and to investigate their pharmacokinetic and safety profiles."	( Pharmacokinetics, Bioequivalence, and Safety Studies of Amlodipine Besylate in Healthy Subjects. Chen, B; Chen, H; Chen, Z; Lv, D; Sun, Y, 2022)	1.22
" This study aimed to examine the pharmacokinetic drug interaction between tadalafil and amlodipine and the tolerability of their combined administration in healthy male subjects."	( Pharmacokinetic Drug Interaction Between Amlodipine and Tadalafil: An Open-Label, Randomized, Multiple-Dose Crossover Study in Healthy Male Volunteers. Hong, S; Jung, J; Kim, H; Lee, SH; Lim, HS, 2022)	1.21
" Pharmacokinetic parameters were calculated using non-compartmental analysis."	( Pharmacokinetic Drug Interaction Between Amlodipine and Tadalafil: An Open-Label, Randomized, Multiple-Dose Crossover Study in Healthy Male Volunteers. Hong, S; Jung, J; Kim, H; Lee, SH; Lim, HS, 2022)	0.99
"A substantial pharmacokinetic drug interaction between tadalafil and amlodipine was observed with respect to the concentration of tadalafil when administered concomitantly."	( Pharmacokinetic Drug Interaction Between Amlodipine and Tadalafil: An Open-Label, Randomized, Multiple-Dose Crossover Study in Healthy Male Volunteers. Hong, S; Jung, J; Kim, H; Lee, SH; Lim, HS, 2022)	1.22

Excerpt	Reference	Relevance
"The antihypertensive and metabolic effects of amlodipine, a new calcium-channel blocker, in combination with hydrochlorothiazide (HCTZ) were compared with those of HCTZ in combination with placebo."	( Antihypertensive effectiveness of amlodipine in combination with hydrochlorothiazide. Chrysant, C; Chrysant, SG; Hitchcock, A; Trus, J, 1989)	0.81
" Therefore, acute intravenous administration of amlodipine alone or in combination with a beta-blocker does not appear to compromise left ventricular performance, sinus node function, or intracardiac conduction."	( Evaluation of the acute hemodynamic and electrophysiologic effects of intravenous amlodipine alone and in combination with a beta-blocker in patients with angina pectoris. Epstein, AE; Kay, GN; Plumb, V; Vetrovec, GW, 1993)	0.77
"This prospective, randomized study assessed the safety and efficacy of metoprolol alone or combined with amlodipine on hemodynamic parameters at baseline, 2 hours after the first dose of study medication, and after 12 weeks of therapy in patients receiving background triple therapy for mild to severe heart failure."	( Short-term and long-term hemodynamic and clinical effects of metoprolol alone and combined with amlodipine in patients with chronic heart failure. Buchholz-Varley, C; Freudenberger, RS; Kalman, J; Kukin, ML; Mannino, MM; Ocampo, ON; Steinmetz, M, 1999)	0.74
"This multicenter study evaluated the efficacy of candesartan cilexetil, an angiotensin II type 1 receptor antagonist, used alone or in combination with amlodipine or in combination with amlodipine and hydrochlorothiazide in the treatment of patients with moderate-to-severe essential hypertension."	( Efficacy of candesartan cilexetil alone or in combination with amlodipine and hydrochlorothiazide in moderate-to-severe hypertension. UK and Israel Candesartan Investigators. Antonios, TF; He, FJ; MacGregor, GA; Viskoper, JR, 2000)	0.75
"To investigate the effects of the mixed endothelin receptor antagonist, bosentan, combined with the long-acting calcium channel blocker, amlodipine, compared to the angiotensin-converting enzyme inhibitor, cilazapril, on the progressive renal injury in spontaneous hypertensive rats (SHR) with diabetes."	( Endothelin receptor antagonist combined with a calcium channel blocker attenuates renal injury in spontaneous hypertensive rats with diabetes. Chen, J; Gu, Y; Lin, F; Lin, S; Ma, J; Yang, H; Zhu, W, 2002)	0.52
"Bosentan combined with amlodipine can offer similar renoprotective effects on that of cilazapril and may be a potent therapy to attenuate renal injury by reducing renal protein levels of TGF-beta1 in diabetes with a hypertensive state."	( Endothelin receptor antagonist combined with a calcium channel blocker attenuates renal injury in spontaneous hypertensive rats with diabetes. Chen, J; Gu, Y; Lin, F; Lin, S; Ma, J; Yang, H; Zhu, W, 2002)	0.63
"The aim of this study was to compare the time-effect profiles of a once-daily administration of valsartan and amlodipine, each given alone or in combination with hydrochlorothiazide, in terms of ambulatory blood pressure (BP) and heart rate in elderly patients with isolated systolic hypertension."	( Comparison of the effects on 24-h ambulatory blood pressure of valsartan and amlodipine, alone or in combination with a low-dose diuretic, in elderly patients with isolated systolic hypertension (Val-syst Study). Ambrosia, GB; Caiazza, A; Malacco, E; Mugellini, A; Palatini, P; Santonastaso, M; Spagnuolo, V, 2004)	0.76
"These results suggest that olmesartan medoxomil combined with amlodipine is effective and well tolerated in reducing BP in patients with moderate to severe hypertension."	( Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Brommer, P; Haag, U; Miele, C; Volpe, M, 2009)	0.83
"To investigate the effects of amlodipine, a dihydropyridine calcium-channel blocker, alone or combined with terazosin, on urodynamics in rats with benign prostatic hyperplasia (BPH) and in female rats with detrusor instability (DI)."	( Amlodipine alone or combined with terazosin improves lower urinary tract disorder in rat models of benign prostatic hyperplasia or detrusor instability: focus on detrusor overactivity. Chen, GL; Liu, HP; Liu, P; Xu, XP, 2009)	2.08
" The rats were intragastrically administered with assigned drugs (amlodipine, terazosin or both combined) for 14 days in three experiments."	( Amlodipine alone or combined with terazosin improves lower urinary tract disorder in rat models of benign prostatic hyperplasia or detrusor instability: focus on detrusor overactivity. Chen, GL; Liu, HP; Liu, P; Xu, XP, 2009)	2.03
"Amlodipine alone or combined with terazosin might have the potential to alleviate lower urinary tract symptoms (LUTS)."	( Amlodipine alone or combined with terazosin improves lower urinary tract disorder in rat models of benign prostatic hyperplasia or detrusor instability: focus on detrusor overactivity. Chen, GL; Liu, HP; Liu, P; Xu, XP, 2009)	3.24
"Amlodipine alone or combined with terazosin can improve the PVR of the LUTS patient effectively, but had no significant difference compared with terazosin."	( [Amlodipine combined with terazosin reduces postvoid residual and the risk of acute urinary retention]. Fang, J; Li, YL; Liu, HP; Qin, XH; Xu, XP; Yang, C; Zhang, X, 2009)	2.71
"We hypothesized that atorvastatin combined with amlodipine has additive beneficial vascular and metabolic effects that are superior to monotherapy in patients with hypertension."	( Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension. Han, SH; Kim, SJ; Koh, KK; Koh, Y; Lee, Y; Park, JB; Quon, MJ; Shin, EK, 2011)	0.87
"Atorvastatin combined with amlodipine therapy improves endothelial function and increases adiponectin levels and insulin sensitivity to a greater extent than monotherapy with either drug in hypertensive patients."	( Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension. Han, SH; Kim, SJ; Koh, KK; Koh, Y; Lee, Y; Park, JB; Quon, MJ; Shin, EK, 2011)	0.91
" We analysed pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in two separate studies."	( Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. Bolbrinker, J; Huber, M; Kreutz, R; Scholze, J, 2009)	0.8
"59 patients with bronchial asthma (BA) combined with hypertension have been observed."	( [Level of steroid hormones in patients with bronchial asthma combined with hypertension and their dynamics after using antihypertensive medications]. Altunina, NV; Lyzohub, VH, )	0.13
" The present study was designed to investigate whether calcium channel blockers (CCBs) in combination with an ARB differentially affect kidney function."	( Renoprotective effect of calcium channel blockers in combination with an angiotensin receptor blocker in elderly patients with hypertension. A randomized crossover trial between benidipine and amlodipine. Dohi, Y; Kimura, G; Miyagawa, K; Nakazawa, A; Sato, K; Sugiura, T; Yamashita, S, 2010)	0.55
"In patients with hypertension and metabolic syndrome, manidipine, both alone and in combination with the ACE inhibitor lisinopril, is significantly superior to amlodipine for improving insulin sensitivity as well as several metabolic, inflammatory and prothrombotic markers."	( Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: the MARCADOR study. Comi-Diaz, C; Macias-Batista, A; Martinez-Martin, FJ; Pedrianes-Martin, P; Rodriguez-Rosas, H; Soriano-Perera, P, 2011)	0.57
" The aim of this study was to evaluate the effects of losartan or amlodipine alone or combined with simvastatin on hepatic steatosis degree, and on insulin sensitivity in normocholesterolemic, hypertensive patients with nonalcoholic hepatic steatosis."	( Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. Derosa, G; Fogari, R; Lazzari, P; Maffioli, P; Mugellini, A; Zoppi, A, 2012)	0.92
" Mean extraction recoveries of three QCs for the triple drug combination were 76."	( Simple RP-HPLC method for determination of triple drug combination of valsartan, amlodipine and hydrochlorothiazide in human plasma. Pancholi, SS; Sharma, RN, 2012)	0.61
"To compare the effects of valsartan combined with amlodipine or hydrochlorothiazide regimen on blood pressure variation and plasma nitric oxide (NO) and endothelin (ET) in elderly hypertensive patients."	( [Effects of valsartan combined with amlodipine or hydrochlorothiazide regimen on blood pressure variation in elderly hypertensive patients]. Sun, CX; Tao, CW; Wu, ZB; Yu, QG; Zhang, Y, 2012)	0.91
"Valsartan in combination with amlodipine or hydrochlorothiazide can both effectively lower BPV in elderly hypertensive patients and improve the vascular endothelial function and the former regimen is more suitable for elderly hypertensive patients."	( [Effects of valsartan combined with amlodipine or hydrochlorothiazide regimen on blood pressure variation in elderly hypertensive patients]. Sun, CX; Tao, CW; Wu, ZB; Yu, QG; Zhang, Y, 2012)	0.94
"We compared the effects of exercise alone and in combination with a calcium channel blocker (amlodipine) or an angiotensin receptor blocker (valsartan) in hypertensive patients."	( Effects of exercise therapy alone and in combination with a calcium channel blocker or an angiotensin receptor blocker in hypertensive patients. Ikeda, M; Ohta, M; Tajiri, Y; Yamato, H, 2012)	0.6
"To investigate the effects and safety of Western medicine combined with Chinese medicine (CM) based on syndrome differentiation in the treatment of elderly polarized hypertension (PHPT), or isolated systolic hypertension with low diastolic blood pressure (DBP)."	( Clinical study of western medicine combined with Chinese medicine based on syndrome differentiation in the patients with polarized hypertension. Chen, SL; Chen, XL; Liu, XY; Mei, WY; Xu, WM, 2012)	0.38
"A total of 125 elderly patients with PHPT were randomly assigned to two groups: 59 in the control group treated by Western medicine and 66 in the intervention group treated by Western medicine combined with CM treatment."	( Clinical study of western medicine combined with Chinese medicine based on syndrome differentiation in the patients with polarized hypertension. Chen, SL; Chen, XL; Liu, XY; Mei, WY; Xu, WM, 2012)	0.38
"Western medicine combined with CM treatment based on syndrome differentiation was safer and more effective than Western medicine alone in the treatment of elderly PHPT, because it not only reduced SBP but also improved DBP, which might lower the incidence of the cardiovascular and cerebrovascular events."	( Clinical study of western medicine combined with Chinese medicine based on syndrome differentiation in the patients with polarized hypertension. Chen, SL; Chen, XL; Liu, XY; Mei, WY; Xu, WM, 2012)	0.38
"The objective of this study was to evaluate the effect of the CYP3A5*3 allele on the pharmacokinetics of tacrolimus and amlodipine, and drug-drug interactions between them in healthy subjects."	( Effect of CYP3A5*3 polymorphism on pharmacokinetic drug interaction between tacrolimus and amlodipine. Barrett, JS; Cheng, ZN; Guo, R; Li, J; Li, PJ; Li, ZJ; Liu, SK; Liu, Z; Ouyang, DS; Tan, HY; Wang, CJ; Wang, JL; Xie, YL; Yang, GP; Yuan, H; Zhang, BK; Zhou, LY; Zhou, YN; Zuo, XC, 2013)	0.82
" The application of SOHGA for automated model selection, combined with traditional model selection strategies, appears to save time for model development, which also can generate new hypotheses that are biologically more plausible."	( Genetic algorithm guided population pharmacokinetic model development for simvastatin, concurrently or non-concurrently co-administered with amlodipine. Chaturvedula, A; Lee, H; Sale, ME, 2014)	0.6
"Four simple, accurate, reproducible, and selective methods have been developed and subsequently validated for the determination of Benazepril (BENZ) alone and in combination with Amlodipine (AML) in pharmaceutical dosage form."	( Comparative study between univariate spectrophotometry and multivariate calibration as analytical tools for quantitation of Benazepril alone and in combination with Amlodipine. Elaziz, OA; Farouk, M; Hemdan, A; Shehata, MA; Tawakkol, SM, 2014)	0.79
"The current study addresses the 24-h antihypertensive efficacy and safety of arotinolol combined with a different calcium channel blocker."	( The efficacy and safety of arotinolol combined with a different calcium channel blocker in the treatment of Chinese patients with essential hypertension: a one-year follow-up study. Chen, W; Fang, H; Liu, X; Xu, W, 2014)	0.4
"The result showed that the effective rate of one year antihypertensive treatment of arotinolol combined with nifedipine was 51 of 53, significantly effective (p < 0."	( The efficacy and safety of arotinolol combined with a different calcium channel blocker in the treatment of Chinese patients with essential hypertension: a one-year follow-up study. Chen, W; Fang, H; Liu, X; Xu, W, 2014)	0.4
"The therapy approached of arotinolol combined with nifedipine or amlodipine could be effective and well-tolerated, and they can be used as the better chosen antihypertensive drug."	( The efficacy and safety of arotinolol combined with a different calcium channel blocker in the treatment of Chinese patients with essential hypertension: a one-year follow-up study. Chen, W; Fang, H; Liu, X; Xu, W, 2014)	0.64
" We have now compared the effects of the ARB valsartan combined with cilnidipine or amlodipine on cardiac pathophysiology in DS rats."	( Comparative effects of valsartan in combination with cilnidipine or amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats. Harada, E; Hattori, T; Matsuura, N; Murohara, T; Nagasawa, K; Nagata, K; Niinuma, K; Takahashi, K; Takatsu, M; Watanabe, S, 2015)	0.88
"This study aimed to quantify the pharmacokinetic drug-drug interaction between CsA and nicardipine, amlodipine, and lacidipine."	( Pharmacokinetic drug-drug interaction of calcium channel blockers with cyclosporine in hematopoietic stem cell transplant children. Bernard, E; Bertrand, Y; Bleyzac, N; Goutelle, S, 2014)	0.62
"To estimate effectiveness and safety of losartan and its combination with amlodipine in therapy of arterial hypertension."	( [Effectiveness and safety of losartan and its combination with amlodipine in therapy of arterial hypertension]. Bazaeva, EV; Boitsov, SA; Drapkina, OM; Luk'ianov, MM; Panov, AV; Shchukina, GN; Terent'ev, BP; Tiurin, VP, 2013)	0.86
" Losartan was used at a dose of 50-100 mg/24 h for 8 weeks (stage 1) and thereafter from week 9 to 26 (stage 2) in combination with amlodipine (5-10 mg/24 hr) if the desired AP level (< 140/90 mmHg) was not achieved."	( [Effectiveness and safety of losartan and its combination with amlodipine in therapy of arterial hypertension]. Bazaeva, EV; Boitsov, SA; Drapkina, OM; Luk'ianov, MM; Panov, AV; Shchukina, GN; Terent'ev, BP; Tiurin, VP, 2013)	0.83
" In this study, the possibility of drug-drug interactions between amlodipine and coadministered antibiotics (ampicillin) was investigated in rats; thus, changes in the metabolic activities of gut microflora and the consequent pharmacokinetic pattern of amlodipine following ampicillin treatment were characterized."	( Effects of orally administered antibiotics on the bioavailability of amlodipine: gut microbiota-mediated drug interaction. Kim, DH; Kim, IS; Yoo, DH; Yoo, HH, 2016)	0.91
" Because of interaction between amlodipine and simvastatin, in combination with physical activity, the patient reported: muscle pain, weakness of the muscles, dizziness, and confusion."	( [Drug interaction in 63-year-old male sportsman--a case report]. Foerster, J; Schetz, D; Sein Anand, J, 2015)	0.7
" The study aimed to evaluate the feasibility of different doses of DXM combined with standard AM treatment in clinical hypertension."	( Combination With Low-dose Dextromethorphan Improves the Effect of Amlodipine Monotherapy in Clinical Hypertension: A First-in-human, Concept-proven, Prospective, Dose-escalation, Multicenter Study. Chen, JW; Chen, P; Cheng, SM; Hung, YJ; Tseng, WK; Wang, KY; Wen, MS; Wu, CC; Wu, TC; Yeh, HI; Yin, WH, 2016)	0.67
" In 3 separate studies, pharmacokinetic drug-drug interactions (DDIs) potential was assessed when LCZ696 was coadministered with hydrochlorothiazide (HCTZ), amlodipine, or carvedilol."	( Pharmacokinetic drug-drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol. Greeley, M; Hsiao, HL; Langenickel, TH; Pal, P; Rajman, I; Rebello, S; Roberts, J; Sunkara, G; Zhou, W, 2015)	0.82
" The drug-drug interaction assay also showed that the concomitant use of kinsenoside has a non-significant effect on the concentration of lovastatin or amlodipine, and their major metabolites."	( In Vitro Assessment of CYP-Mediated Drug Interactions for Kinsenoside, an Antihyperlipidemic Candidate. Choi, MS; Kim, IS; Luo, Z; Rehman, SU; Xue, Y; Yao, G; Yoo, HH; Zhang, Y, 2016)	0.63
"The aims of this study are to find the prevalence of potential drug-drug interactions (DDIs) in patients with Hemodialysis and identify factors associated with these interactions if present."	( Evaluation of potential drug- drug interactions among Palestinian hemodialysis patients. Abu-Ghazaleh, D; Al-Ramahi, R; Bsharat, A; Raddad, AR; Rashed, AO; Shehab, O; Yasin, E, 2016)	0.43
" The new model is useful for estimating the risk of drug interaction in clinical practice when AST-120 is used in combination with other drugs."	( Prediction of drug interaction between oral adsorbent AST-120 and concomitant drugs based on the in vitro dissolution and in vivo absorption behavior of the drugs. Kotegawa, T; Koya, Y; Machi, Y; Namiki, N; Shobu, Y; Uchida, S, 2016)	0.43
"To build a physiologically based pharmacokinetic (PBPK) model for fimasartan, amlodipine, and hydrochlorothiazide, and to investigate the drug-drug interaction (DDI) potentials."	( Physiologically Based Pharmacokinetic Modeling of Fimasartan, Amlodipine, and Hydrochlorothiazide for the Investigation of Drug-Drug Interaction Potentials. Jeon, I; Kim, E; Lee, HA; Lee, S; Rhee, SJ; Song, IS; Yu, KS, 2018)	0.95
"To study the effect and molecular mechanisms of amlodipine besylate combined with acupoint application of traditional Chinese medicine nursing on the treatment methods of renal failure and hypertension."	( Effect of amlodipine besylate combined with acupoint application of traditional Chinese medicine nursing on the treatment of renal failure and hypertension by the PI3K/AKT pathway. Chi, R; Feng, L; Liang, W; Lv, S; Su, J; Zhu, Q, 2019)	1.17
" The aim of this study was to investigate the possible pharmacokinetic drug-drug interactions between amlodipine, valsartan, and rosuvastatin in healthy Korean male volunteers."	( Pharmacokinetic Drug Interactions Between Amlodipine, Valsartan, and Rosuvastatin in Healthy Volunteers. Cho, S; Gwon, MR; Kang, WY; Kim, BK; Lee, HW; Ohk, B; Seong, SJ; Yang, DH; Yoon, YR, 2019)	0.99
" As the management of drug-drug interactions (DDIs) constitutes a key aspect of the care of PLWH, the magnitude of pharmacokinetic DDIs between cardiovascular and anti-HIV drugs needs to be more thoroughly characterized."	( UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV. Alves Saldanha, S; Buclin, T; Cavassini, M; Courlet, P; Csajka, C; Decosterd, LA; Desfontaine, V; Marzolini, C; Spaggiari, D, 2019)	0.76
" Participants were divided into six treatment groups based on the hypertensive drug therapy they were using; lisinopril, losartan or valsartan alone or in combination with hydrochlorothiazide (A, B and C group respectively) or combination of lisinopril, losartan or valsartan with/without hydrochlorothiazide together with amlodipine (D, E and F respectively)."	( Effects of Different Antihypertensive Drug Combinations on Blood Pressure and Arterial Stiffness. Hebibovic, S; Jatic, Z; Rustempasic, E; Skopljak, A; Sukalo, A; Valjevac, A, 2019)	0.69
"These data suggest that lisinopril/lisinopril + hydrochlorothiazide, losartan/losartan + hydrochlorothiazide and valsartan/valsartan + hydrochlorothiazide alone or in combination with amlodipine are equally effective and well tolerated for the reduction of both systolic and diastolic blood pressure and improve arterial stiffness in patients with essential hypertension."	( Effects of Different Antihypertensive Drug Combinations on Blood Pressure and Arterial Stiffness. Hebibovic, S; Jatic, Z; Rustempasic, E; Skopljak, A; Sukalo, A; Valjevac, A, 2019)	0.71
" SIGNIFICANCE AND IMPACT OF THE STUDY: Drug combination is an effective approach for the treatment of resistant bacterial infection."	( In vitro interactions of ambroxol hydrochloride or amlodipine in combination with antibacterial agents against carbapenem-resistant Acinetobacter baumannii. Li, X; Lu, C; Sun, S; Wang, D; Wang, Y, 2020)	0.81
": The risk of drug-drug interactions (DDIs) is elevated in aging people living with HIV (PLWH) because of highly prevalent age-related comorbidities leading to more comedications."	( Aging does not impact drug--drug interaction magnitudes with antiretrovirals. Battegay, M; Cavassini, M; Courlet, P; Decosterd, L; Marzolini, C; Saldanha, SA; Stader, F; Stoeckle, M, 2020)	0.56
" In order to determine which combination was better as the next-step therapy for standard-dose combination of ARBs and CCBs, a combination with high-dose CCBs or a triple combination with diuretics, the authors conducted a prospective, randomized, open-label trial to determine which of the following combination is better as the next-step treatment: a combination with high-dose CCBs or a triple combination with diuretics."	( Assessment of suitable antihypertensive therapies: Combination with high-dose amlodipine/irbesartan vs triple combination with amlodipine/irbesartan/indapamide (ASAHI-AI study). Hasebe, N; Koyama, S; Maruyama, J; Morimoto, H; Nakagawa, N; Nakamura, Y; Ogawa, Y; Ohta, T; Saijo, Y; Sato, N; Takeuchi, T; Uekita, K, 2020)	0.79
"Objectives For revealing the peculiarities of the drug-drug interaction of rivaroxaban (substrate CYP3A4 and P-gp) and calcium channel blockers (CCBs) (verapamil - inhibitor CYP3A4 and P-gp and amlodipine - substrate CYP3A4) in patients 80 years and older with nonvalvular atrial fibrillation (NAF) we studied 128 patients."	( Drug-drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation. Bahteeva, D; Bochkov, P; Cherniaeva, M; Golovina, O; Gorbatenkova, S; Kulikova, M; Mirzaev, K; Ostroumova, O; Rytkin, E; Shevchenko, R; Sychev, D, 2020)	0.75
"This open-label, repeat-dose, fixed-sequence study in healthy subjects examined pharmacokinetic drug-drug interactions between the components of a novel fixed-dose combination product containing ramipril, amlodipine, and atorvastatin."	( Mechanistic Considerations About an Unexpected Ramipril Drug-Drug Interaction in the Development of a Triple Fixed-Dose Combination Product Containing Ramipril, Amlodipine, and Atorvastatin. Gundlach, K; Hermann, R; Seiler, D, 2021)	1.01
"Conclusion Patients with IHD and AH in combination with early CKD have pronounced impairment of the condition of arterial blood vessels and the heart."	( [Vasoprotective effects hypotensive therapy in patients with coronary heart disease combined with chronic kidney disease stage 2-3 after coronary stenting]. Barbashina, TA; Gavriljuk, EV; Mal, GS; Pribylov, CA; Pribylov, VS; Pribylova, NN; Yakovleva, MV, 2021)	0.62
" The aim of this study was to evaluate the efficacy and safety of TJT combined with Val/Aml in the treatment of stage 2 hypertension with hyperactivity of liver yang."	( Efficacy and safety of Tengfu Jiangya tablet combined with valsartan/amlodipine in the treatment of stage 2 hypertension: study protocol for a randomized controlled trial. Chen, W; Hua, Z; Li, Y; Wang, Y; Zhu, Y, 2022)	0.96
" Eligible patients will be randomly assigned (1:1) into groups receiving either TJT or placebo three times daily for 28 days, both combined with Val/Aml 80/5 mg."	( Efficacy and safety of Tengfu Jiangya tablet combined with valsartan/amlodipine in the treatment of stage 2 hypertension: study protocol for a randomized controlled trial. Chen, W; Hua, Z; Li, Y; Wang, Y; Zhu, Y, 2022)	0.96
"This is the first placebo-controlled randomized trial conducted to evaluate the efficacy and safety of a Chinese herbal extract combined with Val/Aml in patients with stage 2 hypertension."	( Efficacy and safety of Tengfu Jiangya tablet combined with valsartan/amlodipine in the treatment of stage 2 hypertension: study protocol for a randomized controlled trial. Chen, W; Hua, Z; Li, Y; Wang, Y; Zhu, Y, 2022)	0.96
" The availability of OM combined with HCTZ, AML or both at different dosages makes it a valuable option to customize therapy based on the levels of BP and the clinical characteristics of hypertensive patients."	( Single-Pill Combination with Three Antihypertensive Agents to Improve Blood Pressure Control in Hypertension: Focus on Olmesartan-Based Combinations. Burnier, M; Redon, J; Volpe, M, 2023)	0.91
" However, there are few studies on the regulation and efficacy of atorvastatin combined with amlodipine on Th17/Treg balance in hypertension combined with carotid atherosclerosis."	( Effects of amlodipine combined with atorvastatin on Th17/Treg imbalance and vascular microcirculation in hypertensive patients with atherosclerosis: A double-blind, single-center randomized controlled trial. Qiu, Y; Yang, G, 2023)	1.52
"These data indicate that amlodipine combined with atorvastatin can improve Th17/Treg imbalance, vascular endothelial function and efficacy in patients with hypertension and atherosclerosis."	( Effects of amlodipine combined with atorvastatin on Th17/Treg imbalance and vascular microcirculation in hypertensive patients with atherosclerosis: A double-blind, single-center randomized controlled trial. Qiu, Y; Yang, G, 2023)	1.6
" Therefore, the results of valsartan and amlodipine tablets combined with alpha-lipoic acid on total antioxidant capacity (T-AOC) need to be investigated."	( Effects of Valsartan and Amlodipine Tablets Combined with α-Lipoic Acid on T-AOC, IL-6 and β2-MG Levels in Patients with Diabetic Nephropathy. Su, F; Xia, Q, 2023)	1.48
"To observe the effect of amlodipine besylate combined with metoprolol in treating hypertension and heart failure."	( Improvement in hemodynamics of amlodipine besylate combined with metoprolol in patients with hypertension complicated by heart failure. Chen, C; Jiao, D; Shen, J; Zhang, W; Zhang, X; Zhu, G, 2023)	1.5

Excerpt	Reference	Relevance
" Following oral administration, bioavailability is 60 to 65% and plasma concentrations rise gradually to peak 6 to 8h after administration."	( Clinical pharmacokinetics of amlodipine. Elliott, HL; Meredith, PA, 1992)	0.57
" It has high oral bioavailability (60-80%) and accumulates to a steady-state with once-daily administration over a period of 1-1 1/2 weeks."	( Pharmacokinetics and pharmacodynamics of amlodipine. Abernethy, DR, 1992)	0.55
" A high oral bioavailability of amlodipine has been demonstrated in a number of animal species and man, together with a long elimination half-life."	( Amlodipine: a once daily calcium antagonist. Burges, RA, 1991)	2.01
" Bioavailability of unchanged drug after oral administration was high with values of 63, 88, 100, and 100% in humans, dogs, mice, and rats, respectively."	( The metabolism and pharmacokinetics of amlodipine in humans and animals. Beresford, AP; Humphrey, MJ; Macrae, PV; Stopher, DA, 1988)	0.54
"The oral bioavailability of amlodipine in healthy volunteers was compared in two separate studies after solution and capsule doses, and after capsule doses in fed and fasting states."	( Absorption of amlodipine unaffected by food. Solid dose equivalent to solution dose. Chasseaud, LF; Faulkner, JK; Hayden, ML; Taylor, T, 1989)	0.93
"Amlodipine, a dihydropyridine calcium antagonist, was synthesized in an attempt to develop a compound with a pharmacokinetic profile characteristic of this class, which would also have an increased oral bioavailability and extended clearance time."	( The pharmacokinetic profile of amlodipine. Abernethy, DR, 1989)	2.01
" Amlodipine, a new member of this family of dihydropyridines, has a unique pharmacokinetic profile with high bioavailability and an extended period of pharmacodynamic activity."	( The efficacy of amlodipine in myocardial ischemia. Taylor, SH, 1989)	1.53
" Oral bioavailability approached 100%, and hemodynamic responses were gradual in onset and long-lasting in effect."	( Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents. Arrowsmith, JE; Blackburn, KJ; Burges, RA; Campbell, SF; Cross, PE; Gardiner, DG; Stubbs, JK, 1986)	0.27
" The drug was well absorbed by the oral route while the mean oral bioavailability for unchanged drug was 62."	( Metabolism and kinetics of amlodipine in man. Beresford, AP; Humphrey, MJ; Macrae, PV; McGibney, D; Stopher, DA, 1988)	0.57
"In the present study we investigated the pharmacokinetics and comparative bioavailability of three oral doses of amlodipine in 12 healthy male volunteers."	( Amlodipine pharmacokinetics in healthy volunteers. Cubeddu, LX; Williams, DM, 1988)	1.93
" Nifedipine, diltiazem, and verapamil are all high-clearance agents with significant hepatic extraction and rapid clearance, leading to limited and short-lived bioavailability necessitating frequent daily administration."	( Amlodipine once a day in stable angina: double-blind crossover comparison with placebo. Cheitlin, MD; Das, SK; Deedwania, PC; Pasternak, RC; Pool, PE; Singh, JB, 1993)	1.73
" They are very liposoluble molecules which are well absorbed after oral prescription (90-100%); they show an important effect in their first step, they join the serum proteins in a high proportion, present a wide tissue distribution, they are quickly biotransformed in the liver and only a minimum proportion is discharged by urine without any modification."	( [Clinical pharmacokinetics of calcium antagonists]. Sesin, J; Tamargo, J, 1997)	0.3
" Amlodipine once-daily, a calcium channel blocker structurally related to nifedipine with an excellent bioavailability and a long elimination half-time, has been shown to reduce blood pressure in adults."	( Amlodipine once-daily in systemic hypertension. Bianchetti, MG; Busch, K; Clericetti-Affolter, C; Laux-End, R; Pfammatter, JP; Truttmann, AC, 1998)	2.65
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."	( QSAR model for drug human oral bioavailability. Topliss, JG; Yoshida, F, 2000)	0.31
" Bioavailability enhancement by grapefruit juice, noted with other dihydropyridine calcium antagonists, does not occur with amlodipine."	( Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine. Dogolo, LC; Foulds, G; Friedman, HL; Harris, SI; Vincent, J; Willavize, S, 2000)	0.74
"To determine the effects of the angiotensin II receptor antagonist irbesartan, the calcium-channel blocker amlodipine, and hydrochlorothiazide/hydralazine on superoxide, NAD(P)H oxidase and nitric oxide bioavailability in spontaneously hypertensive stroke-prone rats (SHRSP)."	( Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats. Brosnan, MJ; Dominiczak, AF; Graham, D; Hamilton, CA; Jardine, E; Lygate, CA, 2002)	0.53
" In vitro the effects of exposure to drugs and vehicle for 30 min and 4 h on superoxide levels and nitric oxide bioavailability were examined."	( Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats. Brosnan, MJ; Dominiczak, AF; Graham, D; Hamilton, CA; Jardine, E; Lygate, CA, 2002)	0.31
"62 nmoles/mg per min and increased nitric oxide bioavailability in carotid arteries."	( Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats. Brosnan, MJ; Dominiczak, AF; Graham, D; Hamilton, CA; Jardine, E; Lygate, CA, 2002)	0.31
"These studies support the hypothesis that AT1 receptor blockade has beneficial effects on superoxide production and nitric oxide bioavailability above that of other classes of antihypertensive agents."	( Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats. Brosnan, MJ; Dominiczak, AF; Graham, D; Hamilton, CA; Jardine, E; Lygate, CA, 2002)	0.31
" A comparative bioavailability study of a tablet and suspension formulation of amlodipine was completed in 20 healthy adult volunteers."	( Bioavailability of a pediatric amlodipine suspension. Hard, M; Koren, G; Kozer, E; Levichek, Z; Lyszkiewicz, DA; Moretti, M; Yagev, Y, 2003)	0.83
" Many factors, including P-glycoprotein (PGP), influence the oral bioavailability and interpatient variability of CsA."	( Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients. Kobayashi, T; Kuzuya, T; Moriyama, N; Nabeshima, T; Nagasaka, T; Nakao, A; Uchida, K; Yokoyama, I, 2003)	1.76
"05), whereas the response to an NO donor was unaffected, suggesting decreased bioavailability of NO."	( Oxidant stress leads to impaired regulation of renal cortical oxygen consumption by nitric oxide in the aging kidney. Adler, S; Huang, H; Kaminski, PM; Wolin, MS, 2004)	0.32
" The rate of absorption reflected by tmax had a difference of -0."	( Bioequivalence study of generic amlodipine in healthy Thai male volunteers. Arnold, P; Chaichana, N; Gaupp, M; Jakob, K; Martin, W; Rojanasthien, N; Teekachunhatean, S, 2004)	0.61
" On average, bioavailability of amlodipine was slightly higher in females than in males, but these differences could be explained by the lower body weight of women."	( Assessment of sex differences in pharmacokinetics and pharmacodynamics of amlodipine in a bioequivalence study. Abad-Santos, F; Almeida, S; Gallego-Sandín, S; Gálvez-Múgica, MA; García, AG; Novalbos, J; Vallée, F, 2005)	0.84
" Amlodipine is absorbed gradually after oral administration (peak plasma levels 6-12 h postdose) and has an absolute bioavailability of 64%."	( Amlodipine: pharmacokinetic profile of a low-clearance calcium antagonist. Abernethy, DR, 1991)	2.63
" Damage to the endothelium leads to reduced NO bioavailability and facilitates vessel wall permeability to low-density lipoprotein."	( A rationale for combination therapy in risk factor management: a mechanistic perspective. Mason, RP, 2005)	0.33
" The validated method has been successfully used to analyze human plasma samples for application in pharmacokinetic, bioavailability or bioequivalence studies."	( Sensitive and rapid liquid chromatography/tandem mass spectrometry assay for the quantification of amlodipine in human plasma. Kandikere, VN; Maurya, S; Mudigonda, K; Nirogi, RV; Shukla, M, 2006)	0.55
"To improve the bioavailability and photostability of poorly water-soluble and photosensitive amlodipine, dry emulsion (DE) was prepared by spray-drying the oil-in-water emulsion of amlodipine."	( Improvement of bioavailability and photostability of amlodipine using redispersible dry emulsion. Jang, DJ; Jeong, EJ; Kim, BC; Kim, CK; Lee, HM; Lim, SJ, 2006)	0.8
"Two different tablets containing amlodipine besylate (CAS 111470-99-6) (Vazkor 10 mg tablet as test preparation and 10 mg tablet of the originator product as reference preparation) were investigated in 18 healthy male volunteers in order to compare the bioavailability and prove the bioequivalence between both treatments after oral single dose administration."	( Pharmacokinetics and bioequivalence study of a generic amlodipine tablet formulation in healthy male volunteers. Arnold, P; Erenmemişoğlu, A; Hincal, AA; Kanzik, I; Martin, W; Sailer, R; Tamur, U, 2007)	0.87
"The present study was conducted to find out whether the bioavailability of a 10 mg amlodipine (CAS 88150-42-9) tablet (Intervask, "test") was equivalent to that that of a reference formulation ("reference")."	( Comparative bioavailability cf two amlodipine formulation in healthy volunteers. Deniati, SH; Handayani, LR; Harinanto, G; Santoso, ID; Setiawati, E; Yunaidi, DA, 2007)	0.84
"Salt-sensitive (SS) hypertension is a vascular diathesis characterized by reduced cardiovascular and renal nitric oxide bioavailability and local upregulation of ANG II."	( Upregulation of cortical COX-2 in salt-sensitive hypertension: role of angiotensin II and reactive oxygen species. Jaimes, EA; Pearse, DD; Puzis, L; Raij, L; Zhou, MS, 2008)	0.35
"Chronic kidney disease (CKD) and hypertension have been associated with decreased bioavailability of nitric oxide (NO) and endothelial dysfunction."	( Plasma asymmetric dimethylarginine, symmetric dimethylarginine, l-arginine, and nitrite/nitrate concentrations in cats with chronic kidney disease and hypertension. Elliott, J; Jepson, RE; Syme, HM; Vallance, C, )	0.13
" In particular, reduced bioavailability of endothelial-dependent nitric oxide production as a result of enhanced oxidative stress represents a common pathological mechanism of cardiovascular risk factors."	( Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor: a new approach to risk factor management. Mason, RP, 2008)	0.35
" The relative bioavailability of a newly developed dispersible tablet as compared with an established branded formulation has not been reported in a Chinese population."	( Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. Jia, J; Li, S; Liu, G; Liu, Y; Lu, C; Yu, C, 2009)	0.58
" The relative bioavailability of the test formulation was 90."	( Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. Jia, J; Li, S; Liu, G; Liu, Y; Lu, C; Yu, C, 2009)	0.58
" After transdermal administration to rats, the absolute bioavailability was 88."	( A drug-in-adhesive transdermal patch for S-amlodipine free base: in vitro and in vivo characterization. Fang, L; He, Z; Li, L; Li, W; Meng, P; Sun, Y; Zhu, M, 2009)	0.62
" The relative bioavailability was 103."	( Liquid chromatography-mass spectrometry method for the determination of amlodipine in human plasma and its application in a bioequivalence study. Ge, Z; Ouyang, P; Wei, P; Zhan, Y; Zou, Q, 2009)	0.59
"Pioglitazone improved endothelial function in hypertensive patients with IGT through an increase in nitric oxide bioavailability by, in part, a decrease in oxidative stress."	( Pioglitazone improves endothelium-dependent vasodilation in hypertensive patients with impaired glucose tolerance in part through a decrease in oxidative stress. Chayama, K; Fujii, Y; Fujimura, N; Goto, C; Hata, T; Hidaka, T; Higashi, Y; Idei, N; Kihara, Y; Nakagawa, K; Soga, J, 2010)	0.36
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."	( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010)	0.36
" The bioavailability of amlodipine and atorvastatin with a single-tablet, fixed-dose amlodipine/atorvastatin combination was not significantly different to that with coadministered separate amlodipine and atorvastatin tablets."	( Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease. Curran, MP, 2010)	2.11
"Nanoemulsion (NE) of amlodipine besilate (AB) was developed by spontaneous emulsification method with the aim to enhance the solubility and oral bioavailability of AB and to achieve localized delivery of drug at target site."	( Design and development of nanoemulsion drug delivery system of amlodipine besilate for improvement of oral bioavailability. Chhabra, G; Chuttani, K; Mishra, AK; Pathak, K, 2011)	0.93
" The aim of this study was to estimate the influence of hypotensive drugs (angiotensine converting enzyme inhibitors (ACE-I), β-blockers, Ca-antagonists, diuretics) on the potential bioavailability of magnesium, iron, zinc and copper from buckwheat groats in vitro enzymatic digestion."	( The influence of selected hypotensive drugs on the bioavailability of minerals from buckwheat groats in vitro enzymatic digestion. Bogdański, P; Chiniewicz, B; Suliburska, J, )	0.13
"25, indicating that the extent of bioavailability of S-amlodipine was not affected by telmisartan."	( Pharmacokinetic interaction of telmisartan with s-amlodipine: an open-label, two-period crossover study in healthy Korean male volunteers. Bae, KS; Choi, HY; Jin, SJ; Kim, MJ; Kim, YH; Lim, HS; Lim, J; Noh, YH; Sung, HR, 2012)	0.88
"In this study, the authors compared the effects of amlodipine (AML) on the bioavailability of cephalexin (LEX) and cefuroxime axetil (CXM)."	( Effects of amlodipine on the oral bioavailability of cephalexin and cefuroxime axetil in healthy volunteers. Ding, L; Ding, Y; Jia, Y; Jin, X; Liu, W; Lu, C; Song, Y; Wen, A; Yang, J; Yang, L; Zhu, Y, 2013)	1.03
"This study was aimed to investigate the relative bioavailability of fixed-dose-combination (FDC) product of amlodipine, telmisartan and hydrochlorothiazide with individual marketed products in healthy male volunteers."	( A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. Biswas, E; Choudhury, H; Ghosh, B; Gorain, B; Halder, D; Pal, TK; Sarkar, AK; Sarkar, P, 2013)	0.6
"The authors investigated the relative bioavailability under a fasting state of the 3 drugs in a randomized, open-label, 2-treatment, 2-period, 2-sequence, crossover bioequivalence study with a washout period of 21 days."	( A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. Biswas, E; Choudhury, H; Ghosh, B; Gorain, B; Halder, D; Pal, TK; Sarkar, AK; Sarkar, P, 2013)	0.39
" Amlodipine concentrations were assumed to influence the clearance of simvastatin and simvastatin acid, which as well as the oral bioavailability was allowed to vary depending on genetic polymorphisms of metabolic enzymes."	( Development of a pharmacokinetic interaction model for co-administration of simvastatin and amlodipine. Jang, SB; Lee, D; Lim, LA; Park, K; Roh, H; Son, H, 2014)	1.53
" In this study, we elucidated the effect of amlodipine on nitric oxide (NO) bioavailability and cytotoxic peroxynitrite (ONOO(-)) and blood pressure (BP)."	( Amlodipine increased endothelial nitric oxide and decreased nitroxidative stress disproportionately to blood pressure changes. Corbalan, JJ; Jacob, RF; Kaliszan, R; Malinski, T; Mason, RP, 2014)	2.11
"Amlodipine increased NO bioavailability and decreased nitroxidative stress in SHRs with EC dysfunction disproportionately to BP changes."	( Amlodipine increased endothelial nitric oxide and decreased nitroxidative stress disproportionately to blood pressure changes. Corbalan, JJ; Jacob, RF; Kaliszan, R; Malinski, T; Mason, RP, 2014)	3.29
"These results showed that antibiotic intake might increase the bioavailability of amlodipine by suppressing gut microbial metabolic activities, which could be followed by changes in therapeutic potency."	( Effects of orally administered antibiotics on the bioavailability of amlodipine: gut microbiota-mediated drug interaction. Kim, DH; Kim, IS; Yoo, DH; Yoo, HH, 2016)	0.89
" The study (NCT02075619) evaluated the bioavailability of 2 prototype FDC tablet formulations (FDC1 and FDC2) of amlodipine/rosuvastatin (10 mg/20 mg) compared with coadministered reference tablets."	( The relative bioavailability of 2 prototype fixed-dose combination formulations for amlodipine and rosuvastatin in healthy white and Chinese subjects. Bullman, JN; Joshi, SM; Kapsi, SG; Nwe, HH; Stylianou, A, 2016)	0.87
"Pharmacokinetic analyses revealed an increase in the bioavailability of simvastatin when co-administered with amlodipine [Nishio S et al."	( Analysis of secondary care data to evaluate the clinical relevance of the drug-drug interaction between amlodipine and simvastatin. Fuhrmann, S; Knoth, H; Koppen, A; Schröder, J; Seeling, A, 2019)	0.94
" The elution of AML from prepared PGA gels was complete within an hour and the gel did not appear to influence the bioavailability of AML."	( Preparation and Evaluation of Poly-γ-glutamic Acid Hydrogel Mixtures with Amlodipine Besylate: Effect on Ease of Swallowing and Taste Masking. Haraguchi, T; Ikegami, S; Kawasaki, I; Kojima, H; Nishikawa, H; Ozeki, M; Uchida, T; Yoshida, M, 2019)	0.74
"Transdermal drug delivery has been developed to increase drug bioavailability and improve patient compliance."	( Microneedle-assisted transdermal delivery of amlodipine besylate loaded nanoparticles. Al-Nemrawi, NK; Nasereddin, J; Nimrawi, S; Zaid Alkilani, A, 2022)	0.98

Excerpt	Relevance	Reference
" However, amlodipine reduced ambulatory systolic (SBP) and DBP almost every hour over the whole circadian cycle, whereas the antihypertensive effect of captopril was attenuated during the final 3 hours of each dosing interval."	( Comparison of the effects of amlodipine and captopril on clinic and ambulatory blood pressure. Lacourcière, Y; Poirier, L; Provencher, P, 1992)	0.98
" This study used sphygmomanometric and intra-arterial ambulatory blood pressure (BP) monitoring to confirm the antihypertensive effect of a once-daily dose of amlodipine over the dosing interval."	( Intra-arterial monitoring of the antihypertensive effects of once-daily amlodipine. al-Khawaja, I; Brigden, G; Broadhurst, P; Heber, ME; Raftery, EB, 1992)	0.71
" This study demonstrates that once-daily administration of amlodipine or atenolol to mild-to-moderate hypertensive patients was well-tolerated and provided adequate blood pressure control throughout the 24-h dosing interval."	( A randomized, placebo-controlled, double-blind comparison of amlodipine and atenolol in patients with essential hypertension. Brobyn, R; Brown, RD; Frishman, WH; Johnson, BF; Reeves, RL; Wombolt, DG, 1992)	0.77
" Due to the low incidence of side effects and the once-daily dosage regimen, an improvement in patient compliance can be expected."	( [Effectiveness and tolerance of amlodipine in treatment of patients with mild to moderate hypertension. Results of a long-term study with a new calcium antagonist]. Ganzinger, U; Habeler, G; Lenzhofer, R; Pall, H; Tomaschek, A; Ziebart-Schroth, A; Zirm, B, 1992)	0.57
" Amlodipine shows linear dose-related pharmacokinetic characteristics and, at steady-state, there are relatively small fluctuations in plasma concentrations across a dosage interval."	( Clinical pharmacokinetics of amlodipine. Elliott, HL; Meredith, PA, 1992)	1.49
" Fluctuation of plasma drug concentration between doses is between 20 and 25% when once-daily dosing is used."	( Pharmacokinetics and pharmacodynamics of amlodipine. Abernethy, DR, 1992)	0.55
" Dose-response curves were obtained with intravenous injection of the four drugs."	( Hemodynamic profile of Ro 40-5967 in conscious rats: comparison with diltiazem, verapamil, and amlodipine. Clozel, JP; Hess, P; Véniant, M; Wolfgang, R, 1991)	0.5
"Sixty patients (31 male, 29 female) were studied in a 4-week double-blind parallel dose-response study."	( A double-blind dose-response study of amlodipine in patients with stable angina pectoris. Alfiero, R; Cocco, G, 1991)	0.55
"2 mg/kg/day for 20 days) chronically receiving AML, there was an enhancement of the antihypertensive effect of AML within a few days after starting chronic dosing, and thereafter a significant reduction of BP at 24 hr after dosing and constant effects of AML during subsequent treatment."	( [Antihypertensive effects of amlodipine, a new calcium antagonist]. Ishiko, J; Munehasu, S; Suzuki, M; Yamanaka, K, 1991)	0.57
" The pharmacokinetics of the molecule mean that effective blood levels and hence good control of blood pressure are maintained throughout the dosing interval."	( Amlodipine: an effective once-daily antihypertensive agent. Tyler, HM, 1991)	1.72
" Ambulatory monitoring studies have confirmed that once-daily dosing provides 24-h control of blood pressure."	( Amlodipine in the treatment of hypertension. Kaplan, NM, 1991)	1.72
" It is concluded that once-daily dosing with either amlodipine or atenolol significantly reduces blood pressures."	( Multicenter placebo-controlled comparison of amlodipine and atenolol in mild to moderate hypertension. Cocco, G; de Bruijn, B; Tyler, HM, 1988)	0.79
" After intravenous administration, the percentages of the dosed radioactivity recovered in urine were 62% in humans, 45% in dogs, 38% in rats, and 25% in mice."	( The metabolism and pharmacokinetics of amlodipine in humans and animals. Beresford, AP; Humphrey, MJ; Macrae, PV; Stopher, DA, 1988)	0.54
" These results suggest that once-daily administration of amlodipine is suitable for all degrees of renal function and that dosage adjustment is not necessary in renal impairment."	( Pharmacokinetics of amlodipine in renal impairment. Carmody, M; Donohoe, JF; Doyle, GD; Greb, H; Kelly, JG; Laher, MS; Volz, M, 1988)	0.84
" Ambulatory blood pressure recordings revealed adequate blood pressure control throughout the 24-h dosing interval."	( A double-blind evaluation of the effect of amlodipine on ambulatory blood pressure in hypertensive patients. Allenby, KS; Burris, JF; Mroczek, WJ, 1988)	0.54
"The antihypertensive efficacy and suitability for once daily dosing of amlodipine, a new calcium antagonist, was studied in a series of 205 patients with mild to moderate hypertension."	( A dose-response study of amlodipine in mild to moderate hypertension. Frick, MH; McGibney, D; Tyler, HM, 1989)	0.81
" These results suggest that once daily administration of amlodipine is suitable for all degrees of renal function and that dosage adjustment is not necessary in renal impairment."	( Pharmacokinetics of amlodipine in renal impairment. Carmody, M; Donohue, J; Doyle, GD; Greb, H; Laher, M; Volz, M, 1989)	0.85
" With chronic oral dosing of amlodipine once daily for 14 days, support was provided for the linearity of amlodipine's pharmacokinetics and absence of such with chronic oral dosing with verapamil, diltiazem, and nifedipine."	( The pharmacokinetic profile of amlodipine. Abernethy, DR, 1989)	0.85
" Dosage modifications are unnecessary in renal impairment, but the dosage regimen for patients with hepatic impairment is not yet established."	( The safety of amlodipine. Osterloh, I, 1989)	0.64
"The haemodynamic dose-response effects of a new long-acting slow-calcium channel blocking agent, amlodipine were evaluated in 20 patients with angiographically confirmed coronary heart disease."	( A haemodynamic dose finding study with a new slow-calcium channel blocker (amlodipine) in coronary artery disease. Frais, MA; Jackson, NC; Reynolds, G; Sharma, SK; Silke, B; Taylor, SH; Verma, SP, 1986)	0.72
" After a stable control period, dose-response curves were constructed for each drug with hemodynamics measured 10 minutes after intravenous boluses."	( Comparative hemodynamic dose-response effects of five slow calcium channel-blocking agents in coronary artery disease. Frais, MA; Jackson, N; Midtbo, KA; Reynolds, G; Sharma, S; Silke, B; Taylor, SH; Verma, SP, 1987)	0.27
" Renal elimination was the major route of excretion with about 60% of the dosed radioactivity recovered in urine."	( Metabolism and kinetics of amlodipine in man. Beresford, AP; Humphrey, MJ; Macrae, PV; McGibney, D; Stopher, DA, 1988)	0.57
" However, the concentrations at which these calcium channel blockers elicit antiproliferative effects may not be attainable during therapeutic dosing in humans."	( Effect of calcium channel blockers on the growth of human vascular smooth muscle cells derived from saphenous vein and vascular graft stenoses. Betteridge, L; Chan, P; Gallagher, K; Munro, E; Patel, M; Schachter, M; Sever, P; Wolfe, J, 1994)	0.29
" In contrast, however, the effects of captopril were no longer evident during the final 3 h of the dosing interval."	( Comparison of amlodipine and captopril in hypertension based on 24-hour ambulatory monitoring. Lacourcière, Y; Poirier, L; Provencher, P, 1993)	0.65
"01), although the once-daily dosing of enalapril and the maximum dose of 20 mg might not have been optimal for this agent."	( Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment. Adegbile, IA; Alemayehu, D; Carr, AA; Lefkowitz, MP; Papademetriou, V; Prisant, LM; Weber, MA; Weir, MR, 1995)	0.29
" If office diastolic pressure was greater than or equal to 90 mm Hg after 4 weeks, the dosage was doubled and continued for another 4 weeks."	( Comparison of perindopril and amlodipine in cyclosporine-treated renal allograft recipients. Lamote, J; Sennesael, J; Tasse, S; Verbeelen, D; Violet, I, 1995)	0.58
" The effects of three long-acting calcium antagonists, amlodipine, lacidipine and nifedipine GITS (gastrointestinal therapeutic system), on vascular reactivity were assessed over 24h and 48h dosage intervals."	( Vascular reactivity: a measurement of calcium channel blockade. Elliott, HL, 1995)	0.54
" Blood pressure measurements were taken at the end of the dosing interval to assess the antihypertensive efficacy of the two drugs."	( At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild-to-moderate hypertension: a double-blind, randomized, parallel-group study. De Keyser, P; Deblander, A; Hermans, L; Lesaffre, E; Scheys, I; Westelinck, KJ, 1994)	0.53
" Exercise tests and blood sampling for plasma concentrations of amlodipine were performed at 8 and at 24 h after dosing on both days of acute testing as well as on day 18 of chronic treatment."	( Pharmacokinetics and additional anti-ischaemic effectiveness of amlodipine, a once-daily calcium antagonist, during acute and long-term therapy of stable angina pectoris in patients pre-treated with a beta-blocker. Beyerle, A; Lehmann, G; Reiniger, G; Rudolph, W, 1993)	0.76
" About 8% of patients had a low compliance rate, irrespective of the dosage regimen."	( [Time of drug intake in hypertension and angina pectoris. A controlled monitoring study]. Erne, P; Heynen, G; Saxenhofer, H; Waeber, B, 1994)	0.29
" Correspondingly there was less variability with amlodipine in the blood pressure reductions across the dosage interval."	( A comparative assessment of amlodipine and felodipine ER: pharmacokinetic and pharmacodynamic indices. Bainbridge, AD; Elliott, HL; Herlihy, O; Meredith, PA, 1993)	0.83
" The number of days with missed medication was thus significantly higher for the evening dosing regimen."	( The use of self-measured blood pressure determinations in assessing dynamics of drug compliance in a study with amlodipine once a day, morning versus evening. Binswanger, B; Mengden, T; Spühler, T; Vetter, W; Weisser, B, 1993)	0.5
" Furthermore, the use of self-measurement and the MEMS may provide useful additional information on the pharmacodynamic impact of different dosing patterns in hypertensive patients."	( The use of self-measured blood pressure determinations in assessing dynamics of drug compliance in a study with amlodipine once a day, morning versus evening. Binswanger, B; Mengden, T; Spühler, T; Vetter, W; Weisser, B, 1993)	0.5
" Gingival changes occurred within 3 months of dosage and appeared to be compounded by the patient's existing periodontal condition."	( Amlodipine-induced gingival overgrowth. Ellis, JS; Idle, JR; Monkman, S; Seymour, RA; Thomason, JM, 1994)	1.73
" Amlodipine maintained blood pressure reduction throughout the 24-hours dosing interval with a once-daily dose."	( Amlodipine in mild and moderate hypertension: initial Indian experience. Ailiani, R; Bajan, KD; Chawla, KP; Chopra, P; Joseph, TA; Karnik, ND; Khokhani, RC; Waknis, SS, 1993)	2.64
" Results of temporal and dose-response studies showed that memory enhancement (significant increase in step-through latency) occurred when amlodipine (5, 7, 9, 15, and 30 mg/kg) was given either immediately post-training or (15 mg/kg) 15 min pretesting."	( Effect of the calcium channel blocker amlodipine on memory in mice. Ermita, B; Hawxhurst, A; Puente, J; Quartermain, D, 1993)	0.76
" In comparison with other antianginal drugs, once-daily amlodipine at a dosage range of 5-10 mg demonstrated antianginal activity comparable to thrice-daily diltiazem and once-daily nadolol."	( Usefulness of amlodipine for angina pectoris. Taylor, SH, 1994)	0.9
"m-2] had been on prior treatment with a thiazide diuretic in low dosage and/or a beta-adrenoceptor blocker (group A), and 10 matched patients [BMI 31."	( Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension. Böhlen, L; de Courten, M; Ferrari, P; Heynen, G; Riesen, W; Schneider, M; Shaw, S; Weidmann, P, 1993)	0.58
"To determine the dose-response efficacy of once-daily administration of placebo or a new long-acting calcium channel blocker amlodipine in patients with mild to moderate hypertension, a randomized, multicenter, placebo-controlled, double-blind trial was conducted."	( Double-blind evaluation of the dose-response relationship of amlodipine in essential hypertension. Garland, WT; Gradman, AH; Lopez, LM; Mehta, JL; Nash, DT; O'Connell, MT; Pickering, BI; Vlachakis, ND, 1993)	0.73
" After two weeks, the dosage was able to be increased (according to clinical efficacy) to 10 mg of amlodipine as a single dose or 240 mg of diltiazem in four divided doses."	( [Evaluation of amlodipine in stable effort angina. Comparison with diltiazem in terms of efficacy, tolerability and maintenance of the anti-ischemic action 24 hours after the last dose]. Bernaud, C; Marchand, X; Morand, P; Tibi, T, 1996)	0.86
" The dosage of amlodipine was 5 to 10 mg/day."	( -Efficacy and safety of using amlodipine in treatment of mild and moderate essential hypertension-. Kokot, F; Kokot, M; Raszewska, J; Rychlik, G; Witkowicz, J, 1995)	0.93
" Newer calcium channel blockers of the dihydropyridine group have longer elimination half-lives (t1/2) that permit once-daily dosage and are generally better tolerated than their parent compound."	( Relative efficacy and tolerability of lacidipine and amlodipine in patients with mild-to-moderate hypertension: a randomized double-blind study. Cheung, BM; Lau, CP, 1996)	0.54
" From these results, the optimal dosage of amlodipine in the treatment of angina pectoris is 10 mg for the initial 3 days followed by 5 mg thereafter."	( Clinical evaluation of serum amlodipine level in patients with angina pectoris. Inomata, T; Izumi, T; Miyakita, Y; Nagatomo, T; Ochiai, Y; Qu, YL; Shiba, M; Shibata, A; Washizuka, T; Watanabe, K, 1996)	0.85
" An analysis was also performed on 84 outpatients with stable angina pectoris, who were included in an open, parallel study and received the same dosing regimen of either amlodipine or nifedipine SR as the patients in the hypertension arm of the study."	( Patient compliance and therapeutic coverage: amlodipine versus nifedipine SR in the treatment of hypertension and angina: interim results. Steering Committee and Cardiologists and General Practitioners involved in the Belgium Multicentre Study on Patient Detry, JM, 1994)	0.74
"To date, the clinical utility of first-generation, shortacting calcium antagonists has not been optimal due to their multiple dosing requirements."	( A double-blind evaluation of amlodipine in patients with chronic, stable angina: sustained efficacy and lack of "withdrawal phenomenon" upon abrupt discontinuation. Lopez, LM; Mehta, JL, 1994)	0.58
" The slow elimination of amlodipine explains the long duration of action, which allows a convenient once-daily dosage schedule."	( Amlodipine: an overview of its pharmacodynamic and pharmacokinetic properties. van Zwieten, PA, 1994)	2.03
" We have compared the pulmonary vasodilator effects, dose-response characteristics, and tolerability of two calcium channel blockers, amlodipine and extended-release (ER) felodipine, in 10 patients (seven men, age 68+/-4."	( A comparison of two long-acting vasoselective calcium antagonists in pulmonary hypertension secondary to COPD. Alpers, JA; Bune, AJ; Frith, PA; McEvoy, RD; Sajkov, D; Wang, T, 1997)	0.5
" Their dose-response characteristics are similar, but amlodipine treatment was associated with fewer side effects."	( A comparison of two long-acting vasoselective calcium antagonists in pulmonary hypertension secondary to COPD. Alpers, JA; Bune, AJ; Frith, PA; McEvoy, RD; Sajkov, D; Wang, T, 1997)	0.55
" The results suggest that the negative consequences of partial compliance for blood pressure control can be offset by choosing agents with a duration of action well beyond the dosing interval."	( Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring. Boileau, G; Bolli, P; Handa, SP; Larochelle, P; Leenen, FH; Myers, M; Tanner, J; Wilson, TW, 1997)	0.3
" The good anti-anginal and hypotensive efficacy and safety of amiodipine with once daily dosage regimen makes this drug an excellent choice of treatment for hypertensive patients with severe coronary artery disease."	( [Comparative study to assess the efficacy and adverse effects of amlodipine and nifedipine retard in patients with stable exertional angina and hypertension]. Hlawaty, M; Kubler, G; Negrusz-Kawecka, M; Olszowska, M; Salamon, P; Tracz, W; Witkowska, M, 1997)	0.53
" The coefficients of variation of maximal drug concentration and AUC after single dosing and at steady-state were significantly higher for felodipine ER than for amlodipine."	( Crossover comparison of the pharmacokinetics of amlodipine and felodipine ER in hypertensive patients. Jacobsen, IA; Videbaek, LM, 1997)	0.75
" In patients whose trough SDBP was greater than 90 mm Hg after 4 or 8 weeks of double-masked therapy, the dosage was titrated upward to mibefradil 100 mg or amlodipine 10 mg for the remainder of the 12-week active treatment period."	( Comparative efficacy and tolerability of two long-acting calcium antagonists, mibefradil and amlodipine, in essential hypertension. Mibefradil Hypertension Study Group. Benz, JR; Carr, A; Karch, FE; Lunde, NM; Marbury, T; Pordy, R; Tarro, JN, )	0.55
"The calcium antagonist amlodipine may have the potential for expanded use in children owing to its physiochemistry and pharmacokinetic profile that facilitates once-daily dosing in a liquid formulation."	( Efficacy of amlodipine in pediatric bone marrow transplant patients. Arbus, GS; Khattak, S; Koren, G; Rogan, JW; Saunders, EF; Theis, JG, 1998)	0.99
"Anginal patients who remain symptomatic despite optimally dosed beta blockade may also be given dihydropyridine calcium antagonists."	( Value of the addition of amlodipine to atenolol in patients with angina pectoris despite adequate beta blockade. Bernink, PJ; Bouwens, LH; Dunselman, PH; Herweijer, AH; Holwerda, KJ; van Kempen, LH, 1998)	0.6
" injection of amlodipine (1, 3, 10 mg/kg body weight) either at 8:00 or at 20:00 h dose-dependently reduced blood pressure irrespective of the dosing time."	( Effects of amlodipine once or twice daily on circadian blood pressure profile, myocardial hypertrophy, and beta-adrenergic signaling in transgenic hypertensive TGR(mREN2)27 rats. Lemmer, B; Schmidt, T; Schnecko, A; Voll, C; Witte, K, 1998)	1.05
" Once-daily dosing improves compliance, but 24-h antihypertensive activity should be provided."	( Compliance and antihypertensive efficacy of amlodipine compared with nifedipine slow-release. Bernaud, C; Carré, A; Charpentier, JC; Hotton, JM; Lequeuche, B; Mounier-Vehier, C, 1998)	0.56
" Amlodipine seems to be more effective than felodipine when the drugs are compared in the same dose, with regard to the effect on clinic BP 24 h after dosing and to ambulatory BP during the night."	( Effect of amlodipine versus felodipine extended release on 24-hour ambulatory blood pressure in hypertension. Brodin, U; Isaksson, H; Ohman, KP; Ostergren, J; Schwan, A, 1998)	1.61
" The procedures refer to situations when detailed comparisons make sense only if the sensitivity of the trial has been shown, for example, if a dose-response relationship or a difference between active control and placebo has been established."	( Testing strategies in multi-dose experiments including active control. Bauer, P; Hothorn, L; Maurer, W; Röhmel, J, 1998)	0.3
" Furthermore, amlodipine has the advantage of once-daily dosing and so may also be beneficial in ensuring good patient compliance."	( A comparative study of once-daily amlodipine versus twice-daily diltiazem controlled release (CR) in the treatment of stable angina pectoris. Amlodipine Study Group. van Kesteren, HA; Withagen, AJ, 1998)	0.94
" The impact of these agents will also be compared during irregular dosing periods."	( Amlodipine versus diltiazem CR in the reduction of the total ischemic burden: the Circadian Anti-Ischemia Program in Europe (CAPE) II trial--clinical rationale and methodology. Deanfield, JE, 1998)	1.74
" The amlodipine dosage was increased."	( Severe neuromuscular complications possibly associated with amlodipine. Muller, BA; Phillips, BB, 1998)	1.06
"To evaluate the appropriate dosing of amlodipine when converting patients from nifedipine extended-release (nifedipine ER) to amlodipine in the treatment of hypertension."	( Evaluation of amlodipine dosing for conversion of nifedipine extended-release to amlodipine in the treatment of hypertension. Enlow, AM; Halverson, VJ; Kilpatrick, DM; Lower, DL; Montopoli, G; Yamreudeewong, W, 1999)	0.94
" Dosing titration of amlodipine was required in 16 of 27 patients after the switch."	( Evaluation of amlodipine dosing for conversion of nifedipine extended-release to amlodipine in the treatment of hypertension. Enlow, AM; Halverson, VJ; Kilpatrick, DM; Lower, DL; Montopoli, G; Yamreudeewong, W, 1999)	0.98
"This study indicates the amlodipine dosage of 5 or 10 mg once daily can be used when nifedipine ER is converted to amlodipine in the treatment of hypertension."	( Evaluation of amlodipine dosing for conversion of nifedipine extended-release to amlodipine in the treatment of hypertension. Enlow, AM; Halverson, VJ; Kilpatrick, DM; Lower, DL; Montopoli, G; Yamreudeewong, W, 1999)	0.97
"This multicenter, randomized, double-blind, parallel group, placebo lead-in, placebo-controlled study compared the antianginal and anti-ischemic effects of once-daily bedtime dosing of controlled-onset extended-release (COER-24) verapamil to a once-daily morning dosing of amlodipine +/- atenolol in patients with chronic stable angina."	( Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. Deedwania, PC; Fakouhi, TD; Frishman, WH; Glasser, S; Johnson, M; Stone, P, 1999)	0.72
" The aim of the study reported here was to determine whether an early increase in dosage of amlodipine provided an advantage in terms of antihypertensive effect."	( Is initial dose titration of amlodipine worthwhile in patients with mild to moderate hypertension? Adamczak, M; Hayduk, K; Nowitzki, G, 1999)	0.81
" Clinical inputs include agent efficacy, side effects, and compliance with dosing schedules."	( An economic evaluation of the JNC hypertension guidelines using data from a randomized controlled trial. Joint National Committee. Neil, N; Perfetto, E; Ramsey, SD; Sullivan, SD, )	0.13
"To determine the stability of amlodipine besylate in two liquid dosage forms under refrigeration and at room temperature."	( Stability of amlodipine besylate in two liquid dosage forms. Hipple, TF; Morosco, RS; Nahata, MC, )	0.79
" The liquid dosage form would also permit accurate administration of amlodipine doses to infants and young children based on their body weight."	( Stability of amlodipine besylate in two liquid dosage forms. Hipple, TF; Morosco, RS; Nahata, MC, )	0.74
"Amlodipine is a calcium antagonist with a long elimination half-life (35 to 50 h) allowing a once daily dosing in the treatment of hypertension."	( Prolonged antihypertensive effect of amlodipine: a prospective double-blind randomized study. Biston, P; Clement, D; Degaute, JP; Mélot, C; Quoidbach, A, 1999)	2.02
" Dosage was doubled after 4 weeks when diastolic blood pressure was > 90 mmHg in sitting position, the treatment was continued for 12 weeks."	( Effects of amlodipine and enalapril on platelet function in patients with mild to moderate hypertension. Armas de Hernández, MJ; Armas-Padilla, MC; Carvajal, AR; Guerrero-Pajuelo, J; Hernández-Hernández, R; Pacheco, B; Velasco, M, 1999)	0.69
"3% of hypertensive patients with an average dosage of 31."	( Effects of amlodipine and enalapril on platelet function in patients with mild to moderate hypertension. Armas de Hernández, MJ; Armas-Padilla, MC; Carvajal, AR; Guerrero-Pajuelo, J; Hernández-Hernández, R; Pacheco, B; Velasco, M, 1999)	0.69
" Ambulatory blood pressure monitoring showed that blood pressure control was sustained over the 24-h dosing interval."	( Amlodipine lowers blood pressure without affecting cerebral blood flow as measured by single photon emission computed tomography in elderly hypertensive subjects. Clarke, SE; Pandita-Gunawardena, ND, 1999)	1.75
" To evaluate the dose-response relation between this pharmacological interference and dependent edema, a frequent side effect of CCBs during antihypertensive treatment, skin blood flow (laser Doppler flowmetry) at the dorsum of the foot, both supine and with the limb passively placed 50 cm below the heart level, and leg weight (Archimedes principle) were measured at baseline, during increasing doses of the dihydropyridine amlodipine (5 and 10 mg UID each for 2 weeks), and after drug withdrawal in 10 hypertensive men."	( Amlodipine, enalapril, and dependent leg edema in essential hypertension. Dell'Omo, G; Mariani, M; Melillo, E; Pedrinelli, R, 2000)	1.91
" The age, gender, current drug regimen and dosage were recorded for each participant and alginate impressions taken of both arches."	( The calcium channel blocker used with cyclosporin has an effect on gingival overgrowth. Boomer, S; Campbell, BA; Hull, PS; Irwin, CR; Jamal, S; James, JA; Johnson, RW; Linden, GJ; Marley, JJ; Maxwell, AP; Short, CD; Spratt, H, 2000)	0.31
" Earlier studies combining short acting drugs from these classes require multiple dosing and were associated with poor compliance."	( Evaluation of amlodipine, lisinopril, and a combination in the treatment of essential hypertension. Naidu, MU; Rao, TR; Shobha, JC; Usha, PR, 2000)	0.67
"Various studies have indicated that acute ethanol dosage perturbs cardiac function and/or structure with concomitant reductions in protein synthesis."	( Alcohol-induced reductions in cardiac protein synthesis in vivo are not ameliorated by treatment with the dihydropyridine calcium channel blocker amlodipine. Patel, VB; Preedy, VR; Richardson, PJ; Siddiq, T, 2000)	0.51
" Acute alcohol dosage reduced cardiac protein synthesis in mixed, myofibrillary, and sarcoplasmic protein fractions."	( Alcohol-induced reductions in cardiac protein synthesis in vivo are not ameliorated by treatment with the dihydropyridine calcium channel blocker amlodipine. Patel, VB; Preedy, VR; Richardson, PJ; Siddiq, T, 2000)	0.51
" In addition, data were collected and analyzed with regard to adverse drug reactions, average dosage of the alternative calcium channel blocker, number of additional antihypertensives begun or discontinued, and number of dosage changes in antihypertensives within the two visits after conversion, and the overall cost impact of conversion."	( Retrospective evaluation of the conversion of amlodipine to alternative calcium channel blockers. Beckey, NP; Korman, L; Parra, D, 2000)	0.57
" Conversion to calcium channel antagonists other than felodipine or less than equal dosages of felodipine may require dosage titration."	( Retrospective evaluation of the conversion of amlodipine to alternative calcium channel blockers. Beckey, NP; Korman, L; Parra, D, 2000)	0.57
" Twice-daily dosing may be required in many children to achieve BP control."	( Treatment of hypertensive children with amlodipine. Bunchman, TE; Flynn, JT; Smoyer, WE, 2000)	0.57
" However, it is difficult clinically to pinpoint the maximum dosage for antihypertensive activity of the drug without having parallel data on the plasma drug concentrations."	( Enzyme linked immunosorbent assay for determination of amlodipine in plasma. Arafat, T; Badwan, A; El-Thaher, T; Jehanli, A; Matalka, K; Saleem, M, 2001)	0.56
" Morning rather than evening dosing appeared to confer a slight advantage."	( Treatment of hypertension in patients > or =65 years of age: experience with amlodipine. Langdon, C, 2000)	0.54
" Given the lower incidence of adverse events with amlodipine and its convenient once daily dosing regimen, however, amlodipine may help to enhance patient compliance."	( [Amlodipine versus nifedipine retard. A randomized double-blind comparative study on long-term efficacy and safety of amlodipine and nifedipine retard in the monotherapy of chronic stable angina pectoris]. Kupper, W; Sauerbrey-Wullkopf, N, 2001)	1.47
" A possible use of the technique is shown using the example of the effect of varying the drug dosage on the contraction of the arteriole muscle."	( A rapid procedure for initial drug evaluation. Macpherson, AK; Macpherson, PA; Neti, S, 2001)	0.31
" In 11 patients concomitantly treated with cyclosporine the dosage and the trough-level of this agent were stable throughout the trial."	( Antihypertensive efficacy of amlodipine in children with chronic kidney diseases. Bianchetti, MG; Bianda, ND; Casaulta Aebischer, C; Franscini, LM; Pfister, R; von Vigier, RO, 2001)	0.6
" Responders continued on the same dosage for 16 additional weeks, while non-responders were titrated to 60 mg NI or 10 mg AM."	( Efficacy, tolerability and influence on "quality of life" of nifedipine GITS versus amlodipine in elderly patients with mild-moderate hypertension. Boari, L; De Dominicis, E; Giusti, C; Kilama, MO; Marchesi, M; Marelli, G; Mattarei, M; Mos, L; Novo, S; Pessina, AC; Pirrelli, A; Santini, M; Santonastaso, M; Semeraro, S; Uslenghi, E, 2001)	0.54
" The proposed method has been applied successfully to the analysis of the bulk drug and its dosage forms."	( Spectrophotometric method for the determination of amlodipine besylate with ninhydrin in drug formulations. Azmi, SN; Rahman, N, 2001)	0.56
" SHRSP were exposed to high dietary salt intake (1% NaCl in drinking solution) from 8 to 14 weeks of age, with or without amlodipine or lacidipine at three dosage regimens producing similar effects on blood pressure."	( Effects of amlodipine and lacidipine on cardiac remodelling and renin production in salt-loaded stroke-prone hypertensive rats. Godfraind, T; Krenek, P; Kyselovic, J; Wibo, M, 2001)	0.91
" Telmisartan (40, 80, and 120 mg) provided greater decreases in mean hourly systolic and diastolic blood pressure throughout the 24-hour dosing interval, including the last 4 hours of the dosing period, than amlodipine (5 and 10 mg)."	( Comparative effects of telmisartan in the treatment of hypertension. White, WB, )	0.32
"The optimal medical therapy for ischemia suppression and the impact of irregular dosing using agents with different pharmacologic properties has not been established in patients with coronary disease."	( Medical treatment of myocardial ischemia in coronary artery disease: effect of drug regime and irregular dosing in the CAPE II trial. Beckerman, B; Brennan, C; Bultas, J; Deanfield, JE; Detry, JM; Lichtlen, PR; Sellier, P; Thaulow, E; Young, ST, 2002)	0.31
" Nevertheless, physicians are often reluctant to prescribe multiple anti-hypertensive drugs due to concerns over side-effects, inconvenient dosing regimens and costs."	( A new fixed-dose combination for added blood pressure control: telmisartan plus hydrochlorothiazide. Lacourcière, Y, )	0.13
" Of these 708 patients 643 patients received once daily dosage of the combination whereas 10 patients received 1/2 daily, 13 patients received 1 1/2 daily and 42 patients received 1 twice daily dosage of the combination."	( Efficacy and safety of losartan-amplodipine combination--an Indian postmarketing surveillance experience. Gokhale, N; Pawar, D; Shahani, S, 2002)	0.31
" Of those who received a dosage adjustment, a significantly greater percentage of amlodipine-treated patients (59%) than losartan/HCTZ-treated patients (42%) reached BP goal at the last visit (p=0."	( The effects of amlodipine compared to losartan in patients with mild to moderately severe hypertension. Grimm, RH; Kloner, RA; Phillips, RA; Weinberger, M, )	0.71
" Both the methods were applied successfully for the analysis of amlodipine besylate in dosage forms."	( Validated spectrophotometric methods for the determination of amlodipine besylate in drug formulations using 2,3-dichloro 5,6-dicyano 1,4-benzoquinone and ascorbic acid. Nasrul Hoda, M; Rahman, N, 2003)	0.8
"Although fitting orders to renal function avoids overdosage and therefore iatrogenic risk, dosage adjustment is rarely made."	( Assessing residents' prescribing behavior in renal impairment. Brücker, G; Deray, G; Launay-Vacher, V; Levu, S; Ravaud, P; Salomon, L, 2003)	0.32
" Although no adjustment to renal function was required, 28% of the residents decreased the dosage of amlodipine and ordered an underdose."	( Assessing residents' prescribing behavior in renal impairment. Brücker, G; Deray, G; Launay-Vacher, V; Levu, S; Ravaud, P; Salomon, L, 2003)	0.53
"Considering the iatrogenic risk related to the lack of dosage adjustment, attention should be drawn to increasing residents' awareness of dosage adjustment in renal impairment and to providing them with better information on patients' renal function."	( Assessing residents' prescribing behavior in renal impairment. Brücker, G; Deray, G; Launay-Vacher, V; Levu, S; Ravaud, P; Salomon, L, 2003)	0.32
" at the same dosage for 6 weeks in three crossover periods each separated by a 2-week placebo wash-out period (3x3 latin square)."	( Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients. Corradi, L; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2003)	0.64
"3-fold in the dose-response curves."	( A comparative assessment of the duration of action of amlodipine and nifedipine GITS in normotensive subjects. Elliott, HL; Howie, CA; Meredith, PA; Ueda, S, 1993)	0.53
" The dosage was doubled if necessary."	( Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood. Bianchetti, MG; Edefonti, A; Fossali, E; Gartenmann, AC; Schmidtko, J; Simonetti, GD; von Vigier, RO, 2003)	0.32
" Dosage of both drugs was increased to irbesartan 300 mg once daily or amlodipine 10 mg once daily in case of sitting diastolic BP still >90 mm Hg after the first 2 weeks of treatment."	( Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy. Fedele, F; Fera, MS; Ferri, FM; Gaudio, C; Giovannini, M; Pannarale, G; Puddu, PE; Vittore, A; Vizza, CD, 2003)	0.82
"To compare the effects of morning and evening dosing of amlodipine on both circadian blood pressure (BP) and heart rate (HR) in mild-to-moderate essential hypertension."	( Differential effects of morning or evening dosing of amlodipine on circadian blood pressure and heart rate. Chen, JZ; Qiu, YG; Yao, XY; Zhu, JH, 2003)	0.81
" After 2 weeks of double-blind therapy, patients with a seated diastolic blood pressure > or =90 mm Hg had their doses titrated upward to 10 mg, while the other patients remained on their original 5 mg doses for another 4 weeks period, than crossover to the alternate dosing regimen for 6 additional weeks."	( Differential effects of morning or evening dosing of amlodipine on circadian blood pressure and heart rate. Chen, JZ; Qiu, YG; Yao, XY; Zhu, JH, 2003)	0.57
"05) were significantly greater with evening dosing compared with morning dosing."	( Differential effects of morning or evening dosing of amlodipine on circadian blood pressure and heart rate. Chen, JZ; Qiu, YG; Yao, XY; Zhu, JH, 2003)	0.57
" Treadmill exercise 12 hours (trough) and 4 hours (peak) after dosing was assessed after 2, 6 (trough only), and 12 weeks of treatment."	( Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. Chaitman, BR; Chumakova, G; Kuch, J; Parker, JO; Pepine, CJ; Skettino, SL; Skopal, J; Wang, W; Wolff, AA, 2004)	0.6
" The influence of CsA dosage and its trough level, HLA phenotype, gender and the administered calcium channel blocker on incidence and severity of overgrowth were studied."	( Risk factors of gingival overgrowth in kidney transplant recipients treated with cyclosporine A. Boratyńska, M; Klinger, M; Radwan-Oczko, M; Zietek, M, 2003)	0.32
" Total yearly CsA dosage was significantly higher in patients with overgrowth."	( Risk factors of gingival overgrowth in kidney transplant recipients treated with cyclosporine A. Boratyńska, M; Klinger, M; Radwan-Oczko, M; Zietek, M, 2003)	0.32
" CCBs were increased in dosage or other drugs were added until blood pressure decreased below 140/90 mmHg, but no inhibitors of the renin-angiotensin (RA) system were added or changed in dosage."	( Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases. Kojima, S; Shida, M; Yokoyama, H, 2004)	0.6
" There was a significant dose-response effect of amlodipine on both systolic and diastolic BP beginning at doses > or =0."	( A randomized, placebo-controlled trial of amlodipine in children with hypertension. Daniels, SR; Flynn, JT; Hogg, RJ; Newburger, JW; Portman, RJ; Sanders, SP; Saul, JP, 2004)	0.84
" Combination therapy of amlodipine besylate (Norvasc, Pfizer Ltd) with atorvastatin calcium (Lipitor, Pfizer Ltd), marketed as Caduet (Pfizer Ltd) is the first dual-therapy compound designed to treat hypertension and/or angina and dyslipidemia concurrently with a single daily pill in the full range of dosing combinations."	( Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease. Frishman, WH; Zuckerman, AL, 2004)	2.07
"5) After a 4-week wash-out period, they were randomized to amlodipine (5 mg) or atorvastatin (20 mg) or their combination at the same oral dosage for 12 weeks in three cross-over periods each separated by a 4-week placebo period (3 by 3 latin square design)."	( Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Rinaldi, A; Zoppi, A, 2004)	0.97
" 24-hour efficacy with once daily dosing was given as the most important argument for using Amlodipine besylate."	( [Safety and antihypertensive efficacy of the dihydropyridine calcium antagonist Amlodipine besylate--results from an observational study in 9,672 patients]. Clemens, A; Keck, M; Regourd, E; Sauerbrey-Wullkopf, N, 2004)	0.77
" In addition to recommending lifestyle modifications, eight dosage strengths of amlodipine/atorvastatin single pill (5/10, 5/20, 5/40, 5/80, 10/10, 10/20, 10/40, and 10/80 mg) were electively titrated to improve blood pressure and lipid control."	( Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study). Blank, R; LaSalle, J; Maroni, J; Reeves, R; Sun, F; Tarasenko, L, 2005)	0.78
" This study has shown that amlodipine effectively reduced blood pressure for 24 h after once-daily dosing and was well tolerated."	( 24-hour blood pressure control with the once-daily calcium antagonist amlodipine. Al-Khawaja, I; Brigden, G; Heber, ME; Raftery, EB, 1991)	0.81
" Exercise testing before and 6 h after dosing showed that an acute 10 mg dose of amlodipine reduced BP without modifying the physiologic response to dynamic exercise."	( Amlodipine in hypertension: its effects on platelet aggregation and dynamic exercise. Armas-de Hernande, MJ; Armas-Padilla, MC; Barragan, O; Carvajal, AR; Guerrero-Pajuelo, J; Hernández, R; Machado-de Alvarado, I, 1991)	1.95
"A placebo-controlled, double-blind, dose-response study of amlodipine (1."	( A double-blind, placebo-controlled, parallel dose-response study of amlodipine in stable exertional angina pectoris. Cocco, G; Jackson, N; Lee, P; Taylor, SH, 1991)	0.76
" It is concluded that amlodipine is an antihypertensive and anti-ischemic agent that has the combined advantages of a good safety profile with once-daily dosage and a smooth onset and long duration of action."	( An update on the safety of amlodipine. Osterloh, IH, 1991)	0.89
" Moreover, mice receiving morphine for 8 days demonstrated a significant rightward shift of the morphine antinociceptive dose-response curve, indicative of antinociceptive tolerance, whereas those that also received amlodipine along with morphine did not demonstrate tolerance."	( Spinal L-type calcium channel blockade abolishes opioid-induced sensory hypersensitivity and antinociceptive tolerance. Bilsky, EJ; Dogrul, A; Lai, J; Ossipov, MH; Porreca, F, 2005)	0.51
" Twenty-four-hour ambulatory blood pressure monitoring showed that telmisartan plus HCTZ (n=448) and amlodipine plus HCTZ (n=424) changed systolic blood pressure for the last 6 hours of the dosing interval by -18."	( Telmisartan plus HCTZ vs. amlodipine plus HCTZ in older patients with systolic hypertension: results from a large ambulatory blood pressure monitoring study. Edwards, C; Neldam, S, )	0.65
" Our data suggest that the DE may be a potential oral dosage form for amlodipine to improve its bioavailability."	( Improvement of bioavailability and photostability of amlodipine using redispersible dry emulsion. Jang, DJ; Jeong, EJ; Kim, BC; Kim, CK; Lee, HM; Lim, SJ, 2006)	0.82
" Amlodipine concentrations were similar in subjects dosed either once or twice daily."	( Population pharmacokinetics of amlodipine in hypertensive children and adolescents. Flynn, JT; Mahan, JD; Nahata, MC; Portman, RJ, 2006)	1.53
"Stable patients with coronary disease and > or =3 anginal attacks per week despite maximum recommended dosage of amlodipine (10 mg/day) were randomized to 1,000 mg ranolazine or placebo twice a day for 6 weeks."	( Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. Blokhin, A; Gratsiansky, NA; Huang, IZ; Meng, L; Stone, PH, 2006)	0.78
" In each study, subjects received multiple once-daily doses of aliskiren and the test antihypertensive drug alone or in combination in two dosing periods separated by a drug-free washout period."	( Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Bizot, MN; Denouel, J; Dieterich, HA; Dole, WP; Kemp, C; Vaidyanathan, S; Valencia, J; Yeh, CM; Zhao, C, 2006)	0.53
"5 mg; n=22), captopril (50 mg twice daily; n=22) or a capsule containing each of the 4 above at one-quarter dosage (n=22) in a parallel group design for 4 weeks."	( Low-dose quadruple antihypertensive combination: more efficacious than individual agents--a preliminary report. Feely, J; Mahmud, A, 2007)	0.34
" However, during the first 7 h after dosing, ABP was lower on VAL, whereas AML exerted a significantly stronger effect during the last 4 h of the dosing interval--possibly influencing the differences in office BP found in the main study."	( Ambulatory blood pressure monitoring after 1 year on valsartan or amlodipine-based treatment: a VALUE substudy. Høegholm, A; Julius, S; Kjeldsen, SE; Mancia, G; Nielsen, ES; Pedersen, OL; Pickering, T; Refsgaard, J; Weber, M, 2007)	0.58
" Different dosing regimens have been employed."	( Acute amlodipine overdose treated by high dose intravenous calcium in a patient with severe renal insufficiency. Hung, YM; Olson, KR, 2007)	0.82
" The proposed method was successfully applied to the pharmaceutical dosage forms containing the above-mentioned drug combination without any interference by the excipients."	( Simultaneous high-performance liquid chromatographic determination of atenolol and amlodipine in pharmaceutical-dosage form. Ahmed, M; Barman, RK; Hossain, MB; Ibne Wahed, MI; Islam, MA; Islam, R; Khan, A; Rahman, BM, 2007)	0.56
" The proposed methods were successfully applied to the analysis of AML in pure and pharmaceutical dosage forms with good accuracy; the recovery percentages ranged from 100."	( Validated spectrofluorometric methods for determination of amlodipine besylate in tablets. Abdel-Wadood, HM; Mahmoud, AM; Mohamed, NA, 2008)	0.59
" No adjustment in dosage based on pharmacokinetic considerations is required should vildagliptin be coadministered with amlodipine, valsartan, or ramipril in patients with type 2 diabetes and hypertension."	( Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects. Campestrini, J; Dole, K; Dole, WP; He, YL; Howard, D; Ligueros-Saylan, M; Marion, A; Pommier, F; Sabo, R; Sunkara, G; Wang, Y; Zhao, C, 2008)	0.76
"A simple, precise, specific and accurate reverse phase HPLC method has been developed for the simultaneous determination of metoprolol succinate (MS) and amlodipine besylate (AB) in tablet dosage form."	( Simultaneous determination of metoprolol succinate and amlodipine besylate in pharmaceutical dosage form by HPLC. Dongre, VG; Jadhav, VK; Karmuse, PP; Phadke, M; Shah, SB, 2008)	0.79
" Eight dosage strengths of single-pill amlodipine/atorvastatin were flexibly titrated."	( Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial. Bruschi, P; Ferdinand, KC; Flack, JM; Jamieson, MJ; Saunders, E; Shi, H; Tarasenko, L; Victor, R; Watson, K, 2008)	0.84
" The aim of this study was to clarify the add-on effects of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning blood pressure in patients with essential hypertension who were under long-acting calcium channel blocker amlodipine monotherapy."	( Add-on effect of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning hypertension and left ventricular hypertrophy in patients undergoing long-term amlodipine monotherapy. Gomi, T; Ikeda, T; Matsuda, N; Shibuya, Y; Shinozaki, S; Suzuki, Y, 2007)	0.71
" Amlodipine/valsartan, at approved dosage regimens, achieved significantly greater reductions in mean sitting diastolic and systolic blood pressure (BP) than amlodipine or valsartan monotherapy, or placebo in two randomized, double-blind, factorial trials in patients with mild to moderate hypertension."	( Amlodipine/Valsartan: fixed-dose combination in hypertension. Plosker, GL; Robinson, DM, 2008)	2.7
"Treatment regimens that require fewer dosage units and less frequent dosing to decrease the complexity and cost of care are among the strategies recommended to improve compliance with antihypertensive therapy."	( Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Dickson, M; Plauschinat, CA, 2008)	0.56
" Likewise, few studies have directly compared more than two agents or ARB/hydrochlorothiazide fixed-dose combinations, and most ARBs have not been compared across their full recommended dosage ranges."	( Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Smith, DH, 2008)	0.35
" Eight dosage strengths of single-pill amlodipine/atorvastatin (5/10, 10/10, 5/20, 10/20, 5/40, 10/40, 5/80 and 10/80 mg) were titrated to improve blood pressure and lipid control."	( Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). Aguilar-Salinas, CA; Chaves, H; Chopra, P; Erdine, S; Guindy, R; Howes, LG; Moller, RA; Ro, YM; Schou, IM; Tse, HF, 2009)	1
"The pharmacokinetics of amlodipine and olmesartan in healthy volunteers after coadministration of amlodipine besylate and olmesartan medoxomil concomitantly as separate dosage forms and together in a fixed-dose combination tablet were characterized in 5 phase I, randomized, crossover studies."	( Pharmacokinetics of amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed-dose combination. Allison, M; Bathala, MS; Haworth, S; Heyrman, R; Lee, J; Noveck, R; Rohatagi, S; Rubets, I; Salazar, DE; Shenouda, M, 2008)	0.98
" Real plasma samples from hypertensive patients receiving a dosing of 5mg antagonists were examined by using the proposed method."	( Determination of nicardipine and amlodipine in human plasma using on-line solid-phase extraction with a monolithic weak cation-exchange column. Chen, Y; Qi, L; Wei, X; Yang, G, 2009)	0.63
" black triangle In the comparison with amlodipine monotherapy, >70% of olmesartan medoxomil/amlodipine recipients, some requiring upwards dosage adjustment, met BP goals."	( Olmesartan medoxomil/amlodipine. Keam, SJ; Sanford, M, 2009)	0.94
" After a 4-week wash-out period, 209 patients were randomized to either CC 8 mg or AML 5 mg once daily for a minimum of 1 month, after which, if BP was not normalized, the dosage was doubled, followed by the addition of hydrochlorothiazide 12."	( Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study. Asmar, R; Baguet, JP; Mallion, JM; Nisse-Durgeat, S; Valensi, P, 2009)	0.35
"The purposes of this study were to describe amlodipine poisoning in children and to determine whether a dose-response relationship could be detected in this population using standardized call data from United States (US) poison centers."	( Amlodipine toxicity in children less than 6 years of age: a dose-response analysis using national poison data system data. Bakhireva, LN; Benson, BE; Spyker, DA; Troutman, WG; Watson, WA, 2010)	2.06
" Ingestions reported as a "taste or lick" (n = 53) were included as a dose of 1/10 of the dosage form involved."	( Amlodipine toxicity in children less than 6 years of age: a dose-response analysis using national poison data system data. Bakhireva, LN; Benson, BE; Spyker, DA; Troutman, WG; Watson, WA, 2010)	1.8
" In each subgroup, > or =1 dosage combination of amlodipine + OM significantly reduced SeDBP and SeSBP compared with constituent monotherapies."	( Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use. Karki, S; Lee, J; Melino, M; Oparil, S, 2009)	0.83
"A rapid, precise, specific, and accurate ultra performance liquid chromatography (UPLC) method has been developed and subsequently validated for simultaneous determination of amlodipine present as amlodipine basylate (AB) and benazepril hydrochloride (BH) in capsule dosage form."	( Simultaneous determination of amlodipine besylate and benazepril hydrochloride in pharmaceutical dosage form by LC. Farooqui, MN; Kasawar, GB, 2009)	0.83
" Blood pressure (BP) and heart rate were measured in the sitting position before dosing and at 1, 2, 4, 5, 6, 7, 8, 10, 12, 14, 24, 48, and 72 hours after oral administration of S-amlodipine or amlodipine racemate."	( Pharmacodynamic (hemodynamic) and pharmacokinetic comparisons of S-amlodipine gentisate and racemate amlodipine besylate in healthy Korean male volunteers: two double-blind, randomized, two-period, two-treatment, two-sequence, double-dummy, single-dose cr Jang, IJ; Kim, BH; Kim, JR; Kim, KP; Kim, MG; Lee, BY; Shin, SG; Yu, KS, 2010)	0.79
" h/mL after dosing with S-amlodipine and 129."	( Pharmacodynamic (hemodynamic) and pharmacokinetic comparisons of S-amlodipine gentisate and racemate amlodipine besylate in healthy Korean male volunteers: two double-blind, randomized, two-period, two-treatment, two-sequence, double-dummy, single-dose cr Jang, IJ; Kim, BH; Kim, JR; Kim, KP; Kim, MG; Lee, BY; Shin, SG; Yu, KS, 2010)	0.9
" Oral dosing of amlodipine (0."	( Protective effect of amlodipine against osteoporosis in stroke-prone spontaneously hypertensive rats. Ando, H; Fujimura, A; Ishikawa, E; Liu, Y; Maekawa, T; Motosugi, Y; Tsuruoka, S; Ushijima, K, 2010)	1.03
" We present a case of iatrogenic lipid emulsion overdose because of a dosing error."	( Iatrogenic lipid emulsion overdose in a case of amlodipine poisoning. Hendrickson, RG; McKeown, NJ; West, PL, 2010)	0.62
"The aim of the present study was to use ambulatory blood pressure (BP) monitoring (ABPM) to determine the efficacy of a fixed-dose combination of amlodipine (AML) and olmesartan medoxomil (OM) over the 24-hour dosing interval."	( Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study. Dubiel, R; Kereiakes, DJ; Maa, JF; Neutel, JM; Punzi, H; Shojaee, A; Waverczak, WF, 2010)	0.94
" Our data demonstrate the potential of SRS microscopy in high-speed screening of pharmaceutical solid dosage forms."	( Vibrational imaging of tablets by epi-detected stimulated Raman scattering microscopy. Carvajal, MT; Chen, H; Cheng, JX; Ely, DR; Jung, Y; Slipchenko, MN, 2010)	0.36
" They were successfully applied to the determination of AML and VAL in synthetic mixtures and in a pharmaceutical dosage form."	( High-performance liquid chromatographic and first derivative of the ratio spectrophotometric determination of amlodipine and valsartan in their binary mixtures. Dogan-Topal, B; Kul, D; Kutucu, T; Ozkan, SA; Uslu, B, )	0.34
"To explore if non-concurrent amlodipine dosing results in less drug interaction, the pharmacokinetic profiles, safety and efficacy endpoints were assessed following repeated doses of simvastatin, co-administered concurrently or non-concurrently with amlodipine in patients with coexisting hypertension and hyperlipidemia."	( Non-concurrent dosing attenuates the pharmacokinetic interaction between amlodipine and simvastatin. Choi, JW; Kim, SH; Lee, H; Lee, SJ; Lim, HE; Park, CG, 2010)	0.88
"The Cmax and AUClast and of simvastatin acid in the non-concurrent amlodipine dosing group were 63."	( Non-concurrent dosing attenuates the pharmacokinetic interaction between amlodipine and simvastatin. Choi, JW; Kim, SH; Lee, H; Lee, SJ; Lim, HE; Park, CG, 2010)	0.83
"Non-concurrent dosing may be a useful and safe therapeutic option for patients who require two or more drugs administered concomitantly, but who are likely to develop unwanted drug interactions."	( Non-concurrent dosing attenuates the pharmacokinetic interaction between amlodipine and simvastatin. Choi, JW; Kim, SH; Lee, H; Lee, SJ; Lim, HE; Park, CG, 2010)	0.59
" Amlodipine, however, has been shown to be effective in reducing BP throughout the day and night, independent of dosing time."	( Chronotherapy with valsartan/amlodipine fixed combination: improved blood pressure control of essential hypertension with bedtime dosing. Ayala, DE; Fernández, JR; Fontao, MJ; Hermida, RC; Mojón, A, 2010)	1.56
"A simple, rapid, and precise method is developed for the quantitative simultaneous estimation of amlodipine (AM) and olmesartan (OL) in combined pharmaceutical dosage form."	( Stability indicating LC method for the simultaneous determination of amlodipine and olmesartan in dosage form. Patil, KR; Rane, VP; Sangshetti, JN; Shinde, DB; Yeole, RD, 2010)	0.81
" The bedtime dosing of amlodipine and olmesartan seems more apt than the morning dose to obtain the therapeutic goal."	( The bedtime administration ameliorates blood pressure variability and reduces urinary albumin excretion in amlodipine-olmesartan combination therapy. Hoshino, A; Matsubara, H; Nakamura, T, 2010)	0.88
" In the young subjects, the first dose of either DHP did not decrease BP and chronic dosing decreased BP by approximately 10 mm Hg, which had disappeared by 24 hours."	( Pharmacokinetic and antihypertensive profile of amlodipine and felodipine-ER in younger versus older patients with hypertension. Coletta, E; Leenen, FH, 2010)	0.62
" In particular, mean 24-h BP and BP variability both correlate closely with hypertension end-organ damage and rate of CV events, which suggests that antihypertensive therapy should provide smooth BP control over the full 24-h dosing interval."	( Efficacy and tolerability of olmesartan/amlodipine combination therapy in patients with mild-to-severe hypertension: focus on 24-h blood pressure control. Bilo, G; Hoshide, S; Lonati, L; Ochoa, JE; Parati, G; Ramos, C, 2010)	0.63
" Once-daily treatment with amlodipine/valsartan/hydrochlorothiazide (10/320/25 mg) reduces ABP to a significantly greater extent than component-based dual therapy and maintains its effectiveness over the entire 24-h dosing period."	( 24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension. Calhoun, DA; Crikelair, N; Glazer, RD; Lacourcière, Y; Yen, J, 2011)	0.91
" The present study indicated that the implemention of both 5 mg and 10 mg dosage could enable accurate predictions of AUC(0-24 h) by the same LSS model."	( [Limited sampling strategy models for estimating AUC for amlodipine in Chinese healthy volunteers]. He, YC; Sheng, YC; Shi, JM; Wang, K; Xu, L; Yang, J; Zhang, M; Zheng, QS, 2010)	0.61
"This study compared the effects of morning and evening dosing of amlodipine/valsartan combination on 24-h blood pressure (BP) in patients uncontrolled by amlodipine (5 mg)."	( Efficacy of morning and evening dosing of amlodipine/valsartan combination in hypertensive patients uncontrolled by 5 mg of amlodipine. Achouba, A; Asmar, R; Gosse, P; Queré, S, 2011)	0.87
"Morning and evening dosing with amlodipine/valsartan had equivalent effects on systolic BP (mean 24 h, daytime, night-time, and 24-30 h) and diastolic BP (mean 24 h, daytime, night-time, and 24-30 h)."	( Efficacy of morning and evening dosing of amlodipine/valsartan combination in hypertensive patients uncontrolled by 5 mg of amlodipine. Achouba, A; Asmar, R; Gosse, P; Queré, S, 2011)	0.92
"In this first randomized trial evaluating the effects of intensive versus moderate dosing of the combination of amlodipine/valsartan, our data suggest that ABPM was a better method for assessing between-treatment differences than clinic or home BP recordings, although measurement of home BP as a single recording was a limitation of our trial."	( The role of ambulatory blood pressure monitoring compared with clinic and home blood pressure measures in evaluating moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker mo Giles, TD; Hilkert, R; Ofili, EO; Oparil, S; Pitt, B; Purkayastha, D; Samuel, R; Sowers, JR, 2011)	0.77
" In the two groups the patients with SeDBP ≥ 90 mm Hg were doubled the dosage of the initial regimen at the end of 4-week treatment for additional 4 weeks, and the patients with SeDBP < 90 mm Hg remained the initial regimen for additional 4 weeks."	( [Comparison of benazepril monotherapy to amlodipine plus benazepril in the treatment of patients with mild and moderate hypertension: a multicentre, randomized, double-blind, parallel-controlled study]. Fan, CM; Gao, MM; Li, CX; Li, YQ; Li, YS; Lu, XL; Pang, HM; Tao, YK; Wang, L; Wang, XW; Wang, YN; Yan, LR, 2011)	0.64
" Moreover, consistent reductions in BP were observed over the 24-hour dosing interval using ambulatory measurements."	( Olmesartan/amlodipine: a review of its use in the management of hypertension. Kreutz, R, 2011)	0.76
" In conclusion, this amlodipine/OM-based titration regimen was well tolerated and effectively lowered BP throughout the 24-hour dosing interval in patients with hypertension and type 2 diabetes."	( Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen. Littlejohn, T; Neutel, JM; Qian, C; Ram, CV; Sachson, R; Shojaee, A; Stoakes, KA, 2011)	0.93
" Twenty-two dogs were treated with amlodipine, at a median daily dosage of 0·38 mg/kg (interquartile range 0·28 to 0·49) divided in one to two applications per day."	( Occurrence of systemic hypertension in dogs with acute kidney injury and treatment with amlodipine besylate. Doherr, M; Francey, T; Geigy, CA; Schweighauser, A, 2011)	0.87
" The primary objective of the study was to determine the effect of once-daily dosing of a combination therapy for blood pressure (BP) and dyslipidemia using home BP monitoring on reaching clinical BP and the effect of daily dosing of combination therapy on reaching lipid goals."	( Improving adherence with amlodipine/atorvastatin therapy: IMPACT study. Crabbe, A; Delkhah, Y; Jones, J; Leonard, D; Nesbitt, S; Oliver, S, 2011)	0.67
"Three simple, specific, accurate and precise spectrophotometric methods manipulating ratio spectra are developed for the simultaneous determination of Amlodipine besylate (AM) and Atorvastatin calcium (AT) in tablet dosage forms."	( Three different spectrophotometric methods manipulating ratio spectra for determination of binary mixture of Amlodipine and Atorvastatin. Darwish, HW; El-Zeiny, BA; Hassan, SA; Salem, MY, 2011)	0.78
" The combination of amlodipine and atorvastatin in 8 different dosage strengths were flexibly titrated over a period of 14 weeks."	( Impact of combination therapy with amlodipine and atorvastatin on plasma adiponectin levels in hypertensive patients with coronary artery disease: combination therapy and adiponectin. Cheung, BM; Lam, KS; Li, M; Tse, HF; Xu, A, 2011)	0.97
" The preparation was prescribed in different fixed dosage depending on duration of hypertension, quantity of taken hypertension groups of preparations and blood pressure level."	( [Estimation of antihypertension efficiency and use of fixed combination perindopril+amlodipin by uncontrollable hypertension patients within the limits of routine treatment]. Ishmurzin, GP, 2011)	0.37
" Greater efficacy was also found during daytime and nighttime hours and during the last 6, 4, or 2 hours of the dosing interval."	( 24-hour efficacy and safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: the TRINITY ambulatory blood pressure substudy. Chrysant, SG; Fernandez, V; Heyrman, R; Izzo, JL; Kereiakes, DJ; Lee, J; Littlejohn Iii, T; Melino, M; Oparil, S, 2011)	0.6
"6 mmHg), ABP in the last 4 hours of the dosing period (-21."	( Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ. Duprez, D; Ferdinand, K; Purkayastha, D; Samuel, R; Wright, R, 2011)	0.37
"The aim of this study was to determine the dose-response relationship and assess the efficacy and safety of amlodipine or losartan monotherapy and amlodipine camsylate/losartan combination therapy in patients with essential hypertension."	( Evaluation of the dose-response relationship of amlodipine and losartan combination in patients with essential hypertension: an 8-week, randomized, double-blind, factorial, phase II, multicenter study. Chae, SC; Cho, SY; Choi, YJ; Hong, BK; Hong, TJ; Jeong, JW; Kim, CH; Kim, JJ; Kim, MH; Kwan, J; Park, CG; Park, SH; Yang, JY; Youn, HJ, 2012)	0.85
" Clinical assessment of GO was correlated with patient's age, gender, drug dosage (2."	( Prevalence of gingival overgrowth among elderly patients under amlodipine therapy at a large Indian teaching hospital. Bhat, GS; Bhat, KM; Karnik, R, 2012)	0.62
" Plaque and gingival inflammation were highly correlated with this condition, while demographic characteristics and drug dosage did not relate significantly."	( Prevalence of gingival overgrowth among elderly patients under amlodipine therapy at a large Indian teaching hospital. Bhat, GS; Bhat, KM; Karnik, R, 2012)	0.62
"A simple, specific, accurate and precise stability-indicating reversed-phase high-performance liquid chromatographic method was developed for simultaneous estimation of olmesartan medoxomile (OLME), amlodipine besylate (AMLO) and hydrochlorothiazide (HCTZ) in tablet dosage form."	( Stability-indicating method for simultaneous estimation of olmesartan medoxomile, amlodipine besylate and hydrochlorothiazide by RP-HPLC in tablet dosage form. Chaudhari, AJ; Gorle, AP; Jain, PS; Patel, MK; Surana, SJ, 2012)	0.79
" In the intervention group, Shiyiwei Shenqi Capsule was given additionally to the subgroup of yang-qi deficiency at the dosage of 3-5 capsules, thrice a day, while Dengzhan Shengmai Capsule was given additionally to the subgroup of yin-qi deficiency at the dosage of 2 capsules, 2-3 times per day."	( Clinical study of western medicine combined with Chinese medicine based on syndrome differentiation in the patients with polarized hypertension. Chen, SL; Chen, XL; Liu, XY; Mei, WY; Xu, WM, 2012)	0.38
" First, optimized sample scenarios were designed using WinPOPT software according to the aim, dosage regimen and visit schedule of the clinical study protocol, and the amlodipine population model reported by Rohatagi et al."	( [Modeling and simulation activities to design sampling scheme for population pharmacokinetic study on amlodipine]. Barrett, JS; Di, W; Guo, R; Huang, ZJ; Jing, NN; Ng, CM; Pei, Q; Yang, GP; Yuan, H; Zhang, BK; Zhou, YN; Zuo, XC, 2012)	0.79
" The single pill triple combination of aliskiren, amlodipine, and hydrochlorothiazide offers five different formulations of escalating dosages of the three agents, allowing dosing flexibility."	( The single pill triple combination of aliskiren, amlodipine, and hydrochlorothiazide in the treatment of hypertension. Huan, Y; Townsend, R, 2012)	0.89
" BP reductions were maintained throughout the 24 h dosing period, and 24 h goal rates were obtained in a high proportion of patients."	( Telmisartan plus amlodipine single-pill combination for the management of hypertensive patients with a metabolic risk profile (added-risk patients). Ley, L; Schumacher, H, 2013)	0.73
" Steady states of both compounds were attained after once-daily dosing for 8 days."	( Pharmacokinetic and pharmacodynamic profiles of a fixed-dose combination of olmesartan medoxomil and amlodipine in healthy Chinese males and females. Chen, X; Hu, P; Jiang, J; Liu, H; Liu, T; Zhao, Q; Zhong, W, 2012)	0.59
"Three simple, specific, accurate and precise spectrophotometric methods depending on the proper selection of two wavelengths are developed for the simultaneous determination of Amlodipine besylate (AML) and Atorvastatin calcium (ATV) in tablet dosage forms."	( Three different methods for determination of binary mixture of Amlodipine and Atorvastatin using dual wavelength spectrophotometry. Darwish, HW; El-Zeany, BA; Hassan, SA; Salem, MY, 2013)	0.82
"Accurate, sensitive and reproducible reversed-phase high-performance liquid chromatography (RP-HPLC), high-performance thin-layer chromatography (HPTLC) and ultraviolet (UV) spectrophopometric methods were developed for the concurrent estimation of amlodipine besylate (AMLO), hydrochlorothiazide (HCTZ) and valsartan (VALS) in bulk and combined tablet dosage forms."	( Concurrent estimation of amlodipine besylate, hydrochlorothiazide and valsartan by RP-HPLC, HPTLC and UV-spectrophotometry. Kothari, C; Mehta, P; Sharma, M; Sherikar, O, 2014)	0.89
" Control of blood pressure with fixed dose combination of the above drugs acting through different mechanism have a benefit of convenient dosing in terms of compliance, lower the dose and subsequently reduce the side effects."	( A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. Biswas, E; Choudhury, H; Ghosh, B; Gorain, B; Halder, D; Pal, TK; Sarkar, AK; Sarkar, P, 2013)	0.39
"5 mg) (ARB+D; n = 72) or a combination of amlodipine (5 mg) and the typical dosage of ARBs (ARB+C; n = 68) to evaluate the change in the BP, laboratory values and cognitive function."	( Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. Hasebe, N; Kikuchi, K; Koyama, S; Maruyama, J; Morimoto, H; Morita, K; Saijo, Y; Sano, H; Sasagawa, Y; Sato, N; Sumitomo, K; Takehara, N; Takeuchi, T, 2013)	0.65
" Antihypertensive efficacy was maintained throughout the 24-hour dosing interval."	( Efficacy/safety of a fixed-dose amlodipine/olmesartan medoxomil-based treatment regimen in hypertensive blacks and non-blacks with uncontrolled BP on prior antihypertensive monotherapy. Maa, JF; Nesbitt, S; Shojaee, A, 2013)	0.67
" At inclusion, previous angiotensin-converting enzyme (ACE) inhibitors and/or calcium channel blockers (CCBs) were replaced by a perindopril/amlodipine fixed-dose combination at a dosage (5/5, 5/10, 10/5, or 10/10 mg) chosen by the physician and uptitrated at month 1, if required."	( Twenty-four-hour ambulatory blood pressure reduction with a perindopril/amlodipine fixed-dose combination. Nagy, VL, 2013)	0.82
" Amlodipine is often favored clinically over other calcium channel blockers for its vascular selectivity and relative lack of negative ionotropy, once daily dosing and prolonged duration of effect."	( Postoperative hypotension associated with amlodipine. Kadam, PG; Shah, VR, 2013)	1.56
" The proposed method was successfully applied to amlodipine besylate and aliskiren hemifumarate in pharmaceutical dosage mixtures without any interference from the excipients."	( Simultaneous determination of amlodipine and aliskren in tablets by high-performance liquid chromatography. Akyüz, A; Özdemir, FA, 2014)	0.95
" A fixed-dose combination (FDC) drug is a formulation including fixed amounts of active drug ingredients combined in a single dosage form that is expected to improve medication compliance."	( Pharmacokinetic comparison of 2 fixed-dose combination tablets of amlodipine and valsartan in healthy male Korean volunteers: a randomized, open-label, 2-period, single-dose, crossover study. Bahng, MY; Chae, D; Kim, Y; Lee, D; Park, K; Roh, H; Son, H; Son, M, 2013)	0.63
" The developed method is applicable for the determination of related substances in bulk drugs and simultaneous assay in a tablet pharmaceutical dosage form."	( A validated stability-indicating RP-LC method for the simultaneous determination of amlodipine and perindopril in tablet dosage form and their stress degradation behavior under ICH-recommended stress conditions. Gumustas, M; Ozkan, SA, )	0.36
"In the observation program AESCULAP using the fixed-dose combination of amlodipine/valsartan as different dosage regimens (5/160 and 10/160 mg) and/or a diuretic, there was a marked antihypertensive effect in different subgroups of patients with previously uncontrolled hypertension and the BP goals being achieved in 79."	( [On the way to achieve hypertension treatment goals: results of the open observational program AESCULAP (exforge--clinical safety and efficiency of using a double combination of antihypertensive drugs in patients with uncontrolled blood pressure)]. Chazova, IE; Martynyuk, TV, 2013)	0.62
" The smoothness index (SI) provides a useful measure of antihypertensive treatment efficacy over the 24 h dosing period, its values being highest with antihypertensive agents that have large and consistent effects across 24 h."	( Blood pressure variability over 24 h: prognostic implications and treatment perspectives. An assessment using the smoothness index with telmisartan-amlodipine monotherapy and combination. Parati, G; Schumacher, H, 2014)	0.6
" The methods were used for the quantitative analysis of the drugs in raw materials and pharmaceutical dosage form via handling the UV spectral data."	( Different approaches in Partial Least Squares and Artificial Neural Network models applied for the analysis of a ternary mixture of Amlodipine, Valsartan and Hydrochlorothiazide. Darwish, HW; El-Zeany, BA; Hassan, SA; Salem, MY, 2014)	0.61
"Four simple, accurate, reproducible, and selective methods have been developed and subsequently validated for the determination of Benazepril (BENZ) alone and in combination with Amlodipine (AML) in pharmaceutical dosage form."	( Comparative study between univariate spectrophotometry and multivariate calibration as analytical tools for quantitation of Benazepril alone and in combination with Amlodipine. Elaziz, OA; Farouk, M; Hemdan, A; Shehata, MA; Tawakkol, SM, 2014)	0.79
" The specificity of the developed methods is investigated by analyzing laboratory prepared mixtures containing different ratios of the three drugs and their combined dosage form."	( Spectrophotometric methods for simultaneous determination of ternary mixture of amlodipine besylate, olmesartan medoxomil and hydrochlorothiazide. Diab, SS; Merey, HA; Moustafa, AA; Ramadan, NK, 2014)	0.63
"A novel, specific, reliable, and accurate capillary zone electrophoretic method was developed and validated for the simultaneous determination of aliskiren hemifumarate, amlodipine besylate, and hydrochlorothiazide in their triple mixture dosage form."	( Simultaneous determination of aliskiren hemifumarate, amlodipine besylate, and hydrochlorothiazide in their triple mixture dosage form by capillary zone electrophoresis. Belal, F; Ebeid, WM; El-Enany, N; Patonay, G; Salim, MM; Walash, M, 2014)	0.85
" There were no differences between 4 dosing regimens in laboratory and clinical parameters of safety and tolerability."	( [Fixed irbesartan/amlodipine combination: efficacy and safety of the use of four dosing regimens in patients with arterial hypertension]. Kobalava, ZhD, 2014)	0.74
" We investigated the relevant impact of different dosing times of antihypertensive drugs beyond CPAP application."	( Evening versus morning dosing of antihypertensive drugs in hypertensive patients with sleep apnoea: a cross-over study. Andrikou, I; Aragiannis, D; Bilo, G; Dimitriadis, K; Filis, K; Kasiakogias, A; Parati, G; Sideris, S; Stefanadis, C; Thomopoulos, C; Tsiachris, D; Tsioufis, C, 2015)	0.42
"Evening dosing of antihypertensive drugs improves night-time BP and dipping status in nonsleepy patients with OSA, irrespective of CPAP application."	( Evening versus morning dosing of antihypertensive drugs in hypertensive patients with sleep apnoea: a cross-over study. Andrikou, I; Aragiannis, D; Bilo, G; Dimitriadis, K; Filis, K; Kasiakogias, A; Parati, G; Sideris, S; Stefanadis, C; Thomopoulos, C; Tsiachris, D; Tsioufis, C, 2015)	0.42
" In June 2011, the US FDA released a Drug Safety Communication that provided updated product labeling with dosing restrictions for simvastatin to minimize the risk of myopathies."	( Simvastatin prescribing patterns before and after FDA dosing restrictions: a retrospective analysis of a large healthcare claims database. Ghushchyan, V; Nair, K; Saseen, JJ; Tuchscherer, RM, 2015)	0.42
"Our objective was to describe prescribing patterns of simvastatin in combination with medications known to increase the risk of myopathies following updated product labeling dosing restrictions in June 2011."	( Simvastatin prescribing patterns before and after FDA dosing restrictions: a retrospective analysis of a large healthcare claims database. Ghushchyan, V; Nair, K; Saseen, JJ; Tuchscherer, RM, 2015)	0.42
" The patients were treated with a fixed combination of dosage forms ofp erindopril and amlodipine at 10/5 mg/days or 10/10 mg/days for 24 weeks."	( [Organoprotective effects of the combination of perindopril and amlodipine depending on the renal functional state in patients with arterial hypertension]. Budagovskaia, ZM; Iskenderov, BG; Sisina, ON, 2013)	0.85
"A new rapid stability-indicating UPLC method for separation and determination of impurities in amlodipine besylate, valsartan and hydrochlorothiazide in their combined tablet dosage form was developed."	( A new, rapid, stability-indicating UPLC method for separation and determination of impurities in amlodipine besylate, valsartan and hydrochlorothiazide in their combined tablet dosage form. Coufal, P; Janečková, L; Jedlička, A; Vojta, J, 2015)	0.85
" It is a major determinant of half-life and dosing frequency of a drug."	( Volume of Distribution in Drug Design. Beaumont, K; Di, L; Maurer, TS; Smith, DA, 2015)	0.42
" This study aims to investigate whether calcium channel blockers plus low dosage aspirin therapy can reduce the incidence of complications during pregnancy with chronic hypertension and improve the prognosis of neonates."	( The effect of calcium channel blockers on prevention of preeclampsia in pregnant women with chronic hypertension. Jiang, N; Liu, L; Liu, Q; Yang, WW; Zeng, Y, 2015)	0.42
" The ANCOVA showed that changes in patients' HRQoL was likely to have been influenced by patients' achievement of blood pressure control, the amount of concomitant medication and patients' last used dosage strength of antihypertensive."	( Health-related quality of life impact of a triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorotiazide in subjects with hypertension. Brazier, JE; Guest, JF; Haag, U; Marques da Silva, P; Soro, M, 2015)	0.64
" Achieving blood pressure control, amount of concomitant medication and dosage strength of antihypertensive impacted on patients' HRQoL."	( Health-related quality of life impact of a triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorotiazide in subjects with hypertension. Brazier, JE; Guest, JF; Haag, U; Marques da Silva, P; Soro, M, 2015)	0.64
" Commercially available tablet formulations were successfully analysed using the developed methods without interference from other dosage form additives except PLS model, which failed to determine both drugs in their pharmaceutical dosage form."	( Conventional univariate versus multivariate spectrophotometric assisted techniques for simultaneous determination of perindopril arginin and amlodipine besylate in presence of their degradation products. Abbas, SS; Essam, HM; Hegazy, MA; Zaazaa, HE, 2015)	0.62
"Two advanced, accurate and precise chemometric methods are developed for the simultaneous determination of amlodipine besylate (AML) and atorvastatin calcium (ATV) in the presence of their acidic degradation products in tablet dosage forms."	( Advanced stability indicating chemometric methods for quantitation of amlodipine and atorvastatin in their quinary mixture with acidic degradation products. Darwish, HW; El-Zeany, BA; Hassan, SA; Salem, MY, 2016)	0.88
" Specificity was investigated by analyzing the synthetic mixtures containing different ratios of the three studied drugs and their tablets dosage form."	( Application and validation of superior spectrophotometric methods for simultaneous determination of ternary mixture used for hypertension management. Lamie, NT; Mohamed, HM, 2016)	0.43
"Hypertensive patients who had not achieved their target blood pressure with at least 4 weeks of ARB therapy were randomly assigned to receive either a fixed-dose combination of losartan and HCTZ (losartan/HCTZ; n=110) or a combination of amlodipine and a typical ARB dosage (CCB/ARB; n=121) and followed for 24 weeks."	( Effect of Diuretic or Calcium-Channel Blocker Plus Angiotensin-Receptor Blocker on Diastolic Function in Hypertensive Patients. Ishii, K; Ito, H; Iwakura, K; Kihara, H; Toh, N; Watanabe, H; Yoshikawa, J, 2016)	0.62
"Simultaneous spectrophotometric analysis of a multi-component dosage form of olmesartan, amlodipine and hydrochlorothiazide used for the treatment of hypertension has been carried out using various chemometric methods."	( Simultaneous quantitative analysis of olmesartan, amlodipine and hydrochlorothiazide in their combined dosage form utilizing classical and alternating least squares based chemometric methods. Abdelhameed, AS; Bakheit, AH; Darwish, HW, 2016)	0.91
" The specificity of the developed methods is investigated by analyzing laboratory prepared mixtures of the two drugs and their combined dosage form."	( Spectrophotometric Methods for Simultaneous Determination of Amlodipine Besylate and Atenolol in Their Tablet Dosage Form. Lamie, NT, 2015)	0.66
"Three simple, selective, and accurate spectrophotometric methods have been developed and then validated for the analysis of Benazepril (BENZ) and Amlodipine (AML) in bulk powder and pharmaceutical dosage form."	( Development and validation of different methods manipulating zero order and first order spectra for determination of the partially overlapped mixture benazepril and amlodipine: A comparative study. Hemdan, A, 2016)	0.83
"Four new spectrophotometric methods were developed, applied to resolve the overlapped spectra of a ternary mixture of [aliskiren hemifumarate (ALS)-amlodipine besylate (AM)-hydrochlorothiazide (HCT)] and to determine the three drugs in pure form and in combined dosage form."	( Resolution of overlapped spectra for the determination of ternary mixture using different and modified spectrophotometric methods. Ahmed, MS; El-Zaher, AA; Mahrouse, MA; Moussa, BA, 2016)	0.63
" The commercially available tablets of 5 and 10mg do not provide the necessary flexibility in dosing needed for treating children."	( Design and stability study of an oral solution of amlodipine besylate for pediatric patients. Hanff, LM; Koch, BC; Postma, DJ; Smeets, OS; van der Velde, I; van der Vossen, AC; Vermes, A; Vulto, AG, 2016)	0.69
" Microbiological quality was studied in an 18-week in-use test based on a two-times daily dosing schedule."	( Design and stability study of an oral solution of amlodipine besylate for pediatric patients. Hanff, LM; Koch, BC; Postma, DJ; Smeets, OS; van der Velde, I; van der Vossen, AC; Vermes, A; Vulto, AG, 2016)	0.69
" This liquid formulation is preferred over manipulated commercial dosage forms or non-standardized extemporaneously compounded formulations."	( Design and stability study of an oral solution of amlodipine besylate for pediatric patients. Hanff, LM; Koch, BC; Postma, DJ; Smeets, OS; van der Velde, I; van der Vossen, AC; Vermes, A; Vulto, AG, 2016)	0.69
"The median daily dosage of RIS did not differ between the groups (p=0."	( Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions. Gründer, G; Haen, E; Lammertz, SE; Paulzen, M; Schoretsanitis, G; Schruers, KR; Stegmann, B; Walther, S, 2016)	0.43
"BACKGROUND Is the timing of dosing for amlodipine and atorvastatin important with regard to therapeutic efficacy? To answer this question, we designed an outpatient, practice-based, case-control study lasting 8 weeks."	( Is Time an Important Problem in Management of Hypertension and Hypercholesterolemia by Using an Amlodipine-Atorvastatin Single Pill Combination? Wang, M; Zeng, R; Zhang, L, 2016)	0.92
"A total of 108 mild-to-moderate essential hypertension patients in Chinese Han nationality were treated with amlodipine for 8 weeks at a dosage of 5 mg/d."	( [Association between gene polymorphism of calcium/calmodulin-dependent kinase 4 and efficacy of amlodipine in the treatment of hypertension in Chinese Han nationality]. Chen, Y; Liu, L; Liu, Y; Luo, Y; Yang, L; Yao, J; Zhong, G, 2016)	0.86
" The case for fixed-dose combination (FDC) oral dosage forms and orally disintegrating tablet (ODT) technology to enhance outcomes and compliance is strong."	( Fixed-dose combination orally disintegrating tablets to treat cardiovascular disease: formulation, in vitro characterization and physiologically based pharmacokinetic modeling to assess bioavailability. Badhan, RK; Dennison, TJ; Mohammed, AR; Smith, JC, 2017)	0.46
" These advantages inform their uses in the design of drug dosage forms."	( Formulation and Evaluation of Oral Dissolving Films of Amlodipine Besylate Using Blends of Starches With Hydroxypropyl Methyl Cellulose. Ayorinde, JO; Balogun-Agbaje, O; Odeniyi, MA, )	0.38
" Hence, the present study was undertaken to study the chronopharmacokinetic and chronopharmacodynamic phenomena of amlodipine and evaluate the effect of time of dosage in hypertensive subjects."	( Evaluation of the effect of time dependent dosing on pharmacokinetic and pharmacodynamics of amlodipine in normotensive and hypertensive human subjects. Hs, S; Khodadoustan, S; Kumar, C; Nasri Ashrafi, I; S, C; Vanaja Satheesh, K, 2017)	0.88
" The primary objective of the PETRA study was to evaluate the efficacy of blood pressure (BP) control with once daily administration of the different dosage strengths of the once-daily, triple fixed combination of perindopril, indapamide, and amlodipine."	( The Antihypertensive Efficacy of the Triple Fixed Combination of Perindopril, Indapamide, and Amlodipine: The Results of the PETRA Study. Ábrahám, G; Dézsi, CA, 2017)	0.86
" Here, we hypothesized different efficacy of morning versus evening dosing of VA in spontaneously hypertensive rats (SHR) and the involvement of circadian clock genes Bmal1 and Per2."	( mRNA levels of circadian clock components Bmal1 and Per2 alter independently from dosing time-dependent efficacy of combination treatment with valsartan and amlodipine in spontaneously hypertensive rats. Doka, G; Klimas, J; Kralova, E; Krenek, P; Potucek, P; Radik, M, 2017)	0.65
" The purpose of this study was to explore the optimal dosage of a fixed-dose combination of candesartan cilexetil (CAN) and amlodipine besylate (AML), by examining the tolerability and efficacy of CAN/AML combination therapy compared with those of monotherapy with either drug in patients with essential hypertension."	( Efficacy and Tolerability of Combination Therapy Versus Monotherapy with Candesartan and/or Amlodipine for Dose Finding in Essential Hypertension: A Phase II Multicenter, Randomized, Double-blind Clinical Trial. Ahn, T; Chae, SC; Cho, EJ; Cho, JH; Choi, JY; Chung, WB; Hong, TJ; Ihm, SH; Jeon, HK; Jeong, MH; Kim, CJ; Kim, WS; Kim, YK; Lee, HY; Lee, JH; Nam, CW; Park, JI; Park, SM; Shin, ES; Sohn, IS; Yang, TH; Yoon, JH; Youn, HJ, 2017)	0.88
"Drug half-life has important implications for dosing regimen and peak-to-trough ratio at the steady state."	( Relevance of Half-Life in Drug Design. Beaumont, K; Di, L; Maurer, TS; Smith, DA, 2018)	0.48
"The objective of this study was to evaluate non-crystalline cellulose (NCC) as a novel tablet excipient in solid oral dosage forms in comparison with microcrystalline cellulose (MCC) and silicified microcrystalline cellulose (Prosolv®, SMCC)."	( Evaluation of non-crystalline cellulose as a novel excipient in solid dose products. Babu, RJ; Lee, Y; Pawar, K; Rangari, V; Render, D, 2018)	0.48
"Based on the data, it can be concluded that NCC can serve as a cheaper and better alternative to MCC as excipient in solid dosage forms."	( Evaluation of non-crystalline cellulose as a novel excipient in solid dose products. Babu, RJ; Lee, Y; Pawar, K; Rangari, V; Render, D, 2018)	0.48
"For both candesartan and amlodipine, the 90% confidence intervals for the geometric mean ratios of area under the concentration-time curve from time zero to the time of dosing interval of 24 hours and maximum concentration after drug administration fell within the bioequivalence acceptance criteria."	( No pharmacokinetic interactions between candesartan and amlodipine following multiple oral administrations in healthy subjects. Huh, W; Kim, JR; Kim, S; Ko, JW, 2018)	1.03
" It was confirmed that the degradation product was formed by the reaction of amlodipine with formaldehyde originating from the excipients present in the dosage form."	( Identification and structure elucidation of a new degradation impurity in the multi-component tablets of amlodipine besylate. Břicháč, J; Douša, M; Gibala, P; Kalášek, S; Kalužíková, A; Štefko, M; Tkadlecová, M, 2019)	0.96
" Multiple blood and milk samples were obtained from the mothers over a 24 hours dosing interval."	( Low Levels of Amlodipine in Breast Milk and Plasma. Aoki, H; Ito, N; Ito, S; Kaniwa, N; Murashima, A; Nakajima, K; Okamoto, A; Sago, H; Saito, Y; Wada, Y, 2018)	0.84
"Four new, simple, and reproducible spectrophotometric methods were developed and validated for the simultaneous determination of Amlodipine (AML) and Atorvastatin (AT) in bulk powder and pharmaceutical dosage form."	( Determination of amlodipine and atorvastatin mixture by different spectrophotometric methods with or without regression equations. Fares, NV; Farouk, M; Hemdan, A; Magdy, R, 2019)	1.06
"Significant increases in BP control were observed with each dosage increment of perindopril/amlodipine, which was well tolerated, rising from 21% (3."	( Efficacy and Safety of Incremental Dosing of a New Single-Pill Formulation of Perindopril and Amlodipine in the Management of Hypertension. Dolan, E; Gupta, AK; O'Brien, E; Poulter, NR; Sever, PS; Whitehouse, A, 2019)	0.95
" Edema resulting from chronic dosing may be explained by the aforementioned effects."	( Amlodipine alters hemorheological parameters: Increased efficacy at the cost of edema? Arunkumar, S; Lokhandwala, Y; Padgaonkar, K; Panicker, G; Puniyani, RR; Ravindra, RP; Sharma, R; Vadivelu, R, )	1.57
" In the absence of AH, patients received scheme I -(Mertenil® at initial dosage of 10 mg/day)."	( ANICHKOV study: the effect of combined hypotensive and lipid-lowering therapy on cardiovascular complications in patients of high and very high risk. Ansheles, AA; Boytsov, SA; Drapkina, ОМ; Gornyakova, NB; Kuharchuk, VV; Sergienko, IV; Shepel, RN; Zubareva, MY, 2019)	0.51
"5%) were adherent to the therapy (PDC ≥ 80%); among them, a small percentage required dosage modification."	( Treatment with Free Triple Combination Therapy of Atorvastatin, Perindopril, Amlodipine in Hypertensive Patients: A Real-World Population Study in Italy. Degli Esposti, L; Gambera, M; Nati, G; Perone, F; Perrone, V; Tagliabue, PF; Veronesi, C; Volpe, M, 2019)	0.74
"5-mg, 5-mg, and 10-mg amlodipine besylate tablets do not provide the necessary flexibility in dosing needed for treating children."	( Physicochemical Stability of Compounded Amlodipine Besylate Suspensions in PCCA Base, SuspendIt. Bostanian, LA; Graves, RA; Mandal, TK; Morris, TC; Nguyen, AT; Pramar, YV; Swopes, D, )	0.71
" The significance of using drug combination is that it can reduce drug dosage requirements, reduce the toxic effects of agents and prevent or delay the emergence of drug resistance."	( In vitro interactions of ambroxol hydrochloride or amlodipine in combination with antibacterial agents against carbapenem-resistant Acinetobacter baumannii. Li, X; Lu, C; Sun, S; Wang, D; Wang, Y, 2020)	0.81
" A major barrier to entry of this technology is the lack of non-destructive quality control methods capable of verifying the dosage of multiple drugs in polyprintlets at the point of dispensing."	( Non-destructive dose verification of two drugs within 3D printed polyprintlets. Basit, AW; Gaisford, S; Goyanes, A; Rowland, M; Tan, HX; Trenfield, SJ; Wilsdon, D, 2020)	0.56
" Drugs with long half-lives, following multi-compartment pharmacokinetics, and whose distribution-related characteristics are less likely to be assessed within one dosing interval are focused."	( Contribution of Trough Concentration Data in the Evaluation of Multiple-Dose Pharmacokinetics for Drugs with Delayed Distributional Equilibrium and Long Half-Life. Choi, S; Han, S; Jeon, S; Yim, DS, 2020)	0.56
"In multiple-dose studies on drugs with delayed distributional equilibrium, information from a few trough samples can augment the limit of serial sampling within the dosing interval for parameter estimation."	( Contribution of Trough Concentration Data in the Evaluation of Multiple-Dose Pharmacokinetics for Drugs with Delayed Distributional Equilibrium and Long Half-Life. Choi, S; Han, S; Jeon, S; Yim, DS, 2020)	0.56
" Once weekly oral dosing of nano-FDC of amlodipine, CNDT and hydrochlorothiazide provided adequate antihypertensive effect which was not statistically different from daily dosing of free drugs in dexamethasone-induced animal model."	( Pharmacokinetic and pharmacodynamic evaluation of nano-fixed dose combination for hypertension. Bhandari, RK; Bhatia, A; Kaur, N; Malhotra, S; Pandey, AK; Rather, IIG; Shafiq, N; Sharma, S, 2020)	0.83
"Once weekly oral dosing of nano-FDC of amlodipine, CNDT and hydrochlorothiazide provided adequate antihypertensive effect and was not statistically different from daily dosing of free drugs in dexamethasone-induced animal model."	( Pharmacokinetic and pharmacodynamic evaluation of nano-fixed dose combination for hypertension. Bhandari, RK; Bhatia, A; Kaur, N; Malhotra, S; Pandey, AK; Rather, IIG; Shafiq, N; Sharma, S, 2020)	0.83
" Insulin was infused for a total of approximately 37 hours, most of which was dosed at 10 U/kg/hour; following discontinuation, serial serum insulin levels were drawn and remained at supraphysiologic levels for at least 24 hours and well above reference range for multiple days thereafter."	( Persistent Hyperinsulinemia Following High-Dose Insulin Therapy: A Case Report. Bangh, SA; Cole, JB; Corcoran, JN; Jacoby, KJ; Olives, TD, 2020)	0.56
" If BP is not at goal during 4 week's visit, dosage of antihypertensive agents will be doubled."	( A comparative study for the effects of nifedipine GITS and amlodipine besylate administrated in daytime or at nighttime on recovery of blood pressure rhythm and arterial stiffness in the young and middle-aged subjects with non-dipper hypertension (NARRAS) Liu, J, 2020)	0.8
" The current work presents three newly developed UV spectrophotometric methods depending on minimal mathematical manipulations on the zero-order spectrum namely: absorption correction, induced dual-wavelength, and Fourier self deconvoluted method; for the simultaneous determination of celecoxib and ramipril in their pharmaceutical combined dosage forms with amlodipine."	( Smart UV spectrophotometric methods based on simple mathematical filtration for the simultaneous determination of celecoxib and ramipril in their pharmaceutical mixtures with amlodipine: A comparative statistical study. Attala, K; Elsonbaty, A, 2021)	0.98
" The method was successfully used for quality control laboratories and the determination of these drugs combinations in pharmaceutical dosage forms."	( Development and Validation of a UPLC-DAD Method for the Simultaneous Quantification of Eight Antihypertensive Drugs in the Pharmaceutical Matrix. Abousalih, FZ; Azougagh, M; Benchekroun, YH; Bennani, I; Bouatia, M; El Karbane, M; Saffaj, T, 2021)	0.62
" This study aimed at characterizing the magnitude of DDIs between amlodipine and ARV drugs in order to establish dosing recommendations."	( Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs. Alves Saldanha, S; Buclin, T; Cavassini, M; Courlet, P; Csajka, C; Decosterd, LA; Guidi, M; Marzolini, C; Stoeckle, M, 2021)	1.08
" Clinicians should adjust amlodipine dosage accordingly, by halving the dosage in PLWH receiving ARV with inhibitory properties (mainly ritonavir-boosted darunavir), whereas they should double amlodipine doses when coadministering it with efavirenz, under appropriate monitoring of clinical response and tolerance."	( Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs. Alves Saldanha, S; Buclin, T; Cavassini, M; Courlet, P; Csajka, C; Decosterd, LA; Guidi, M; Marzolini, C; Stoeckle, M, 2021)	1.14
" Blood samples were taken over the dosing intervals and drug concentrations quantified by high-performance liquid chromatography-mass spectrometry."	( Mechanistic Considerations About an Unexpected Ramipril Drug-Drug Interaction in the Development of a Triple Fixed-Dose Combination Product Containing Ramipril, Amlodipine, and Atorvastatin. Gundlach, K; Hermann, R; Seiler, D, 2021)	0.82
"4 with the evening dosing (р<0."	( Psychological Continuum of Elderly Patients Suffering from Arterial Hypertension with Metabolic Syndrome, Against the Background of Chronotherapy with a Fixed Combination of Amlodipine, Lisinopril and Rosuvastatin. Agarkov, NM; Kolomiets, VI; Korneeva, SI; Markelova, AM; Markelova, EA; Moskalev, AA; Moskaleva, EO; Okhotnikov, OI, 2021)	0.81
" This work presents novel and green spectrophotometric methods for the concurrent analysis of Amlodipine (AML), Telmisartan (TEL), Hydrochlorothiazide (HCTZ), and Chlorthalidone (CLO) in their pharmaceutical dosage form."	( Advanced eco-friendly UV spectrophotometric approach for resolving overlapped spectral signals of antihypertensive agents in their binary and tertiary pharmaceutical dosage form. Attala, K; Elsonbaty, A, 2021)	0.84
" The former dosage of ACEis/ARBs was continued in one group while in another group, the ACEis/ARBs were replaced by amlodipine ± carvedilol according to the dose equivalents."	( Effects of Renin-Angiotensin-Aldosterone Inhibitors on Early Outcomes of Hypertensive COVID-19 Patients: A Randomized Triple-Blind Clinical Trial. Ashraf, H; Bahreini, M; Ghoghaei, M; Najmeddin, F; Rasooli, F; Salehi, M; Soleimani, A; Solhjoo, M, 2021)	0.83
" Amlodipine is a long-acting dihydropyridine and inappropriate dosage poses a great threat for profound vasodilation, hypotension, and refractory vasopressor-resistant shock."	( Refractory Shock from Amlodipine Overdose Overcomed with Hyperinsulinemia. Kakava, K; Koliastasis, L; Lampadakis, I; Milkas, A; Papaioannou, S; Sourides, V; Strempelas, P; Tsioufis, P, 2022)	1.95
"Pleural effusion resolved within 24 h of reducing the dosage of amlodipine."	( Unusual case of pleural effusion caused by amlodipine in a dog with systemic hypertension. An, JH; Chae, HK; Choi, M; Hwang, SY; Jang, HW; Kang, K; Oh, YI; Park, SM; Youn, HY, 2022)	1.22
"5 hours before dosing to 168 hours after dosing."	( Pharmacokinetics and Bioequivalence Evaluation of 2 Olmesartan Medoxomil and Amlodipine Besylate Fixed-Dose Combination Tablets in Healthy Chinese Volunteers Under Fasting and Fed Conditions. Chen, L; Li, X; Mo, E, 2022)	0.95
"The future of dosage form design is expected to move towards the production of personalized dosage forms tailored to each patient."	( Molding as Innovative Technology for Personalized Tablet Production. Al-Shoubki, AA; Donia, AA; Hagag, Y; Ibrahim, B; Mady, OY, )	0.13
" We also discuss several challenges encountered related to dosing and concentration of medications, which led to fluid overload."	( Single-Pass Albumin Dialysis as Rescue Therapy for Pediatric Calcium Channel Blocker Overdose. Berg, S; Essink, J; Montange, J; Salomon, J; Sankey, A; Taylor, V, )	0.13
"Comparative study of different spectrophotometric approaches used for the simultaneous determination of perindopril, indapamide, and amlodipine in bulk powder and in dosage form Triplixam."	( In Vitro Dissolution Profile of Antihypertensive Mixture: Comparison Between Multivariate Methods and Statistical and Graphical Representation of Different Univariate Spectrophotometric Data. Fares, NV; Farouk, M; Hemdan, A; Magdy, R, 2023)	1.11
"The methods were applied for the analysis of the mixture in the pharmaceutical dosage form Triplixam and in vitro release at intestinal pH (7."	( In Vitro Dissolution Profile of Antihypertensive Mixture: Comparison Between Multivariate Methods and Statistical and Graphical Representation of Different Univariate Spectrophotometric Data. Fares, NV; Farouk, M; Hemdan, A; Magdy, R, 2023)	0.91
"Pedal oedema is a well-known adverse effect of amlodipine, but significantly less frequent if only half of the maximum recommended dosage is used."	( Christensen, B; Helgestad, OK; Henriksen, JN; Oxlund, CS; Skovbjerg, BK, 2023)	1.17
" Along with gingival and plaque index, medication dosage and duration were also assessed."	( Prevalence and Severity of Amlodipine-induced Gingival Enlargement. Dahal, S; Ghimire, P; Rajkarnikar, J; Vaidya, S, 2023)	1.21
"Fixed-dose combinations for treatment of hypertension are observed in many dosages in the global market because of their high efficacy compared to single component dosage forms."	( Derivatization-free conventional and synchronous spectrofluorimetric estimation of atenolol and amlodipine. Abd El-Aziz, H; Zeid, AM, 2024)	1.66
" During follow-up, the OA dosage is adjusted according to the ABPM and OBPM results."	( The effects of Olmesartan/amlodipine administered in the Morning or At Night on nocturnal blood pressure reduction in Chinese patients with mild-moderate essential hypertension (OMAN Trial): study protocol for a prospective, multicenter, randomized, open- Chen, X; Jia, S; Li, X; Liao, H; Liu, K; Liu, X; Meng, Q; Shi, R; Sun, L; Wang, S; Wang, Z; Xu, M; Ye, R; Zhang, X; Zhang, Z, 2023)	1.21

Role	Description
antihypertensive agent	Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
calcium channel blocker	One of a class of drugs that acts by selective inhibition of calcium influx through cell membranes or on the release and binding of calcium in intracellular pools.
vasodilator agent	A drug used to cause dilation of the blood vessels.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
dihydropyridine
monochlorobenzenes	Any member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
ethyl ester	Any carboxylic ester resulting from the formal condensation of the carboxy group of a carboxylic acid with ethanol.
methyl ester	Any carboxylic ester resulting from the formal condensation of a carboxy group with methanol.
primary amino compound	A compound formally derived from ammonia by replacing one hydrogen atom by an organyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Amlodipine Action Pathway	47	8

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Ferritin light chain	Equus caballus (horse)	Potency	50.1187	5.6234	17.2929	31.6228	AID485281
acid sphingomyelinase	Homo sapiens (human)	Potency	31.6228	14.1254	24.0613	39.8107	AID504937
TDP1 protein	Homo sapiens (human)	Potency	19.7347	0.0008	11.3822	44.6684	AID686978; AID686979
Smad3	Homo sapiens (human)	Potency	35.4813	0.0052	7.8098	29.0929	AID588855
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	0.0849	0.0123	7.9835	43.2770	AID1645841
G	Vesicular stomatitis virus	Potency	2.6837	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	16.9330	0.0010	8.3798	61.1304	AID1645840
IDH1	Homo sapiens (human)	Potency	29.0929	0.0052	10.8652	35.4813	AID686970
chromobox protein homolog 1	Homo sapiens (human)	Potency	89.1251	0.0060	26.1688	89.1251	AID540317
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	12.5893	0.0079	8.2332	1,122.0200	AID2551
geminin	Homo sapiens (human)	Potency	21.0441	0.0046	11.3741	33.4983	AID624296; AID624297
histone acetyltransferase KAT2A isoform 1	Homo sapiens (human)	Potency	39.8107	0.2512	15.8432	39.8107	AID504327
Interferon beta	Homo sapiens (human)	Potency	2.6837	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	2.6837	0.0123	8.9648	39.8107	AID1645842
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	6.3096	0.0096	10.5250	35.4813	AID1479145
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	2.6837	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	2.6837	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Voltage-dependent L-type calcium channel subunit alpha-1C	Cavia porcellus (domestic guinea pig)	IC50 (µMol)	1.2000	0.0220	1.6422	8.9000	AID1207608
Potassium channel subfamily K member 2	Homo sapiens (human)	IC50 (µMol)	0.4000	0.4000	3.9227	9.0000	AID726094
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	74.5000	0.1100	7.1903	10.0000	AID1449628; AID1473738
ATP-dependent translocase ABCB1	Homo sapiens (human)	IC50 (µMol)	22.0000	0.0002	2.3185	10.0000	AID678836
Alpha-2A adrenergic receptor	Homo sapiens (human)	IC50 (µMol)	0.6020	0.0000	1.4421	7.3470	AID625201
Alpha-2A adrenergic receptor	Homo sapiens (human)	Ki	0.2260	0.0001	0.8074	10.0000	AID625201
Alpha-2C adrenergic receptor	Homo sapiens (human)	IC50 (µMol)	1.8000	0.0000	1.4725	7.8980	AID625203
Alpha-2C adrenergic receptor	Homo sapiens (human)	Ki	0.2610	0.0003	0.4834	10.0000	AID625203
Alpha-2B adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	5.3700	0.0000	0.9296	10.0000	AID35892
Voltage-dependent L-type calcium channel subunit alpha-1C	Rattus norvegicus (Norway rat)	Ki	0.0020	0.0008	0.5796	5.4000	AID42528
Alpha-2C adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	5.3700	0.0000	0.9708	10.0000	AID35892
Alpha-2A adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	5.3700	0.0000	0.9375	10.0000	AID35892
Alpha-1D adrenergic receptor	Homo sapiens (human)	Ki	5.3700	0.0000	0.3609	10.0000	AID35892
Alpha-1A adrenergic receptor	Homo sapiens (human)	Ki	2.3440	0.0000	0.2726	10.0000	AID35755
Alpha-1B adrenergic receptor	Homo sapiens (human)	Ki	7.9430	0.0000	0.4713	10.0000	AID35883
5-hydroxytryptamine receptor 6	Homo sapiens (human)	IC50 (µMol)	2.8980	0.0017	0.8381	5.4200	AID625221
5-hydroxytryptamine receptor 6	Homo sapiens (human)	Ki	1.3460	0.0002	0.5229	10.0000	AID625221
Sodium-dependent dopamine transporter	Homo sapiens (human)	IC50 (µMol)	5.5210	0.0007	1.8419	46.0000	AID625256
Sodium-dependent dopamine transporter	Homo sapiens (human)	Ki	4.3870	0.0002	1.1115	8.0280	AID625256
Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)	IC50 (µMol)	2.7000	0.0003	2.2545	9.6000	AID1207607; AID1207608
Potassium channel subfamily K member 2	Bos taurus (cattle)	IC50 (µMol)	0.4300	0.4300	2.5760	8.2000	AID1307729
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Potassium channel subfamily K member 2	Homo sapiens (human)	EC50 (µMol)	0.4300	0.1870	2.7224	8.1800	AID1802150
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cardiac ventricle development	Potassium channel subfamily K member 2	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Potassium channel subfamily K member 2	Homo sapiens (human)
memory	Potassium channel subfamily K member 2	Homo sapiens (human)
response to mechanical stimulus	Potassium channel subfamily K member 2	Homo sapiens (human)
response to axon injury	Potassium channel subfamily K member 2	Homo sapiens (human)
negative regulation of cardiac muscle cell proliferation	Potassium channel subfamily K member 2	Homo sapiens (human)
cellular response to hypoxia	Potassium channel subfamily K member 2	Homo sapiens (human)
potassium ion transmembrane transport	Potassium channel subfamily K member 2	Homo sapiens (human)
cochlea development	Potassium channel subfamily K member 2	Homo sapiens (human)
positive regulation of cellular response to hypoxia	Potassium channel subfamily K member 2	Homo sapiens (human)
negative regulation of DNA biosynthetic process	Potassium channel subfamily K member 2	Homo sapiens (human)
stabilization of membrane potential	Potassium channel subfamily K member 2	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
G2/M transition of mitotic cell cycle	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic metabolic process	ATP-dependent translocase ABCB1	Homo sapiens (human)
response to xenobiotic stimulus	ATP-dependent translocase ABCB1	Homo sapiens (human)
phospholipid translocation	ATP-dependent translocase ABCB1	Homo sapiens (human)
terpenoid transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
regulation of response to osmotic stress	ATP-dependent translocase ABCB1	Homo sapiens (human)
transmembrane transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
transepithelial transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
stem cell proliferation	ATP-dependent translocase ABCB1	Homo sapiens (human)
ceramide translocation	ATP-dependent translocase ABCB1	Homo sapiens (human)
export across plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
transport across blood-brain barrier	ATP-dependent translocase ABCB1	Homo sapiens (human)
positive regulation of anion channel activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
carboxylic acid transmembrane transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	ATP-dependent translocase ABCB1	Homo sapiens (human)
regulation of chloride transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
positive regulation of cytokine production	Alpha-2A adrenergic receptor	Homo sapiens (human)
DNA replication	Alpha-2A adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
Ras protein signal transduction	Alpha-2A adrenergic receptor	Homo sapiens (human)
Rho protein signal transduction	Alpha-2A adrenergic receptor	Homo sapiens (human)
female pregnancy	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of norepinephrine secretion	Alpha-2A adrenergic receptor	Homo sapiens (human)
regulation of vasoconstriction	Alpha-2A adrenergic receptor	Homo sapiens (human)
actin cytoskeleton organization	Alpha-2A adrenergic receptor	Homo sapiens (human)
platelet activation	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of cell migration	Alpha-2A adrenergic receptor	Homo sapiens (human)
activation of protein kinase activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
activation of protein kinase B activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of epinephrine secretion	Alpha-2A adrenergic receptor	Homo sapiens (human)
cellular response to hormone stimulus	Alpha-2A adrenergic receptor	Homo sapiens (human)
receptor transactivation	Alpha-2A adrenergic receptor	Homo sapiens (human)
vasodilation	Alpha-2A adrenergic receptor	Homo sapiens (human)
glucose homeostasis	Alpha-2A adrenergic receptor	Homo sapiens (human)
fear response	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of potassium ion transport	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of MAP kinase activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of calcium ion-dependent exocytosis	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of insulin secretion	Alpha-2A adrenergic receptor	Homo sapiens (human)
intestinal absorption	Alpha-2A adrenergic receptor	Homo sapiens (human)
thermoception	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of lipid catabolic process	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of membrane protein ectodomain proteolysis	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of calcium ion transport	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulus	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of uterine smooth muscle contraction	Alpha-2A adrenergic receptor	Homo sapiens (human)
adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of wound healing	Alpha-2A adrenergic receptor	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of calcium ion transmembrane transporter activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
regulation of smooth muscle contraction	Alpha-2C adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-2C adrenergic receptor	Homo sapiens (human)
cell-cell signaling	Alpha-2C adrenergic receptor	Homo sapiens (human)
negative regulation of norepinephrine secretion	Alpha-2C adrenergic receptor	Homo sapiens (human)
regulation of vasoconstriction	Alpha-2C adrenergic receptor	Homo sapiens (human)
platelet activation	Alpha-2C adrenergic receptor	Homo sapiens (human)
activation of protein kinase B activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
negative regulation of epinephrine secretion	Alpha-2C adrenergic receptor	Homo sapiens (human)
receptor transactivation	Alpha-2C adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-2C adrenergic receptor	Homo sapiens (human)
positive regulation of neuron differentiation	Alpha-2C adrenergic receptor	Homo sapiens (human)
adrenergic receptor signaling pathway	Alpha-2C adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-2C adrenergic receptor	Homo sapiens (human)
negative regulation of insulin secretion	Alpha-2C adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-1D adrenergic receptor	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Alpha-1D adrenergic receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Alpha-1D adrenergic receptor	Homo sapiens (human)
neuron-glial cell signaling	Alpha-1D adrenergic receptor	Homo sapiens (human)
cell-cell signaling	Alpha-1D adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-1D adrenergic receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Alpha-1D adrenergic receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Alpha-1D adrenergic receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Alpha-1D adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-1D adrenergic receptor	Homo sapiens (human)
MAPK cascade	Alpha-1A adrenergic receptor	Homo sapiens (human)
negative regulation of heart rate involved in baroreceptor response to increased systemic arterial blood pressure	Alpha-1A adrenergic receptor	Homo sapiens (human)
norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrine	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrine	Alpha-1A adrenergic receptor	Homo sapiens (human)
apoptotic process	Alpha-1A adrenergic receptor	Homo sapiens (human)
smooth muscle contraction	Alpha-1A adrenergic receptor	Homo sapiens (human)
signal transduction	Alpha-1A adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-1A adrenergic receptor	Homo sapiens (human)
activation of phospholipase C activity	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Alpha-1A adrenergic receptor	Homo sapiens (human)
adult heart development	Alpha-1A adrenergic receptor	Homo sapiens (human)
negative regulation of cell population proliferation	Alpha-1A adrenergic receptor	Homo sapiens (human)
response to xenobiotic stimulus	Alpha-1A adrenergic receptor	Homo sapiens (human)
response to hormone	Alpha-1A adrenergic receptor	Homo sapiens (human)
negative regulation of autophagy	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of cardiac muscle hypertrophy	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Alpha-1A adrenergic receptor	Homo sapiens (human)
intracellular signal transduction	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of action potential	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of smooth muscle contraction	Alpha-1A adrenergic receptor	Homo sapiens (human)
calcium ion transport into cytosol	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of cardiac muscle contraction	Alpha-1A adrenergic receptor	Homo sapiens (human)
cell growth involved in cardiac muscle cell development	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of protein kinase C signaling	Alpha-1A adrenergic receptor	Homo sapiens (human)
pilomotor reflex	Alpha-1A adrenergic receptor	Homo sapiens (human)
neuron-glial cell signaling	Alpha-1A adrenergic receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Alpha-1A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-1A adrenergic receptor	Homo sapiens (human)
cell-cell signaling	Alpha-1A adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-1B adrenergic receptor	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Alpha-1B adrenergic receptor	Homo sapiens (human)
regulation of vasoconstriction	Alpha-1B adrenergic receptor	Homo sapiens (human)
intracellular signal transduction	Alpha-1B adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-1B adrenergic receptor	Homo sapiens (human)
regulation of cardiac muscle contraction	Alpha-1B adrenergic receptor	Homo sapiens (human)
neuron-glial cell signaling	Alpha-1B adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-1B adrenergic receptor	Homo sapiens (human)
cell-cell signaling	Alpha-1B adrenergic receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Alpha-1B adrenergic receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Alpha-1B adrenergic receptor	Homo sapiens (human)
cerebral cortex cell migration	5-hydroxytryptamine receptor 6	Homo sapiens (human)
positive regulation of TOR signaling	5-hydroxytryptamine receptor 6	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	5-hydroxytryptamine receptor 6	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 6	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 6	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 6	Homo sapiens (human)
monoamine transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
neurotransmitter transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
lactation	Sodium-dependent dopamine transporter	Homo sapiens (human)
sensory perception of smell	Sodium-dependent dopamine transporter	Homo sapiens (human)
locomotory behavior	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to xenobiotic stimulus	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to iron ion	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
adenohypophysis development	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to nicotine	Sodium-dependent dopamine transporter	Homo sapiens (human)
positive regulation of multicellular organism growth	Sodium-dependent dopamine transporter	Homo sapiens (human)
regulation of dopamine metabolic process	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to cocaine	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine biosynthetic process	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine catabolic process	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to ethanol	Sodium-dependent dopamine transporter	Homo sapiens (human)
cognition	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine uptake involved in synaptic transmission	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to cAMP	Sodium-dependent dopamine transporter	Homo sapiens (human)
norepinephrine uptake	Sodium-dependent dopamine transporter	Homo sapiens (human)
prepulse inhibition	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine uptake	Sodium-dependent dopamine transporter	Homo sapiens (human)
hyaloid vascular plexus regression	Sodium-dependent dopamine transporter	Homo sapiens (human)
amino acid transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
norepinephrine transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
sodium ion transmembrane transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
immune system development	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
heart development	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
embryonic forelimb morphogenesis	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
camera-type eye development	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
positive regulation of adenylate cyclase activity	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
positive regulation of muscle contraction	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
calcium ion transport into cytosol	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
cardiac conduction	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
calcium ion transmembrane transport via high voltage-gated calcium channel	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
calcium ion transmembrane transport	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
cardiac muscle cell action potential involved in contraction	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
membrane depolarization during cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
membrane depolarization during AV node cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
cell communication by electrical coupling involved in cardiac conduction	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
regulation of ventricular cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
calcium ion import across plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
outward rectifier potassium channel activity	Potassium channel subfamily K member 2	Homo sapiens (human)
potassium ion leak channel activity	Potassium channel subfamily K member 2	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATP binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
efflux transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATP hydrolysis activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ubiquitin protein ligase binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
carboxylic acid transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylcholine floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylethanolamine flippase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ceramide floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
alpha2-adrenergic receptor activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein kinase binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
alpha-1B adrenergic receptor binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
alpha-2C adrenergic receptor binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
thioesterase binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
heterotrimeric G-protein binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein homodimerization activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
epinephrine binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
norepinephrine binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
guanyl-nucleotide exchange factor activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
alpha2-adrenergic receptor activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-2C adrenergic receptor	Homo sapiens (human)
alpha-2A adrenergic receptor binding	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein homodimerization activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
epinephrine binding	Alpha-2C adrenergic receptor	Homo sapiens (human)
guanyl-nucleotide exchange factor activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-1D adrenergic receptor	Homo sapiens (human)
identical protein binding	Alpha-1D adrenergic receptor	Homo sapiens (human)
alpha1-adrenergic receptor activity	Alpha-1D adrenergic receptor	Homo sapiens (human)
alpha1-adrenergic receptor activity	Alpha-1A adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-1A adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-1A adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-1B adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-1B adrenergic receptor	Homo sapiens (human)
alpha1-adrenergic receptor activity	Alpha-1B adrenergic receptor	Homo sapiens (human)
histamine receptor activity	5-hydroxytryptamine receptor 6	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 6	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 6	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 6	Homo sapiens (human)
protease binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
signaling receptor binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine:sodium symporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
protein binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
amine binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
protein-containing complex binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
metal ion binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
protein phosphatase 2A binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
heterocyclic compound binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
norepinephrine:sodium symporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
protein binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
calmodulin binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
metal ion binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
alpha-actinin binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
endoplasmic reticulum membrane	Potassium channel subfamily K member 2	Homo sapiens (human)
plasma membrane	Potassium channel subfamily K member 2	Homo sapiens (human)
cell surface	Potassium channel subfamily K member 2	Homo sapiens (human)
apical plasma membrane	Potassium channel subfamily K member 2	Homo sapiens (human)
neuronal cell body	Potassium channel subfamily K member 2	Homo sapiens (human)
calyx of Held	Potassium channel subfamily K member 2	Homo sapiens (human)
astrocyte projection	Potassium channel subfamily K member 2	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium channel subfamily K member 2	Homo sapiens (human)
plasma membrane	Potassium channel subfamily K member 2	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cytoplasm	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
cell surface	ATP-dependent translocase ABCB1	Homo sapiens (human)
membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
apical plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
extracellular exosome	ATP-dependent translocase ABCB1	Homo sapiens (human)
external side of apical plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
cytoplasm	Alpha-2A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
basolateral plasma membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
neuronal cell body	Alpha-2A adrenergic receptor	Homo sapiens (human)
axon terminus	Alpha-2A adrenergic receptor	Homo sapiens (human)
presynaptic active zone membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
dopaminergic synapse	Alpha-2A adrenergic receptor	Homo sapiens (human)
postsynaptic density membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
glutamatergic synapse	Alpha-2A adrenergic receptor	Homo sapiens (human)
GABA-ergic synapse	Alpha-2A adrenergic receptor	Homo sapiens (human)
receptor complex	Alpha-2A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
cytoplasm	Alpha-2C adrenergic receptor	Homo sapiens (human)
endosome	Alpha-2C adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2C adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2C adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1D adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1D adrenergic receptor	Homo sapiens (human)
nucleus	Alpha-1A adrenergic receptor	Homo sapiens (human)
nucleoplasm	Alpha-1A adrenergic receptor	Homo sapiens (human)
cytoplasm	Alpha-1A adrenergic receptor	Homo sapiens (human)
cytosol	Alpha-1A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1A adrenergic receptor	Homo sapiens (human)
caveola	Alpha-1A adrenergic receptor	Homo sapiens (human)
nuclear membrane	Alpha-1A adrenergic receptor	Homo sapiens (human)
intracellular membrane-bounded organelle	Alpha-1A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1A adrenergic receptor	Homo sapiens (human)
nucleus	Alpha-1B adrenergic receptor	Homo sapiens (human)
cytoplasm	Alpha-1B adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1B adrenergic receptor	Homo sapiens (human)
caveola	Alpha-1B adrenergic receptor	Homo sapiens (human)
nuclear membrane	Alpha-1B adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1B adrenergic receptor	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 6	Homo sapiens (human)
cilium	5-hydroxytryptamine receptor 6	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 6	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 6	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 6	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
cytoplasm	Sodium-dependent dopamine transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
cell surface	Sodium-dependent dopamine transporter	Homo sapiens (human)
membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
axon	Sodium-dependent dopamine transporter	Homo sapiens (human)
neuron projection	Sodium-dependent dopamine transporter	Homo sapiens (human)
neuronal cell body	Sodium-dependent dopamine transporter	Homo sapiens (human)
axon terminus	Sodium-dependent dopamine transporter	Homo sapiens (human)
membrane raft	Sodium-dependent dopamine transporter	Homo sapiens (human)
postsynaptic membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopaminergic synapse	Sodium-dependent dopamine transporter	Homo sapiens (human)
flotillin complex	Sodium-dependent dopamine transporter	Homo sapiens (human)
axon	Sodium-dependent dopamine transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
neuronal cell body membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
cytoplasm	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
postsynaptic density	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
membrane	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
Z disc	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
dendrite	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
perikaryon	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
postsynaptic density membrane	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
L-type voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID224235	In vivo evaluation for the antihypertensive effect in the spontaneously hypertensive rat is % decrease in blood pressure during post drug administration at 15 uM/kg peroral; 34/20	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Dihydropyrimidine calcium channel blockers. 4. Basic 3-substituted-4-aryl-1,4-dihydropyrimidine-5-carboxylic acid esters. Potent antihypertensive agents.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID444052	Hepatic clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID197523	Evaluated for the negative logarithm of the molar concentration required to block [Ca2+] induced contraction of K+ depolarized rat aorta by 50%.	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Long-acting dihydropyridine calcium antagonists. 6. Structure-activity relationships around 4-(2,3-dichlorophenyl)-3-(ethoxycarbonyl)-2-[(2-hydroxyethoxy)methyl]-5 -(methoxycarbonyl)-6-methyl-1,4-dihydropyridine.
AID60643	Percent decrease in coronary vascular resistance in dogs after intravenous dosage of 450 ug/kg compound	1986	Journal of medicinal chemistry, Sep, Volume: 29, Issue:9	Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents.
AID467611	Dissociation constant, pKa of the compound	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID427818	Toxicity in BALB/c mouse assessed as heart function at 10 mg/kg, po	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Oral Therapy with Amlodipine and Lacidipine, 1,4-Dihydropyridine Derivatives Showing Activity against Experimental Visceral Leishmaniasis.
AID42528	Binding affinity against rat L-type calcium channel	1999	Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19	Design and synthesis of novel dihydropyridine alpha-1a antagonists.
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID496825	Antimicrobial activity against Leishmania mexicana	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496824	Antimicrobial activity against Toxoplasma gondii	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1217717	Time dependent inhibition of CYP2C9 (unknown origin) at 30 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID23635	Plasma half-life in dogs after intravenous administration	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Long-acting dihydropyridine calcium antagonists. 4. Synthesis and structure-activity relationships for a series of basic and nonbasic derivatives of 2-[(2-aminoethoxy)methyl]-1,4-dihydropyridine calcium antagonists.
AID537133	Antileishmanial activity against promastigotes of Leishmania major MHOM/1L/80/Fredlin after 18 hrs by MTT assay	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID444051	Total clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID73832	Negative inotropy measured as the concentration required to depress contraction in the isolated Langendorff-perfused guinea pig heart by 25%	1986	Journal of medicinal chemistry, Sep, Volume: 29, Issue:9	Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents.
AID427808	Antileishmanial activity against Leishmania donovani MHOH/IN/1983/AD83 amastigotes infected in BALB/c mouse peritoneal macrophage at 3 ug/mL treated 6 hrs after infection measured after 48 hrs using Giemsa staining relative to control	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Oral Therapy with Amlodipine and Lacidipine, 1,4-Dihydropyridine Derivatives Showing Activity against Experimental Visceral Leishmaniasis.
AID409956	Inhibition of mouse brain MAOB	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1217729	Intrinsic clearance for reactive metabolites formation assessed as summation of [3H]GSH adduct formation rate-based reactive metabolites formation and cytochrome P450 (unknown origin) inactivation rate-based reactive metabolites formation	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID22995	Volume of distribution in dogs after intravenous administration	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Long-acting dihydropyridine calcium antagonists. 4. Synthesis and structure-activity relationships for a series of basic and nonbasic derivatives of 2-[(2-aminoethoxy)methyl]-1,4-dihydropyridine calcium antagonists.
AID427806	Antileishmanial activity against Leishmania donovani MHOH/IN/1983/AD83 promastigotes assessed as growth inhibition after 3 days by MTT assay	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Oral Therapy with Amlodipine and Lacidipine, 1,4-Dihydropyridine Derivatives Showing Activity against Experimental Visceral Leishmaniasis.
AID678713	Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID496826	Antimicrobial activity against Entamoeba histolytica	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1207608	Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in Xenopus oocyte heterologically expressing alpha-1C subunit	2012	Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10	Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID678836	TP_TRANSPORTER: inhibition of Daunorubicin transepithelial transport (basal to apical) (Daunorubicin: 0.035 uM) in MDR1-expressing LLC-PK1 cells	2000	Pharmaceutical research, Oct, Volume: 17, Issue:10	Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4.
AID427805	Antileishmanial activity against Leishmania donovani MHOH/IN/1983/AD83 promastigotes assessed as cell killing at 30 ug/mL after 2 hrs by MTT assay relative to control	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Oral Therapy with Amlodipine and Lacidipine, 1,4-Dihydropyridine Derivatives Showing Activity against Experimental Visceral Leishmaniasis.
AID678714	Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID669779	Inhibition of norA-mediated ethidium bromide efflux in Staphylococcus aureus SA-1199B harboring grlA A116E mutant at 50 uM after 5 mins by fluorometric analysis	2012	ACS medicinal chemistry letters, Mar-08, Volume: 3, Issue:3	Ligand Promiscuity between the Efflux Pumps Human P-Glycoprotein and S. aureus NorA.
AID1232306	Dissociation constant of the compound	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Volume of Distribution in Drug Design.
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID427813	Antileishmanial activity against Leishmania donovani MHOH/IN/1983/AD83 promastigotes assessed as increase in caspase 3 like activation in parasite cytosol at 3 to 30 ug/mL after 2 hrs by spectrofluorimetric analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Oral Therapy with Amlodipine and Lacidipine, 1,4-Dihydropyridine Derivatives Showing Activity against Experimental Visceral Leishmaniasis.
AID29854	Compound was evaluated for the plasma half-life to investigate its pharmacokinetic profile in dogs after intravenous administration.	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Long-acting dihydropyridine calcium antagonists. 6. Structure-activity relationships around 4-(2,3-dichlorophenyl)-3-(ethoxycarbonyl)-2-[(2-hydroxyethoxy)methyl]-5 -(methoxycarbonyl)-6-methyl-1,4-dihydropyridine.
AID781326	pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X	2014	Pharmaceutical research, Apr, Volume: 31, Issue:4	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID28681	Partition coefficient (logD6.5)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID311932	Inhibition of ASM in human H4 cells assessed as residual activity at 10 uM	2008	Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2	Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID169100	In vitro calcium antagonist activity was assessed against calcium induced constriction of potassium-depolarized rat aorta	1986	Journal of medicinal chemistry, Sep, Volume: 29, Issue:9	Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents.
AID496818	Antimicrobial activity against Trypanosoma brucei brucei	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1207607	Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in Xenopus oocyte heterologically expressing alpha-1C subunit	2012	Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10	Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID640615	Clearance in human liver microsomes at 1 uM measured after 60 mins by HPLC analysis	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.
AID231283	Ratio of binding affinity against human alpha 2a-adrenoceptor by human alpha 1A-adrenoceptor	1999	Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19	Design and synthesis of novel dihydropyridine alpha-1a antagonists.
AID1217709	Time dependent inhibition of CYP3A4 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID537135	Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi infected in rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID237474	Percentage of drug bound in bovine plasma albumin	2004	Journal of medicinal chemistry, Jul-29, Volume: 47, Issue:16	Contribution of ionization and lipophilicity to drug binding to albumin: a preliminary step toward biodistribution prediction.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID231282	Ratio of binding affinity against human alpha 1d-adrenoceptor by human alpha 1A-adrenoceptor	1999	Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19	Design and synthesis of novel dihydropyridine alpha-1a antagonists.
AID537136	Cytotoxicity against rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID496828	Antimicrobial activity against Leishmania donovani	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID444057	Fraction escaping hepatic elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID467612	Fraction unbound in human plasma	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1217704	Time dependent inhibition of CYP1A2 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1232307	Lipophilicity, log P of the compound	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Volume of Distribution in Drug Design.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID227699	Virtual screen for compounds with anticonvulsant activity	2003	Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16	Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
AID60642	Percent decrease in coronary vascular resistance in dogs after intravenous dosage of 1500 ug/kg compound	1986	Journal of medicinal chemistry, Sep, Volume: 29, Issue:9	Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID35755	Binding affinity against human Alpha-1a adrenergic receptor	1999	Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19	Design and synthesis of novel dihydropyridine alpha-1a antagonists.
AID30135	Volume of distribution of the compound	2001	Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9	Property-based design: optimization of drug absorption and pharmacokinetics.
AID1207606	Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes	2012	Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10	Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID21474	Compound was tested for the plasma half life in dogs	1986	Journal of medicinal chemistry, Sep, Volume: 29, Issue:9	Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents.
AID678717	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID235901	Selectivity index calculated as the ratio of Calcium pIC50 to that of negative inotropy IC25	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Long-acting dihydropyridine calcium antagonists. 6. Structure-activity relationships around 4-(2,3-dichlorophenyl)-3-(ethoxycarbonyl)-2-[(2-hydroxyethoxy)methyl]-5 -(methoxycarbonyl)-6-methyl-1,4-dihydropyridine.
AID444050	Fraction unbound in human plasma	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1217707	Time dependent inhibition of CYP2C19 in human liver microsomes at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID239884	pKa value of the compound	2004	Journal of medicinal chemistry, Jul-29, Volume: 47, Issue:16	Contribution of ionization and lipophilicity to drug binding to albumin: a preliminary step toward biodistribution prediction.
AID444058	Volume of distribution at steady state in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID181533	Antihypertensive activity when administered orally to spontaneously hypertensive rats	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Dihydropyrimidine calcium channel blockers. 3. 3-Carbamoyl-4-aryl-1,2,3,4-tetrahydro-6-methyl-5-pyrimidinecarboxylic acid esters as orally effective antihypertensive agents.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID427809	Antileishmanial activity against Leishmania donovani MHOH/IN/1983/AD83 amastigotes infected in BALB/c mouse peritoneal macrophage treated 6 hrs after infection measured after 48 hrs using Giemsa staining relative to control	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Oral Therapy with Amlodipine and Lacidipine, 1,4-Dihydropyridine Derivatives Showing Activity against Experimental Visceral Leishmaniasis.
AID496830	Antimicrobial activity against Leishmania major	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID29359	Ionization constant (pKa)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID19424	Partition coefficient (logD7.4)	2001	Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15	ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
AID427807	Antileishmanial activity against Leishmania donovani MHOH/IN/1983/AD83 amastigotes infected in BALB/c mouse peritoneal macrophage assessed as cell killing at 15 ug/mL treated 6 hrs after infection measured after 48 hrs using Giemsa staining relative to co	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Oral Therapy with Amlodipine and Lacidipine, 1,4-Dihydropyridine Derivatives Showing Activity against Experimental Visceral Leishmaniasis.
AID496827	Antimicrobial activity against Leishmania amazonensis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1217708	Time dependent inhibition of CYP2D6 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID311935	Partition coefficient, log P of the compound	2008	Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2	Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID427810	Toxicity in BALB/c mouse peritoneal macrophage assessed as toxic dose	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Oral Therapy with Amlodipine and Lacidipine, 1,4-Dihydropyridine Derivatives Showing Activity against Experimental Visceral Leishmaniasis.
AID1217710	Covalent binding in human liver microsomes measured per mg of protein using radiolabelled compound at 10 uM after 1 hr incubation by liquid scintillation counting	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID669780	Inhibition of human recombinant MDR1 expressed in mouse L5178Y cells assessed as inhibition of rhodamine-123 efflux at 10'-5 M preincubated for 10 mins measured after 20 mins by FACS analysis	2012	ACS medicinal chemistry letters, Mar-08, Volume: 3, Issue:3	Ligand Promiscuity between the Efflux Pumps Human P-Glycoprotein and S. aureus NorA.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1217728	Intrinsic clearance for reactive metabolites formation per mg of protein based on cytochrome P450 (unknown origin) inactivation rate by TDI assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID195355	Concentration required to block Ca+2-induced contraction of K+ depolarized rat aorta	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Long-acting dihydropyridine calcium antagonists. 5. Synthesis and structure-activity relationships for a series of 2-[[(N-substituted-heterocyclyl)ethoxy]methyl]-1,4-dihydropyridine calcium antagonists.
AID537137	Selectivity index, ratio of IC50 for rhesus monkey LLC-MK2 cells to IC50 for amastigotes of Leishmania chagasi MHOM/BR/1972/LD	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID467613	Volume of distribution at steady state in human	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID496819	Antimicrobial activity against Plasmodium falciparum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID167819	In vitro inhibition of potassium-contracted rabbit aorta strips	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Dihydropyrimidine calcium channel blockers. 4. Basic 3-substituted-4-aryl-1,4-dihydropyrimidine-5-carboxylic acid esters. Potent antihypertensive agents.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID678722	Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID726094	Inhibition of TREK-1 (unknown origin)	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Ion channels as therapeutic targets: a drug discovery perspective.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID21233	Partition coefficient of compound in to biological membranes	1991	Journal of medicinal chemistry, Mar, Volume: 34, Issue:3	Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes.
AID1217727	Intrinsic clearance for reactive metabolites formation per mg of protein in human liver microsomes based on [3H]GSH adduct formation rate at 100 uM by [3H]GSH trapping assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1217731	Time dependent inhibition of CYP2B6 (unknown origin) at 3 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1232312	Clearance in human	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Volume of Distribution in Drug Design.
AID231284	Ratio of binding affinity against human alpha 2b-adrenoceptor by human alpha 1A-adrenoceptor	1999	Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19	Design and synthesis of novel dihydropyridine alpha-1a antagonists.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID235556	Ratio of pIC50 of rat aorta to pIC25 of guinea pig	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Long-acting dihydropyridine calcium antagonists. 5. Synthesis and structure-activity relationships for a series of 2-[[(N-substituted-heterocyclyl)ethoxy]methyl]-1,4-dihydropyridine calcium antagonists.
AID537130	Antileishmanial activity against promastigotes of Leishmania chagasi MHOM/BR/1972/LD after 18 hrs by MTT assay	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID29813	Oral bioavailability in human	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID444056	Fraction escaping gut-wall elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1057863	Cytotoxicity against mouse dividing ScN2a-cl3 cells assessed as cell viability after 5 days by calcein-AM staining-based fluorescence assay	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells.
AID311934	Dissociation constant, pKa of the compound	2008	Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2	Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID427814	Antileishmanial activity against Leishmania donovani MHOH/IN/1983/AD83 promastigotes assessed as inhibition of calcium uptake	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Oral Therapy with Amlodipine and Lacidipine, 1,4-Dihydropyridine Derivatives Showing Activity against Experimental Visceral Leishmaniasis.
AID17662	Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle	1991	Journal of medicinal chemistry, Mar, Volume: 34, Issue:3	Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes.
AID35883	Binding affinity against human Alpha-1b adrenergic receptor	1999	Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19	Design and synthesis of novel dihydropyridine alpha-1a antagonists.
AID21434	Plasma clearance in dogs after intravenous administration	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Long-acting dihydropyridine calcium antagonists. 4. Synthesis and structure-activity relationships for a series of basic and nonbasic derivatives of 2-[(2-aminoethoxy)methyl]-1,4-dihydropyridine calcium antagonists.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID21438	Compound was tested for the plasma clearance in dogs	1986	Journal of medicinal chemistry, Sep, Volume: 29, Issue:9	Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1380098	Inhibition of Cch1 in Candida albicans isolate 16 assessed as potentiation of fluconazole-induced antifungal activity by measuring fractional inhibitory concentration index after 24 hrs by checkerboard assay	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Emerging New Targets for the Treatment of Resistant Fungal Infections.
AID537139	Cytotoxicity in BALB/c mouse erythrocytes assessed as hemolysis at 50 uM after 3 hrs	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID1217724	Time dependent inhibition of CYP2D6 (unknown origin) at 30 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1057862	Inhibition of RML prion protein infected in mouse dividing ScN2a-cl3 cells expressing full length mouse PrP assessed as reduction of PrPsc level after 5 days by ELISA	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells.
AID427804	Antileishmanial activity against Leishmania donovani MHOH/IN/1983/AD83 promastigotes assessed as viability after 2 hrs by MTT assay	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Oral Therapy with Amlodipine and Lacidipine, 1,4-Dihydropyridine Derivatives Showing Activity against Experimental Visceral Leishmaniasis.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678712	Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID231285	Ratio of binding affinity against human alpha 2c-adrenoceptor by human alpha 1A-adrenoceptor	1999	Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19	Design and synthesis of novel dihydropyridine alpha-1a antagonists.
AID22992	Compound was tested for the volume of distribution in dogs	1986	Journal of medicinal chemistry, Sep, Volume: 29, Issue:9	Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents.
AID227119	In vivo evaluation for the antihypertensive effect in the spontaneously hypertensive rat is % decrease in blood pressure during post drug administration at 5 umol/kg peroral; 23/11	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Dihydropyrimidine calcium channel blockers. 4. Basic 3-substituted-4-aryl-1,4-dihydropyrimidine-5-carboxylic acid esters. Potent antihypertensive agents.
AID496817	Antimicrobial activity against Trypanosoma cruzi	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID79826	Evaluated for the negative ionotropy logarithm of the molar concentration required to depress contraction in the Langendorff-perfused guinea pig heart by 25%	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Long-acting dihydropyridine calcium antagonists. 6. Structure-activity relationships around 4-(2,3-dichlorophenyl)-3-(ethoxycarbonyl)-2-[(2-hydroxyethoxy)methyl]-5 -(methoxycarbonyl)-6-methyl-1,4-dihydropyridine.
AID678716	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID496821	Antimicrobial activity against Leishmania	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1057864	Ratio of LC50 for dividing mouse ScN2a-cl3 cells to EC50 for inhibition of RML prion protein	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID27900	Plasma clearance of the compound	2001	Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9	Property-based design: optimization of drug absorption and pharmacokinetics.
AID27167	Delta logD (logD6.5 - logD7.4)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID537138	Selectivity index, ratio of IC50 for rhesus monkey LLC-MK2 cells to IC50 for trypomastigotes of Trypanosoma cruzi	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1367794	Half life in human at 5 to 10 mg, qd	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Relevance of Half-Life in Drug Design.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1217711	Metabolic activation in human liver microsomes assessed as [3H]GSH adduct formation rate measured per mg of protein at 100 uM by [3H]GSH trapping assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID223060	Concentration required to depress contraction in the Langendorff-perfused guinea pig heart	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Long-acting dihydropyridine calcium antagonists. 5. Synthesis and structure-activity relationships for a series of 2-[[(N-substituted-heterocyclyl)ethoxy]methyl]-1,4-dihydropyridine calcium antagonists.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID237416	Distribution coeeficient for the compound at pH7.4 (Log D7.4)	2004	Journal of medicinal chemistry, Jul-29, Volume: 47, Issue:16	Contribution of ionization and lipophilicity to drug binding to albumin: a preliminary step toward biodistribution prediction.
AID1232310	Volume of distribution at steady state in human	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Volume of Distribution in Drug Design.
AID1367796	Unbound intrinsic clearance in human at 5 to 10 mg, qd	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Relevance of Half-Life in Drug Design.
AID21234	Partition coefficient of compound in to octanol/buffer	1991	Journal of medicinal chemistry, Mar, Volume: 34, Issue:3	Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes.
AID427815	Toxicity in BALB/c mouse at 10 mg/kg, po	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Oral Therapy with Amlodipine and Lacidipine, 1,4-Dihydropyridine Derivatives Showing Activity against Experimental Visceral Leishmaniasis.
AID1380097	Inhibition of Cch1 in Candida albicans isolate 10 assessed as potentiation of fluconazole-induced antifungal activity by measuring fractional inhibitory concentration index after 24 hrs by checkerboard assay	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Emerging New Targets for the Treatment of Resistant Fungal Infections.
AID444054	Oral bioavailability in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID537131	Antileishmanial activity against amastigotes of Leishmania chagasi MHOM/BR/1972/LD after 24 hrs by MTT assay	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID1217713	Time dependent inhibition of CYP3A4 (unknown origin) at 10 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID497005	Antimicrobial activity against Pneumocystis carinii	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID427819	Antileishmanial activity against Leishmania donovani MHOH/IN/1983/AD83 promastigotes assessed as decrease in rate of oxygen consumption at 30 ug/mL after 2 hrs by polarographically with Clark electrode	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Oral Therapy with Amlodipine and Lacidipine, 1,4-Dihydropyridine Derivatives Showing Activity against Experimental Visceral Leishmaniasis.
AID227110	In vivo evaluation for the antihypertensive effect in the spontaneously hypertensive rat is % decrease in blood pressure during post drug administration at 45 umol/kg peroral; 46/37	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Dihydropyrimidine calcium channel blockers. 4. Basic 3-substituted-4-aryl-1,4-dihydropyrimidine-5-carboxylic acid esters. Potent antihypertensive agents.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1307729	Activation of bovine TREK1 expressed in AZT cells assessed as reduction in channel currents	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
AID427812	Antileishmanial activity against Leishmania donovani MHOH/IN/1983/AD83 promastigotes assessed as suppression of oxygen consumption after 2 hrs by polarographically with Clark electrode	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Oral Therapy with Amlodipine and Lacidipine, 1,4-Dihydropyridine Derivatives Showing Activity against Experimental Visceral Leishmaniasis.
AID28677	Partition coefficient (logD)	2001	Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9	Property-based design: optimization of drug absorption and pharmacokinetics.
AID73833	Negative inotropy measured as the concentration required to depress contraction in the isolated Langendorff-perfused guinea pig heart by 25%; Not tested	1986	Journal of medicinal chemistry, Sep, Volume: 29, Issue:9	Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID409954	Inhibition of mouse brain MAOA	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1232313	Elimination half life in human	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Volume of Distribution in Drug Design.
AID29851	Half life was measured as time taken to decrease half of its initial concentration	2001	Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9	Property-based design: optimization of drug absorption and pharmacokinetics.
AID678715	Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1367790	Inhibition of human calcium channel	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Relevance of Half-Life in Drug Design.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID427816	Toxicity in BALB/c mouse assessed as liver function at 10 mg/kg, po	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Oral Therapy with Amlodipine and Lacidipine, 1,4-Dihydropyridine Derivatives Showing Activity against Experimental Visceral Leishmaniasis.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID444053	Renal clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1449628	Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID496832	Antimicrobial activity against Trypanosoma brucei rhodesiense	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1367792	Unbound concentration in human at 5 to 10 mg, qd	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Relevance of Half-Life in Drug Design.
AID231281	Ratio of binding affinity against human alpha 1b-adrenoceptor by human alpha 1A-adrenoceptor	1999	Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19	Design and synthesis of novel dihydropyridine alpha-1a antagonists.
AID231286	Ratio of binding affinity against rat L-type calcium channel by human alpha 1A-adrenoceptor	1999	Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19	Design and synthesis of novel dihydropyridine alpha-1a antagonists.
AID35892	Binding affinity against human Alpha-1d adrenergic receptor	1999	Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19	Design and synthesis of novel dihydropyridine alpha-1a antagonists.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID496829	Antimicrobial activity against Leishmania infantum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID537134	Antileishmanial activity against promastigotes of Leishmania braziliensis MHO/BR/75/M2903 after 18 hrs by MTT assay	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID444055	Fraction absorbed in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID17659	Equilibrium dissociation constant based on membrane concentration in rat smooth muscle	1991	Journal of medicinal chemistry, Mar, Volume: 34, Issue:3	Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes.
AID1070215	Inhibition of Trichomonas vaginalis uridine nucleoside ribohydrolase using 5-fluorouridine as substrate at 0.04 to 200 uM after 40 mins by NMR spectrometric analysis	2014	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4	Identification of proton-pump inhibitor drugs that inhibit Trichomonas vaginalis uridine nucleoside ribohydrolase.
AID496823	Antimicrobial activity against Trichomonas vaginalis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496820	Antimicrobial activity against Trypanosoma brucei	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID28412	Compound was evaluated for the plasma clearance to investigate its pharmacokinetic profile in dogs after intravenous administration.	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Long-acting dihydropyridine calcium antagonists. 6. Structure-activity relationships around 4-(2,3-dichlorophenyl)-3-(ethoxycarbonyl)-2-[(2-hydroxyethoxy)methyl]-5 -(methoxycarbonyl)-6-methyl-1,4-dihydropyridine.
AID30133	Compound was evaluated for the volume of distribution to investigate its pharmacokinetic profile in dogs after intravenous administration.	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Long-acting dihydropyridine calcium antagonists. 6. Structure-activity relationships around 4-(2,3-dichlorophenyl)-3-(ethoxycarbonyl)-2-[(2-hydroxyethoxy)methyl]-5 -(methoxycarbonyl)-6-methyl-1,4-dihydropyridine.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID427817	Toxicity in BALB/c mouse assessed as kidney function at 10 mg/kg, po	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Oral Therapy with Amlodipine and Lacidipine, 1,4-Dihydropyridine Derivatives Showing Activity against Experimental Visceral Leishmaniasis.
AID1232308	Distribution coefficient, log D of the compound	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Volume of Distribution in Drug Design.
AID537132	Antileishmanial activity against promastigotes of Leishmania amazonensis WHO/BR/00/LT0016 after 18 hrs by MTT assay	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID1217712	Time dependent inhibition of CYP2C8 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID496831	Antimicrobial activity against Cryptosporidium parvum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID60644	Percent decrease in coronary vascular resistance in dogs after intravenous dosage of 50 ug/kg compound	1986	Journal of medicinal chemistry, Sep, Volume: 29, Issue:9	Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1346650	Human Cav1.3 (Voltage-gated calcium channels)	2009	Molecular pharmacology, Feb, Volume: 75, Issue:2	Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms.
AID1802150	TREK1 Assay from Article 10.1111/cbdd.12810: \\Identification of the first in silico-designed TREK1 antagonists that block channel currents dose dependently.\\	2016	Chemical biology & drug design, Dec, Volume: 88, Issue:6	Identification of the first in silico-designed TREK1 antagonists that block channel currents dose dependently.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	85 (2.16)	18.7374
1990's	690 (17.52)	18.2507
2000's	1334 (33.88)	29.6817
2010's	1459 (37.05)	24.3611
2020's	370 (9.40)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1,504 (35.81%)	5.53%
Reviews	319 (7.60%)	6.00%
Case Studies	359 (8.55%)	4.05%
Observational	60 (1.43%)	0.25%
Other	1,958 (46.62%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (541)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase 1, Open Label, Non-randomized, Two-cohort, Single-sequence, Crossover Study to Investigate the Pharmacokinetic Drug-drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers [NCT02233218]	Phase 1	60 participants (Actual)	Interventional	2014-07-31	Completed
Salt Sensitive Hypertension and Striatin [NCT03683069]	Phase 4	400 participants (Actual)	Interventional	2019-01-15	Active, not recruiting
Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major [NCT01125254]	Phase 2/Phase 3	10 participants (Actual)	Interventional	2008-09-30	Completed
A Single-dose, Randomized, Two-period, Two-treatment, Two-sequence, Crossover Bioequivalence Study of Amlodipine and Losartan Versus Two Co-administration of Amlodipine and Losartan in Healthy Caucasian Subjects [NCT01197014]	Phase 1	72 participants (Anticipated)	Interventional	2010-09-30	Completed
Phase IV Study for Effect of Intensive Blood-Pressure Control Using Anti-hypertensive Agents in Essential Hypertension With History of Stroke [NCT01198496]	Phase 4	5,000 participants (Anticipated)	Interventional	2010-10-31	Recruiting
An Open-label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Two Way Crossover, Single Oral Dose Comparative Pharmacokinetic Study of Amlodipine Besylate Controlled-release Tablets, EQ 5mg Base of Overseas Pharmaceuticals Ltd., China and [NCT05667818]	Phase 1	16 participants (Anticipated)	Interventional	2023-01-28	Not yet recruiting
Exercise and Intensive Vascular Risk Reduction in Preventing Dementia [NCT02913664]	Phase 2/Phase 3	513 participants (Actual)	Interventional	2017-02-02	Completed
A Phase I, Double-Blind, Randomized, Placebo-Controlled, Two-Period, Two-Cohort Crossover Study to Assess the Potential Interaction of Avanafil on the Pharmacokinetic and/or Hemodynamic Effects of Enalapril or Amlodipine in Male Subjects [NCT01117038]	Phase 1	48 participants (Actual)	Interventional	2010-04-30	Completed
A Randomized, Controlled, Multicenter Trial of Levamlodipine Besylate Versus Amlodipine Maleate in Patients With Essential Hypertension [NCT01131546]	Phase 4	1,080 participants (Anticipated)	Interventional	2009-12-31	Completed
An Open-Label Randomized Single-Dose Bioequivalence Study of Amlodipine 10 mg Tablets and Norvasc ® 10 mg Tablets Under Fed Conditions [NCT01131936]	Phase 1	24 participants (Actual)	Interventional	2002-08-31	Completed
A Randomized, Double-blind, Multi-center, Phase III Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil Combination in Patients With Essential Hypertension Who Are Not Adequately Controlled [NCT02368665]	Phase 3	180 participants (Actual)	Interventional	2014-12-31	Completed
A Randomized, Double-blind, Multi-center, Phase III Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil Combination in Patients With Essential Hypertension Who Are Not Adequately Controlled [NCT02368652]	Phase 3	181 participants (Actual)	Interventional	2014-12-31	Completed
A Multi-center, Double-blind, Randomized, Placebo- and Active-controlled, Parallel-group, Proof-of-concept Study to Evaluate the Efficacy, Safety, and Tolerability of 10 mg of ACT-280778 in Patients With Mild to Moderate Essential Hypertension [NCT01264692]	Phase 2	196 participants (Actual)	Interventional	2011-02-28	Completed
Effects and Safety of Clonidine Patch on Young and Middle-aged Smokers With Mild Hypertension: a Randomized Controlled Trial (ECLIPSE) [NCT05416840]	Phase 4	80 participants (Anticipated)	Interventional	2022-08-31	Not yet recruiting
Effect of Amlodipine on Platelet Inhibition by Clopidogrel in Patients With Ischemic Heart Disease- a Prospective Randomized Controlled Trial [NCT01203696]	Phase 4	97 participants (Actual)	Interventional	2010-07-31	Completed
Short-term Effects of Perindopril-amlodipine Versus Perindopril-indapamide on Blood Pressure Control in Newly Diagnosed Type 2 Diabetes Individuals With Hypertension [NCT03747978]	Phase 4	30 participants (Actual)	Interventional	2016-10-01	Completed
Evaluation of spironolactoNe Versus Indapamide on Target Organ Damage in Patients With Obesity and hYpertension(ENVOY) [NCT03626506]		400 participants (Anticipated)	Interventional	2019-02-13	Recruiting
A Double-blind, Randomized, Multi-center Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of CJ-30061 Compared With Amlodipine/Valsartan Combination Therapy and Valsartan/Atorvastatin Combination Therapy in Hypertensive Patients With Hyperlipide [NCT03639480]	Phase 3	180 participants (Anticipated)	Interventional	2017-10-13	Enrolling by invitation
A Cohort Study of Telmisartan on Metabolic Components and Left Ventricular Remodeling in Obese Patients With Hypertension [NCT03956823]		300 participants (Anticipated)	Interventional	2019-08-01	Recruiting
Efficacy of Sevikar® Compared to the Combination of Perindopril/ Amlodipine on Central Arterial Blood Pressure in Patients With Moderate to Severe Hypertension- [NCT01101009]	Phase 4	486 participants (Actual)	Interventional	2010-04-30	Completed
A Randomized, Open-label, Single Dose, Replicate Crossover Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Healthy Volunteers [NCT03662620]	Phase 1	67 participants (Actual)	Interventional	2018-10-05	Completed
Randomized Open-label Single-Dose Two-Way Crossover Study to Assess the Relative Bioavailability of 5mg Levamlodipine Tablet vs. 10mg Amlodipine Besylate Tablet in Healthy Subjects Followed by a Phase to Study Food Effect on the PK of Levamlodipine [NCT03657550]	Phase 1	36 participants (Actual)	Interventional	2018-05-31	Completed
Efficacy and Safety of Two Fixed-combination Antihypertensive Regimens, Amtrel® and Co-Diovan® in Type 2 Diabetes Hypertension Patients With Microalbuminuria [NCT01375322]	Phase 4	226 participants (Actual)	Interventional	2007-06-30	Completed
The Multicenter, Randomized, Double Blind Phase 3 Clinical Trial to Compare Efficacy and Safety of Combination of Amlodipine and Losartan Compared to Amlodipine Monotherapy in Patients With Stage 2 Hypertension [NCT01127217]	Phase 3	149 participants (Actual)	Interventional	2009-05-31	Completed
Relative Bioavailability of Telmisartan 40 mg/Amlodipine 5 mg Fixed-dose Combination Tablet Compared to Concomitant Use of Its Mono-components (i.e., Telmisartan 40 mg Tablet and Amlodipine 5 mg Tablet in Concomitant Use) Following Oral Administration in [NCT02259790]	Phase 1	30 participants (Actual)	Interventional	2007-07-31	Completed
Pharmacokinetic and Hemodynamic Interactions Between Amlodipine and Losartan in Humans [NCT03912285]	Phase 1	24 participants (Actual)	Interventional	2008-01-10	Completed
Effects of Intensive Vasodilating add-on Therapy on Peripheral Vascular Resistance and Coronary Flow Reserve in Patients With Essential Hypertension [NCT01180413]	Phase 4	48 participants (Actual)	Interventional	2010-12-31	Completed
A 24-week Open-label Clinical Trial to Assess Tolerability and Antihypertensive Effect and in Hemodynamic Parameters and Arterial Stiffness of Fimasartan 60 mg Plus Amlodipine Besylate 5 mg Given Once a Day in Patients With Hypertension in Stadiums 2/3 [NCT03294070]	Phase 4	53 participants (Anticipated)	Interventional	2017-09-30	Not yet recruiting
A Randomised Double-blind Cross-over Single-centre Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension [NCT03276598]	Phase 4	233 participants (Actual)	Interventional	1999-11-25	Completed
A Randomized, Double-blind, Multi-center, Phase Ⅳ Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety Between Amlodipine Besylate/Candesartan Cilexetil Combination Tablets and Co-administration of Amlodipine Besylate and Candesartan Cilexe [NCT03231982]	Phase 4	210 participants (Anticipated)	Interventional	2017-04-17	Recruiting
An Open-label, Fixed-sequence, Crossover Study to Evaluate the Pharmacokinetic Interaction and Safety After Multiple Oral Doses of Fimasartan/Amlodipine and Rosuvastatin in Healthy Male Subjects [NCT02397538]	Phase 1	50 participants (Actual)	Interventional	2015-02-28	Completed
An Open Label, Randomized, Single-dose, 4-period Cross-over Study to Compare the Pharmacokinetics and Safety Following Administration of JLP-1401 and Co-administration of Telmisartan/Amlodipine and Rosuvastatin in Healthy Adult Volunteers [NCT03707899]	Phase 1	49 participants (Actual)	Interventional	2018-12-13	Completed
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication [NCT05103332]	Phase 2	672 participants (Actual)	Interventional	2021-11-05	Active, not recruiting
A Multicenter Trial to Evaluate the Safety and Efficacy of the Combination of Valsartan/Amlodipine 160/10 mg Versus Amlodipine 10 mg Alone for 8 Weeks in Hypertensive Patients Who Are Not Adequately Controlled on Amlodipine 10 mg Monotherapy [NCT00171002]	Phase 3	936 participants (Actual)	Interventional	2004-11-30	Completed
Evaluation of Amlodipine Pharmacokinetics in Patients Receiving Hi Flux Hemodialysis [NCT03722381]		0 participants (Actual)	Observational	2020-01-31	Withdrawn(stopped due to Study activities were not initiated, and we do not plan to initiate them in the future.)
A Randomized Clinical Trial of the N-of-1 Approach in Children With Hypertension [NCT03461003]	Phase 4	49 participants (Actual)	Interventional	2018-04-02	Completed
Effect of Spirulina Compared to Amlodipine on Cardiac Iron Overload in Children With Beta Thalassemia [NCT02671695]		40 participants (Actual)	Interventional	2015-04-30	Completed
EffecTs of Amlodipine and Other Blood PREssure Lowering Agents on Microvascular FuncTion in Small Vessel Diseases [NCT03082014]	Phase 3	101 participants (Actual)	Interventional	2018-02-22	Terminated(stopped due to completed for the primary study group of sporadic SVD patients, halted prematurely for the additional study group due to slow recruitment at 26 of 30 CADASIL patients in December 2022)
An Observational Study to Evaluate the Efficacy and Safety of Amosartan Plus Tablet in Uncontrolled Essential Hypertension Patients [NCT05462535]		4,785 participants (Actual)	Observational	2018-02-26	Completed
DescripTion of the Effectiveness, Safety, Tolerability and Adherence to Amlodipine/atoRvastatin/Perindopril sinGle Pill Combination trEatmenT in Patients With Arterial Hypertension and Dyslipidemia in the Daily Clinical Practice. (TARGET) [NCT05764317]		400 participants (Anticipated)	Observational	2023-04-30	Not yet recruiting
Effect of Fixed Triple Combination With Losartan-Amlodipin-HCTZ vs. Free Triple Combination on Blood Pressure Control [NCT03578042]	Phase 4	100 participants (Anticipated)	Interventional	2017-04-01	Recruiting
Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study [NCT03785067]	Phase 3	1 participants (Actual)	Interventional	2020-02-27	Terminated(stopped due to Contractual and financial issues.)
Effect of L-type Calcium Channel Blocker (Amlodipine) on Myocardial Iron Deposition in Thalassemic Patients With Moderate to Severe Myocardial Iron Deposition: A Randomized Pilot Study [NCT02065492]	Phase 2/Phase 3	20 participants (Actual)	Interventional	2014-02-28	Completed
An Open-label, Randomized, 2X2 Crossover Study to Compare the Pharmacokinetics and Safety Between DWJ1351 and Co-administration of Amlodipine/Olmesartan and Rosuvastatin in Healthy Male Subjects [NCT03753477]	Phase 1	64 participants (Actual)	Interventional	2017-12-22	Completed
A Randomized, Open-label, Multiple Doses, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction and Safety of Amlodipine Between Free Combination of Amlodipine and Candesartan and Amlodipine Monotherapy in Healthy Male Volunteers [NCT02064556]	Phase 1	24 participants (Actual)	Interventional	2014-05-31	Completed
A Multi-center, Randomized, Double-blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Olmesartan/Amlodipine/Rosuvastatin Combination Treatment in Patients With Concomitant Hypertension and Hyperlipidemia [NCT03009487]	Phase 3	265 participants (Actual)	Interventional	2017-01-31	Completed
A Randomized, Double-blind, Multi-center, PhaseⅡ Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Candesartan Cilexetil and Amlodipine Besylate for the Dose Selection in Patients With Essential Hypertension [NCT02059616]	Phase 2	384 participants (Anticipated)	Interventional	2014-02-28	Recruiting
An Open-label, Postmarketing Study of Amlodipine/Valsartan Single-Pill Combination for the Treatment of Hypertension [NCT02058446]	Phase 4	36 participants (Actual)	Interventional	2013-10-31	Completed
A Randomized, Open-label, Multiple Doses, Crossover Study to Evaluate the Pharmacokinetic Drug Interaction and Safety of S-amlodipine Between Free Combination of S-amlodipine and Telmisartan and S-amlodipine Monotherapy in Healthy Male Volunteers [NCT01356043]	Phase 1	24 participants (Actual)	Interventional	2011-05-31	Completed
A Randomized, Double-Blind, Multicenter, Phase 2/3 Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB (Fix-dose Combination of Azilsartan and Amlodipine) and Hydrochlorothiazide in Comparison With TAK-536CCB or Hydrochlorot [NCT02072330]	Phase 2/Phase 3	353 participants (Actual)	Interventional	2013-03-31	Completed
A Comparative Study for the Effects of Nifedipine GITS and Amlodipine Besylate on Recovery of Blood Pressure Rhythm and Arterial Stiffness in the Young and Middle-aged Subjects With Non-dipper Hypertension [NCT02940548]	Phase 4	99 participants (Actual)	Interventional	2016-12-31	Terminated(stopped due to The patient recruitment and follow-ups were influenced with the pandemic of COVID-19)
Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction [NCT01354613]		14 participants (Actual)	Interventional	2011-04-30	Completed
A 12-week, Multi-Center, Randomized Double-Blind, Active Control Parallel Group Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertens [NCT01368536]	Phase 4	975 participants (Actual)	Interventional	2011-05-31	Terminated(stopped due to Based on results from an ALTITUDE study interim analysis, testing aliskiren concomitantly with an ACE inhibitor or ARB, in diabetics with renal impairment)
Effect of the Administration of Losartan / Amlodipine in Fixed Combination Versus Losartan on Hemodynamic and Arterial Stiffness Parameters in Patients With Systemic Hypertension Grade 1 and 2 [NCT03626259]	Phase 4	28 participants (Anticipated)	Interventional	2018-08-06	Recruiting
A Randomized, Open-label, Multiple Doses, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction and Safety of Telmisartan Between Free Combination of Telmisartan and S-amlodipine and Telmisartan Monotherapy in Healthy Male Volunteers [NCT01356017]	Phase 1	32 participants (Anticipated)	Interventional	2011-06-30	Completed
Pharmacokinetics of Repeated Oral Doses of 80 mg Telmisartan (Micardis®) at Steady State Alone and in Combination With Repeated Oral Doses of Amlodipine 10 mg (Norvasc®) at Steady State. A Two-way Crossover, Open, Randomised Design Study [NCT02259816]	Phase 1	38 participants (Actual)	Interventional	2006-05-31	Completed
Randomized, Double-blind, Multi-center Phase III Clinical Trial to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine and Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia [NCT03566316]	Phase 3	134 participants (Actual)	Interventional	2015-11-24	Completed
"Multinational Observational Uncontrolled Open Programme The Use of TRIple Fixed-dose COmbination in the Treatment of arteriaL Hypertension: Opportunity for Effective BP Control With cOmbined Antihypertensive Therapy" [NCT03722524]		1,247 participants (Actual)	Observational	2018-10-01	Completed
Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) MRI Sub-study [NCT03783754]		4 participants (Actual)	Interventional	2018-08-09	Terminated(stopped due to Not feasible to continue)
Assessment of Immediate Postoperative Delirium (IPD) in Adult Patients: Incidence, Implication of Type of Anesthesia and Identification of Other Etiological Factors [NCT03967496]		402 participants (Actual)	Observational [Patient Registry]	2019-01-01	Completed
A Cluster Randomized Trial On Cardiovascular Risk Factor Management: Caduet Versus Usual Care In Subjects With Hypertension And Additional Cardiovascular Risk Factors In Clinical Practice [NCT00407537]	Phase 4	1,531 participants (Actual)	Interventional	2007-03-31	Completed
Study to Evaluate the Safety and Efficacy of Two Fixed Dose Combinations of Irbesartan / Amlodipine and Monotherapy After Eight Weeks of Treatment in Subjects With Uncomplicated Mild to Moderate Essential Hypertension [NCT00950066]	Phase 2	270 participants (Actual)	Interventional	2009-07-31	Completed
ACCESS STUDY (Angiotensin Receptor Blocker Combined With Calcium Antagonist Evaluation of Safety and Lowering of Systolic Blood Pressure Study) ARB/CCB Combination Therapy: Efficacy vs an ACE-inhibitor/CCB Combination and Use as First Line Therapy. [NCT01089452]	Phase 4	0 participants (Actual)	Interventional		Withdrawn(stopped due to Study not started due to administrative reasons.)
A Prospective Randomized Open-Label, Blinded-Endpoint (PROBE) Trial Comparing MICARDIS® (Telmisartan) (80 mg QD) and Amlodipine (5 mg QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring. [NCT02177409]	Phase 3	431 participants (Actual)	Interventional	1998-04-30	Completed
The Use of the Calcium Channel Blocker Amlodipine as an Adjuvant Treatment to Iron Chelation for the Prevention of Iron Overload Cardiomyopathy in Patients With Thalassemia [NCT02474420]		60 participants (Anticipated)	Interventional	2015-06-30	Recruiting
A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study of Amlodipine 10 mg Tablets Versus Norvasc® 10 mg Tablets in Normal Healthy Non-Smoking Male and Female Subjects [NCT00841815]	Phase 1	28 participants (Actual)	Interventional	2003-04-30	Completed
Evaluation of the Efficacy and Safety of S-amlodipine+Chlorthalidone Combination Therapy and S-amlodipine+Telmisartan Combination Therapy in Hypertensive Patients Inadequately Controlled With Calcium Channel Blocker Monotherapy [NCT03226340]	Phase 4	170 participants (Anticipated)	Interventional	2015-12-02	Recruiting
A Double-Blind, Comparative Study Between Amlodipine 5mg And 10mg In Patients With Essential Hypertension For Whom Amlodipine 5mg Is Insufficiently Effective [NCT00415623]	Phase 3	305 participants (Actual)	Interventional	2007-01-31	Completed
A Randomized, Open-label, Single Dose, Crossover Clinical Trial to Compare the Safety and Pharmacokinetics of YHP1604 in Comparison to the Co-administration of Telmisartan/Amlodipine and Rosuvastatin in Healthy Volunteers [NCT03116516]	Phase 1	62 participants (Actual)	Interventional	2017-04-21	Completed
Open Label, Randomized, Two-treatment, Two-period, Two-sequence, Oral Bioequivalence Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10mg/80mg Under Fed Condition [NCT02292069]	Phase 1	90 participants (Actual)	Interventional	2011-09-30	Completed
A Phase I Clinical Trial to Compare the Pharmacokinetics and Safety of CKD-828(Telmisartan 80mg/S-amlodipine 5mg Combination Tablet) to Coadministration of Telmisartan 80mg and S-amlodipine 5mg in Healthy Male Volunteers [NCT02358824]	Phase 1	48 participants (Actual)	Interventional	2015-02-28	Completed
A Prospective Randomized Placebo Controlled Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine on Renal and Vascular Function in Subjects With Existing Hypertension Requiring Antihypertensive Therapy [NCT02979197]	Phase 3	105 participants (Actual)	Interventional	2016-11-03	Completed
The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combine Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension [NCT00921570]	Phase 4	105 participants (Actual)	Interventional	2008-02-29	Completed
Folic Acid and Intensive Antihypertensive Therapy for Cerebrovascular and Cardiovascular Events Prevention Among Patients With Hypertension and Cerebral Small Vascular Diseases (FAITH)----A Multicenter, Randomized, Controlled, Open-label, 2x2 Factorial, B [NCT05169021]	Phase 4	15,000 participants (Anticipated)	Interventional	2021-12-31	Not yet recruiting
An Open-label, Randomized, Single Dose, 6-Sequence, 3-Period, Cross-over Study to Evaluate a Drug Interaction Between Fixed-dose Combination of Fimasartan/Amlodipine and Hydrochlorothiazide in Healthy Male Subjects [NCT03390465]	Phase 1	36 participants (Actual)	Interventional	2017-12-15	Completed
An Open-Label, Superiority, Randomized, Comparative Study to Evaluate the Efficacy and Safety of Telmisartan, Amlodipine, and Chlorthalidone Fixed-Dose Combination Versus Telmisartan, Amlodipine, and Hydrochlorothiazide in Elderly Patients With Essential [NCT06041529]	Phase 4	250 participants (Anticipated)	Interventional	2023-09-14	Not yet recruiting
Open Label, Randomized, Two-treatment, Two-period, Two-sequence,Crossover, Single Dose, Oral Bioequivalence Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10mg/80mg Under Fasting Condition [NCT02295046]	Phase 1	80 participants (Actual)	Interventional	2011-10-31	Completed
Bioequivalence of 80 mg Telmisartan / 10 mg Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers. An Open-label, Randomised, Single-dose, Two Sequence, Two-period Crossover Study [NCT02193308]	Phase 1	84 participants (Actual)	Interventional	2007-09-30	Completed
Comparison of Tandospirone, Amlodipine and Their Combination in Adults With Hypertension and Anxiety: a Multicentre, Randomized, Double-blind, Double-dummy, Placebo-controlled Trial [NCT03667677]	Phase 4	256 participants (Anticipated)	Interventional	2019-02-01	Not yet recruiting
Multicenter, Randomized, Open-label Trial to Assess the Efficacy of Sacubitril/Valsartan vs. Amlodipine/Losartan on Left Ventricular Remodeling in Patients With Chronic Severe Aortic Regurgitation [NCT05212597]	Phase 2	100 participants (Anticipated)	Interventional	2022-01-12	Recruiting
Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of 10 mg Amlodipine Besylate/20 mg Benazepril Hydrochloride Capsules in Healthy Adult Male Volunteers Under Non-fasting (Fed) Conditions [NCT01155908]	Phase 1	48 participants (Actual)	Interventional	2005-04-30	Completed
Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects [NCT03648333]	Phase 1	27 participants (Actual)	Interventional	2013-12-31	Completed
An Observational Study to Evaluate the Effects of Twynsta Tablets (Telmisartan and Amlodipine FDC, q.d.) With Life Style Modifications on Blood Pressure, Quality of Life, and Other Risk Factors in Korean Patients With Hypertension [NCT01316419]		2,089 participants (Actual)	Observational	2011-03-31	Completed
Influence of Food on the Bioavailability of Telmisartan 40 mg/Amlodipine 5 mg Fixed-dose Combination and of Telmisartan 80 mg/Amlodipine 5 mg Fixed-dose Combination in Healthy Japanese Male Volunteers (a Phase I, Open-label, Randomised, Single-dose, Two-w [NCT02261064]	Phase 1	32 participants (Actual)	Interventional	2008-12-31	Completed
Influence of Food on the Bioavailability of 80 mg Telmisartan/10 mg Amlodipine Fixed Dose Combination in Healthy Male and Female Volunteers. An Open-label, Randomised, Single-dose, Two Period, Crossover Study [NCT02259777]	Phase 1	40 participants (Actual)	Interventional	2007-09-30	Completed
Impact of Intensive Treatment of Systolic Blood Pressure on Brain Perfusion, Amyloid, and Tau in Older Adults (IPAT Study) [NCT05331144]	Phase 2	180 participants (Anticipated)	Interventional	2022-10-25	Recruiting
A Double-blind, Randomized, Multi-center Phase III Clinical Trial to Evaluate the Safety and Efficacy of CJ-30060 Compared With Amlodipine/Valsartan Combination Therapy and Valsartan/Rosuvastatin Combination Therapy in Hypertensive Patients With Hyperlipi [NCT03536598]	Phase 3	203 participants (Actual)	Interventional	2016-10-14	Completed
A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Compare the Safety and Pharmacokinetics of CKD-330 (Fixed-dose Combination of Candesartan 8 mg and Amlodipine 5 mg) With Coadministration of the Two Separate Drugs in Healthy Male Volunteers [NCT02186496]	Phase 1	32 participants (Actual)	Interventional	2014-07-31	Completed
Bariatric Surgery and Pharmacokinetics Amlodipine: BAR-MEDS Amlodipine [NCT02904291]		12 participants (Anticipated)	Observational	2016-11-30	Recruiting
A Phase III, Randomized, Double-Blind, Placebo Controlled Clinical Trial Evaluating the Benefits and Mechanism Of Action Of Angiotensin-II Receptor Blocker On Cardiovascular Remodeling In Patients With Repaired Coarctation Of Aorta [NCT06150560]	Phase 3	120 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
A Two-Way Crossover, Open-Label, Single-Dose, Fasting, Bioequivalence Study of Amlodipine 10 mg Tablets Versus Norvasc® 10 mg Tablets in Normal Healthy Non-Smoking Male and Female Subjects [NCT00841542]	Phase 1	28 participants (Actual)	Interventional	2003-04-30	Completed
A Randomized, Open-label, Multiple Doses, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction and Safety of Candesartan Between Free Combination of Candesartan and Amlodipine and Candesartan Monotherapy in Healthy Male Volunteers [NCT02064621]	Phase 1	24 participants (Actual)	Interventional	2014-06-30	Completed
An Open-label, Randomized, Single Dose, Three-way Crossover, Six Sequence Pilot Study to Evaluate the Relative Bioavailability of One Amlodipine 10mg Tablet and Rosuvastatin 20mg Tablet to Two Fixed Dose Combination Tablet Formulations of Amlodipine (10mg [NCT02075619]	Phase 1	24 participants (Actual)	Interventional	2014-03-24	Completed
A Randomized, Double-blind, Multi-center, Multi-factorial, Phase 2 Trial to Evaluate the Efficacy and Safety of S-Amlodipine/Telmisartan Combined or Alone and Select Better Dose of CKD-828 in Patients With Essential Hypertension [NCT01128322]	Phase 2	430 participants (Anticipated)	Interventional	2010-07-31	Completed
Open-label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetics and Safety Following Administration of CJ-30059 and Co-administration of Candesartan Cilexetil and Amlodipine Besylate in Healthy Volunteers. [NCT02173912]	Phase 1	32 participants (Anticipated)	Interventional	2014-06-30	Recruiting
A Multicenter, Prospective, Randomized, Open-label, Phase 4 Trial to Evaluate the Efficacy of Telmisartan/S-Amlodipine(Telminuvo® Tab. 40/2.5mg) on 24-hour Ambulatory BP Control Compared With Telmisartan Monotherapy in Hypertensive Patients Inadequately C [NCT02231788]	Phase 4	217 participants (Actual)	Interventional	2014-06-30	Completed
A Study to Evaluate the Co-Administration of MK-4618 With Antihypertensive Agents [NCT01337674]	Phase 1	26 participants (Actual)	Interventional	2011-04-01	Completed
Effect of Nocturnal Administration of Anti-hypertensive Medications in NoN-dippers [NCT01091753]	Phase 4	28 participants (Actual)	Interventional	2008-03-31	Completed
Trial of Amlodipine Combined With Botulinum Toxin Injections for Focal Dystonia [NCT00015457]	Phase 2	16 participants (Actual)	Interventional	2001-04-30	Completed
Single-Dose Fasting In Vivo Bioequivalence Study of Amlodipine and Benazepril HCl Capsules (10 mg/20 mg; Mylan) to Lotrel® Capsules (10 mg/20 mg; Novartis) in Healthy Volunteers [NCT00649519]	Phase 1	54 participants (Actual)	Interventional	2004-05-31	Completed
A 16-week Double-blind, Randomized, Multicenter, Force-titration Study to Evaluate the Antihypertensive Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Therapy Compared to HCTZ Based Therapy in Obese, Hypertensive Patients [NCT00439738]	Phase 4	412 participants (Actual)	Interventional	2006-12-31	Completed
A Randomized, Open-label, Multiple Dose, Three-treatment, Three-period, Six-sequence Crossover Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between CKD-501 and Amlodipine After Oral Administration in Healthy Male Volunteers [NCT01341392]	Phase 1	25 participants (Actual)	Interventional	2011-04-30	Completed
A Pilot Study Exploring Efficacy and Safety of Amlodipine in the Stented Angina Patients [NCT01120327]	Phase 4	212 participants (Anticipated)	Interventional	2010-07-31	Not yet recruiting
Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of 10 mg Amlodipine Besylate/20 mg Benazepril Hydrochloride Capsules in Healthy Adult Male Volunteers Under Fasting Conditions [NCT01155895]	Phase 1	54 participants (Actual)	Interventional	2004-03-31	Completed
A Single-dose, Randomized, Two-period, Two-treatment, Two-sequence, Crossover Bioequivalence Study of Amlodipine and Losartan Versus Two Co-administration of Amlodipine and Losartan in Healthy Caucasian Subjects [NCT01197001]	Phase 1	72 participants (Anticipated)	Interventional	2010-08-31	Completed
An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of a 4 Week Therapy With the Single Pill (SPC) Combination of Aliskiren 300 mg / Amlodipine 10 mg in Hypertensive Patients Not Adequately Respond to an Uptitrated 4 Week Therapy With the [NCT01113047]	Phase 3	347 participants (Actual)	Interventional	2010-05-31	Completed
A Randomized, Open Label, Multiple Dose, Crossover Study to Investigate Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide(HCTZ) in Subjects With (Pre)Hypertension [NCT01198249]	Phase 1	23 participants (Actual)	Interventional	2010-09-30	Completed
An Open-Label Randomized Single-Dose Bioequivalence Study of Amlodipine 10 mg Tablets and Norvasc ® 10 mg Tablets Under Fasting Conditions [NCT01131923]	Phase 1	26 participants (Actual)	Interventional	2002-10-31	Completed
Effect of Blood Pressure Reduction in Patients With Chronic Heart Failure - Randomized, Double-blind, Placebo-controlled Trial [NCT01255475]	Phase 2/Phase 3	21 participants (Actual)	Interventional	2011-01-31	Completed
A Randomized, Open-label, Single Dose, 3-way Crossover Study to Evaluate the Drug-drugs Interaction Between Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers [NCT03889145]	Phase 1	30 participants (Actual)	Interventional	2013-12-19	Completed
A Multicenter, Prospective, Randomized, Open-label, Phase 4 Trial Designed to Evaluate the Efficacy of a Telmisartan/S-Amlodipine(Telminuvo®Tab. 40/2.5mg) on 24-hour BP Control in Hypertensive Patients Inadequately Controlled [NCT02526875]	Phase 4	208 participants (Anticipated)	Interventional	2015-04-30	Recruiting
A Randomized, Two-period Crossover Trial Examining Bioequivalence of Bisoprolol-Amlodipine 5 mg/5 mg Combination Tablets Versus Bisoprolol 5 mg Tablets and Amlodipine 5 mg Tablets Given Concomitantly in Healthy Subjects in Fasting and Fed State [NCT03226275]	Phase 1	32 participants (Actual)	Interventional	2017-08-09	Completed
A TElmisartan and AMlodipine STudy to Assess the Cardiovascular PROTECTive Effects as Measured by Endothelial Dysfunction in Hypertensive at Risk Patients Beyond Blood Pressure [NCT01180205]	Phase 4	576 participants (Anticipated)	Interventional	2010-08-31	Active, not recruiting
An Open-label PET-observer-blinded Pilot Study of the Effect of Aliskiren- Versus Amlodipine-based Antihypertensive Treatment in Patients With Small Abdominal Aortic Aneurysm and Mild to Moderate Hypertension on Aneurysmal FDG-uptake [NCT01425242]		3 participants (Actual)	Interventional	2011-09-30	Terminated(stopped due to Insufficient number of participants)
A Randomized,Open-label,Single Dose,Crossover Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Comparison to the Co-administration of Twynsta and Hygroton in Healthy Volunteers [NCT02496910]	Phase 1	180 participants (Anticipated)	Interventional	2015-06-30	Completed
Role of LSD1 in Hypertension in Blacks [NCT04840342]	Phase 4	300 participants (Anticipated)	Interventional	2022-02-03	Recruiting
NORVASC10MG DRUG USE INVESTIGATION [NCT01252563]		14,141 participants (Actual)	Observational	2010-12-31	Completed
Double Blind, Randomized, Parallel Group, Multicentre Study to Evaluate the Effects of Manidipine 20 MG Vs. Amlodipine 10 MG and the Combination of Manidipine 10 MG Plus Delapril 30 MG Vs. Amlodipine 5 MG Plus Delapril 30 MG on Intraglomerular Pressure in [NCT00627952]	Phase 3	100 participants (Actual)	Interventional	2007-11-30	Completed
An Open, Randomized, Parallel-Cohort, 2-Periods, Crossover, Single Dose Bioequivalence Study For 5 Mg Amlodipine Orally-Disintegrating Tablet In Healthy Male Subjects [NCT01004614]	Phase 1	48 participants (Actual)	Interventional	2009-11-30	Completed
A Multi-national, Multi-center, Double-blind, Randomized, Parallel Study Comparing the Efficacy and Safety of Valsartan/Amlodipine 160/5 mg to Valsartan 160 mg Alone in Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With V [NCT01001572]	Phase 3	932 participants (Actual)	Interventional	2009-09-30	Completed
A Randomized, Eight-week Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / Amlodipine (300/5 mg and 300/10 mg) in Comparison With Aliskiren 300 mg in Patients With Essential Hypertension [NCT00777946]	Phase 3	818 participants (Actual)	Interventional	2008-10-31	Completed
Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg [NCT00687973]	Phase 4	393 participants (Actual)	Interventional	2008-01-31	Completed
The Effect of Losartan Versus Amlodipine-based Antihypertensive Therapy on Atherosclerotic Inflammatory Markers and Cerebrovascular Regulation in Ischemic Stroke Patients [NCT00754429]	Phase 4	40 participants (Actual)	Interventional	2004-06-30	Completed
A 6-Week, Prospective, Randomized, Double-Blind, Double-Dummy Phase IV Clinical Trial Designed to Evaluate the Efficacy of an Aggressive Multi-Risk Factor Management Strategy With Caduet (A3841045) Versus a Guideline-Based Approach in Achieving Blood Pres [NCT00412113]	Phase 4	245 participants (Actual)	Interventional	2007-01-31	Completed
An 8-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 80 + Amlodipine 10mg Versus Amlodipine 10 mg Monotherapy as First Line Therapy in Type 2 Diabetes Patients With Hypertension. [NCT00877929]	Phase 3	706 participants (Actual)	Interventional	2009-02-28	Completed
A Phase 1, Open Label, Two-cohort, Single-Sequence, Crossover Study to Investigate the Pharmacokinetic Drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers [NCT02951962]	Phase 1	60 participants (Anticipated)	Interventional	2016-08-31	Completed
A Prospective, Open-label, Ambulatory Blood Pressure Monitoring (ABPM) Dose Titration Study to Evaluate the Safety and Efficacy of an Olmesartan Medoxomil and Amlodipine Based Treatment Regimen in Hypertensive, Type 2 Diabetic Subjects [NCT00654745]	Phase 4	207 participants (Actual)	Interventional	2008-05-31	Completed
Comparison of Optimal Hypertension Regimens (Part of the Ancestry Informative Markers in Hypertension (AIMHY) Programme - AIMHY-INFORM) [NCT02847338]	Phase 4	1,320 participants (Anticipated)	Interventional	2016-11-30	Recruiting
Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia: a Multi-center-database Real-world Study [NCT05660135]		4,000 participants (Anticipated)	Observational	2022-06-20	Recruiting
A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Compare the Safety and Pharmacokinetics of CKD-330 (Fixed-dose Combination of Candesartan 16 mg and Amlodipine 5 mg) With Coadministration of the Two Separate Drugs in Healthy Male Volunteers [NCT02801526]	Phase 1	32 participants (Actual)	Interventional	2015-04-30	Completed
Comparative, Randomized, Single Dose, 2-way Crossover Bioavailability Study of Actavis Group hf and Pfizer Inc. (Norvasc®)10 mg Amlodipine Besylate Tablets in Healthy Adult Volunteers Under Fed Conditions. [NCT00870571]	Phase 1	26 participants (Actual)	Interventional	2005-04-30	Completed
A Randomized, Double-blind, Multi-center Clinical Trial to Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin Combination Tablets and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets [NCT03847506]	Phase 4	127 participants (Actual)	Interventional	2018-07-05	Completed
An Open-label, Randomized, Single-dose, 2×2 Crossover Study to Compare the Pharmacokinetics of Fimasartan/Amlodipine Combination Tablet and Coadministration of Fimasartan and Amlodipine as Individual Tablets in Healthy Male Volunteers [NCT02205151]	Phase 1	86 participants (Actual)	Interventional	2014-07-31	Completed
A Randomized, Double-blind, Multi-center, Phase 2 Trial to Evaluate the Efficacy and Safety of Candesartan/Amlodipine Combined or Alone and Select Better Dose of CKD-330 in Patients With Essential Hypertension [NCT02206165]	Phase 2	456 participants (Anticipated)	Interventional	2014-03-31	Recruiting
A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan/Amlodipine in Healthy Male Volunteers [NCT02387619]	Phase 1	41 participants (Actual)	Interventional	2015-02-28	Completed
Morning Versus Bedtime Dosing of Antihypertensive Medication in Grade 1 Day-night Hypertension: a Multicenter Randomized Controlled Trial (Dosing-Time Trial) [NCT05089448]	Phase 4	300 participants (Anticipated)	Interventional	2021-01-28	Recruiting
Bioequivalence of 40 mg Telmisartan/5 mg Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers. An Open-label, Randomised, Single-dose, Two-period Crossover Study [NCT02259829]	Phase 1	84 participants (Actual)	Interventional	2007-09-30	Completed
Cardiovascular and Metabolic Physiological Adaptations to Intermittent Hypoxia. Physiological Aspects and Expression of Receptors and Cellular Mediators [NCT02058823]	Phase 4	12 participants (Actual)	Interventional	2013-08-07	Terminated(stopped due to budget constraints)
Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity [NCT04329806]	Phase 1	72 participants (Anticipated)	Interventional	2021-02-23	Suspended(stopped due to Study being replaced by crossover design)
Calcium Channel Blockade in Primary Aldosteronism [NCT04179019]	Phase 2	15 participants (Anticipated)	Interventional	2020-09-01	Active, not recruiting
Relative Bioavailability of Telmisartan 80 mg/Amlodipine 5 mg Fixed-dose Combination Tablet Compared to Concomitant Use of Its Mono-components (i.e., Two Telmisartan 40 mg Tablets and Amlodipine 5 mg Tablet in Concomitant Use) Following Oral Administratio [NCT02259803]	Phase 1	30 participants (Actual)	Interventional	2007-10-31	Completed
A Randomized, Double-blind, Active-controlled, Multicenter Phase3 Trial to Evaluate the Efficacy and Safety of Co-administrated Temisartan/Amlodipine and Rosuvastatin in Subjects With Hypertension and Hyperlipidemia [NCT03067688]	Phase 3	202 participants (Actual)	Interventional	2017-04-11	Completed
An Open-label, Multiple-dose, Two-arm Clinical Study to Evaluate the Drug-drug Interaction and Safety of Telmisartan, Amlodipine and/or Chlorthalidone in Healthy Adult Volunteers [NCT02152969]	Phase 1	66 participants (Actual)	Interventional	2014-05-31	Completed
To Compare the Pharmacokinetics and Safety of CKD-828 80/5mg to Coadministration of Telmisartan 80mg and S-amlodipine 5mg in Healthy Male Volunteers [NCT02250833]	Phase 1	69 participants (Actual)	Interventional	2014-09-30	Completed
Clinical Phase Ib/II Trial of L-NMMA Plus Taxane Chemotherapy in the Treatment of Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients [NCT02834403]	Phase 1/Phase 2	37 participants (Actual)	Interventional	2016-11-30	Completed
A Multicenter, Double-blind, Controlled, Randomized Trial to Evaluate the Association Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension [NCT05920005]	Phase 3	698 participants (Anticipated)	Interventional	2023-08-22	Recruiting
Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of 40 mg Telmisartan/5 mg Amlodipine and 80 mg Telmisartan/5 mg Amlodipine (Free Dose Combination) in Healthy Male Volunteers [NCT02194309]	Phase 1	24 participants (Actual)	Interventional	2006-09-30	Completed
Investigating the Relevance of Skin Sodium and Salt Sensitivity of Blood Pressure in Determining the Response to Anti-Hypertensive Drugs (INTREPID) [NCT05976438]		60 participants (Anticipated)	Interventional	2023-08-31	Not yet recruiting
A Phase III, 8-week, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Amlodipine 5mg+Losartan 100mg Versus Losartan 100mg in Patients With Essential Hypertension Not Controlled on Losartan Monotherapy [NCT00940680]	Phase 3	142 participants (Actual)	Interventional	2008-04-30	Completed
A Randomized, Double-Blind, Parallel, Placebo or Amlodipine-Controlled Study of the Effects of Losartan on Proteinuria in Pediatric Patients With or Without Hypertension [NCT00568178]	Phase 3	306 participants (Actual)	Interventional	2007-06-01	Completed
Efficacy and Safety of Amlodipine Used as add-on Therapy in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil 20 mg Monotherapy [NCT00220220]	Phase 3	429 participants (Anticipated)	Interventional	2005-04-30	Completed
An 8-week, Multicenter, Randomized, Double-blind, Factorial Phase II Study to Evaluate Dose-response Relationship of Amlodipine and Losartan Combination in Patients With Essential Hypertension. [NCT00942344]	Phase 2	320 participants (Actual)	Interventional	2007-05-31	Completed
Efficacy and Safety of Irbesartan/Amlodipine Fixed Combination Therapy Compared With Irbesartan Monotherapy in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy [NCT00957554]	Phase 3	435 participants (Actual)	Interventional	2009-07-31	Completed
Double Blind Study of Irbesartan vs. Amlodipine in Obese Hypertensive Subjects- The OBI Study [NCT00987662]	Phase 4	0 participants (Actual)	Interventional	2012-01-31	Withdrawn(stopped due to no funding)
The Objective of This Study Was to Compare the Rate and Extent of Absorption of Ranbaxy Amlodipine 10 mg Tablet to That of Norvasc® 10 mg Tablet After a Single, One Tablet Dose in Fed State Subjects. [NCT00775151]		40 participants (Actual)	Interventional	2005-07-31	Completed
Vascular Improvement With Olmesartan Medoxomil Study [NCT00772499]	Phase 4	100 participants (Actual)	Interventional	2002-11-30	Completed
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled, Factorial Study to Evaluate the Efficacy and Safety of 8-week Treatment With Valsartan (40 and 80 mg) and Amlodipine (2.5 and 5 mg) Combined and Alone in Essential Hypertensive [NCT00425373]	Phase 2/Phase 3	1,474 participants (Actual)	Interventional	2006-11-30	Completed
A Multi-Center, Randomized Study To Evaluate Efficacy And Safety Of A Fixed Combination Therapy Of Amlodipine And Atorvastatin In The Treatment Of Concurrent Hypertension And Hyper-LDL-Cholesterolemia [NCT00530946]	Phase 3	165 participants (Actual)	Interventional	2007-09-30	Completed
A Double-blind, Randomized, Multicenter, Parallel Group Study to Evaluate the Efficacy, Tolerability, and Safety of Treatment With the Combination of Valsartan/Amlodipine 160/5 mg Compared to Amlodipine 10 mg in Patients With Essential Hypertension Not Ad [NCT00437645]	Phase 3	1,183 participants (Actual)	Interventional	2007-01-31	Completed
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]		22,213 participants (Actual)	Observational	2020-01-19	Completed
Comparison of Effects Between Calcium Channel Blocker and Diuretics in Combination With Angiotensin II Receptor Blocker on 24-hr Central Blood Pressure and Vascular Hemodynamic Parameters in Hypertensive Patients Multicenter, Double-blind, Active-controll [NCT02294539]	Phase 4	231 participants (Actual)	Interventional	2014-08-31	Completed
The Precision Hypertension Care Study [NCT02774460]	Phase 4	280 participants (Actual)	Interventional	2017-02-20	Completed
A Randomized, Double-Blind, Parallel, Multi-Center, Phase 2 Clinical Trial to Determine the Optimal Dose of AD-209 in Patients With Essential Hypertension [NCT04218552]	Phase 2	176 participants (Actual)	Interventional	2020-02-25	Completed
DP-R212 Pharmacokinetic Study Pharmacokinetic Characteristics of DP-R212 in Comparison to Each Component Coadministered in Healthy Volunteers [NCT02814500]	Phase 1	36 participants (Anticipated)	Interventional	2016-07-31	Not yet recruiting
A Randomized, Open-label, Single Dose, Replicate Crossover Clinical Trial to Compare the Pharmacokinetics of TAH Tablet in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers [NCT02739672]	Phase 1	40 participants (Actual)	Interventional	2016-01-02	Completed
Open Label, Comparative, Multiple-dose, Fixed-sequence Steady State Trial in Healthy Volunteers to Assess the Pharmacokinetic Interaction of Ramipril, Atorvastatin and Amlodipine After a Multiple Oral Dose Administration [NCT04262765]	Phase 1	18 participants (Actual)	Interventional	2019-02-23	Completed
Pharmacological Association of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on Blood Pressure and Cardiovascular Risk in Relation to Anti-hypertensive Treatment [NCT00006294]		37,939 participants (Actual)	Observational	1999-09-30	Completed
An Open-label, Multiple-dosing, and Crossover Study to Evaluate the Pharmacokinetic Drug Interaction After Oral Concurrent Administration of Fimasartan and Amlodipine in Healthy Male Volunteers [NCT00938197]	Phase 1	34 participants (Anticipated)	Interventional	2009-06-30	Completed
A Pilot Study of N-of-1 Trials of Blood Pressure Medications in Adults With Hypertension [NCT02744456]	Early Phase 1	10 participants (Actual)	Interventional	2014-08-01	Completed
Thiazide Diuretics for Hypertension in Kidney Transplant Recipients Using Tacrolimus [NCT02644395]	Phase 3	49 participants (Actual)	Interventional	2013-01-18	Completed
Effects Of Losartan On Myocardial Structure And Function And On Epicardial Fat Deposition In Diabetic Hypertensive Patients With Left Ventricular: Qualitative And Quantitative Alteration [NCT00659451]	Phase 3	100 participants (Anticipated)	Interventional	2008-04-30	Recruiting
Ultrasonographic Modification of Liver Steatosis and Visceral Fat Induced by Treatment With Losartan and Simvastatin in Hypertensive Normocholesterolemic Obese Patients [NCT00669435]	Phase 4	75 participants (Anticipated)	Interventional	2008-04-30	Recruiting
Effects of Intensive Antihypertensive Therapies on the Risk of Stroke in Hypertensive Adults: A Prospective Randomized Open-Label Blinded-Endpoint Trial, a Feasibility Study [NCT02817503]	Phase 4	100 participants (Anticipated)	Interventional	2015-12-31	Enrolling by invitation
A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Compare the Safety and Pharmacokinetics of CKD-330(Fixed-dose Combination of Candesartan 16 mg and Amlodipine 5 mg) With Coadministration of the Two Separate Drugs in Healthy Male Volunteers [NCT02811731]	Phase 1	32 participants (Actual)	Interventional	2015-04-30	Completed
A Randomized, Open-label, Single-Dose, 2-Way Cross-over Study To Compare the Safety and Pharmacokinetic Characteristics of Combination of Amlodipine, Olmesartan and Rosuvastatin and DWJ1351 in Healthy Male Volunteers [NCT02665832]	Phase 1	58 participants (Anticipated)	Interventional	2016-01-31	Not yet recruiting
A Twelve Week, Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren/Ramipril/Amlodipine (300/10/5-10 mg) Compared to the Combinations of Ramipril/Amlodipine (10/5-10 mg) and Aliski [NCT00542269]	Phase 4	178 participants (Actual)	Interventional	2008-03-31	Terminated(stopped due to Early termination of the study due to slow recruitment.)
A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Candesartan and Amlodipine Versus Candesartan Monotherapy in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy [NCT02651870]	Phase 3	135 participants (Actual)	Interventional	2015-04-22	Completed
Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans [NCT02742467]	Phase 4	702 participants (Actual)	Interventional	2017-06-07	Completed
A Prospective, Open-label Study to Assess the Efficacy and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Subjects With Stage 1 and Stage 2 Hypertension [NCT00527514]	Phase 3	185 participants (Actual)	Interventional	2007-09-30	Completed
Pilot Study to Assess Blockade of Calcium Channels and Sodium Chloride Cotransporters for Physiologic Abnormalities in Liver Transplant Associated Hypertension [NCT05275907]	Phase 4	0 participants (Actual)	Interventional	2022-07-12	Withdrawn(stopped due to Screened participants did not meet inclusion criteria prior to study completion date)
Phase 4 Study of Effects of ARB Compared With Diuretics in Hypertension Patients With High Cardiovascular Risks [NCT01011660]	Phase 4	13,542 participants (Anticipated)	Interventional	2007-10-31	Recruiting
A Phase III, 8-week, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Amlodipine 5mg+Losartan 50mg Versus Amlodipine 10mg in Patients With Essential Hypertension Not Controlled on Amlodipine Monotherapy [NCT00940667]	Phase 3	185 participants (Actual)	Interventional	2008-05-31	Completed
A Multi-national, Multicenter, Double-blind, Double-dummy, Randomized, Active-controlled, Parallel Study Comparing the Efficacy and Safety of Valsartan/Amlodipine 80/5 mg to Amlodipine 5 mg Alone Once Daily in Patients With Mild to Moderate Essential Hype [NCT00413049]	Phase 3	698 participants (Actual)	Interventional	2007-01-31	Completed
[NCT01048047]	Phase 4	88 participants (Anticipated)	Interventional	2009-11-30	Active, not recruiting
A 36 Week Randomized, Double-blind, Parallel Group, Multi-center, Active-controlled, Optional Titration Study Comparing an Aliskiren-based Regimen to a Ramipril-based Regimen in Patients ≥ 65 Years Old With Systolic Essential Hypertension [NCT00368277]	Phase 3	901 participants (Actual)	Interventional	2006-09-30	Completed
A Randomized, Double-blind Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Amlodipine Versus Fimasartan Monotherapy in Patients With Essential Hypertension Who Fail to Respond Adequately to Fimasartan Monother [NCT02152306]	Phase 3	143 participants (Actual)	Interventional	2014-04-30	Completed
Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes [NCT03264352]	Phase 4	11,414 participants (Anticipated)	Interventional	2018-02-01	Recruiting
An Open Label Trial of the Efficacy and Safety of Chronic Administration of the Fixed Dose Combination of Telmisartan 40mg + Amlodipine 10mg or Fixed Dose Combination of Telmisartan 80mg + Amlodipine 10mg Tablets Alone or in Combination With Other Antihyp [NCT00624052]	Phase 3	838 participants (Actual)	Interventional	2008-03-31	Completed
Lack of Effect of Antihypertensive Treatment With Amlodipine and Lisinopril on Retinal Autoregulation in Patients With Type 1 Diabetes and Mild Diabetic Retinopathy. A Prospective Randomized Clinical Trial. [NCT00337298]		25 participants (Actual)	Interventional	2006-07-31	Completed
Part 1: An Open Label Pilot Study to Determine Interstitial and Tissue Concentrations of Aliskiren and Effects on the Renin- Angiotensin System (RAS) in Fat and Skeletal Muscle of Hypertensive Patients With Abdominal Obesity. Part 2: A Randomized, Double [NCT00498433]	Phase 2	46 participants (Actual)	Interventional	2007-06-30	Terminated(stopped due to Early termination resulted from interim analysis of the ALTITUDE trial)
An 8-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 80 mg & Amlodipine 10mg Versus Telmisartan 80 mg Monotherapy or Amlodipine 10 mg Monotherapy as First Line Therapy in Patients With Severe Hypertension (Grade 3) [NCT00860262]	Phase 3	858 participants (Actual)	Interventional	2009-03-31	Completed
Prospective, Non-interventional Study for the Recording of Adherence to Treatment With Perindopril/Indapamide/Amlodipine Fixed Dose Combination, in a Greek Population With Hypertension [NCT02655029]		2,285 participants (Actual)	Observational [Patient Registry]	2015-11-25	Completed
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 When Co-administered With Amlodipine 5 mg in Subjects With Essential Hypertension [NCT00591266]	Phase 3	566 participants (Actual)	Interventional	2007-10-31	Completed
An 8 Week Prospective, Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ Versus Amlodipine in African American Patients With Stage 2 Hypertension [NCT00739596]	Phase 4	332 participants (Actual)	Interventional	2008-07-31	Completed
A Prospective, Open-Label, Titration Study to Evaluate the Efficacy and Safety Safety of AZOR in Multiple Subgroups of Hypertensive Subjects Who Are Non-Responders to Anti-Hypertensive Monotherapy [NCT00791258]	Phase 4	999 participants (Actual)	Interventional	2008-11-30	Completed
An 8 Week, Double-blind, Randomized, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate to Severe Hypertension [NCT00765674]	Phase 3	1,191 participants (Actual)	Interventional	2008-09-30	Completed
A Randomized, Open-label, Single Dose, Crossover Clinical Trial to Compare the Safety and Pharmacokinetics of YH22189 in Comparison to Telmisartan/Amlodipine and Rosuvastatin in Healthy Volunteers [NCT02608242]	Phase 1	123 participants (Actual)	Interventional	2015-11-30	Terminated(stopped due to sponsor decision)
Effect of Amlodipine Versus Bisoprolol on Hypertensive Patients With End-stage Renal Disease on Maintenance Hemodialysis. [NCT04085562]	Phase 4	46 participants (Actual)	Interventional	2019-09-01	Completed
A Randomized Clinical Trial to Evaluate the Effects of Multiple Doses of Amlodipine 10 mg on Pedal Edema Measurements in Middle-Aged and Elderly Healthy Subjects and Patient With Hypertension [NCT00789321]	Phase 1	47 participants (Actual)	Interventional	2008-07-31	Completed
An 8-week Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ (300/25 mg) Compared to Amlodipine (10 mg) in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus [NCT00787605]	Phase 4	860 participants (Actual)	Interventional	2008-11-30	Completed
An Open-label, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Amlodipine in Combination With Valsartan Compared to Losartan in Combination With Hydrochlorothiazide Given for 52 Weeks on the Regression of Left Ventricular Hypertrophy [NCT00446563]	Phase 3	90 participants (Actual)	Interventional	2007-03-31	Completed
Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment [NCT00741585]	Phase 4	21,983 participants (Actual)	Interventional	2008-09-01	Completed
A Randomized, 32 Week Double-blind, Parallel-group, Multicenter Study to Compare the Efficacy and Safety of Initiating Treatment With Combination (Aliskiren/Amlodipine) Therapy in Comparison With the Sequential add-on Treatment Strategies in Patients With [NCT00797862]	Phase 3	1,254 participants (Actual)	Interventional	2008-11-30	Completed
Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy Based on Database Data in Real-world Japanese Therapeutic Practic [NCT03205137]		0 participants (Actual)	Observational	2022-06-01	Withdrawn(stopped due to Sponsor decision)
The Objective of This Study Was to Compare the Rate and Extent of Absorption of Ranbaxy Amlodipine 10 mg Tablet to That of Norvasc® 10 mg Tablet After a Single, One Tablet Dose in Fasted Subjects. [NCT00775905]		40 participants (Actual)	Interventional	2005-07-31	Completed
A 28 to 54-week, Open-label, Multicenter Study to Assess the Long-term Safety and Tolerability of the Combination of Aliskiren / Amlodipine / Hydrochlorothiazide in Patients With Essential Hypertension [NCT00667719]	Phase 3	564 participants (Actual)	Interventional	2008-06-05	Completed
Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension [NCT00139555]	Phase 4	125 participants (Actual)	Interventional	2004-07-31	Completed
A Randomized Controlled Phase Ⅳ Trial With Two Equally Sized Treatment Groups: Amlodipine And Nifedipine GITS [NCT01030081]	Phase 4	510 participants (Actual)	Interventional	2009-10-31	Completed
Real Life Experience With Caduet Evaluating Effectiveness, Safety and Tolerability in the Management of Cardiovascular Risk Factors (EXCEL Study) [NCT00579254]		112 participants (Actual)	Observational	2007-12-31	Terminated(stopped due to See the termination reason in detailed description.)
An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80 mg+ Amlodipine 5 mg Fixed-dose Combination vs. Telmisartan 80 mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Te [NCT01222520]	Phase 3	174 participants (Actual)	Interventional	2010-10-31	Completed
Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor (ARNI) With Amlodipine on Ventricular Remodeling in Hypertension and Left Ventricular Hypertrophy. [NCT04929600]	Phase 4	120 participants (Anticipated)	Interventional	2021-11-28	Recruiting
An Evaluation of the Effect of an Angiotensin-converting Enzyme (ACE) Inhibitor on the Growth Rate of Small Abdominal Aortic Aneurysms. [NCT01118520]	Phase 2	224 participants (Actual)	Interventional	2011-09-30	Completed
[NCT02569814]	Phase 1	100 participants (Actual)	Interventional	2015-09-30	Completed
Additive Beneficial Effects of Atorvastatin Combined With Amlodipine In Treatment of Hypertension [NCT00741078]	Phase 4	0 participants	Interventional	2004-12-31	Completed
A Multi-center, Randomized, Double-Blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DWJ1451 in Patients With Hypertension and Dyslipidemia [NCT04161001]	Phase 3	237 participants (Anticipated)	Interventional	2019-11-20	Recruiting
Open Label, Comparative, Multiple-dose, Fixed-sequence Steady State Trial in Healthy Volunteers to Assess the Pharmacokinetic Interaction of Candesartan, Atorvastatin and Amlodipine After a Multiple Oral Dose Administration [NCT04245046]	Phase 1	18 participants (Actual)	Interventional	2019-01-18	Completed
An Open Label Follow-up Trial of the Efficacy and Safety of Chronic Administration of the Combination of Telmisartan 40mg + Amlodipine 5mg or the Combination of Telmisartan 80mg + Amlodipine 5mg Tablets Alone or in Combination With Other Antihypertensive [NCT00614380]	Phase 3	976 participants (Actual)	Interventional	2008-01-31	Completed
A Multi-national, Multicenter, Double-blind, Double-dummy, Randomized, Active-controled, Parallel Study, Comparing Efficacy and Safety of Valsartan/Amlodipine 80/5 mg to Valsartan 80 mg and Valsartan 160 mg Alone Once Daily in Patients With Mild to Modera [NCT00413413]	Phase 3	1,134 participants (Actual)	Interventional	2007-01-31	Completed
A Randomized, Double-Blind, Parallel Group Study Evaluating the Efficacy and Safety of Co-Administration of a Triple Combination Therapy of Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide in Subjects With Hypertension [NCT00649389]	Phase 3	2,500 participants (Actual)	Interventional	2008-05-31	Completed
A Multicenter, Open-label, 18 Month Study to Evaluate the Long-term Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age With Hypertension and With or Without Chronic Kidney Disease [NCT01365481]	Phase 3	150 participants (Actual)	Interventional	2011-08-31	Completed
A Multicenter, Double-blind, Randomized, Parallel-group Study to Evaluate the Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 mg as Compared to Amlodipine/Valsartan 5/40 mg or to Amlodipine 5 mg Once Daily in Elderly Patients Wi [NCT00699192]	Phase 3	965 participants (Actual)	Interventional	2008-05-31	Completed
Randomized, Double-Blind, Multi-Center, Phase 3 Trial to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Hydrochlorothiazide Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients Not Controlled by [NCT02738632]	Phase 3	300 participants (Anticipated)	Interventional	2015-05-31	Completed
Randomized Comparison of Fixed Low-dose Combination of THREE Antihypertensive Drugs Versus Fixed High-dose Combination of Two Antihypertensive Drugs in Arterial Hypertension (the 3D Trial) [NCT02710552]	Phase 4	100 participants (Anticipated)	Interventional	2016-04-30	Not yet recruiting
Caduet® Drug Use Investigation (Regulatory Post Marketing Commitment Plan) [NCT01107743]		1,291 participants (Actual)	Observational	2010-06-30	Completed
Evaluation of a Primary Treatment Algorithm Using Combination Therapy for the Management of Patients With Hypertension and Hypercholesterolemia [NCT00637078]	Phase 4	1,000 participants (Actual)	Interventional	2008-02-29	Completed
Randomised, Double-Blind, Parallel-Group Study Evaluating Efficacy and Safety of Co-Administration of Triple Combinations of Olmesartan Medoxomil, Amlodipine Besylate, and Hydrochlorothiazide Compared With Corresponding Olmesartan - Amlodipine Combination [NCT00923091]	Phase 3	2,689 participants (Actual)	Interventional	2009-06-30	Completed
An 8-week Multicenter, Randomized, Double-blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine (150/5 mg, 300/10 mg) Versus Amlodipine Alone (5 mg, 10 mg) in African Ameri [NCT00853957]	Phase 4	443 participants (Actual)	Interventional	2009-02-28	Completed
Effects of Direct Renin Inhibition on Atherosclerotic Biomarkers in Patients With Stable Coronary Heart Disease and Type 2 Diabetes Mellitus [NCT00818779]	Phase 4	38 participants (Actual)	Interventional	2008-01-31	Completed
Efficacy and Safety of Irbesartan/Amlodipine Fixed Combination Therapy Compared With Amlodipine Monotherapy in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy [NCT00956644]	Phase 3	406 participants (Anticipated)	Interventional	2009-07-31	Completed
A Prospective Multicenter Randomized Controlled Trial of Efficacy and Safety of Renal Denervation for Resistant Hypertension [NCT02900729]	Phase 3	254 participants (Anticipated)	Interventional	2016-10-31	Not yet recruiting
Cardiovascular Events in Hypertensive Hemodialysed Patients: Aliskiren Versus Amlodipine. A Randomized, Double-blind Study. [NCT01394770]	Phase 4	350 participants (Anticipated)	Interventional	2009-09-30	Active, not recruiting
Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major: a Randomized, Controlled Trial [NCT01395199]	Phase 3	62 participants (Actual)	Interventional	2012-08-31	Completed
Comparison Between Amlodipine and Aliskiren in Diabetic Hypertensive Patient With Blood Pressure Not Controlled by Losartan: Effects on Endothelial Function and Renin Concentration and Activity [NCT01409408]	Phase 4	0 participants (Actual)	Interventional	2011-04-30	Withdrawn(stopped due to Due to preliminary results of Altitude Trial.)
Effect of Amlodipine and Clomid on Blood Flow of Preovulatory Follicle in Polycystic Ovarian Patients [NCT02544776]		60 participants (Actual)	Interventional	2015-01-31	Completed
Effect of Olmesartan Medoxomil on Vascular Markers in Hypertensive Patients With Metabolic Syndrome [NCT00891267]	Phase 3	60 participants (Anticipated)	Interventional	2008-10-31	Completed
Treatment Optimisation for Blood Pressure With Single-Pill Combinations in India [NCT05683301]	Phase 4	1,968 participants (Anticipated)	Interventional	2022-08-30	Recruiting
A Randomized, Double-blinded, Multi-center, Phase III Study to Compare The Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia [NCT04074551]	Phase 3	145 participants (Actual)	Interventional	2019-07-16	Completed
8 Week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80mg+ Amlodipine 5 mg vs. Amlodipine 5mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Amlodipine 5mg Monotherapy [NCT01103960]	Phase 3	324 participants (Actual)	Interventional	2010-07-31	Completed
A Randomized, Parallel, Double Blind Study of Losartan Versus Amlodipine in Patients With Mild to Moderate Hypertension and Chronic Nondiabetic Proteinuric Nephropathy: Evaluation of the Effect on Proteinuria and on the Plasmatic Levels of Growth Factors [NCT00140985]	Phase 4	97 participants (Actual)	Interventional	2000-02-29	Completed
A 12-week Multicenter, Randomized, Double-blind, Parallel-group, Active-control Study to Evaluate the Antihypertensive Efficacy and Safety of Valsartan/Amlodipine-based Regimen Versus a Losartan-based Regimen in Patients With Stage 2 Systolic Hypertension [NCT00931710]	Phase 4	488 participants (Actual)	Interventional	2009-07-31	Completed
An Open-Label, Randomized, Two-Way Crossover, Single Dose Study to Evaluate the Bioavailability of the Test Formulation of Amlodipine 10 mg Tablets (Torrent Pharmaceuticals Limited, India) Compared to a 10 mg Dose of Norvasc® (Pfizer, USA) in 22 Fasted, H [NCT00932763]	Phase 1	0 participants	Interventional		Completed
A Randomized, Eight Week Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / Amlodipine (150/10 mg and 300/10 mg) in Comparison With Amlodipine 10 mg in Patients With Essential Hypertension [NCT00778921]	Phase 3	847 participants (Actual)	Interventional	2008-10-31	Completed
An 8-week, Double-blind, Randomized, Parallel Group, Multi-center Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren 300 mg and Amlodipine 10 mg Compared to Amlodipine 10 mg in Patients [NCT00841672]	Phase 3	485 participants (Actual)	Interventional	2009-01-31	Completed
[NCT02789475]	Phase 1	38 participants (Anticipated)	Interventional	2016-05-31	Recruiting
Add-on Study of Hydrochlorothiazide in Patients With Moderate to Severe Hypertension Not Achieving Target Blood Pressure on Olmesartan/Amlodipine Alone [NCT00902538]	Phase 3	2,204 participants (Actual)	Interventional	2009-04-30	Completed
A 6-Week Multi-center, Randomized, Double-Blind, Parallel Group Study Comparing the Efficacy of Amlodipine Besylate/Benazepril Versus Amlodipine in the Treatment of Severe Hypertension [NCT00136851]	Phase 4	259 participants (Actual)	Interventional	2004-12-31	Completed
Efficacy of Amlodipine-folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine in Patients With Mild to Moderate Hypertension and Hyperhomocysteinemia ：a Double-blind Randomized Controlled Trial [NCT01848873]	Phase 2/Phase 3	756 participants (Anticipated)	Interventional	2013-01-31	Recruiting
An 8-week Randomized, Double-blind, Placebo-controlled Factorial Study to Evaluate the Efficacy and Safety of LCZ696 Alone and in Combination With Amlodipine in Patients With Essential Hypertension [NCT01865188]	Phase 3	0 participants (Actual)	Interventional	2014-04-30	Withdrawn
An Open-label, Multicenter Study to Evaluate the Efficacy and Tolerability of a 4 Week Therapy With the Fixed Dose Combination of Amlodipine 10 mg Plus Valsartan 160 mg in Hypertensive Patients Not Adequately Responding to a 4 Week Therapy With the Free C [NCT00523744]	Phase 3	257 participants (Actual)	Interventional	2007-07-31	Completed
Treat-to-Target Study of Olmesartan Medoxomil and an Add-on Treatment Algorithm Consisting of Hydrochlorothiazide and Amlodipine Besylate in Patients With Mild to Moderate Hypertension [NCT00311155]	Phase 4	694 participants (Actual)	Interventional	2006-03-31	Completed
A Clinical Trial of Renin Profiling in Selection of Initial Antihypertensive Drug [NCT00834600]		185 participants (Actual)	Interventional	2005-12-31	Completed
A Randomized, Open-label, Multiple-dose, Two-arm, One-sequence • Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration Telmisartan/S-amlodipine and Rosuvastatin in Healthy Volunteers [NCT02047175]	Phase 1	64 participants (Actual)	Interventional	2014-02-28	Completed
A Multicenter, Randomized, Double Blind, Parallel Design Trial to Evaluate the Blood Pressure Lowering Efficacy Comparing Moderate Versus Aggressive Treatment Regimen of Valsartan + Amlodipine in Patients Uncontrolled on ARB Monotherapy [NCT00666536]	Phase 4	728 participants (Actual)	Interventional	2008-03-31	Completed
An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination [NCT00618774]	Phase 3	259 participants (Actual)	Interventional	2008-01-31	Completed
[NCT00000522]	Phase 2	0 participants	Interventional	1985-08-31	Completed
Open-laBel, Multicenter, multinatiOnal, inTerventional Clinical Trial to Assess effIcacy and Safety of the Extemporaneous Combination of nEbivoLol and amLodipine in Grade 1-2 Hypertensive patIents Versus Each Monotherapy [NCT05513937]	Phase 4	291 participants (Actual)	Interventional	2022-05-12	Completed
An 8-week Double-blind, Multicenter, Randomized, Multifactorial, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Amlodipine in Patients With Essential Hypertension [NCT00739973]	Phase 3	2,694 participants (Actual)	Interventional	2008-09-30	Completed
Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression [NCT00518479]		42 participants (Actual)	Interventional	2003-09-30	Completed
A Multi-Center, Randomized, Open-Label Study To Evaluate Efficacy And Safety Of Dual Therapy With Atorvastatin Plus Amlodipine When Compared Amlodipine Therapy Alone In The Treatment Of Subjects With Concurrent Hyperlipidemia And Hypertension. [NCT00174330]	Phase 4	330 participants	Interventional	2005-05-31	Completed
A 54 Week, Extension to the Double-blind, Multicenter, Multifactorial, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Valsartan (160 mg and 320 mg) and Amlodipine (10 mg) Combined and Alone in Hypertensive Patients [NCT00170976]	Phase 3	403 participants (Actual)	Interventional	2004-04-30	Completed
A Multicenter, Group Study to Evaluate the Safety and Efficacy of Amlodipine and Benazepril Administered in Combination Compared to Amlodipine Monotherapy in Hypertensive Patients Not Adequately Controlled With Amlodipine Alone [NCT00171366]	Phase 3	1,422 participants (Actual)	Interventional	2004-07-31	Completed
Effect of Amlodipine on the Lipid Profile of Newly Diagnosed Hypertensive Patients [NCT05467384]	Phase 4	80 participants (Actual)	Interventional	2016-03-01	Completed
Regional and Systemic Hemodynamic Effects of a Long-term Administration of Amlodipine in Patients With Chronic Heart Failure Treated With a Combination of Enalapril, Furosemide and Digoxin [NCT00151619]	Phase 2	7 participants (Actual)	Interventional	1999-02-10	Terminated
Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment: An Open and Randomized Clinical Trial [NCT00813722]	Phase 4	400 participants (Actual)	Interventional	1999-03-31	Active, not recruiting
A Five-arm, Randomised, Open Label, Multi-centre, Prospective Study to Compare the Efficacy, Safety and Tolerability of Metoprolol XL Plus Amlodipine Combination (Selomax TM) With Metoprolol XL and Amlodipine as Individual Components in Management of Hype [NCT00819104]	Phase 4	402 participants (Actual)	Interventional	2008-11-30	Completed
A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS [NCT04686643]	Phase 3	306 participants (Anticipated)	Interventional	2021-02-01	Not yet recruiting
Which is the Best Treatment for Non-diabetic Hypertension With Obesity: Telmisartan, Amlodipine or Candesartan, Alone or Plus MEtformin? (HOT-ACME 1) [NCT00538486]	Phase 4	360 participants (Actual)	Interventional	2008-02-29	Completed
Comparative Open-label,Randomized, Fasting/Fed, Single Dose, Three-way Crossover Bioequivalence Study of Valsartan and Amlodipine Tablets (Hua Yuan Pharmaceutical LLC, China) and Valsartan and Amlodipine Tablets (Ⅰ) (Novartis Pharma Schweiz AG, Switzerlan [NCT04085627]	Phase 1	84 participants (Actual)	Interventional	2018-10-08	Active, not recruiting
A Multi-Center, Randomized, Double-Blind, Double-Dummy Study Evaluating The Safety and Efficacy Of The Addition Of Amlodipine To Quinapril Or Losartan In The Treatment Of Diabetic Hypertensive Subjects [NCT00159692]	Phase 4	739 participants (Actual)	Interventional	2003-03-31	Completed
An Open-Label, Randomized, Two-Way Crossover, Single Dose Study to Evaluate the Bioavailability of the Test Formulation of Amlodipine 10 mg Tablets [Torrent Pharmaceuticals Limited,India] Compared to a 10 mg Dose of Norvasc®, [Pfizer, USA] in 18 Fed, Heal [NCT00932880]	Phase 1	0 participants	Interventional		Completed
Long-Term Study For Amlodipine 10mg In Patients With Essential Hypertension For Whom Amlodipine 5mg Is Insufficiently Effective [NCT00443456]	Phase 3	134 participants (Actual)	Interventional	2007-05-31	Completed
Investigation of Reduction of Blood Pressure and Metabolic Rate in Obese Hypertensive Patients Using Eplerenone: Implications for Treatment of Hypertension and Heart Failure [NCT00825188]		10 participants (Actual)	Interventional	2009-01-31	Terminated(stopped due to funding to complete was inadequate)
Valsartan Versus Amlodipine Effect on Left Ventricular Multidirectional Deformation and Adipocytokines Level in Hypertensive Patients: Speckle Tracking Echocardiography [NCT03990480]	Phase 4	230 participants (Actual)	Interventional	2018-12-01	Completed
A Double-blind, Double Dummy, Randomized Parallel Design Trial to Study the Effects of 12 Weeks of Treatment With 300mg Aliskiren vs. 5mg Amlodipine on Insulin Resistance and Endothelial Dysfunction in Hypertensive Patients With Metabolic Syndrome [NCT00417170]	Phase 2	48 participants (Actual)	Interventional	2007-10-31	Completed
A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension [NCT00170950]	Phase 3	11,506 participants (Actual)	Interventional	2003-10-31	Terminated(stopped due to The study was terminated early because of significant efficacy results for the primary endpoint in favor of benazepril/amlodipine treatment.)
Efficacy and Safety of GMRx2 (a Single Pill Combination Containing Telmisartan/Amlodipine/Indapamide) Compared to Dual Combinations for the Treatment of Hypertension [NCT04518293]	Phase 3	1,385 participants (Actual)	Interventional	2021-06-26	Completed
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of BR1010 in Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination [NCT03991442]	Phase 3	257 participants (Actual)	Interventional	2019-06-17	Completed
An Open Label, Single Arm Prospective Study to Evaluate Efficacy and Safety of Losartan Based Therapy Reslio® (Losartan) and Resilo-h® (Losartan+Hydrochlorthiazide) in Diabetic and Uncontrolled Hypertensive Patients [NCT03978884]	Phase 4	0 participants (Actual)	Interventional	2019-06-01	Withdrawn(stopped due to Unable to effective arrange trial logistics)
A Randomized, Double-blind, Double-dummy, Placebo-controlled, 4x4 Factorial Design Trial to Evaluate Telmisartan 20, 40 and 80 mg Tablets in Combination With Amlodipine 2.5, 5 and 10 mg Capsules After Eight Weeks of Treatment in Patients With Stage I or I [NCT00281580]	Phase 3	1,461 participants (Actual)	Interventional	2006-04-30	Completed
Multi-center, Open Label, 18-week Study to Demonstrate the Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II HT [NCT01070030]	Phase 4	230 participants (Actual)	Interventional	2010-01-31	Completed
An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE of FDC of Olmesaartan Medoxomil, Amlopdipine and Hydrochlorothiazide (40+10+25) mg Tab [Torrent,India] Vs Tribenzor(40+10+25) mg Tab [ Daichi Sankyo, Inc USA] in Health [NCT02962336]	Phase 1	34 participants (Actual)	Interventional	2011-05-31	Completed
A Randomized, Double-blind, Multicenter, Placebo-control, Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients [NCT05476354]	Phase 3	271 participants (Actual)	Interventional	2022-07-05	Completed
Glucose Optimisation With Angiotensin II Antagonist Losartan in Patients With Hypertension and Other Risk Factors for Metabolic Syndrome (GOAAL) [NCT00237588]	Phase 4	25 participants	Interventional	2004-12-31	Completed
A Comparison of Telmisartan 80 mg + Hydrochlorothiazide 12.5 mg With Amlodipine 10 mg + Hydrochlorothiazide 12.5 mg in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension. A Prospective, Randomised, Open-label, Blinded [NCT00240474]	Phase 4	1,000 participants	Interventional	2002-12-31	Completed
Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine in Patients With Mild to Moderate Hypertension, Hyperhomocysteinemia and Angiotension-Converting Enzyme Inhibitor Intolerance [NCT01956786]	Phase 2/Phase 3	540 participants (Anticipated)	Interventional	2013-09-30	Recruiting
The COMPAriSon of Systolic Blood Pressure Variability and Central Blood Pressure of Calcium Channel Blocker (Amlodipine) in Comparison With Angiotensin Receptor Blocker (Losartan) in Patients With Essential Hypertension [NCT01964079]	Phase 4	144 participants (Actual)	Interventional	2013-04-30	Completed
A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a Fixed Dose Combination of Telmisartan and S-Amlodipine(TELMINUVO TAB.) Versus S-Amlodipine Monotherapy in Patients With Stage 2 Hypertension [NCT01983735]	Phase 3	200 participants (Anticipated)	Interventional	2014-01-31	Not yet recruiting
The Usefulness of Non-invasive Assessment of Haemodynamic Profile in the Diagnosis and Treatment of Hypertension [NCT01996085]		144 participants (Actual)	Interventional	2013-01-31	Completed
Management of Resistant Hypertension -Pharmacokinetic Assessment of Different Antihypertensive Regimen -Comparison of Two Treatment Strategies: Increase Sodium Depletion or Combined Blockage of Renin-angiotensin System (RAS) [NCT00224549]	Phase 4	180 participants (Actual)	Interventional	2005-04-30	Completed
Pharmacokinetics of Amlodipine Besylate at Delivery and During Lactation [NCT02353806]	Phase 4	16 participants (Actual)	Interventional	2015-01-31	Completed
Phase 1, Open-Label, Randomized, Single-Dose, 2-Treatment, 2-Period Crossover Bioavailability Study Comparing 10 Mg Amlodipine Besylate Orally Disintegrating Tablets, Manufactured By Aurobindo Pharma Ltd., India To 10 Mg Amlodipine Besylate Capsules, Manu [NCT01177293]	Phase 1	14 participants (Actual)	Interventional	2010-03-31	Completed
An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80mg Plus Amlodipine 5 mg Fixed-dose Combination vs. Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination in Patients With Hypertension [NCT01286558]	Phase 3	225 participants (Actual)	Interventional	2011-01-31	Completed
The Reduction of Microalbuminuria in Japanese Hypertensive Subjects With Type 2 Diabetes Mellitus Treated With Valsartan or Amlodipine: Study Design for the Shiga Microalbuminuria Reduction Trial (SMART) [NCT00202618]	Phase 4	160 participants	Interventional	2003-12-31	Recruiting
Open-label Randomized Crossover Two Period Single Dose Bioequivalence Study of Two Formulations of Perindopril Erbumine/Indapamide/Amlodipine 8 mg/2.5 mg/10 mg Tablets (Pharmtechnology LLC, Republic of Belarus) and Triplixam® 10 mg/2.5 mg/10 mg Tablets (L [NCT05940909]	Phase 1	50 participants (Anticipated)	Interventional	2023-06-24	Recruiting
Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity, Crossover Design Study. [NCT05312892]	Phase 1/Phase 2	12 participants (Anticipated)	Interventional	2022-05-20	Recruiting
A Double Blind, Randomized, Parallel Study to Assess the Effects of Aliskiren/Amlodipine and Amlodipine Monotherapy on Ankle Foot Volume (AFV) in Patients naïve to Trial Drugs With Mild to Moderate Hypertension [NCT01080768]	Phase 2	31 participants (Actual)	Interventional	2010-02-28	Terminated(stopped due to Publication of data from a similar study made the current study redundant.)
A 12 Weeks, Multi-center, Randomized, Open Label, Active Control, Phase IV Clinical Trial to Compare Evaluated Improvement of Edema Index, Safety and Efficacy of Amlodipine Versus S Amlodipine in Patients With Essential Hypertension [NCT04554303]		80 participants (Anticipated)	Observational	2020-10-28	Recruiting
A Randomized, Double-blind, Parallel Group, Active-controlled, 38-week Study to Evaluate the Efficacy of Valsartan Versus Amlodipine on the Arterial Properties of Postmenopausal Women With Mild to Moderate Hypertension [NCT00171054]	Phase 4	125 participants (Actual)	Interventional	2003-09-30	Completed
A Single-centre, Randomized, Open-label, Three-period Crossover Pharmacokinetic Study of 80 mg Telmisartan / 5 mg Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Chinese Subjects [NCT01181011]	Phase 1	28 participants (Actual)	Interventional	2010-08-31	Completed
Newer vs Older Antihypertensive Agents in African Hypertensive Patients Trial [NCT01030458]	Phase 4	183 participants (Actual)	Interventional	2010-09-30	Completed
A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of 10 mg Amlodipine Besylate Tablets Under Fed Conditions [NCT00601302]		40 participants (Actual)	Interventional	2004-04-30	Completed
Evaluation of Carotid Intima Media Thickness by Treatment of Vascular and Metabolic Factors With Combined Antihypertensive and Hypolipidemic Therapy [NCT04306627]	Phase 4	200 participants (Anticipated)	Interventional	2020-04-15	Not yet recruiting
Carotid Endarterectomy Versus Optimal Medical Treatment of Asymptomatic High Grade Carotid Artery Stenosis [NCT00805311]	Phase 4	400 participants (Actual)	Interventional	2009-04-30	Terminated(stopped due to Due to the clear advantage of carotid endarterectomy)
Comparative, Randomized, Single Dose, 2-way Crossover Bioavailability Study of Actavis Group hf and Pfizer Inc. (Norvasc®)10 mg Amlodipine Besylate Tablets in Healthy Adult Volunteers Under Fasting Conditions. [NCT00870142]	Phase 1	26 participants (Actual)	Interventional	2005-04-30	Completed
A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Trial to Evaluate the Safety and Efficacy of YH22162 in Subjects With Essential Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment [NCT02620163]	Phase 3	381 participants (Actual)	Interventional	2015-12-31	Completed
A 54-week, Open-label, Multicenter Study to Assess the Long-term Safety and Tolerability of the Combination of Aliskiren 300 mg / Amlodipine 10 mg in Patients With Essential Hypertension [NCT00402103]	Phase 3	556 participants (Actual)	Interventional	2006-11-30	Completed
ANALYSIS OF THE EFFECTIVENESS OF A STAGED MANAGEMENT PROGRAM AIMED AT CONTROLLING BLOOD PRESSURE AND BLOOD GLUCOSE OF TYPE 2 DIABETIC PATIENTS USING EXCLUSIVELY THE RESOURCES AVAILABLE IN A PRIMARY CARE SETTING IN BRAZIL [NCT00935805]		124 participants (Anticipated)	Observational	2006-07-31	Active, not recruiting
A Randomized, Open-label, Single-dosing, Crossover Study to Compare the Safety and Pharmacokinetics of CKD-330(Fixed-dose Combination of Candesartan Cilexetil 8 mg and Amlodipine 5 mg) With Coadministration of the Two Separate Drugs in Healthy Male Volunt [NCT02548286]	Phase 1	53 participants (Actual)	Interventional	2015-08-31	Completed
Clinical Bioequivalence Study on Two Amlodipine Tablet 10mg Formulations [NCT02707913]	Phase 1	17 participants (Actual)	Interventional	2016-03-31	Completed
A Multi-center, Prospective, Randomized, Open-label Study With Blinded Outcome Evaluation to Evaluate the Effects of Systolic Blood Pressure Lowering to Different Targets (Less Than 130 mmHg vs. Less Than 140 mmHg) on Diastolic Function Using Valsartan + [NCT00523549]	Phase 4	229 participants (Actual)	Interventional	2006-11-30	Completed
Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT), Substudies: MRI, Cognitive [NCT02699645]	Phase 3	1,500 participants (Anticipated)	Interventional	2017-09-28	Recruiting
An 8-week Multicenter, Randomized, Double-blind, Active Controlled, Parallel Group, Forced Titration Study to Evaluate the Efficacy and Safety of Aliskiren/Amlodipine/HCTZ Compared to Aliskiren/Amlodipine in US Minority Patients With Stage 2 Hypertension [NCT00942994]	Phase 4	412 participants (Actual)	Interventional	2009-06-30	Completed
AN OPEN LABEL, NON-INTERVENTIONAL STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF AMLODIPINE AND OLMESARTAN MEDOXOMIL (NORMETECTM) IN FILIPINO PATIENTS WITH HYPERTENSION: A POST MARKETING SURVEILLANCE STUDY [NCT01200407]		615 participants (Actual)	Observational	2010-06-09	Terminated(stopped due to The requirement for Post Marketing Surveillance was lifted by the Philippine FDA)
[NCT00693199]		360 participants (Actual)	Interventional	2006-07-31	Completed
"The ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling (ALLMARK) Study" [NCT01176032]	Phase 4	74 participants (Actual)	Interventional	2010-06-30	Completed
An Open-label Study to Evaluate the Antihypertensive Effects of the Fixed-dose Combination of Telmisartan 80 mg and Amlodipine 5 mg (T80/A5) Given Once Daily by 24 h ABPM in Patients With Moderate to Severe Hypertension [NCT01204398]	Phase 3	27 participants (Actual)	Interventional	2010-11-30	Completed
Single-Dose Food in Vivo Bioequivalence Study of Amlodipine and Benazepril HCl Capsules (10 mg/20 mg; Mylan) to Lotrel® Capsules (10 mg/20 mg; Novartis) in Healthy Volunteers [NCT00649402]	Phase 1	64 participants (Actual)	Interventional	2004-05-31	Completed
Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance [NCT01252238]		24 participants (Actual)	Interventional	2010-06-30	Terminated(stopped due to Study sponsor terminated study due to AE's reported with valsartan and aliskiren)
An 8-week Double-blind, Multicenter, Randomized, 6-arm, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren and Amlodipine) in Patients With Essential Hypertension [NCT01237223]	Phase 3	1,342 participants (Actual)	Interventional	2010-10-31	Completed
A Double-Blind, Randomized, Placebo-Controlled, 3-Period, Crossover Study to Evaluate the Effects of Antihypertensive Agents on Central Blood Pressure in Healthy Subjects and Patients With Hypertension [NCT01130168]	Phase 1	38 participants (Actual)	Interventional	2010-05-31	Completed
A Randomized, Double-blind, Active-controlled, Multicenter Phase III Trial to Evaluate the Efficacy and Safety of Co-administrated AD-2071 and AD-2073 in Patients With Primary Hypercholesterolemia and Essential Hypertension [NCT04158076]	Phase 3	131 participants (Actual)	Interventional	2020-01-23	Completed
A Single Center, Randomized, Double-blind, Active Controlled, Parallel Group Study to Demonstrate Non-inferiority of a Fixed Dose Combination of 5 mg Amlodipine and 80 mg Valsartan to 160 mg Valsartan in the Treatment of Hypertension [NCT01070043]	Phase 4	60 participants (Actual)	Interventional	2009-06-30	Completed
Antihypertensive Effects of a Fixed-dose Combination of Losartan and Hydrochlorothiazide Plus Amlodipine Versus a Hydrochlorothiazide and Atenolol Combination Plus Amlodipine in Subjects With Ambulatory Systolic Hypertension. [NCT00140959]	Phase 4	120 participants	Interventional	2003-02-01	Completed
Phase 1, Open-Label, Randomized, Single-Dose, 3-Treatment, 6-Sequence, 3-Period Crossover Bioavailability Study Comparing 10 Mg Amlodipine Besylate Orally Disintegrating Tablets, Manufactured By Aurobindo Pharma Ltd., India To Amlodipine Besylate 10 Mg Ta [NCT01138826]	Phase 1	18 participants (Actual)	Interventional	2010-05-31	Completed
A Randomized, Double-blind, Placebo-controlled Factorial Study Evaluating the Efficacy and Safety of Co-administration of Olmesartan Medoxomil Plus Amlodipine Compared to Monotherapy in Patients With Mild to Severe Hypertension [NCT00185133]	Phase 3	1,900 participants	Interventional	2005-05-31	Completed
Treatment of Early Hypertension Among Persons Living With HIV in Haiti [NCT04692467]	Phase 2	250 participants (Actual)	Interventional	2021-02-26	Active, not recruiting
Effect of Antihypertensive Agents on Diastolic Function in Patients With Sleep Apnea: Protocol for a Randomized Controlled Trial [NCT02896621]	Phase 3	69 participants (Actual)	Interventional	2014-12-07	Completed
Valsartan/Amlodipine 160/5 mg or 160/10 mg Versus Valsartan 160 mg Alone for 8 Weeks in Hypertensive Patients Who Are Not Adequately Controlled on Valsartan 160 mg Monotherapy [NCT00170963]	Phase 3	1,018 participants (Actual)	Interventional	2004-10-31	Completed
A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a CKD-330 Versus Amlodipine Monotherapy in Hypertensive Patients Inadequately Controlled by Amlodipine Monotherapy [NCT02586311]	Phase 3	160 participants (Actual)	Interventional	2016-01-31	Completed
An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of a 4 Week Therapy With Aliskiren 300 mg Plus Hydrochlorothiazide 25 mg in Hypertensive Patients Not Adequately Responding to a 4 Week Therapy With Candesartan 32 mg Plus Hydrochlorothi [NCT00867490]	Phase 3	186 participants (Actual)	Interventional	2009-03-31	Completed
A Phase IV Clinical Trial of Intensified Blood Pressure Management in Primary Care Using Valsartan Alone and as Combination Anti-Hypertensive Therapy [NCT00902304]	Phase 4	2,337 participants (Actual)	Interventional	2009-07-31	Completed
Randomized Comparison of Once-daily Fixed combiNation vErsus freE-drug cOmbination of Three aNtihypertensive Agents in arteriaL hYpertension (the ONE&ONLY Trial) [NCT02710539]	Phase 4	100 participants (Anticipated)	Interventional	2016-04-30	Not yet recruiting
Double Blind Atorvastatin Amlodipine Study (DUAAL) Effect Of Amlodipine, Atorvastatin And The Combination On Transient Myocardia Ischemia In Coronary Artery Disease. [NCT00159718]	Phase 4	360 participants	Interventional	2001-07-31	Completed
ONgoing Evaluation of Depressor Effect And Safety of Combination Therapy With Telmisartan and Low-dose Hydrochlorothiazide in Patients With Hypertension Uncontrolled on Amlodipine Treatment [NCT00509470]	Phase 4	75 participants (Actual)	Interventional	2007-07-31	Completed
A Randomized, Double-blind, Parallel Group, Single-Centre Study to Evaluate the Efficacy and Safety of Lacidipine and Amlodipine Once-daily Treatment in Hypertensive Adult Patients [NCT00338338]	Phase 4	70 participants	Interventional	2005-11-07	Completed
Clinical Utility Of Caduet In Simultaneously Achieving Blood Pressure And Lipid Endpoints In A Specific Patient Population (CAPABLE) [NCT00150384]	Phase 4	500 participants	Interventional	2004-07-31	Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Therapeutic Exploratory Study to Evaluate the Efficacy and Safety of PletaalÒ(Cilostazol) in Subjects With Vasospastic Angina (STELLA) [NCT01444885]	Phase 2	50 participants (Actual)	Interventional	2011-10-31	Completed
A Study on the Efficacy and Safety of Olmesartan Medoxomil and Its Combination With Hydrochlorothiazide Compared With an ACE Inhibitor and Its Combination With a Calcium Channel Blocker in Patients With Stage 2 Hypertension [NCT00185120]	Phase 4	152 participants	Interventional	2005-09-30	Completed
Add-on Study of Olmesartan Medoxomil in Patients With Moderate to Severe Hypertension Not Achieving Target Blood Pressure on Amlodipine 5 mg Alone [NCT00220233]	Phase 3	632 participants	Interventional	2005-04-30	Completed
Clinical Trial to Investigate the Influence of SK3530 on the Blood Pressure of Patients With Hypertension Taking Amlodipine [NCT00626743]	Phase 1	13 participants (Actual)	Interventional	2008-05-31	Completed
Multi-Omics to Predict the Blood Pressure Response to Antihypertensives [NCT05917275]	Phase 4	96 participants (Anticipated)	Interventional	2023-10-31	Not yet recruiting
Comparison of Phosphodiesterase-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon, Double Blind, Randomized, Cross-over Trial [NCT01280266]	Phase 2/Phase 3	29 participants (Actual)	Interventional	2011-01-31	Completed
A Multi-center, Multiple Dose, Open-label, Four-cohort, Parallel Study to Assess the Pharmacokinetic Drug Interaction Following Co-administration of Valsartan, Hydrochlorothiazide and Amlodipine in Patients With Hypertension. [NCT00548067]	Phase 3	111 participants (Actual)	Interventional	2007-09-30	Completed
A Randomized, Double-blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of HCP1401 for Stage 2 Hypertension Patients Not Controlled by HCP0605 [NCT02916602]	Phase 3	340 participants (Actual)	Interventional	2015-04-30	Completed
Efficacy of Olmesartan on Cerebral Glucose Metabolism, Vascular Inflammation and Adipose Tissue [NCT02996916]	Phase 4	100 participants (Anticipated)	Interventional	2015-12-31	Recruiting
Comparison of the Pharmacodynamic Effects of RanOlazine Versus aMlodipine on Platelet Reactivity in Stable Patients With Coronary Artery Disease Treated With Dual ANtiplatelet Therapy - The ROMAN Randomized Study [NCT01490255]	Phase 4	100 participants (Anticipated)	Interventional	2012-01-31	Recruiting
A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg Tablet and Novartis Exforge 10/160mg Tablet After a Single Oral Administration in Healthy Male Volu [NCT01494727]	Phase 1	48 participants (Anticipated)	Interventional	2012-02-29	Completed
Combination of OLMesartan and Calcium Channel Blocker or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study) [NCT00454662]	Phase 4	5,141 participants (Actual)	Interventional	2007-04-30	Completed
An 8-week Multicenter Study to Evaluate the Efficacy and Safety of Orally Administered Valsartan/Amlodipine Combination Based Therapy Versus Amlodipine Monotherapy in Patients With Stage II Hypertension [NCT00350168]	Phase 3	647 participants (Actual)	Interventional	2006-06-30	Completed
A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of 10 mg Amlodipine Besylate Tablets Under Fasting Conditions [NCT00602017]		40 participants (Actual)	Interventional	2004-04-30	Completed
A Phase III, Randomized, Active-Comparator Controlled Clinical Trial to Study the Efficacy and Safety of MK-0954E in Japanese Patients With Essential Hypertension Uncontrolled With Losartan and Amlodipine Co-administration [NCT01302691]	Phase 3	327 participants (Actual)	Interventional	2011-01-01	Completed
An 8 Weeks Open Label National Multicentre Study to Assess the Efficacy of the Fixed Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled by Monotherapy [NCT01241487]	Phase 4	150 participants (Anticipated)	Interventional	2009-02-28	Completed
Comparative Trial of Combination Therapy of ARB/Diuretic Versus ARB/CCB in Uncontrolled Hypertensive Patients With Monotherapy of ARB [NCT00492128]	Phase 4	196 participants (Actual)	Interventional	2007-09-30	Completed
A Phase-3 Randomized, Double-Blind, Parallel-Group Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine (8/5 mg) in Chinese Subjects With Mild/Moderate Essential Hypertension, Who Do Not Achieve Target Blood Press [NCT02969265]	Phase 3	0 participants (Actual)	Interventional	2017-05-09	Withdrawn(stopped due to Business reasons unrelated to product safety)
Influence of Amlodipine on the Mortality of Patients With End-Stage Renal Failure (ADAM [Amlodipine and Dialysis Patients, Action on Mortality]) [NCT00124969]	Phase 4	356 participants (Actual)	Interventional	2002-01-31	Completed
A Randomized, Open-label, Single Dose, 3x3 Partial Replicated Crossover Study to Evaluate the Pharmacokinetics and Safety/Tolerability Between a Fixed Dose Combination of Fimasartan/Amlodipine and Co-administration of Fimasartan and Amlodipine in Healthy [NCT02920047]	Phase 1	60 participants (Actual)	Interventional	2016-10-31	Completed
[NCT02933658]	Phase 1	71 participants (Actual)	Interventional	2015-11-30	Completed
"Randomized, Open-label, Single-dose, Two-sequence, Two-period, Crossover, Comparative, Oral Bioequivalence Study of Test Product PERINDOPRES® TRIO, 8 mg Perindopril Tert-Butylamine / 2.5 mg Indapamide/ 10 mg Amlodipine Tablets (PrJSC Pharmaceutical Firm [NCT05470764]	Phase 1	52 participants (Actual)	Interventional	2021-05-30	Completed
Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of COZAAR XQ in Usual Practice [NCT01041807]		669 participants (Actual)	Observational	2010-02-28	Completed
African American Study of Kidney Disease and Hypertension [NCT04364139]	Phase 3	1,094 participants (Actual)	Interventional	1995-02-01	Completed
A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Lotrel® on Albuminuria in Hypertensive, Type 2 Diabetic Subjects With Diabetic Nephropathy [NCT00234871]	Phase 4	357 participants (Actual)	Interventional	2004-01-31	Completed
Effect of Atorvastatin in the Management of Hypertension [NCT05679102]		120 participants (Actual)	Interventional	2022-12-20	Completed
A Randomized, Open-label, Crossover, Phase 1 Study to Evaluate Pharmacokinetics and Safety of Irbesartan/Amlodipine High Fixed Dose Combination in Comparison With Co-administration of Mono Compounds in Healthy Volunteers [NCT05688098]	Phase 1	44 participants (Actual)	Interventional	2022-09-23	Completed
A Randomized, Open-label, Crossover, Phase 1 Study to Evaluate Pharmacokinetics and Safety of Irbesartan High/Amlodipine Fixed Dose Combination in Comparison With Co-administration of Mono Compounds in Healthy Volunteers [NCT05688085]	Phase 1	44 participants (Actual)	Interventional	2022-10-18	Completed
A Randomized, Open-label, Crossover, Phase 1 Study to Evaluate Pharmacokinetics and Safety of Irbesartan/Amlodipine Fixed Dose Combination in Comparison With Co-administration of Mono Compounds in Healthy Volunteers [NCT05663073]	Phase 1	46 participants (Actual)	Interventional	2022-09-13	Completed
A Randomized, Double-blind, Multicenter, Placebo-control, Parallel Group Phase # Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients [NCT05475665]	Phase 3	157 participants (Actual)	Interventional	2022-07-14	Completed
BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in Heart Failure With Preserved Ejection Fraction (BLOCK HFpEF) Trial [NCT04434664]	Phase 4	50 participants (Anticipated)	Interventional	2021-05-01	Recruiting
Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus [NCT02046395]	Phase 4	28 participants (Actual)	Interventional	2012-01-31	Completed
A Muticenter, Randomized, Double-blind, Parallel, Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension [NCT03897868]	Phase 2	248 participants (Actual)	Interventional	2019-03-21	Completed
A Double-blind, Randomized, Multicenter Study to Evaluate the Effectiveness of the Combination of Valsartan & Amlodipine in Hypertensive Patients Not Controlled on Monotherapy [NCT00327145]	Phase 3	894 participants (Actual)	Interventional	2006-03-31	Completed
The Comparison of the Antihypertensive Efficacy and Tolerability Between Valsartan Plus Hydrochlorothiazide 80mg/12.5mg and Amlodipine 5mg in the Essential Hypertensive Patients [NCT00426478]	Phase 4	80 participants (Anticipated)	Interventional	2006-11-30	Completed
The Study Comparing the Incidence of Cardiovascular Events Between High-dose ARB Monotherapy and Combination Therapy With ARB and Calcium Channel Blocker in Japanese Elderly Hypertensive Patients at High Cardiovascular Risk [NCT00134160]	Phase 4	1,000 participants (Anticipated)	Interventional	2005-08-31	Completed
Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes Mellitus [NCT00136773]	Phase 4	332 participants (Actual)	Interventional	2003-04-30	Completed
[NCT01738945]	Phase 4	32 participants (Actual)	Interventional	2008-02-29	Completed
An Open-Label Randomized, Single-Dose, 2-way Crossover Bioequivalence Study of Amlodipine and Norvasc Under Fasting Condition Sand Under Non-fasting(FED) Conditions in Chinese Healthy Volunteers [NCT02974439]	Phase 1	60 participants (Actual)	Interventional	2016-12-23	Completed
An 8 Week Extension to a Randomized, Double-blind, Parallel Group, Active-controlled, Multi-center, 14 Week Study to Evaluate the Effectiveness of a Valsartan Versus and Amlodipine Treatment Strategy in Achieving Blood Pressure Control in Patients With St [NCT00351130]	Phase 4	79 participants (Actual)	Interventional	2006-06-30	Completed
A 54-week Extension to the Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled, Factorial Study to Evaluate the Efficacy and Safety of VAA489 (Valsartan and Amlodipine Combined) and Alone in Essential Hypertensive Patients - Long Te [NCT00446524]	Phase 3	403 participants (Actual)	Interventional	2007-02-28	Completed
Korea University Guro Hospital [NCT00460915]	Phase 4	204 participants (Anticipated)	Interventional	2007-01-31	Completed
Open Label Study Comparing Amlodipine vs Long-acting Nitrates in Patients With Chronic Stable Angina. [NCT00143195]	Phase 4	200 participants	Interventional	2001-04-30	Completed
Clinical Utility of Amlodipine/Atorvastatin to Improve Concomitant Cardiovascular Risk Factors of Hypertension and Dyslipidemia [NCT00143234]	Phase 3	1,825 participants	Interventional	2004-05-31	Completed
Effect of Add-on of Amlodipine Versus Valsartan on Diastolic Dysfunction Associated With Hypertension [NCT02973035]	Phase 4	104 participants (Actual)	Interventional	2016-12-31	Completed
Benefit of Amlodipine in HRT Cycle (Hormone Replacement Therapy) for Frozen Embryo Transfer in the Correction of Uterine Pulsatility Index: Randomized Controlled Double-blind Trial. [NCT04954196]	Phase 2	0 participants (Actual)	Interventional	2021-10-08	Withdrawn(stopped due to No participants enrolled)
Comparison of Anti-inflammatory Effects of Amlodipine and Levamlodipine in Patients With Hypertension [NCT04740840]	Phase 2/Phase 3	200 participants (Actual)	Interventional	2010-05-01	Completed
A Randomized, Double-blind, Parallel Group, Active-controlled Study to Compare the Systolic Blood Pressure Lowering Efficacy of Aliskiren, Ramipril and a Combination of Aliskiren and Amlodipine, With an Initial 8-week Evaluation, Followed by a 2-3 Year Fo [NCT01922141]	Phase 4	0 participants (Actual)	Interventional	2015-05-31	Withdrawn
Comparative Effectiveness of Ambulatory Blood Pressure Monitoring vs Usual Care for Diagnosing and Managing Hypertension: A Pilot Study [NCT02121041]		28 participants (Actual)	Interventional	2014-05-31	Completed
Comparative Efficacy of Amlodipine Folic Acid vs. Amlodipine on the Risk of First Ischemic Stroke Among Patients With H-type Hypertension and MTHFR 677 CC/CT Genotype: A Multi-center, Randomized, Controlled Clinical Trial [NCT04974138]	Phase 4	25,000 participants (Anticipated)	Interventional	2022-04-01	Not yet recruiting
A 52 Week, Open Label Extension to the Randomized, Double-blind, Multicenter, Multifactorial, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients. [NCT00409851]	Phase 3	1,293 participants (Actual)	Interventional	2003-04-30	Completed
A Randomized, Double-blind, Multicenter, Multifactorial, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Valsartan (160 mg and 320 mg) and Amlodipine (10 mg) Combined and Alone in Hypertensive Patients [NCT00409643]	Phase 3	1,259 participants (Actual)	Interventional	2004-01-31	Completed
A Randomized, Double-blind, Multicenter, Multifactorial, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients. [NCT00409760]	Phase 3	1,930 participants (Actual)	Interventional	2003-01-31	Completed
A 12 Weeks, Multi-center, Open Label, Randomized, Active Drug Parallel Control Trial to Compare the Effectiveness of Valsartan/Amlodipine and Nifedipine in Treating Chinese Hypertensive Patients Not Respond to Mono Antihypertensive Treatment [NCT01167153]	Phase 4	564 participants (Actual)	Interventional	2010-05-31	Completed
The Pleiotropic Effects of Atorvastatin When Combined With Common Antihypertenisve Medications: A Comparison of Amlodipine and Hydrochlorothiazide [NCT00656331]		0 participants (Actual)	Interventional	2005-08-31	Withdrawn
"A Prospective, Open-label TElmisartan/AMlodipine Single Pill STudy to Assess the Efficacy in Patients With Essential Hypertension..." [NCT01134393]	Phase 3	502 participants (Actual)	Interventional	2010-05-31	Completed
Cognitive and Physical Impairment in Frail Older Adults [NCT04962841]		485 participants (Anticipated)	Observational	2020-04-01	Recruiting
A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People [NCT01259297]	Phase 3	2,336 participants (Actual)	Interventional	2011-01-31	Terminated(stopped due to Terminated early in agreement with Health Authorities for feasibility reasons)
An Open-label, Long-term Extension Study to Evaluate the Safety, Tolerability and Efficacy of 12 Months of LCZ696 Treatment in Patients With Essential Hypertension [NCT01256411]	Phase 2	341 participants (Actual)	Interventional	2010-11-30	Completed
An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine -Atorvastatin Combination In Subjects With Hypertension and Dyslipidaemia. (The JEWEL Study) [NCT00330785]	Phase 3	1,250 participants	Interventional	2004-10-31	Completed
A 12-week, Multicenter Study to Evaluate the Efficacy and Safety of Orally Administered Valsartan/Amlodipine Combo Based Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension [NCT00353912]	Phase 3	571 participants (Actual)	Interventional	2006-06-30	Completed
A Multi-center, Randomized, Double-blind, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy vs. Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension [NCT02944734]	Phase 2	392 participants (Actual)	Interventional	2014-09-30	Completed
Clinical Effect and Cost Effectiveness of Ca Antagonist in Combination With AII Receptor Antagonist in Patient With Essential Hypertension (PMS Study) [NCT01518855]	Phase 4	514 participants (Actual)	Interventional	2004-03-31	Completed
[NCT01518998]	Phase 2	420 participants (Actual)	Interventional	2011-08-31	Completed
A Drug Interaction Study Investigating the Effect of Boceprevir on the Pharmacokinetics of the Calcium Channel Blockers Amlodipine and Diltiazem and Vice Versa in Healthy Volunteers [NCT01549496]	Phase 1	0 participants (Actual)	Interventional	2012-05-31	Withdrawn(stopped due to Investigator left this hospital)
An Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy of the Combination of Valsartan and Hydrochlorothiazide and Amlodipine in Hypertensive Patients Not Controlled With Valsartan and Hydrochlorothiazide [NCT00400777]	Phase 4	460 participants (Anticipated)	Interventional	2006-08-31	Completed
An Open-label Randomized, Single Dose, Two Way Crossover Oral Bioequivalence Study of Amlodipine Besylate/Benazepril HCl Capsules of Dr. Reddy's With Lotrel® Capsules of Novartis in Human Subjects Under Fasting Conditions. [NCT01506011]	Phase 1	50 participants (Actual)	Interventional	2007-03-31	Completed
Action to Control Cardiovascular Risk in Diabetes (ACCORD) [NCT00000620]	Phase 3	10,251 participants (Actual)	Interventional	1999-09-30	Completed
An Multicenter Study to Evaluate the Efficacy and Tolerability of a 4-week Therapy With the Combination of Valsartan 160mg + Amlodipine 5mg in Hypertensive Patients Not Adequately Responding to 4-week Treatment With Amlo 5mg or Felodipine 5mg in Monothera [NCT00392262]	Phase 3	224 participants (Actual)	Interventional	2006-08-31	Completed
Randomized, Multicenter, Parallel, Open, Phase 4 Study to Compare the Efficacy and Safety of Rosuvastatin/Amlodipine Combination Therapy Versus Atorvastatin/Amlodipine Combination Therapy in Hypertension Patient With Dyslipidemia [NCT03951207]	Phase 4	259 participants (Actual)	Interventional	2019-05-30	Completed
Clinical Trial to Compare the Pharmacokinetics of TAH Tablet(80/10/12.5mg) in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers [NCT03032315]	Phase 1	44 participants (Actual)	Interventional	2016-10-01	Completed
An Open-label, Multiple-dose, Two-arm, One-sequence, Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of amlodipine10mg and candesartan32mg in Healthy Male Volunteers [NCT01806311]	Phase 1	34 participants (Anticipated)	Interventional	2012-12-31	Completed
Hypertension With Obesity Trial: Diabetes Mellitus Branch [NCT00847262]	Phase 4	120 participants (Actual)	Interventional	2008-06-30	Completed
The Novel Antihypertensive Goal Of hYpertension With diAbetes - Hypertensive Events and ARb Treatment (NAGOYA-HEART) Study [NCT00129233]	Phase 4	1,150 participants (Actual)	Interventional	2004-10-31	Completed
Evaluation of Potential Pharmacokinetic Interactions Between HIV Protease Inhibitors and Calcium Channel Blockers [NCT00039975]	Phase 1	32 participants	Interventional		Completed
Hereditary Pancreatitis Amlodipine Trial(H-PAT): A Pilot Study [NCT00156403]	Phase 1/Phase 2	8 participants	Interventional	2005-08-31	Completed
A Study to Evaluate the Safety and Efficacy of Valsartan/Amlodipine Compared to Lisinopril/Hydrochlorothiazide Given Once Daily for 6 Weeks is Patients With Severe Hypertension [NCT00171535]	Phase 3	130 participants (Actual)	Interventional	2004-10-31	Completed
An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine/Atorvastatin Combination In Subjects With Hypertension And Dyslipidaemia. (The JEWEL II Study) [NCT00174304]	Phase 4	1,120 participants	Interventional	2004-10-31	Completed
Hypertension Control Based on Home Systolic Pressure Study (HOSP Study) [NCT00198562]	Phase 4	2,600 participants (Anticipated)	Interventional	2000-04-30	Active, not recruiting
An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE of FDC of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tab 40+10+25 mg [Torrent,India] Vs Tribenzor 40+10+25 mg Tablets [ Daichi,USA] in Healthy Subjects-Fe [NCT02962258]	Phase 1	34 participants (Actual)	Interventional	2011-05-31	Completed
Filtered Trial for Telmisartan 40mg Non-responder [NCT00550953]	Phase 3	314 participants (Actual)	Interventional	2007-10-31	Completed
Nephropathy in Type 2 Diabetes: Effects of an Intensive Multifactorial Intervention Trial on Cardio-renal Events. [NCT00535925]	Phase 4	850 participants (Actual)	Interventional	2005-10-31	Completed
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia Who Fail to Respond Adequately to Fimasart [NCT03156842]	Phase 3	138 participants (Actual)	Interventional	2017-05-29	Completed
Randomized, 2-Way, Crossover, Bioequivalence Study of Amlodipine-Benazepril 10mg-20mg Capsules and Lotrel® Administered as 1 x 10 mg-20 mg Capsule in Healthy Subjects Under Fasting Conditions. [NCT00834977]	Phase 1	48 participants (Actual)	Interventional	2004-04-30	Completed
Black Education and Treatment of Hypertension (BEAT HTN) [NCT00661895]	Phase 4	99 participants (Actual)	Interventional	2005-08-31	Completed
A Single-Dose, Comparative Bioavailability Study of Telmisartan/Amlodipine 80 mg/10 mg Tablets Versus Micardis 80 mg Tablets With Norvasc 10 mg Tablets Under Fasting Conditions [NCT01278797]	Phase 1	28 participants (Actual)	Interventional	2011-01-31	Completed
A Twenty-four Week, Open-label, Non-comparative, Multi-center Study to Assess the Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension. [NCT00765947]	Phase 4	256 participants (Actual)	Interventional	2008-09-30	Completed
Comparison of the Effects of Amlodipine and Losartan on Blood Pressure and Diurnal Variation in Hypertensive Stroke Patients [NCT01830517]	Phase 4	84 participants (Actual)	Interventional	2007-08-31	Completed
Personalised Electronic Record Supported Optimisation When Alone for Patients With Hypertension- Pilot Study for Remote Medical Management of Hypertension During the COVID-19 Pandemic [NCT04559074]	Phase 4	1,000 participants (Anticipated)	Interventional	2020-10-23	Recruiting
Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial [NCT02213224]	Phase 4	180 participants (Anticipated)	Interventional	2014-08-31	Recruiting
An Open-label, Randomized, Single Dose, Three-way Crossover Study to Determine the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Amlodipine (5mg) and Losartan (100mg) in Healthy Adult Male and Female Subjects Under Fasti [NCT01648231]	Phase 1	23 participants (Actual)	Interventional	2012-08-06	Completed
Azelnidipine and Amlodipine Anti-Coronary Atherosclerotic Trial in Hypertensive Patients Undergoing Coronary Intervention by Serial Volumetric Intravascular Ultrasound Analysis in Junten Medical University (ALPS-J) [NCT00294567]	Phase 4	199 participants (Actual)	Interventional	2005-12-31	Completed
An 8 Weeks, Multi-Center, Randomized, Double Blinded, Comparative Phase 3 Clinical Trial to Assess the Efficacy and Safety of S-Amlodipine Gentisate Compared to Amlodipine Besylate in Patients With Mild-to-Moderate Hypertension [NCT00289406]	Phase 3	110 participants	Interventional	2006-01-31	Completed
A 14 Week Study to Evaluate Effectiveness of a Valsartan Versus an Amlodipine Treatment Strategy in Achieving Blood Pressure Control in Patients With Stage 1 or Stage 2 Hypertension or Uncontrolled on Present Monotherapy [NCT00304226]	Phase 4	1,288 participants (Actual)	Interventional	2006-02-28	Completed
Impact of High-Dose Quinapril Versus Low-Dose Quinapril Plus Amlodipine on Autonomic Regulation and on Sympathetic Activation in Response to Cold Exposure in Hypertensive Patients With Impaired Glucose Tolerance, Diabetes or Coronary Artery Disease [NCT00313547]	Phase 4	40 participants (Anticipated)	Interventional	2006-04-30	Terminated(stopped due to Very difficult to recruit patients/slow recruitment(2 patients in nearly 2 years).)
Evaluate the Efficacy and Safety of a Fixed Dose Combination of S-Amlodipine and Telmisartan(CKD-828) vs. S-Amlodipine Monotherapy in Hypertensive Patients Inadequately Controlled by S-Amlodipine Monotherapy. [NCT01501253]	Phase 3	187 participants (Actual)	Interventional	2011-08-31	Completed
An Open-label Randomized, Single Dose, Two Way Crossover Oral Bioequivalence Study of Amlodipine Besylate/Benazepril HCl Capsules of Dr. Reddy's With Lotrel® Capsules of Novartis in Human Subjects Under Fed Conditions [NCT01505998]	Phase 1	49 participants (Actual)	Interventional	2007-03-31	Completed
A Prospective Open-label Multicentre Study of Efficacy and Safety of Irbesartan/Amlodipine 4 Fixed Combination Therapy in Hypertensive Patients Uncontrolled on Irbesartan 150 mg or Amlodipine 5 mg Monotherapy [NCT01625494]	Phase 3	158 participants (Actual)	Interventional	2012-05-31	Completed
Estimation of the Long Term Effectiveness of Routine Use of Cardiac Shock Wave Therapy in the General System of Noninvasive, Invasive, and Surgical Treatment of Ischemic Heart Disease in the Conditions of a Large General City Hospital [NCT01631409]		0 participants (Actual)	Observational	2013-09-30	Withdrawn(stopped due to The study has been withdrawn due to organizational problems)
A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a Fixed Dose Combination of S-Amlodipine and Telmisartan(CKD-828) Versus S-Amlodipine Monotherapy in Patients With Stage 2 Hypertension [NCT01634295]	Phase 3	103 participants (Actual)	Interventional	2012-07-31	Completed
[NCT01652339]	Phase 1	40 participants (Actual)	Interventional	2012-07-31	Completed
The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension [NCT01996449]	Phase 2	14 participants (Actual)	Interventional	2013-07-31	Completed
The Correlation Study Between Blood Pressure Variability and the Prognosis of Ischemic Stroke With Intracranial Artery Stenosis [NCT01665235]		200 participants (Anticipated)	Interventional	2012-08-31	Recruiting
Prevalence and Incidence of Dyskalemia in Hypertensive Patients Initiating a Fixed Dose Combination Pill of Telmisartan and Amlodipine [NCT05155436]	Phase 4	1,090 participants (Actual)	Interventional	2022-01-15	Completed
Efficacy and Tolerability of Combination Antihypertensive Drug in Non-Responders to Angiotensin Receptor Blocker(ARB) monoTHerapy Using 24h ABPM. [NCT01713920]	Phase 4	68 participants (Actual)	Interventional	2010-04-30	Completed
A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg Tablet and Novartis Exforge 10/160mg Tablet After a Single Oral Administration in Healthy Male Volu [NCT01735890]	Phase 1	48 participants (Actual)	Interventional	2012-09-30	Completed
ARB and CCB Longest Combination Treatment on Ambulatory and Home BP in Hypertension With Atrial Fibrillation -Multicenter Study on Time of Dosing [NCT01748253]		80 participants (Anticipated)	Interventional	2012-11-30	Recruiting
Efficacy and Safety of GMRx2 (a Single Pill Combination Containing Telmisartan/Amlodipine/Indapamide) Compared to Placebo for the Treatment of Hypertension [NCT04518306]	Phase 3	295 participants (Actual)	Interventional	2021-06-06	Completed
[NCT01819220]	Phase 4	16 participants (Actual)	Interventional	2009-04-30	Completed
Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects [NCT01819779]	Phase 1	53 participants (Actual)	Interventional	2013-03-31	Completed
Polipill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt in Primary Health Care [NCT05155137]	Phase 3	12,268 participants (Anticipated)	Interventional	2021-12-20	Recruiting
An Open-Label, Randomized, Single Dose, Two-Way Crossover Pilot Study to Evaluate the Relative Bioavailability of One Amlodipine 5 mg Tablet and One Enalapril Maleate 20mg Tablet to a Fixed Dose Combination Tablet Formulation of Amlodipine (5 mg) and Enal [NCT01822639]	Phase 1	15 participants (Actual)	Interventional	2013-04-03	Completed
An Eight-week, Randomized, Double-blind Multicenter Study to Compare the Efficacy and Safety of Amosartan® Tab 5/100mg Versus Cozaar® Plus Pro Tab in Patients With Essential Hypertension Uncontrolled With Losartan 100mg Monotherapy [NCT01828359]	Phase 4	199 participants (Actual)	Interventional	2010-08-31	Completed
Bedtime Administration of Amlodipine Versus Lisinopril: a Randomized Trial [NCT01835418]		100 participants (Anticipated)	Interventional	2013-04-30	Not yet recruiting
A Randomized, Open-label, Single Dose, Two-treatment, Two-period, Two-sequence Crossover Study to Investigate the Effect of Atorvastatin on the Pharmacokinetic Properties of Telmisartan/S-amlodipine After Oral Administration in Healthy Volunteers [NCT01842230]	Phase 1	24 participants (Actual)	Interventional	2013-04-30	Completed
A Randomized, Open-label, Single Dose, Two-treatment, Two-period, Two-sequence Crossover Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin After Oral Administration in Healthy Volunteers [NCT01842256]	Phase 1	24 participants (Actual)	Interventional	2013-04-30	Completed
Open-label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Interactions of Candesartan Cilexetil and Amlodipine Besylate in Healthy Male Volunteers. [NCT01845272]	Phase 1	40 participants (Anticipated)	Interventional	2013-04-30	Active, not recruiting
Azilsartan Circadian and Sleep Pressure - the 1st Study [NCT01762501]		957 participants (Actual)	Interventional	2012-12-31	Completed
An Eight-week Randomized, 4-arm, Double-blind Study to Compare the Efficacy and Safety of Combinations of Telmisartan 40mg + Amlodipine 5mg Versus Telmisartan 80mg + Amlodipine 5mg Versus Amlodipine 5mg Versus Amlodipine 10mg Monotherapy in Patients With [NCT00558428]	Phase 3	1,098 participants (Actual)	Interventional	2007-10-31	Completed
An Open-label, Randomized, Cross-over Study to Evaluate Pharmacokinetics and the Safety of HL068 16/10mg Compared to Candesartan 16mg and Amlodipine 10mg Co-administered in Healthy Male Volunteers. [NCT02988362]	Phase 1	40 participants (Anticipated)	Interventional	2016-12-31	Not yet recruiting
Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension [NCT04474899]	Phase 4	120 participants (Anticipated)	Interventional	2015-06-24	Recruiting
Italian Study on the Cardiovascular Effects of Systolic Blood Pressure Control - CARDIOSIS Study [NCT00421863]	Phase 4	1,111 participants (Actual)	Interventional	2005-02-28	Completed
Comparative Efficacy of Amlodipine Folic Acid vs. Amlodipine on the Risk of First Ischemic Stroke Among Patients With Hypertension and MTHFR 677 TT Genotype: A Multi-center, Randomized, Controlled Clinical Trial [NCT04974151]	Phase 4	24,000 participants (Anticipated)	Interventional	2022-04-01	Not yet recruiting
National, Multicenter, Open-Label and Prospective Study Assessment of Efficacy and Safety in Stage 1 and 2 Essential Hypertension With Olmesartan Medoxomil Based Treatment Algorithm From Monotherapy to Association With Hydrochlorothiazide and Amlodipine B [NCT00890591]	Phase 4	144 participants (Actual)	Interventional	2006-08-31	Completed
Effects of Fimasartan on Insulin Secretion, and Interaction With DPP4 Inhibitors in Patients With Type 2 Diabetes [NCT02312375]		46 participants (Actual)	Interventional	2015-03-31	Completed
The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial [NCT04330300]	Phase 4	2,414 participants (Anticipated)	Interventional	2020-04-30	Suspended(stopped due to Challenges with funding and very low incidence of COVID-19 at Irish study site)
A Randomized, Comparative Trial of Concor AM, a Fixed Dose Combination of Bisoprolol and Amlodipine, on the Treatment of Essential Hypertensive Patients Whose Blood Pressure is Not Well Controlled by Monotherapy of Bisoprolol 5mg or Amlodipine 5mg [NCT01977794]	Phase 3	200 participants (Actual)	Interventional	2014-03-31	Completed
A Multi-center, Randomized, Open-label, Active-controlled, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab in Hypertension Patients With Low-Intermediate Risk for Cardiovascular Disease [NCT04120753]	Phase 4	106 participants (Actual)	Interventional	2019-08-26	Completed
Amlodipine Plus/Minus Atorvastatin for Protection of Arteries [NCT01922687]	Phase 4	109 participants (Anticipated)	Interventional	2011-04-30	Recruiting
Fixed Combination for Lipid and Blood Pressure Control. Randomized Cross-over Study [NCT03047538]	Phase 4	0 participants (Actual)	Interventional	2017-09-01	Withdrawn(stopped due to Insufficient funds)
An Open-label, Randomized, Two-sequence, Multiple-dose, Crossover Study to Evaluate Drug-drug Interaction Following Oral Administration of Telmisartan/Amlodipine and Atorvastatin in Healthy Adult Volunteers [NCT03461081]	Phase 1	32 participants (Actual)	Interventional	2017-05-07	Completed
The Effect of Antihypertensive Agents Over Sleep Apnea: a Randomized Controlled Trial [NCT01896661]	Phase 3	53 participants (Actual)	Interventional	2014-12-31	Completed
A Randomized, Open-label, 4-way Crossover Single Dose Clinical Trial to Investigate the Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405 When Administered Alone and in Combination in Healthy Male Volunteers [NCT02387554]	Phase 1	33 participants (Actual)	Interventional	2014-08-31	Completed
An Open-label, Multicenter Study to Evaluate the Efficacy and Tolerability of a 4 Week Therapy With the Fixed Dose Combination of Valsartan 160 mg Plus HCTZ 25 mg in Hypertensive Patients Not Adequately Responding to a 4 Week Therapy With the Free Combina [NCT00360178]	Phase 3	198 participants (Actual)	Interventional	2006-07-31	Completed
Effect of Renin-angiotensin-system (RAS) Blocker Drugs on Chronic Kidney Disease (CKD) Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01) [NCT03195023]	Phase 4	106 participants (Anticipated)	Interventional	2015-06-30	Recruiting
The Study Was Approved by the Ethics Committee of Our Institution, Which is Accredited by the Office of Human Research Protection as an Institutional Review Board [NCT02408172]	Phase 2/Phase 3	20 participants (Anticipated)	Interventional	2013-10-31	Recruiting
A Randomized, Multicenter, Study to Determine the Efficacy and Safety of Amlodipine/Benazepril Hydrochloride Versus Enalapril in the Treatment of Hypertension in an African-American Population With Type 2 Diabetes [NCT00367978]	Phase 4	275 participants (Actual)	Interventional	2001-12-31	Completed
Blood Pressure and Lipids Reduction in High Risk Elderly Patients With Isolated Systolic Hypertension [NCT05165251]	Phase 4	480 participants (Anticipated)	Interventional	2022-01-04	Recruiting
Vascular Augmentation of Late-life Unremitted Depression (VALUeD) [NCT01557153]	Phase 3	80 participants (Anticipated)	Interventional	2012-04-30	Not yet recruiting
Efficacy and Safety of a Sequential Therapy Change From Candesartan 32 mg to the Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg in Patients With Poorly Controlled Moderate Hypertension - an Open Phase IV Trial [NCT01611077]	Phase 4	88 participants (Actual)	Interventional	2012-01-31	Completed
A Phase II Study to Explore the Effect of Different Dose of DMTA07 Combine With Amlodipine Treatment in Patients With Hypertension [NCT01614366]	Phase 2	111 participants (Actual)	Interventional	2012-07-31	Completed
A Multi-center, Randomized, Double-blind, Parellel Phase III Clinical Trial to Evaluate the Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin in Patients With Dyslipidemia and Hypertension [NCT03088254]	Phase 3	126 participants (Actual)	Interventional	2016-09-20	Completed
A Randomized, Double-blind, Multicenter, Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypertension [NCT04488978]	Phase 2	440 participants (Actual)	Interventional	2020-05-21	Completed
A 10-week Multicenter,Forced-titration Study Using 24-hr ABPM to Evaluate the Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Treatment Regimen vs Conventional Treatment Regimen With Amlodipine and Hydrochlorothiazide (HCTZ) in Patients With Stage 2 Hype [NCT00425997]	Phase 4	480 participants (Anticipated)	Interventional	2006-12-31	Completed
An 8-week, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Valsartan/HCTZ/Amlodipine Compared to Valsartan/HCTZ, Valsartan/Amlodipine, and HCTZ/Amlodipine in Patients With Moderate to Severe Hypertension. [NCT00327587]	Phase 3	2,279 participants (Actual)	Interventional	2006-05-31	Completed
A Randomized, Double-blind, Active-controlled, Parallel Group, 52-week Study to Evaluate the Effect of LCZ696 Compared to Olmesartan on Regional Aortic Stiffness in Subjects With Essential Hypertension [NCT01870739]	Phase 2	115 participants (Actual)	Interventional	2013-10-31	Completed
[NCT00000542]	Phase 3	0 participants	Interventional	1993-08-31	Completed
Interventional Clinical Trial to Assess Efficacy and Safety of the Extemporaneous Combination of Zofenopril Calcium and Amlodipine in Grade 1-2 Hypertensive Patients Versus Each Monotherapy - (MASOLINO Study) [NCT05279807]	Phase 4	290 participants (Actual)	Interventional	2021-10-15	Completed
Swiss Interventional Study on Silent Ischemia (SWISSI 1) [NCT00382421]		0 participants	Interventional	1992-02-29	Completed
An Eight-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 40mg + Amlodipine 10mg Versus Telmisartan 80mg + Amlodipine 10mg Versus Amlodipine 10mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequat [NCT00553267]	Phase 3	947 participants (Actual)	Interventional	2007-11-30	Completed
Upstream-therapy by Telmisartan and Amlodipine Combination for Improvement of Left Atrial Mechanical Function After Pulmonary Vein Antrum Isolation [NCT02734355]	Phase 4	64 participants (Actual)	Interventional	2015-11-30	Completed
An Multicenter Study to Evaluate the Efficacy and Safety of a 5 Week Therapy With the Combination of Valsartan 160 mg Plus Amlodipine 10 mg in Hypertensive Patients Not Adequately Responding to a 5 Week Therapy With Ramipril 5 mg and Felodipine 5 mg [NCT00367939]	Phase 3	132 participants (Actual)	Interventional	2005-12-31	Completed
"Azilsartan/Amlodipine (Zacras) Combination Tablets LD & HD Specified Drug-use Survey Long-term Use Survey" [NCT02181816]		1,090 participants (Actual)	Observational	2014-06-26	Completed
Intensive Management of Blood Pressure and Cholesterol in Elderly Chinese With Hypertension and Atrial Fibrillation (IMPRESSION) [NCT04111419]	Phase 4	1,200 participants (Anticipated)	Interventional	2020-07-01	Recruiting
Efficacy of a Combination of Amlodipine / Valsartan on Blood Pressure Control, With One Nocturnal or Diurnal Intake a Day, in Ambulatory Blood Pressure Monitoring Setting, in Essential Uncontrolled Hypertensive Patients With Amlodipine 5mg ; The ExPERT St [NCT00700271]	Phase 4	478 participants (Actual)	Interventional	2007-10-31	Completed
Efficacy and Safety of S-amlodipine 2,5 mg and 5 mg in Hypertension Patients: Open-label, Local, Phase IV Study [NCT03038451]	Phase 4	43 participants (Actual)	Interventional	2013-03-20	Completed
Bioequivalence of Levamlodipine Besylate Tablets in Healthy Chinese Subjects: A Single-dose and Two-period Crossover Study [NCT04411875]	Phase 1	48 participants (Actual)	Interventional	2018-11-13	Completed
Single-center, Randomized, Open-label, Parallel-group Study to Characterize Renin-angiotensin-system (RAS) Peptide Profiles Before and After Treatment Initiation With Different Antihypertensive Drug-classes in Patients With Treatment-naive Arterial Hypert [NCT02449811]		107 participants (Actual)	Observational	2015-04-30	Completed
A Prospective Randomized Placebo Controlled Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy [NCT02172040]	Phase 3	152 participants (Actual)	Interventional	2014-06-26	Completed
Effects and Safety of Sacubitril/Valsartan Versus Valsartan on Refractory Hypertension: The EOSORH Trial [NCT05545059]	Phase 3	138 participants (Anticipated)	Interventional	2022-09-24	Recruiting
A Randomized, 8-week, Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Patients With Essential Hypertension N [NCT01663233]	Phase 3	266 participants (Actual)	Interventional	2012-08-31	Completed
Lowering Blood Pressure in Primary Care in Vienna [NCT02377661]	Phase 4	229 participants (Actual)	Interventional	2015-03-31	Completed
Manidipine Versus Amlodipine in Patients With Hypertension: Effects on Peripheral Edema Evaluated by Bioimpedance Analysis [NCT03106597]	Phase 4	46 participants (Actual)	Interventional	2015-08-20	Terminated(stopped due to Difficulty in enrolling subjects)
An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80 mg and Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg vs. Telmisartan 80 mg and Amlodipine 5 mg in Patients With Hypertension Who Fail to Respond Adequately [NCT01975246]	Phase 3	309 participants (Actual)	Interventional	2013-11-30	Completed
Characterization of Arterial Hypertension and Efficacy of Blood-pressure Lowering Therapy at Different Altitudes Above Sea Level [NCT02373163]	Phase 4	120 participants (Anticipated)	Interventional	2014-09-30	Recruiting
Hypertension in Young Adults Trial [NCT05370599]	Phase 2	120 participants (Anticipated)	Interventional	2022-04-15	Recruiting
A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension [NCT01658657]		17 participants (Actual)	Interventional	2012-10-31	Completed
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopr [NCT01556997]	Phase 3	837 participants (Actual)	Interventional	2012-02-29	Completed
An Open-label, Multiple-dosing, Two-arm, One-sequence, Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Amlodipine 10mg and Candesartan 32mg in Healthy Male Volunteers [NCT01926652]	Phase 1	34 participants (Actual)	Interventional	2013-07-31	Completed
Efficacy and Safety of a Single-pill Fixed Combination of Sufficient Losartan/Hydrochlorothiazide in Chinese Hypertensive Patients (FOCUS) [NCT03946514]	Phase 4	300 participants (Anticipated)	Interventional	2018-09-01	Recruiting
A Two Way Cross Over Pharmacokinetic (PK) Interaction Study Between Raltegravir and Amlodipine in Healthy Volunteers [NCT01841593]	Phase 1	19 participants (Actual)	Interventional	2013-04-30	Completed
Blood Pressure Reduction by Fixed-dose Compared to Free Dose Combination Therapy of ACE Inhibitor and Calcium Antagonist in Hypertensive Patients [NCT02995954]	Phase 4	100 participants (Actual)	Interventional	2014-01-31	Completed
An Open-label, Randomized, Single-dose, 2X3X3 Partial Replicate, Crossover Study to Compare the Pharmacokinetics and Safety Between a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin and Co-administration of a Fixed Dose Combination of Fimasar [NCT02995720]	Phase 1	60 participants (Actual)	Interventional	2016-08-26	Completed
Changes in Central Aortic Pressure, Endothelial Function and Biomarkers in African Americans With Cardiometabolic Syndrome: Comparison of Amlodipine/Olmesartan Versus Hydrochlorothiazide/Losartan [NCT01271374]	Phase 4	80 participants (Anticipated)	Interventional	2010-04-30	Active, not recruiting
A Randomized, Double-blind 52-week Study to Evaluate the Safety and Efficacy of an LCZ696 Regimen Compared to an Olmesartan Regimen on Arterial Stiffness Through Assessment of Central Blood Pressure in Elderly Patients With Hypertension [NCT01692301]	Phase 2	454 participants (Actual)	Interventional	2012-12-31	Completed
[NCT03210532]	Phase 3	129 participants (Actual)	Interventional	2016-10-07	Completed
A Prospective, Multicentre, Randomized, Open Label, Evaluator-Blind, Phase IV Study to Evaluate the Effect on Improvement of Left Ventricular Hypertrophy by the Control of Blood Pressure in Hypertension Patients With Aortic Valve Disease [NCT03666351]	Phase 4	128 participants (Actual)	Interventional	2018-10-18	Completed
"Unisia Combination Tablets LD, HD Special Drug Use Surveillance Hypertension: Long-Term Use" [NCT02068495]		3,409 participants (Actual)	Observational	2010-06-15	Completed
Randomized Controlled Blind End Point Study of Enalapril Folic Acid Tablets Combined With Calcium Antagonist or Diuretic to Prevent Stroke in Patients With Type H Hypertension [NCT04952051]	Phase 3	1,000 participants (Actual)	Interventional	2014-07-01	Completed
Mechanism of Masked Hypertension - Intervention [NCT04121299]	Phase 3	0 participants (Actual)	Interventional	2021-07-31	Withdrawn(stopped due to lack of funding)
Effect of Amlodipine Versus Amlodipine Combined With Atorvastatin on the Symptoms, Function, and Quality of Life in Patients With Coronary Vasospastic Angina [NCT03054467]	Phase 4	150 participants (Anticipated)	Interventional	2018-12-01	Not yet recruiting
A Phase IV Study, Prospective, Randomised, Open Label, Blinded Endpoint, Parallel Group, 9 Weeks of Comparison Between Oral Administration of Telmisartan Tablet (80mg Once Daily) and Amlodipine Tablet (10 mg Once Daily) on Biological PPAR Gamma Activities [NCT00242814]	Phase 4	100 participants (Actual)	Interventional	2005-11-03	Completed
An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80 mg and Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg vs. Telmisartan 80 mg and Hydrochlorothiazide 12.5 mg in Patients With Hypertension Who Fail to Respond [NCT01911780]	Phase 3	132 participants (Actual)	Interventional	2013-07-31	Completed
Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension. A Multicentre [NCT05288400]	Phase 3	150 participants (Actual)	Interventional	2018-05-14	Completed
An Open-label, Randomised, Single Dose, Three-way Crossover, Parallel Groups Study to Determine the Bioequivalence of Two Fixed Dose Combination (FDC) Tablet Formulations of Amlodipine and Losartan FDC5/50 and FDC5/100 to Respective Reference Dosages in H [NCT01797926]	Phase 1	102 participants (Actual)	Interventional	2013-05-23	Completed
The 8 Weeks, Multicenter, Randomized, Double-blind, Clinical Study To Evaluate Efficacy Of Treatment With Losartan/Amlodipine 100/5 mg Combination Compared To Amlodipine 10 mg Monotherapy In Hypertensive Patients Who Are Not Appropriately Respond To Amlod [NCT01277822]	Phase 4	334 participants (Actual)	Interventional	2011-05-30	Completed
Relative Bioavailability Study of Amlodipine Powder for Oral Solution, 5 mg (Base) Under Fasting and Fed Conditions [NCT05808725]	Phase 1	24 participants (Actual)	Interventional	2022-12-29	Completed
Comparative Open-label,Randomized, Fasting, Single Dose, Two-way Crossover Bioequivalence Study of Amlodipine / Valsartan From Amlodipine/Valsartan 10/160 Tablets (Pharmacare, Palestine) and Exforge Tablets (Novartis Pharma, USA) [NCT02519010]	Phase 1	36 participants (Actual)	Interventional	2011-03-31	Completed
Filtered Trial for Amlodipine Non-responder [NCT00558064]	Phase 3	531 participants (Actual)	Interventional	2007-10-31	Completed
Randomized, 2-Way, Crossover, Bioequivalence Study of Amlodipine-Benazepril 10mg-20mg Capsules and Lotrel® Administered as 1 x 10 mg-20 mg Capsule in Healthy Subjects Under Fed Conditions. [NCT00835367]	Phase 1	68 participants (Actual)	Interventional	2004-03-31	Completed
An Experimental Study on the Effect of Tenofovir Amibufenamide on Blood Lipid During Anti-HBV Treatment [NCT05398393]		150 participants (Anticipated)	Interventional	2022-01-01	Enrolling by invitation
Gut Microbiomes and Viromes in Patients With Metabolic Syndrome [NCT03489317]		1,000 participants (Anticipated)	Observational	2017-11-27	Recruiting
Efficacy and Safety of Single Pill Combination (Amlodipine/Valsartan) in Hypertensive Patients Not Controlled on Previous Monotherapy: An Observational Real Life Study [NCT03371797]		800 participants (Actual)	Observational	2018-02-20	Completed
Management of Hypertension Utilizing Trained Community Health Worker in Rural Municipalities of Nepal (MUTU) Study [NCT04521582]		1,428 participants (Actual)	Interventional	2021-04-27	Completed
Bioequivalence of Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg Fixed-dose Combination Tablet Compared to Concomitant Administration of Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg Fixed-dose Combination Tablet and Amlodipine 5 mg Capsule [NCT02129192]	Phase 1	72 participants (Actual)	Interventional	2014-05-31	Completed
Pharmacokinetics of Multiple Oral Doses of Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg Fixed-dose Combination Tablet, Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg Fixed-dose Combination Tablet and Telmisartan 80 mg/Amlodipine 5 mg Fixed [NCT02183675]	Phase 1	36 participants (Actual)	Interventional	2014-07-31	Completed
A Single-Arm Open-Label Multicenter Phase IV Clinical Trial to Explore the Blood Pressure Lowering Effect of Exforge® (Amlodipine/Valsartan: AMLO/VAL) in Hypertensive Patients [NCT02062645]	Phase 4	115 participants (Actual)	Interventional	2014-02-28	Completed
An Open Label, Randomized, Single-dose, 4-period Cross-over Study to Compare the Pharmacokinetics and Safety Following Administration of JLP-1401 and Coadministration of Rosuvastatin and Telmisartan/Amlodipine in Healthy Adult Volunteers [NCT03247140]	Phase 1	40 participants (Actual)	Interventional	2017-06-10	Completed
A Multicenter, Prospective Observational Study to Evaluate the Safety and Efficacy for Levacalm Tab. Versus Valsartan/Amlodipine Combination Therapy in Patient With Essential Hypertension [NCT02415192]		2,001 participants (Anticipated)	Observational	2014-07-31	Recruiting
Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes-----renal Substudy [NCT04978649]	Phase 4	0 participants (Actual)	Interventional	2021-09-01	Withdrawn(stopped due to Cooperation plan has been changed)
The SCCS Polypill Pilot Trial [NCT02278471]	Phase 2	303 participants (Actual)	Interventional	2015-12-31	Completed
Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism [NCT02034435]	Phase 4	44 participants (Actual)	Interventional	2013-10-31	Completed
Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension [NCT02412761]		42 participants (Actual)	Interventional	2013-06-30	Completed
Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension: A Randomized Controlled Noninferiority Trial [NCT04790279]	Phase 4	132 participants (Actual)	Interventional	2021-04-09	Completed
A Randomized, Double-blind, Parallel Group Study to Evaluate Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects [NCT01631864]	Phase 2	98 participants (Actual)	Interventional	2012-10-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00000620 (6) [back to overview]	Death From Any Cause in the Glycemia Trial.
NCT00000620 (6) [back to overview]	First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.
NCT00000620 (6) [back to overview]	First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.
NCT00000620 (6) [back to overview]	First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.
NCT00000620 (6) [back to overview]	First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.
NCT00000620 (6) [back to overview]	Stroke in the Blood Pressure Trial.
NCT00015457 (2) [back to overview]	Duration of Response to Botulinum Toxin Injection With Amlodipine and With Placebo
NCT00015457 (2) [back to overview]	Toronto Western Spasmodic Torticollis Rating Scale (TWSTR) Sum Score
NCT00170950 (3) [back to overview]	Time-to-event Analysis of Percentage of Patients With a Cardiovascular (CV) Mortality Event, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke
NCT00170950 (3) [back to overview]	Time-to-event Analysis of Percentage of Patients With a Composite Cardiovascular (CV) Morbidity or Mortality Event
NCT00170950 (3) [back to overview]	Time-to-event Analysis of Percentage of Patients With a Composite Cardiovascular (CV) Morbidity Event
NCT00171054 (13) [back to overview]	Change From Baseline in Post-ischemic Forearm Skin Reactive Hyperemia at Week 12
NCT00171054 (13) [back to overview]	Change in Left Ventricular Mass Index (LVMI) and Diastolic Function Using Echocardiography From Baseline to Week 38
NCT00171054 (13) [back to overview]	Changes in Baroreflex Sensitivity as it Relates to Changes in Carotid Distensibility From Baseline to Week 12
NCT00171054 (13) [back to overview]	Change From Baseline in Post-ischemic Forearm Skin Reactive Hyperemia at Endpoint (Week 38)
NCT00171054 (13) [back to overview]	Changes in Central Blood Pressure, Evaluated by Applanation Tonometry From Baseline at Weeks 12 and 38
NCT00171054 (13) [back to overview]	Change From Baseline for Endothelial Function Measured by Brachial Artery Flow-mediated Vasodilatation (FMD) Using the Brachial Artery Reactivity Test (BART) at Week 12
NCT00171054 (13) [back to overview]	Changes in Baroreflex Sensitivity as it Relates to Changes in Carotid Distensibility From Baseline to Week 38
NCT00171054 (13) [back to overview]	Changes in Mean Left Carotid Distensibility at Week 12
NCT00171054 (13) [back to overview]	Changes in Mean Left Carotid Distensibility at Week 38
NCT00171054 (13) [back to overview]	Changes in Mean Right Carotid Distensibility at Week 12
NCT00171054 (13) [back to overview]	Changes in Mean Right Carotid Distensibility at Week 38
NCT00171054 (13) [back to overview]	Change From Baseline for Endothelial Function Measured by Brachial Artery Flow-mediated Vasodilatation (FMD) Using the Brachial Artery Reactivity Test (BART) at End-point (Week 38)
NCT00171054 (13) [back to overview]	Change From Baseline to Week 38 in the Carotid-femoral Pulse Wave Velocity (PWV)
NCT00281580 (46) [back to overview]	Change From Baseline in Seated Trough Cuff Mean DBP (Observed Treatment Effects)
NCT00281580 (46) [back to overview]	Change From Baseline in Seated Trough Cuff Mean SBP
NCT00281580 (46) [back to overview]	Change From Baseline in Seated Trough Pulse Rate
NCT00281580 (46) [back to overview]	Change From Baseline in Standing Trough Cuff Mean DBP
NCT00281580 (46) [back to overview]	Change From Baseline in Standing Trough Cuff Mean SBP
NCT00281580 (46) [back to overview]	Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Amlodipine Effects)
NCT00281580 (46) [back to overview]	BP Control
NCT00281580 (46) [back to overview]	DBP Control
NCT00281580 (46) [back to overview]	DBP Control
NCT00281580 (46) [back to overview]	DBP Response
NCT00281580 (46) [back to overview]	DBP Response
NCT00281580 (46) [back to overview]	Orthostatic Change in Trough Cuff Mean DBP
NCT00281580 (46) [back to overview]	Orthostatic Change in Trough Cuff Mean DBP
NCT00281580 (46) [back to overview]	Orthostatic Change in Trough Cuff Mean SBP
NCT00281580 (46) [back to overview]	Orthostatic Change in Trough Cuff Mean SBP
NCT00281580 (46) [back to overview]	SBP Response
NCT00281580 (46) [back to overview]	BP Normality
NCT00281580 (46) [back to overview]	BP Normality
NCT00281580 (46) [back to overview]	Change From Baseline at 2,4,6,and 8 Weeks in Seated Trough Cuff DBP
NCT00281580 (46) [back to overview]	Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Telmisartan Effects)
NCT00281580 (46) [back to overview]	Change From Baseline in ABPM Hourly Mean (Relative to Dosing) DBP
NCT00281580 (46) [back to overview]	Change From Baseline in ABPM Hourly Mean (Relative to Dosing) DBP
NCT00281580 (46) [back to overview]	Change From Baseline in ABPM Hourly Mean (Relative to Dosing) SBP
NCT00281580 (46) [back to overview]	Change From Baseline in Seated Trough Cuff DBP
NCT00281580 (46) [back to overview]	Clinical Relevant Abnormalities for Laboratory Parameters and Electrocardiogram (ECG)
NCT00281580 (46) [back to overview]	Change From Baseline in Seated Trough Pulse Rate
NCT00281580 (46) [back to overview]	Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects, Excluding Pl)
NCT00281580 (46) [back to overview]	Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects)
NCT00281580 (46) [back to overview]	Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Observed Amlodipine Effects)
NCT00281580 (46) [back to overview]	BP Control
NCT00281580 (46) [back to overview]	Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Observed Treatment Effects)
NCT00281580 (46) [back to overview]	Change From Baseline at 8 Weeks in Seated Trough Cuff Mean Diastolic Blood Pressure (DBP) (Observed Telmisartan Effect)
NCT00281580 (46) [back to overview]	Change From Baseline at 8 Weeks in Seated Trough Cuff Mean Systolic Blood Pressure (SBP)
NCT00281580 (46) [back to overview]	Change From Baseline at 8 Weeks in Standing Trough Cuff Mean DBP
NCT00281580 (46) [back to overview]	SBP Response
NCT00281580 (46) [back to overview]	Change From Baseline at 8 Weeks in Standing Trough Cuff Mean SBP
NCT00281580 (46) [back to overview]	Change From Baseline in ABPM 24-hour Mean DBP
NCT00281580 (46) [back to overview]	Change From Baseline in ABPM 24-hour Mean DBP
NCT00281580 (46) [back to overview]	Change From Baseline in ABPM 24-hour Mean SBP
NCT00281580 (46) [back to overview]	Change From Baseline in ABPM 24-hour Mean SBP
NCT00281580 (46) [back to overview]	Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Amlodipine Effects)
NCT00281580 (46) [back to overview]	Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Telmisartan Effects)
NCT00281580 (46) [back to overview]	Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects, Excluding Pl)
NCT00281580 (46) [back to overview]	Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects)
NCT00281580 (46) [back to overview]	Change From Baseline in Seated Trough Cuff Mean DBP (Observed Amlodipine Effects)
NCT00281580 (46) [back to overview]	Change From Baseline in Seated Trough Cuff Mean DBP (Observed Telmisartan Effect)
NCT00311155 (6) [back to overview]	The Percentage of Participants Treated to Target Blood Pressure Goals Overall and for Each Treatment Step From Baseline to Completion of Treatment During Which the Goal Was Achieved.
NCT00311155 (6) [back to overview]	Percentage of Participants Who Were Systolic Responders Overall and for Each Treatment From Baseline to the Completion of the Treatment During Which Blood Pressure Goals Were Achieved
NCT00311155 (6) [back to overview]	Percentage of Participants Who Were Diastolic Responders Overall and for Each Treatment From Baseline to the Completion of Treatment During Which Blood Pressure Goals Were Achieved.
NCT00311155 (6) [back to overview]	Percentage of Participants Who Achieved Normalized Blood Pressure Overall and for Each Treatment From Baseline to Completion of the Treatment During Which Blood Pressure Goals Were Achieved
NCT00311155 (6) [back to overview]	Mean Change in Systolic Blood Pressure Overall and for Each Treatment From Baseline to the Completion of the Treatment
NCT00311155 (6) [back to overview]	Mean Change in Diastolic Blood Pressure Overall and for Each Treatment From Baseline to the Completion of the Treatment
NCT00368277 (4) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure to Week 12
NCT00368277 (4) [back to overview]	Change From Baseline in the Mean Sitting Diastolic Blood Pressure to Week 36
NCT00368277 (4) [back to overview]	Percentage of Patients With Cough
NCT00368277 (4) [back to overview]	Percentage of Patients Achieving Blood Pressure Control at Weeks 12 and 36 Endpoints
NCT00402103 (4) [back to overview]	Overall Percentage of Patients With Adverse Events
NCT00402103 (4) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP)From Baseline to the Indicated Time Points
NCT00402103 (4) [back to overview]	Percentage of Patients Achieving a Blood Pressure Control Target of <140/90 mmHg
NCT00402103 (4) [back to overview]	Percentage of Patients Achieving a Response in Mean Sitting Diastolic Blood Pressure (msDBP)
NCT00407537 (22) [back to overview]	Framingham 10-year Risk of Total Coronary Heart Disease (CHD) at Month 12
NCT00407537 (22) [back to overview]	Change From Baseline European SCORE 10-year Risk of Developing Fatal CVD
NCT00407537 (22) [back to overview]	Change From Baseline in Framingham 10-year Risk of Developing Total CHD
NCT00407537 (22) [back to overview]	Change From Baseline in Lipid Parameters at Month 4
NCT00407537 (22) [back to overview]	Mean Lipid Parameters at Month 12
NCT00407537 (22) [back to overview]	Mean Lipid Parameters at Month 4
NCT00407537 (22) [back to overview]	Mean Systolic and Diastolic Blood Pressure at Month 12
NCT00407537 (22) [back to overview]	Mean Systolic and Diastolic Blood Pressure at Month 4
NCT00407537 (22) [back to overview]	Number of Participants With Increase of Treatment Dosages After 4 Months.
NCT00407537 (22) [back to overview]	Number of Participants With Lipid and Antihypertensive Treatments Used at 4 and 12 Months
NCT00407537 (22) [back to overview]	Percentage of Participants at Conventional Treatment Goals According to Global and Local Guidelines for Blood Pressure at 4 and 12 Months
NCT00407537 (22) [back to overview]	Percentage of Participants at Conventional Treatment Goals According to Global and Local Guidelines for LDL at 4 and 12 Months
NCT00407537 (22) [back to overview]	Change From Baseline in DBP at Month 12
NCT00407537 (22) [back to overview]	Change From Baseline in Diastolic Blood Pressure (DBP) at Month 4
NCT00407537 (22) [back to overview]	Change From Baseline in SBP at Month 12
NCT00407537 (22) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) at Month 4
NCT00407537 (22) [back to overview]	European SCORE 10-year Risk of Fatal CVD at Month 4
NCT00407537 (22) [back to overview]	European Systematic COronary Risk Evaluation (SCORE) 10-year Risk of Fatal Cardiovascular Disease (CVD) at Month 12
NCT00407537 (22) [back to overview]	Framingham 10-year Risk of Stroke at Month 12
NCT00407537 (22) [back to overview]	Framingham 10-year Risk of Stroke at Month 4
NCT00407537 (22) [back to overview]	Framingham 10-year Risk of Total CHD at Month 4
NCT00407537 (22) [back to overview]	Change From Baseline in Lipid Parameters at Month 12
NCT00412113 (24) [back to overview]	Change From Baseline in LDL at Week 4.
NCT00412113 (24) [back to overview]	Change From Baseline in LDL at Week 6.
NCT00412113 (24) [back to overview]	Change From Baseline in Total Cholesterol (TC) to Week 6.
NCT00412113 (24) [back to overview]	Change From Baseline in Triglycerides (TG) at Week 6.
NCT00412113 (24) [back to overview]	Change From Baseline in Triglycerides (TG) to Week 4.
NCT00412113 (24) [back to overview]	Change From Baseline to Week 4 in Diastolic Blood Pressure (DBP)
NCT00412113 (24) [back to overview]	Change From Baseline to Week 4 in Framingham Predicted Absolute 10-year Risk.
NCT00412113 (24) [back to overview]	Change From Baseline to Week 4 in Pulse Rate
NCT00412113 (24) [back to overview]	Change From Baseline to Week 4 in Systolic Blood Pressure (SBP).
NCT00412113 (24) [back to overview]	Change From Baseline to Week 6 in Framingham Predicted Absolute 10-year Risk
NCT00412113 (24) [back to overview]	Change From Baseline to Week 6 in Pulse Rate
NCT00412113 (24) [back to overview]	Change From Baseline to Week 6 in Systolic Blood Pressure (SBP)
NCT00412113 (24) [back to overview]	Change in Total Cholesterol (TC) From Baseline to Week 4.
NCT00412113 (24) [back to overview]	Subjects With Blood Pressure (BP) <140/90 Millimeters of Mercury (mmHg) and Low Density Lipoprotein Cholesterol (LDL-C) <100 Milligrams Per Deciliter(mg/dL) at Week 6
NCT00412113 (24) [back to overview]	Subjects With Blood Pressure of <140/90 mmHg and LDL-C <100 mg/dL at Week 4
NCT00412113 (24) [back to overview]	Subjects With BP < 140/90 mmHg at Week 4
NCT00412113 (24) [back to overview]	Subjects With BP < 140/90 mmHg at Week 6
NCT00412113 (24) [back to overview]	Subjects With BP <140/90 mmHg and LDL-C <130 mg/dL at Week 6.
NCT00412113 (24) [back to overview]	Subjects With LDL-C < 100 mg/dL at Week 4
NCT00412113 (24) [back to overview]	Subjects With LDL-C < 100 mg/dL at Week 6
NCT00412113 (24) [back to overview]	Change From Baseline to Week 6 in Diastolic Blood Pressue (DBP)
NCT00412113 (24) [back to overview]	Subjects With BP <140/90 mmHg and LDL-C <130 mg/dL at Week 4.
NCT00412113 (24) [back to overview]	Change From Baseline in HDL at Week 6.
NCT00412113 (24) [back to overview]	Change From Baseline in High Density Lipoprotein (HDL) at Week 4.
NCT00413049 (6) [back to overview]	Percentage of Patients Achieving a Diastolic Response at the End of the Study (Week 8)
NCT00413049 (6) [back to overview]	Change in 24-hour Mean Ambulatory Diastolic and Systolic BP From Baseline at the End of the Study (Week 8)
NCT00413049 (6) [back to overview]	Percentage of Patients Achieving Diastolic Control at the End of the Study (Week 8)
NCT00413049 (6) [back to overview]	Percentage of Patients Achieving Overall Control at the End of the Study (Week 8)
NCT00413049 (6) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)
NCT00413049 (6) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)
NCT00413413 (5) [back to overview]	Percentage of Patients Achieving Diastolic Blood Pressure Control at the End of the Study (Week 8)
NCT00413413 (5) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)
NCT00413413 (5) [back to overview]	Percentage of Patients Achieving Overall Blood Pressure Control at the End of the Study (Week 8)
NCT00413413 (5) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)
NCT00413413 (5) [back to overview]	Percentage of Patients Achieving a Diastolic Blood Pressure Response at the End of the Study (Week 8)
NCT00415623 (10) [back to overview]	Change in Diastolic Blood Pressure (DBP) From Baseline to Week 8
NCT00415623 (10) [back to overview]	Change in Systolic Blood Pressure (SBP) From Baseline to Week 8
NCT00415623 (10) [back to overview]	Combined Mean Change in DBP From Baseline to Week 6 and Week 8 (Mean by Patient)
NCT00415623 (10) [back to overview]	Combined Mean Change in SBP From Baseline to Week 6 and Week 8 (Mean by Patient)
NCT00415623 (10) [back to overview]	Combined Number of Subjects Achieving the Target Blood Pressure Reduction Value and Whose SBP Decreased From Baseline by >= 10 mmHg at Both Weeks 6 and 8
NCT00415623 (10) [back to overview]	Combined Number of Subjects Achieving the Target Blood Pressure Reduction Value at Both Weeks 6 and 8
NCT00415623 (10) [back to overview]	Number of Subjects Achieving the Target Blood Pressure Reduction Value at Week 8
NCT00415623 (10) [back to overview]	Trough Plasma Concentrations of Amlodipine -Amlodipine 10 mg
NCT00415623 (10) [back to overview]	Trough Plasma Concentrations of Amlodipine -Amlodipine 5 mg
NCT00415623 (10) [back to overview]	Number of Subjects Achieving the Target Blood Pressure Reduction Value and Whose SBP Decreased From Baseline by >= 10 mmHg at Week 8
NCT00417170 (5) [back to overview]	Mean Change in Insulin Concentration as Measured During Oral Glucose Tolerance Test (OGTT) From Baseline and After 12 Weeks of Treatment
NCT00417170 (5) [back to overview]	Mean Change in Arterial Compliance as Measured by Pulse Wave Analysis From Baseline and After 12 Weeks of Treatment
NCT00417170 (5) [back to overview]	Mean Change From Baseline in Inflammatory Marker ( C-peptide) as Measured During Oral Glucose Tolerance Test (OGTT) From Baseline and After 12 Weeks of Treatment [Time Frame: At Baseline and After 12 Weeks of Treatment
NCT00417170 (5) [back to overview]	Mean Change in Insulin Sensitivity as Measured by Glucose Infusion Rate (Last 30 Minutes) From Baseline and After 12 Weeks of Treatment.
NCT00417170 (5) [back to overview]	Mean Change in Endothelial Function as Measured by Myocardial Blood Flow (MBF) From Baseline and After 12 Weeks of Treatment
NCT00425373 (5) [back to overview]	Percentage of Patients Achieving MSDBP < 90 mm Hg and MSSBP < 140 mm Hg at the End of the Study (Week 8)
NCT00425373 (5) [back to overview]	Percentage of Patients Achieving MSDBP < 90mmHg at the End of the Study (Week 8)
NCT00425373 (5) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to End of Study (Week 8)
NCT00425373 (5) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to End of Study (Week 8)
NCT00425373 (5) [back to overview]	Percentage of Patients Achieving MSDBP < 90 mmHg or a => 10 mm Hg Decrease Compared to Baseline at the End of the Study (Week 8)
NCT00437645 (5) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to Week 8
NCT00437645 (5) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to Week 8
NCT00437645 (5) [back to overview]	Percentage of Patients With Peripheral Edema From Baseline to Week 8
NCT00437645 (5) [back to overview]	Percentage of Patients Achieving a Systolic Response at Weeks 4, 8, and 12
NCT00437645 (5) [back to overview]	Change in Mean Sitting Systolic and Diastolic Blood Pressure (msSBP, msDBP) From Baseline to Weeks 4, 8, and 12
NCT00439738 (7) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (MSSBP)
NCT00439738 (7) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (MSDBP)
NCT00439738 (7) [back to overview]	Change From Baseline in Postprandial Glucose
NCT00439738 (7) [back to overview]	Change From Baseline in Postprandial Non-esterified Fatty Acids
NCT00439738 (7) [back to overview]	Change From Baseline in Postprandial Insulin
NCT00439738 (7) [back to overview]	Number of Patients Achieving Blood Pressure (BP)Control by Visit (< 130/80 mm Hg)
NCT00439738 (7) [back to overview]	Number of Patients Achieving Blood Pressure (BP) Control by Visit (< 140/90 mm Hg)
NCT00443456 (12) [back to overview]	Number of Subjects Whose Blood Pressure Reached Target Blood Pressure Reduction Value and Systolic Blood Pressure Had Decreased by 10 mmHg or More From Baseline in the Preceding Study in Treatment Groups With or Without Concomitant Antihypertensive Agent
NCT00443456 (12) [back to overview]	Number of Subjects Whose Blood Pressure Reached Target Blood Pressure Reduction Value and Systolic Blood Pressure Had Decreased by 10 mmHg or More From Baseline in the Preceding Study
NCT00443456 (12) [back to overview]	Number of Subjects Whose Blood Pressure Reached Target Blood Pressure Reduction Value in Treatment Groups With or Without Concomitant Antihypertensive Agent
NCT00443456 (12) [back to overview]	Change in Systolic Blood Pressure From Baseline of This Long-term Study
NCT00443456 (12) [back to overview]	Number of Subjects Whose Blood Pressure Reached Target Blood Pressure Reduction Value
NCT00443456 (12) [back to overview]	Change in Diastolic Blood Pressure From Baseline of This Long-term Study
NCT00443456 (12) [back to overview]	Change in Diastolic Blood Pressure From Baseline of the Preceding Study in Treatment Groups With or Without Concomitant Antihypertensive Agent
NCT00443456 (12) [back to overview]	Change in Diastolic Blood Pressure From Baseline of the Preceding Study
NCT00443456 (12) [back to overview]	Change in Systolic Blood Pressure From Baseline of the Preceding Study
NCT00443456 (12) [back to overview]	Change in Systolic Blood Pressure From Baseline of This Long-term Study in Treatment Groups With or Without Concomitant Antihypertensive Agent
NCT00443456 (12) [back to overview]	Change in Systolic Blood Pressure From Baseline of the Preceding Study in Treatment Groups With or Without Concomitant Antihypertensive Agent
NCT00443456 (12) [back to overview]	Change in Diastolic Blood Pressure From Baseline of This Long-term Study in Treatment Groups With or Without Concomitant Antihypertensive Agent
NCT00446563 (15) [back to overview]	Change From Baseline to the End of Study in Left Ventricular End-diastolic Volume (LVEDV) Normalized to Body Surface Area Assessed by MRI
NCT00446563 (15) [back to overview]	Change From Baseline to the End of Study in Left Ventricular End-Systolic Volume (LVESV) Assessed by MRI
NCT00446563 (15) [back to overview]	Change From Baseline to the End of Study in Left Ventricular End-Systolic Volume (LVESV) Normalized to Body Surface Area Assessed by MRI
NCT00446563 (15) [back to overview]	Change From Baseline to the End of Study in Left Ventricular Mass Index (LVMI) Normalized to Body Surface Area Assessed by MRI
NCT00446563 (15) [back to overview]	Change From Baseline to the End of Study in Posterior Wall Thickness Assessed by MRI
NCT00446563 (15) [back to overview]	Change From Baseline to the End of Study in the Ascending Aortic Diameter Assessed by MRI
NCT00446563 (15) [back to overview]	Percentage of Participants Achieving Target Blood Pressure at Week 52
NCT00446563 (15) [back to overview]	Percentage of Participants Who Experienced Adverse Events (AEs)
NCT00446563 (15) [back to overview]	Change From Baseline to the End of Study in Left Atrial (LA) Area Assessed by MRI
NCT00446563 (15) [back to overview]	Change From Baseline to the End of Study in Left Ventricular Ejection Fraction (LVEF) Assessed by MRI
NCT00446563 (15) [back to overview]	Change From Baseline to the End of Study in Left Ventricular End-diastolic Volume (LVEDV) Assessed by MRI
NCT00446563 (15) [back to overview]	Change From Baseline in Left Ventricular Mass Index (LVMI) Measured Via Magnetic Resonance Imaging (MRI)
NCT00446563 (15) [back to overview]	Change From Baseline to End of Study in Levels of High-sensitivity C-reactive Protein (Hs-CRP)
NCT00446563 (15) [back to overview]	Change From Baseline to End of Study in Levels of N-terminal Pro-B Type Natriuretic Peptide (NT-proBNP)
NCT00446563 (15) [back to overview]	Change From Baseline to the End of Study in Interventricular Septum Thickness (IVS) Assessed by MRI
NCT00498433 (11) [back to overview]	Part 2: Number of Participants With Reported Any Adverse Events, Serious Adverse Events and Death
NCT00498433 (11) [back to overview]	Part 1: Aliskiren Concentrations From Tissue at the End of Aliskiren Treatment Period
NCT00498433 (11) [back to overview]	Part 1: Amlodipine Concentrations From Plasma at the End of Amlodipine Treatment Period
NCT00498433 (11) [back to overview]	Part 1: Renin Concentrations From Plasma During Aliskiren Treatment Period
NCT00498433 (11) [back to overview]	Part 1: Aliskiren Concentrations From Interstitial Fluid (Microdialysis)at the End of Aliskiren Treatment Period
NCT00498433 (11) [back to overview]	Part 1: Angiotensin II Levels in Plasma During Aliskiren Treatment Period
NCT00498433 (11) [back to overview]	Part 1: Angiotensin II Levels in Plasma During Amlodipine Treatment Period
NCT00498433 (11) [back to overview]	Part 1: Renin Activity From Plasma During Aliskiren Treatment Period
NCT00498433 (11) [back to overview]	Part 1: Renin Activity From Plasma During Amlodipine Treatment Period
NCT00498433 (11) [back to overview]	Part 1: Aliskiren Concentrations From Plasma at the End of Aliskiren Treatment Period
NCT00498433 (11) [back to overview]	Part 1: Renin Concentrations From Plasma During Amlodipine Treatment Period
NCT00523549 (7) [back to overview]	Percent Change From Baseline in Vascular Stiffness
NCT00523549 (7) [back to overview]	Change in Ratio of Peak E Wave Velocity/Lateral Mitral Annular Myocardial Relaxation Velocity
NCT00523549 (7) [back to overview]	Change in Lateral Mitral Annular Myocardial Relaxation Velocity
NCT00523549 (7) [back to overview]	Change in Left Atrial Size
NCT00523549 (7) [back to overview]	Change in Estimated Central Aortic Pressure
NCT00523549 (7) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP)
NCT00523549 (7) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (msSBP)
NCT00523744 (12) [back to overview]	Change in Sitting Pulse Pressure During the Core Phase of the Study
NCT00523744 (12) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Extension Phase of the Study
NCT00523744 (12) [back to overview]	Percentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Core Phase of the Study
NCT00523744 (12) [back to overview]	Change in Sitting Pulse Rate During the Extension Phase of the Study
NCT00523744 (12) [back to overview]	Change in Sitting Pulse Rate During the Core Phase of the Study
NCT00523744 (12) [back to overview]	Percentage of Patients Who Achieved Normalized Blood Pressure During the Extension Phase of the Study
NCT00523744 (12) [back to overview]	Change in Sitting Pulse Pressure During the Extension Phase of the Study
NCT00523744 (12) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Core Phase of the Study
NCT00523744 (12) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Extension Phase of the Study
NCT00523744 (12) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Core Phase of the Study
NCT00523744 (12) [back to overview]	Percentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Extension Phase of the Study
NCT00523744 (12) [back to overview]	Percentage of Patients Who Achieved Normalized Blood Pressure During the Core Phase of the Study
NCT00527514 (6) [back to overview]	Change From Baseline in Mean 24-hour Systolic Blood Pressure Measured by Ambulatory Monitoring
NCT00527514 (6) [back to overview]	Change From Baseline in Cuff Systolic Blood Pressure for the Amlodipine 5mg Group.
NCT00527514 (6) [back to overview]	Change From Baseline in Cuff Systolic Blood Pressure for the Amlodipine 5mg + Olmesartan 40 mg Group
NCT00527514 (6) [back to overview]	Change From Baseline in Cuff Systolic Blood Pressure for the Amlodipine 10 mg + Olmesartan 40 mg Group
NCT00527514 (6) [back to overview]	Change From Baseline in Daytime and Nighttime Ambulatory Systolic Blood Pressure
NCT00527514 (6) [back to overview]	Change From Baseline in Cuff Systolic Blood Pressure for the Amlodipine 5mg + Olmesartan 20 mg Group.
NCT00530946 (11) [back to overview]	Percent Change in Triglycerides From Baseline to Each Observation Point
NCT00530946 (11) [back to overview]	Change in Systolic Blood Pressure
NCT00530946 (11) [back to overview]	Change in Diastolic Blood Pressure From Baseline to Each Observation Point
NCT00530946 (11) [back to overview]	Percent Change in Low Density Lipoprotein-Cholesterol
NCT00530946 (11) [back to overview]	Change in Apolipoprotein B From Baseline to Each Observation Point
NCT00530946 (11) [back to overview]	Change in Low Density Lipoprotein-Cholesterol/ High Density Lipoprotein-Cholesterol Ratio (LDL-C/HDL-C) From Baseline to Each Observation Point
NCT00530946 (11) [back to overview]	Change in Systolic Blood Pressure From Baseline to Each Observation Point
NCT00530946 (11) [back to overview]	Change in Total Cholesterol/ High Density Lipoprotein-Cholesterol Ratio (TC/HDL-C) From Baseline to Each Observation Point
NCT00530946 (11) [back to overview]	Percent Change in High Density Lipoprotein-Cholesterol From Baseline to Each Observation Point
NCT00530946 (11) [back to overview]	Percent Change in Low Density Lipoprotein-Cholesterol From Baseline to Each Observation Point
NCT00530946 (11) [back to overview]	Percent Change in Total Cholesterol From Baseline to Each Observation Point
NCT00535925 (2) [back to overview]	"Number of Participants Who Achieved of BP, HbA1c and Total, HDL and LDL Cholesterol Goals at the End of Intervention Phase"
NCT00535925 (2) [back to overview]	"Number of Participants With Overall Fatal and Non-fatal, Major Adverse Cardiovascular Events (MACEs)"
NCT00542269 (10) [back to overview]	Change in HOMA-IR From Baseline to End of Study
NCT00542269 (10) [back to overview]	Percentage of Patients Who Developed Diabetes at End of Study
NCT00542269 (10) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study - Aliskiren/Ramipril/Amlodipine vs Ramipril/Amlodipine)
NCT00542269 (10) [back to overview]	Percentage of Patients Who Achieved Normalized Blood Pressure at End of Study
NCT00542269 (10) [back to overview]	Change in HbA1c (Glycated Hemoglobin) From Baseline to End of Study - Aliskiren/Amlodipine vs Ramipril/Amlodipine)
NCT00542269 (10) [back to overview]	Change in HbA1c (Glycated Hemoglobin) From Baseline to End of Study - Aliskiren/Ramipril/Amlodipine vs Ramipril/Amlodipine
NCT00542269 (10) [back to overview]	Change in HOMA-β From Baseline to End of Study
NCT00542269 (10) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study - Aliskiren/Amlodipine vs Ramipril/Amlodipine
NCT00542269 (10) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study - Aliskiren/Ramipril/Amlodipine vs Ramipril/Amlodipine
NCT00542269 (10) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study - Aliskiren/Amlodipine vs Ramipril/Amlodipine
NCT00550953 (8) [back to overview]	Clinically Relevant Abnormalities for Changes in Blood Pressure and Pulse Rate Due to Position Change, Seated Pulse Rate, Laboratory Parameters and ECG
NCT00550953 (8) [back to overview]	Percentage of Patients With Seated Trough Systolic Blood Pressure Less Than 140 mmHg at 8 Weeks (0 Percent at Baseline)
NCT00550953 (8) [back to overview]	Percentage of Patients Who Achieved an Adequate Response in Seated Trough Systolic Blood Pressure at 8 Weeks (0 Percent at Baseline)
NCT00550953 (8) [back to overview]	Percentage of Patients With Seated Trough Diastolic Blood Pressure Less Than 90 mmHg at 8 Weeks (0 Percent at Baseline)
NCT00550953 (8) [back to overview]	Decrease in Seated Systolic Blood Pressure From Baseline to 8 Weeks
NCT00550953 (8) [back to overview]	Percentage of Patients With Optimal, Normal or High Normal Blood Pressure at 8 Weeks (0 Percent at Baseline)
NCT00550953 (8) [back to overview]	Percentage of Patients Who Achieved an Adequate Response in Seated Trough Diastolic Blood Pressure at 8 Weeks (0 Percent at Baseline)
NCT00550953 (8) [back to overview]	Decrease in Seated Diastolic Blood Pressure From Baseline to 8 Weeks
NCT00553267 (10) [back to overview]	Change From Baseline in Trough Seated Diastolic Blood Pressure
NCT00553267 (10) [back to overview]	Trough Seated Diastolic Blood Pressure Control (Defined as < 90mmHg)
NCT00553267 (10) [back to overview]	Trough Seated SBP Control
NCT00553267 (10) [back to overview]	Trough Seated SBP Response
NCT00553267 (10) [back to overview]	Trough Seated BP Normality Classes
NCT00553267 (10) [back to overview]	Change From Baseline in Trough Seated Systolic Blood Pressure
NCT00553267 (10) [back to overview]	Trough Seated Diastolic Blood Pressure <80 mmHg
NCT00553267 (10) [back to overview]	Oedema Incidence Rate
NCT00553267 (10) [back to overview]	Peripheral Oedema Incidence Rate
NCT00553267 (10) [back to overview]	Trough Seated DBP Response
NCT00558064 (8) [back to overview]	Reduction From Reference Baseline in Mean Seated Systolic Blood Pressure at Trough (24-hour Post-dosing)
NCT00558064 (8) [back to overview]	Percentage of Patients Who Achieved an Adequate Response in Seated Trough Diastolic Blood Pressure at 8 Weeks (0 Percent at Baseline)
NCT00558064 (8) [back to overview]	Clinically Relevant Abnormalities for Blood Chemistry, Pulse Rate, Laboratory Parameters and ECG
NCT00558064 (8) [back to overview]	Percentage of Patients With Optimal, Normal or High Normal Blood Pressure at 8 Weeks (0 Percent at Baseline)
NCT00558064 (8) [back to overview]	Percentage of Patients Who Achieved an Adequate Response in Seated Trough Systolic Blood Pressure at 8 Weeks
NCT00558064 (8) [back to overview]	Percentage of Patients With Seated Trough Diastolic Blood Pressure Less Than 90 mmHg at 8 Weeks (0 Percent at Baseline)
NCT00558064 (8) [back to overview]	Percentage of Patients With Seated Trough Systolic Blood Pressure Less Than 140 mmHg at 8 Weeks (0 Percent at Baseline)
NCT00558064 (8) [back to overview]	Reduction From Reference Baseline in Mean Seated Diastolic Blood Pressure at Trough (24-hour Post-dosing)
NCT00558428 (8) [back to overview]	Trough Seated SBP Control
NCT00558428 (8) [back to overview]	Trough Seated Blood Pressure (BP) Normality Classes
NCT00558428 (8) [back to overview]	Trough Seated DBP Response
NCT00558428 (8) [back to overview]	Number of Patients With Oedema
NCT00558428 (8) [back to overview]	Change From Baseline in Trough Seated Systolic Blood Pressure (SBP)
NCT00558428 (8) [back to overview]	Trough Seated SBP Response
NCT00558428 (8) [back to overview]	Trough Seated Diastolic Blood Pressure Control
NCT00558428 (8) [back to overview]	Change From Baseline in Trough Seated Diastolic Blood Pressure (DBP)
NCT00568178 (5) [back to overview]	Double-Blind Treatment Phase: Percent Change From Baseline in Urinary Protein/Creatinine (Pr/Cr) Ratio (gm/gm) at Week 12
NCT00568178 (5) [back to overview]	Open Label Extension: Percent Change From Baseline of Urinary Pr/Cr Ratio (gm/gm) at Month 36
NCT00568178 (5) [back to overview]	Open Label Extension: Change From Baseline in Glomerular Filtration Rate (GFR) at Month 36
NCT00568178 (5) [back to overview]	Double-Blind Treatment Phase: Change From Baseline in Systolic Blood Pressure in Hypertensive Participants at Week 12
NCT00568178 (5) [back to overview]	Double-Blind Treatment Phase: Change From Baseline in Diastolic Blood Pressure in Hypertensive Participants at Week 12
NCT00591266 (15) [back to overview]	Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00591266 (15) [back to overview]	Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00591266 (15) [back to overview]	Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00591266 (15) [back to overview]	Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00591266 (15) [back to overview]	Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
NCT00591266 (15) [back to overview]	Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
NCT00591266 (15) [back to overview]	Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure
NCT00591266 (15) [back to overview]	Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00591266 (15) [back to overview]	Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00591266 (15) [back to overview]	Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.
NCT00591266 (15) [back to overview]	Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response
NCT00591266 (15) [back to overview]	Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg
NCT00591266 (15) [back to overview]	Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg
NCT00591266 (15) [back to overview]	Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00591266 (15) [back to overview]	Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00614380 (14) [back to overview]	Change in SBP From Last Available Trough in 1235.5 to Last Available Trough in 1235.7
NCT00614380 (14) [back to overview]	Change in DBP From Last Available Trough in 1235.5 to Last Available Trough in 1235.7
NCT00614380 (14) [back to overview]	Change From Baseline in Trough Seated Diastolic Blood Pressure
NCT00614380 (14) [back to overview]	Change From Baseline in Trough Seated Systolic Blood Pressure
NCT00614380 (14) [back to overview]	Additional Reduction in SBP by Use of Additional Antihypertensive Therapy
NCT00614380 (14) [back to overview]	Additional Reduction in DBP by Use of Additional Antihypertensive Therapy
NCT00614380 (14) [back to overview]	Trough Seated Systolic Blood Pressure (SBP) Control
NCT00614380 (14) [back to overview]	Trough Seated SBP Response
NCT00614380 (14) [back to overview]	Trough Seated Diastolic Blood Pressure (DBP) Control
NCT00614380 (14) [back to overview]	Trough Seated DBP Response
NCT00614380 (14) [back to overview]	Trough DBP Control Pre- and Post- Uptitration
NCT00614380 (14) [back to overview]	Trough Blood Pressure (BP) Normality Classes
NCT00614380 (14) [back to overview]	Patients Requiring Additional Antihypertensive Therapy to Achieve DBP Control
NCT00614380 (14) [back to overview]	Time to First Additional Antihypertensive
NCT00618774 (13) [back to overview]	Seated DBP Control Rate at Trough After 6 and 12 Months
NCT00618774 (13) [back to overview]	Change From Baseline in Seated Diastolic Blood Pressure at Week 8
NCT00618774 (13) [back to overview]	Change From Baseline in Seated Systolic Blood Pressure at Week 8
NCT00618774 (13) [back to overview]	Percentage of Participants Who Experienced Adverse Events
NCT00618774 (13) [back to overview]	Seated DBP Control Rate at Trough After 8 Weeks
NCT00618774 (13) [back to overview]	Seated SBP Control Rate at Trough After 8 Weeks
NCT00618774 (13) [back to overview]	Change From Baseline in Seated Diastolic Blood Pressure
NCT00618774 (13) [back to overview]	Change From Baseline in Seated Systolic Blood Pressure
NCT00618774 (13) [back to overview]	Clinically Relevant Abnormalities for Changes in Blood Pressure and Pulse Rate Due to Position Change, Seated Pulse Rate, Laboratory Parameters and ECG
NCT00618774 (13) [back to overview]	Seated Blood Pressure Normalisation at Trough
NCT00618774 (13) [back to overview]	Seated DBP Response Rate at Trough
NCT00618774 (13) [back to overview]	Seated SBP Control Rate at Trough After 6 and 12 Months
NCT00618774 (13) [back to overview]	Seated SBP Response Rate at Trough
NCT00624052 (14) [back to overview]	Additional Reduction in DBP by Use of Additional Antihypertensive Therapy
NCT00624052 (14) [back to overview]	Additional Reduction in SBP by Use of Additional Antihypertensive Therapy
NCT00624052 (14) [back to overview]	Change From Baseline to End of Study in Trough Seated Diastolic Blood Pressure
NCT00624052 (14) [back to overview]	Change From Baseline to End of Study in Trough Seated Systolic Blood Pressure
NCT00624052 (14) [back to overview]	Trough Seated DBP Response
NCT00624052 (14) [back to overview]	Change in DBP From Last Available Trough in NCT00553267 to Last Available Trough in NCT00624052
NCT00624052 (14) [back to overview]	Change in SBP From Last Available Trough in NCT00553267 to Last Available Trough in NCT00624052
NCT00624052 (14) [back to overview]	Time to First Additional Antihypertensive
NCT00624052 (14) [back to overview]	Trough Seated Diastolic Blood Pressure (DBP) Control
NCT00624052 (14) [back to overview]	Trough Seated Systolic Blood Pressure (SBP) Control
NCT00624052 (14) [back to overview]	Number of Patients Requiring Additional Antihypertensive Therapy to Achieve DBP Control
NCT00624052 (14) [back to overview]	Trough BP Normality Classes
NCT00624052 (14) [back to overview]	Trough DBP Control Pre- and Post- Uptitration
NCT00624052 (14) [back to overview]	Trough Seated SBP Response
NCT00626743 (2) [back to overview]	Maximal Change From Baseline in Standing DBP
NCT00626743 (2) [back to overview]	Maximal Change From Baseline in Standing SBP
NCT00649389 (4) [back to overview]	Change in Mean 24-hour Ambulatory Blood Pressure From Baseline to Week 12 or Early Termination
NCT00649389 (4) [back to overview]	Percentage of Subjects Who Reached Blood Pressure Goal (<140/90 mmHg; <130/80 mmHg for Subjects With Diabetes, Chronic Renal Disease, or Chronic Cardiovascular Disease)by 12 Weeks
NCT00649389 (4) [back to overview]	Change in Seated Systolic Blood Pressure From Baseline to Week 12
NCT00649389 (4) [back to overview]	Change From Baseline to Week 12 in Seated Diastolic Blood Pressure (SeDBP).
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Last 4 Hour Ambulatory Blood Pressure Thresholds at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 9
NCT00654745 (29) [back to overview]	Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 6
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 6
NCT00654745 (29) [back to overview]	Change From Week 0 (Baseline) in Mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Systolic Blood Pressure (SBP) After 12 Weeks of Active Treatment
NCT00654745 (29) [back to overview]	Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 3
NCT00654745 (29) [back to overview]	Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 18
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Daytime Ambulatory Blood Pressure Thresholds at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 9
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Nighttime Ambulatory Blood Pressure Thresholds at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Last 2 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Last 2 Hour Ambulatory Blood Pressure Thresholds at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Daytime Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12
NCT00654745 (29) [back to overview]	Change in Mean Seated Systolic Blood Pressure (SeSBP) From Week 0 (Baseline) After 3, 6, 9, 12, 15, and 18 Weeks
NCT00654745 (29) [back to overview]	Change in Mean Seated Diastolic Blood Pressure (SeDBP) From Week 0 (Baseline) After 3, 6, 9, 12, 15, and 18 Weeks
NCT00654745 (29) [back to overview]	Change From Week 0 (Baseline) in Mean ABPM SBP After 12 Weeks of Active Treatment
NCT00654745 (29) [back to overview]	Change From Week 0 (Baseline) in Mean ABPM Diastolic Blood Pressure (DBP) After 12 Weeks of Active Treatment
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean 24-hour Ambulatory Blood Pressure Thresholds at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean 24 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 15
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Last 4 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Last 6 Hour Ambulatory Blood Pressure Thresholds at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Last 6 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Nighttime Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 15
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 18
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 3
NCT00661895 (1) [back to overview]	Percentage of Subjects Achieving Blood Pressure Goals
NCT00666536 (6) [back to overview]	Change From Baseline to Weeks 2, 8 and 12 in MSDBP
NCT00666536 (6) [back to overview]	Change From Baseline to Week 4 in Mean Sitting Diastolic Blood Pressure (MSDBP)
NCT00666536 (6) [back to overview]	Change From Baseline to Weeks 2, 8 and 12 in MSSBP
NCT00666536 (6) [back to overview]	Change From Baseline to Week 4 in Mean Sitting Systolic Blood Pressure (MSSBP)
NCT00666536 (6) [back to overview]	Percentage of Patients Achieving BP Goal of MSSBP < 140mmHg at Weeks 2, 4, 8 and 12
NCT00666536 (6) [back to overview]	Percentage of Patients Achieving the Blood Pressure (BP) Goal of < 140/90 mmHg at Weeks 2,4,8 and 12
NCT00667719 (6) [back to overview]	Percentage of Participants Who Achieved a Blood Pressure Response in Mean Sitting Diastolic Blood Pressure
NCT00667719 (6) [back to overview]	Percentage of Participants Achieving the Blood Pressure Control Target of <140/90 mmHg
NCT00667719 (6) [back to overview]	Number of Participants With Any Adverse Events (AEs), Serious Adverse Events (SAEs) and Death
NCT00667719 (6) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)
NCT00667719 (6) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)
NCT00667719 (6) [back to overview]	Percentage of Participants Who Achieved a Blood Pressure Response in Mean Sitting Systolic Blood Pressure
NCT00687973 (11) [back to overview]	Change From Baseline of Central Systolic Blood Pressure (SBP) at Week 24 (Radial Measurement)
NCT00687973 (11) [back to overview]	Change From Baseline of SBP/DBP at Week 24 (Office BP)
NCT00687973 (11) [back to overview]	Change From Baseline of Brachial SBP/DBP at Week 24 (Tonometry Center)
NCT00687973 (11) [back to overview]	Change From Baseline of Pulse Wave Velocity at Week 24 (Radial Measurement)
NCT00687973 (11) [back to overview]	Change From Baseline of Pulse Pressure at Week 24 (Office BP)
NCT00687973 (11) [back to overview]	Change From Baseline of Central Systolic Blood Pressure (SBP) at Week 8 (Radial Measurement)
NCT00687973 (11) [back to overview]	Change From Baseline of Central Pulse Pressure at Week 24 (Radial Measurement)
NCT00687973 (11) [back to overview]	Change From Baseline of Augmentation Index (Aix) at Week 8
NCT00687973 (11) [back to overview]	Change From Baseline of Aix Corrected to Heart Rate at Week 24
NCT00687973 (11) [back to overview]	Change From Baseline of Aix at Week 24
NCT00687973 (11) [back to overview]	Change From Baseline of Brachial Pulse Pressure at Week 24 (Tonometry Center)
NCT00699192 (5) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)
NCT00699192 (5) [back to overview]	Percentage of Patients Achieving a Systolic Blood Pressure Response at Week 8
NCT00699192 (5) [back to overview]	Percentage of Patients Achieving Overall Blood Pressure Control at the End of the Study (Week 8)
NCT00699192 (5) [back to overview]	Percentage of Patients Achieving Systolic Blood Pressure Control at the End of the Study (Week 8)
NCT00699192 (5) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)
NCT00700271 (11) [back to overview]	Absolute Reduction From Baseline in Nocturnal Mean Systolic Blood Pressure (SBP)/Diastolic Blood Pressure (DBP) on Ambulatory Blood Pressure Monitoring
NCT00700271 (11) [back to overview]	Mean Seated Systolic Blood Pressure (msSBP)/Mean Seated Diastolic Blood Pressure (msDBP) Variation Between Week 0 and Week 8 in Office Blood Pressure
NCT00700271 (11) [back to overview]	Absolute Reduction From Baseline in 6-hour Mean Systolic Blood Pressure (SBP)/Diastolic Blood Pressure (DBP) on Ambulatory Blood Pressure Monitoring
NCT00700271 (11) [back to overview]	Mean Seated Systolic Blood Pressure (msSBP)/Mean Seated Diastolic Blood Pressure (msDBP) Variation Between Week -4 to Week 8 in Office Blood Pressure
NCT00700271 (11) [back to overview]	Percentage of Participants With Nocturnal Mean Systolic Blood Pressure (SBP)/Diastolic Blood Pressure (DBP) < 120/70 mmHg at Endpoint With Ambulatory Blood Pressure Monitoring
NCT00700271 (11) [back to overview]	Absolute Reduction From Baseline in Diurnal Mean Systolic Blood Pressure (SBP)/Diastolic Blood Pressure (DBP) on Ambulatory Blood Pressure Monitoring
NCT00700271 (11) [back to overview]	Absolute Reduction From Baseline in 24-hour Mean Diastolic Blood Pressure (DBP) on Ambulatory Blood Pressure Monitoring
NCT00700271 (11) [back to overview]	Absolute Reduction From Baseline in 24-hour Mean Systolic Blood Pressure (SBP) on Ambulatory Blood Pressure Monitoring
NCT00700271 (11) [back to overview]	Percentage of Participants With 24-hour Mean Systolic Blood Pressure (SBP)/Diastolic Blood Pressure (DBP) < 125/80 mmHg at Endpoint With Ambulatory Blood Pressure Monitoring
NCT00700271 (11) [back to overview]	Percentage of Participants With Diurnal Mean Systolic Blood Pressure (SBP)/Diastolic Blood Pressure (DBP) < 135/85 mmHg at Endpoint With Ambulatory Blood Pressure Monitoring
NCT00700271 (11) [back to overview]	Percentage of Participants With Controlled Office Mean Seated Systolic Blood Pressure (msSBP)/Mean Seated Diastolic Blood Pressure (msDBP) at Endpoint
NCT00739596 (5) [back to overview]	Percentage of Participants Achieving BP Control After 8 Weeks of Treatment
NCT00739596 (5) [back to overview]	Percentage of Responders After 8 Weeks of Treatment.
NCT00739596 (5) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (MSDBP) After 8 Weeks of Treatment
NCT00739596 (5) [back to overview]	Change in Mean Sitting Pulse Pressure (MSPP) After 8 Weeks of Treatment
NCT00739596 (5) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (MSSBP) After 8 Weeks of Treatment
NCT00739973 (27) [back to overview]	Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Aliskiren 300 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)
NCT00739973 (27) [back to overview]	Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)
NCT00739973 (27) [back to overview]	Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
NCT00739973 (27) [back to overview]	Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)
NCT00739973 (27) [back to overview]	Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Aliskiren 150 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
NCT00739973 (27) [back to overview]	Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Aliskiren 150 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)
NCT00739973 (27) [back to overview]	Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
NCT00739973 (27) [back to overview]	Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)
NCT00739973 (27) [back to overview]	Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
NCT00739973 (27) [back to overview]	Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
NCT00739973 (27) [back to overview]	Percentage of Patients With Blood Pressure Control (msSBP < 140 mm Hg and msDBP < 90 mm Hg) at End of Study
NCT00739973 (27) [back to overview]	Percentage of Patients Achieving a Successful Systolic Blood Pressure Response
NCT00739973 (27) [back to overview]	Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)
NCT00739973 (27) [back to overview]	Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
NCT00739973 (27) [back to overview]	Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Aliskiren 300 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)
NCT00739973 (27) [back to overview]	Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
NCT00739973 (27) [back to overview]	Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)
NCT00739973 (27) [back to overview]	Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
NCT00739973 (27) [back to overview]	Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)
NCT00739973 (27) [back to overview]	Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Aliskiren 300 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
NCT00739973 (27) [back to overview]	Percentage of Patients Achieving a Successful Diastolic Blood Pressure Response
NCT00739973 (27) [back to overview]	Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
NCT00739973 (27) [back to overview]	Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)
NCT00739973 (27) [back to overview]	Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)
NCT00739973 (27) [back to overview]	Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Aliskiren 150 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
NCT00739973 (27) [back to overview]	Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Aliskiren 150 mg on Change in Mean Sitting Systolic Blood Pressure (mssBP)
NCT00739973 (27) [back to overview]	Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Aliskiren 300 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
NCT00765674 (4) [back to overview]	Change in Mean 24-hour Ambulatory Systolic and Diastolic Blood Pressure From Baseline to End of Study (Week 8)
NCT00765674 (4) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)
NCT00765674 (4) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)
NCT00765674 (4) [back to overview]	Percentage of Patients Achieving Blood Pressure Control at the End of the Study (Week 8)
NCT00765947 (4) [back to overview]	Changes From Baseline to Week 24 in Mean Sitting Systolic Blood Pressure [msSBP] and Mean Sitting Diastolic Blood Pressure [msDBP]
NCT00765947 (4) [back to overview]	Percentage of Participants (Defined as Estimated Cumulative Control Rate) Reaching Blood Pressure Target in a Stepped Care, Aliskiren-based Regimen
NCT00765947 (4) [back to overview]	Percentage of Patients (Defined as Estimated Cumulative Control Rate) Reaching Blood Pressure Target in a Stepped-care, Aliskiren-based Regimen by Patient Subgroups of Mild and Moderate Hypertensive Patients, and Non-diabetic and Diabetic Patients.
NCT00765947 (4) [back to overview]	Percent of Responders for Mean Sitting Systolic Blood Pressure [msSBP] and for Mean Sitting Diastolic Blood Pressure [msDBP]
NCT00777946 (6) [back to overview]	Number of Participants With Serious Adverse Events and Adverse Events
NCT00777946 (6) [back to overview]	Percentage of Participants Achieving Blood Pressure Control
NCT00777946 (6) [back to overview]	Percentage of Participants Achieving a Systolic Blood Pressure Response
NCT00777946 (6) [back to overview]	Percentage of Participants Achieving a Diastolic Blood Pressure Response
NCT00777946 (6) [back to overview]	Change From Baseline to End of Study in the Mean Sitting Systolic Blood Pressure (msSBP)
NCT00777946 (6) [back to overview]	Change From Baseline to End of Study in the Mean Sitting Diastolic Blood Pressure (msDBP)
NCT00778921 (3) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study
NCT00778921 (3) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study
NCT00778921 (3) [back to overview]	Number of Patients With Any Adverse Event and/or Serious Adverse Event in the Double-blind Period by Treatment Group
NCT00787605 (6) [back to overview]	Evaluate the Safety and Tolerability
NCT00787605 (6) [back to overview]	Percentage of Responders
NCT00787605 (6) [back to overview]	Biomarker Measurements
NCT00787605 (6) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)
NCT00787605 (6) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)
NCT00787605 (6) [back to overview]	Percentage of Patients Achieving Blood Pressure Control
NCT00789321 (2) [back to overview]	Change From Baseline in Foot Volume by Water Displacement (Weight of Water Displaced) at Week 2
NCT00789321 (2) [back to overview]	Change From Baseline in Segmental Bioimpedance Measurements at 10 Kilohertz (KHz) at Week 2
NCT00791258 (59) [back to overview]	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Change From Baseline to Week 12 in Ambulatory Systolic and Diastolic Blood Pressure Values
NCT00791258 (59) [back to overview]	The Percentage of Subjects Achieving Seated Diastolic BP Goal (<90 mmHg for Non-diabetics or < 80 mmHg for Subjects With Diabetes) From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	The Percentage of Subjects Who Achieve BP Goal (<140/90 mmHg for Non-diabetics or <130/80 mmHg for Diabetics) From Baseline to 12 and 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	The Percentage of Patients Who Achieve Seated Systolic Blood Pressure Goal (<140 mm Hg for Non-diabetics and <130 mm Hg for Diabetics) From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	Change From Baseline to Week 20 in Ambulatory Systolic and Diastolic Blood Pressure Values
NCT00791258 (59) [back to overview]	Change in Mean Seated Diastolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Change in Mean Seated Systolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00797862 (7) [back to overview]	Percentage of Participants Achieving Overall Blood Pressure Control at 8, 16, 24 and 32 Weeks Endpoints
NCT00797862 (7) [back to overview]	Overall Mean Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Over 8, 16 and 24 Weeks
NCT00797862 (7) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at Week 24
NCT00797862 (7) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) at Week 32
NCT00797862 (7) [back to overview]	Overall Mean Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) Over 8, 16, and 24 Weeks
NCT00797862 (7) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at Week 32
NCT00797862 (7) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) at Week 24
NCT00818779 (5) [back to overview]	Plasminogen Activator Inhibitor 1
NCT00818779 (5) [back to overview]	Serum Level of Nitric Oxide
NCT00818779 (5) [back to overview]	Serum Level of Intracellular Cell Adhesion Molecule
NCT00818779 (5) [back to overview]	Serum Level of Vascular Cell Adhesion Molecule
NCT00818779 (5) [back to overview]	Serum Level of C-reactive Protein
NCT00834977 (9) [back to overview]	AUC0-inf - Benazepril
NCT00834977 (9) [back to overview]	AUC0-t - Amlodipine
NCT00834977 (9) [back to overview]	AUC0-inf - Benazeprilat
NCT00834977 (9) [back to overview]	AUC0-t - Benazaprilat
NCT00834977 (9) [back to overview]	AUC0-inf - Amlodipine
NCT00834977 (9) [back to overview]	AUC0-t - Benazepril
NCT00834977 (9) [back to overview]	Cmax - Amlodipine
NCT00834977 (9) [back to overview]	Cmax - Benazepril
NCT00834977 (9) [back to overview]	Cmax - Benazeprilat
NCT00835367 (9) [back to overview]	Cmax - Benazepril
NCT00835367 (9) [back to overview]	Cmax - Benazeprilat
NCT00835367 (9) [back to overview]	AUC0-t - Amlodipine
NCT00835367 (9) [back to overview]	AUC0-inf - Amlodipine
NCT00835367 (9) [back to overview]	AUC0-inf - Benazepril
NCT00835367 (9) [back to overview]	AUC0-inf - Benazeprilat
NCT00835367 (9) [back to overview]	AUC0-t - Benazepril
NCT00835367 (9) [back to overview]	AUC0-t - Benazeprilat
NCT00835367 (9) [back to overview]	Cmax - Amlodipine
NCT00841542 (3) [back to overview]	AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)
NCT00841542 (3) [back to overview]	Cmax - Maximum Observed Concentration
NCT00841542 (3) [back to overview]	AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)
NCT00841672 (5) [back to overview]	Mean Sitting Systolic Blood Pressure (msSBP)
NCT00841672 (5) [back to overview]	Mean Sitting Diastolic Blood Pressure (msDBP)
NCT00841672 (5) [back to overview]	Systolic Blood Pressure Response
NCT00841672 (5) [back to overview]	Blood Pressure Control
NCT00841672 (5) [back to overview]	Diastolic Blood Pressure Response
NCT00841815 (3) [back to overview]	AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)
NCT00841815 (3) [back to overview]	Cmax - Maximum Observed Concentration
NCT00841815 (3) [back to overview]	AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)
NCT00853957 (6) [back to overview]	Percentage of Patients With Peripheral Edema by Visit
NCT00853957 (6) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)
NCT00853957 (6) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)
NCT00853957 (6) [back to overview]	Percentage of Patients Achieving Blood Pressure (BP) Control (<140/90 mmHg)
NCT00853957 (6) [back to overview]	Percentage of Responders (Patients With MSSBP < 140 mmHg or Decrease From Baseline of Greater Than or Equal to 20 mmHg)
NCT00853957 (6) [back to overview]	Change From Baseline in MSSBP at Week 1 and 4
NCT00860262 (35) [back to overview]	Patients Achieving Systolic Blood Pressure Response at Week 2
NCT00860262 (35) [back to overview]	Patients Achieving Systolic Blood Pressure Response at Week 4
NCT00860262 (35) [back to overview]	Patients Achieving Systolic Blood Pressure Response at Week 6
NCT00860262 (35) [back to overview]	Patients Achieving Systolic Blood Pressure Response at Week 8
NCT00860262 (35) [back to overview]	Patients Achieving Diastolic Blood Pressure Response at Week 2
NCT00860262 (35) [back to overview]	Change From Baseline in Trough Seated Diastolic Blood Pressure (DBP) at Week 8
NCT00860262 (35) [back to overview]	Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 1
NCT00860262 (35) [back to overview]	Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 2
NCT00860262 (35) [back to overview]	Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 4
NCT00860262 (35) [back to overview]	Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 6
NCT00860262 (35) [back to overview]	Change From Baseline in Trough Seated Systolic Blood Pressure (SBP) at Week 8
NCT00860262 (35) [back to overview]	Change From Baseline in Trough Seated Systolic Blood Pressure at Week 1
NCT00860262 (35) [back to overview]	Change From Baseline in Trough Seated Systolic Blood Pressure at Week 2
NCT00860262 (35) [back to overview]	Change From Baseline in Trough Seated Systolic Blood Pressure at Week 4
NCT00860262 (35) [back to overview]	Change From Baseline in Trough Seated Systolic Blood Pressure at Week 6
NCT00860262 (35) [back to overview]	Number of Patients Achieving Various Blood Pressure Response Levels at Week 1
NCT00860262 (35) [back to overview]	Number of Patients Achieving Various Blood Pressure Response Levels at Week 2
NCT00860262 (35) [back to overview]	Patients Achieving Blood Pressure Control at Week 1
NCT00860262 (35) [back to overview]	Patients Achieving Blood Pressure Control at Week 2
NCT00860262 (35) [back to overview]	Patients Achieving Blood Pressure Control at Week 4
NCT00860262 (35) [back to overview]	Patients Achieving Blood Pressure Control at Week 6
NCT00860262 (35) [back to overview]	Patients Achieving Blood Pressure Control at Week 8
NCT00860262 (35) [back to overview]	Patients Achieving Diastolic Blood Pressure Control at Week 1
NCT00860262 (35) [back to overview]	Patients Achieving Diastolic Blood Pressure Control at Week 2
NCT00860262 (35) [back to overview]	Patients Achieving Diastolic Blood Pressure Control at Week 4
NCT00860262 (35) [back to overview]	Patients Achieving Diastolic Blood Pressure Control at Week 6
NCT00860262 (35) [back to overview]	Patients Achieving Diastolic Blood Pressure Control at Week 8
NCT00860262 (35) [back to overview]	Patients Achieving Diastolic Blood Pressure Response at Week 1
NCT00860262 (35) [back to overview]	Patients Achieving Diastolic Blood Pressure Response at Week 4
NCT00860262 (35) [back to overview]	Patients Achieving Diastolic Blood Pressure Response at Week 6
NCT00860262 (35) [back to overview]	Patients Achieving Diastolic Blood Pressure Response at Week 8
NCT00860262 (35) [back to overview]	Patients Achieving Normal Blood Pressure Response at Week 4
NCT00860262 (35) [back to overview]	Patients Achieving Normal Blood Pressure Response at Week 6
NCT00860262 (35) [back to overview]	Patients Achieving Normal Blood Pressure Response at Week 8
NCT00860262 (35) [back to overview]	Patients Achieving Systolic Blood Pressure Response at Week 1
NCT00867490 (12) [back to overview]	Percentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Core Phase of the Study
NCT00867490 (12) [back to overview]	Percentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Core Phase of the Study
NCT00867490 (12) [back to overview]	Change in Sitting Pulse Pressure During the Extension Phase of the Study
NCT00867490 (12) [back to overview]	Change in Sitting Pulse Rate During the Extension Phase of the Study
NCT00867490 (12) [back to overview]	Percentage of Patients Who Achieved Normalized Blood Pressure During the Core Phase of the Study
NCT00867490 (12) [back to overview]	Change in Sitting Pulse Pressure During the Core Phase of the Study
NCT00867490 (12) [back to overview]	Percentage of Patients Who Achieved Normalized Blood Pressure During the Core Phase of the Study
NCT00867490 (12) [back to overview]	Change in Sitting Pulse Rate During the Core Phase of the Study
NCT00867490 (12) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Extension Phase of the Study
NCT00867490 (12) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Core Phase of the Study
NCT00867490 (12) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Extension Phase of the Study
NCT00867490 (12) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Core Phase of the Study
NCT00877929 (41) [back to overview]	Change From Baseline in Trough Seated Systolic Blood Pressure to Week 1
NCT00877929 (41) [back to overview]	BP Control (SBP<140 mmHg, DBP<90 mmHg) at Two Weeks
NCT00877929 (41) [back to overview]	Change From Baseline in Trough Seated Systolic Blood Pressure to Week 8
NCT00877929 (41) [back to overview]	SBP Control 130 at One Week
NCT00877929 (41) [back to overview]	SBP Control 130 at Six Weeks
NCT00877929 (41) [back to overview]	SBP Response 140 at One Week
NCT00877929 (41) [back to overview]	SBP Response 140 at Two Weeks
NCT00877929 (41) [back to overview]	BP Control (SBP<140 mmHg, DBP<90 mmHg) at Six Weeks
NCT00877929 (41) [back to overview]	BP Control (SBP<140 mmHg, DBP<90 mmHg) at One Week
NCT00877929 (41) [back to overview]	BP Control (SBP<140 mmHg, DBP<90 mmHg) at Four Weeks
NCT00877929 (41) [back to overview]	BP Control (SBP<130 mmHg, DBP<80 mmHg) at Two Weeks
NCT00877929 (41) [back to overview]	BP Control (SBP<130 mmHg, DBP<80 mmHg) at Six Weeks
NCT00877929 (41) [back to overview]	BP Control (SBP<130 mmHg, DBP<80 mmHg) at One Week
NCT00877929 (41) [back to overview]	BP Control (SBP<130 mmHg, DBP<80 mmHg) at Eight Weeks
NCT00877929 (41) [back to overview]	Blood Pressure (BP) Control (SBP<140 mmHg, DBP<90 mmHg) at Eight Weeks
NCT00877929 (41) [back to overview]	BP Control (SBP<130 mmHg, DBP<80 mmHg) at Four Weeks
NCT00877929 (41) [back to overview]	SBP Control 140 at Two Weeks
NCT00877929 (41) [back to overview]	SBP Response 130 at Eight Weeks
NCT00877929 (41) [back to overview]	SBP Response 130 at Four Weeks
NCT00877929 (41) [back to overview]	SBP Response 130 at One Week
NCT00877929 (41) [back to overview]	SBP Response 130 at Six Weeks
NCT00877929 (41) [back to overview]	SBP Response 130 at Two Weeks
NCT00877929 (41) [back to overview]	SBP Response 140 at Eight Weeks
NCT00877929 (41) [back to overview]	SBP Response 140 at Four Weeks
NCT00877929 (41) [back to overview]	SBP Control 130 at Four Weeks
NCT00877929 (41) [back to overview]	SBP Response 140 at Six Weeks
NCT00877929 (41) [back to overview]	Change From Baseline in Trough Seated Systolic Blood Pressure to Week 6
NCT00877929 (41) [back to overview]	Systolic Blood Pressure (SBP) Control 140 at Eight Weeks
NCT00877929 (41) [back to overview]	Change From Baseline in Trough Seated Systolic Blood Pressure to Week 4
NCT00877929 (41) [back to overview]	Change From Baseline in Trough Seated Systolic Blood Pressure to Week 2
NCT00877929 (41) [back to overview]	SBP Control 130 at Two Weeks
NCT00877929 (41) [back to overview]	SBP Control 140 at Four Weeks
NCT00877929 (41) [back to overview]	SBP Control 140 at Six Weeks
NCT00877929 (41) [back to overview]	SBP Control 140 at One Week
NCT00877929 (41) [back to overview]	Change From Baseline in Urine Albumin:Creatinine Ratio (UACR)
NCT00877929 (41) [back to overview]	SBP Control 130 at Eight Weeks
NCT00877929 (41) [back to overview]	DBP Response at Week Two
NCT00877929 (41) [back to overview]	DBP Response at Week One
NCT00877929 (41) [back to overview]	DBP Response at Week Four
NCT00877929 (41) [back to overview]	DBP Response at Six Weeks
NCT00877929 (41) [back to overview]	DBP Response at Eight Weeks
NCT00890591 (4) [back to overview]	Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 (Olmesartan 20 mg Monotherapy)
NCT00890591 (4) [back to overview]	Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 in Third Titrated Group (Olmesartan + Hydrochorothiazide + Amlodipine)
NCT00890591 (4) [back to overview]	Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 in First Titrated Group (Olmesartan 20 mg + 12.5 mg Hydrochlorothiazide)
NCT00890591 (4) [back to overview]	Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 in Second Titrated Group (Olmesartan 40 mg + 25 mg Hydrochlorothiazide)
NCT00902304 (12) [back to overview]	Change in Self-care Behavior Score From Baseline to Week 26
NCT00902304 (12) [back to overview]	Number of 'Early Responder' Patients Who Achieve Individualized Blood Pressure Control After 1 or 2 Adjustments
NCT00902304 (12) [back to overview]	Number of Patients With Depression
NCT00902304 (12) [back to overview]	Number of Patients With Major Clinical Endpoints
NCT00902304 (12) [back to overview]	Participants With End Organ Disease at Baseline and Week 26
NCT00902304 (12) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure
NCT00902304 (12) [back to overview]	Change in Absolute Cardiovascular Risk Score
NCT00902304 (12) [back to overview]	Change in Center for Epidemiologic Studies Depression (CES-D) Score From Baseline to Week 26
NCT00902304 (12) [back to overview]	Change in Mean Sitting Systolic Blood Pressure
NCT00902304 (12) [back to overview]	Change in the EQ-5D Score
NCT00902304 (12) [back to overview]	Number of Patients With at Least One Adverse Events Attributable to Anti-hypertensive Therapy
NCT00902304 (12) [back to overview]	Percentage of Patients Who Have Achieved Their Pre-specified (Individualized National Heart Foundation of Australia Criteria) Blood Pressure (BP) Target
NCT00902538 (10) [back to overview]	Change in 24-hour Diastolic Blood Pressure (DBP) Assessed by 24-hour Ambulatory Blood Pressure Measurement (ABPM).
NCT00902538 (10) [back to overview]	Change in 24-hour Systolic Blood Pressure Assessed by 24-hour Ambulatory Blood Pressure Measurement.
NCT00902538 (10) [back to overview]	Change in Seated Diastolic Blood Pressure (SeDBP) of the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg vs. OM/AML 40/10 mg
NCT00902538 (10) [back to overview]	Change in Seated Systolic Blood Pressure (SeSBP) of the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg vs. OM/AML 40/10 mg
NCT00902538 (10) [back to overview]	In Non-responders, the Change in 24-hour Diastolic Blood Pressure Assessed by 24-hour Ambulatory Blood Pressure Measurement.
NCT00902538 (10) [back to overview]	In Non-responders, the Change in 24-hour Systolic Blood Pressure Assessed by 24-hour Ambulatory Blood Pressure Measurement.
NCT00902538 (10) [back to overview]	In Non-responders, the Change in Seated Systolic Blood Pressure Associated With the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg.
NCT00902538 (10) [back to overview]	Number of Subjects Achieving Blood Pressure (BP) Goal at Week 16.
NCT00902538 (10) [back to overview]	In Non-responders, the Change in Seated Diastolic Blood Pressure Associated With the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg.
NCT00902538 (10) [back to overview]	In Non-responders, the Number of Subject Meeting Their Blood Pressure Goals Associated With the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg.
NCT00923091 (10) [back to overview]	Change in Seated Diastolic Blood Pressure (SeDBP).
NCT00923091 (10) [back to overview]	Change in Seated Diastolic Blood Pressure From Week 22 to Week 26
NCT00923091 (10) [back to overview]	Change in Seated Systolic Blood Pressure (SeDBP) During Open-Label Period VI (Titration Effect From OM/AML/HCTZ 40/5/25 to 40/10/25.
NCT00923091 (10) [back to overview]	Change in Seated Systolic Blood Pressure (SeDBP).
NCT00923091 (10) [back to overview]	Change in Seated Systolic Blood Pressure From Week 22 to Week 26
NCT00923091 (10) [back to overview]	Number of Subjects Reaching Blood Pressure Goal at Week 10
NCT00923091 (10) [back to overview]	Change in Seated Diastolic Blood Pressure From Week 18 to Week 22
NCT00923091 (10) [back to overview]	Change in Seated Systolic Blood Pressure From Week 18 to Week 22
NCT00923091 (10) [back to overview]	Number of Subjects Reaching Blood Pressure Goal at Week 26
NCT00923091 (10) [back to overview]	Number of Subjects Reaching Blood Pressure Goal From Week 18 to Week 22
NCT00931710 (6) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure After 6 Weeks
NCT00931710 (6) [back to overview]	Change in Mean Sitting Systolic and Diastolic Blood Pressure After 12 Weeks
NCT00931710 (6) [back to overview]	Change in Mean Sitting Systolic Blood Pressure After 6 Weeks
NCT00931710 (6) [back to overview]	Cumulative Percentage of Treatment Responders
NCT00931710 (6) [back to overview]	Cumulative Percentage of Patients Achieving Blood Pressure Control
NCT00931710 (6) [back to overview]	Cumulative Percentage of Patients With Incidence of Peripheral Edema Before or at the Corresponding Visit
NCT00942994 (6) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 2 and Week 4
NCT00942994 (6) [back to overview]	Percentage of Responders (Defined as Patients With MSSBP < 140 mmHg or a Reduction From Baseline in MSSBP of ≥20 mmHg) During 8 Weeks.
NCT00942994 (6) [back to overview]	Percentage of Patients Achieving Blood Pressure Control (Defined as MSSBP < 140 mmHg and MSDBP < 90 mmHg) During 8 Weeks
NCT00942994 (6) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8
NCT00942994 (6) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 2 and Week 4
NCT00942994 (6) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8
NCT01001572 (5) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to Week 8 Endpoint
NCT01001572 (5) [back to overview]	Percentage of Participants With a Diastolic Blood Pressure Response at 8 Week Endpoint
NCT01001572 (5) [back to overview]	Percentage of Participants With Overall Blood Pressure Control at 8 Week Endpoint
NCT01001572 (5) [back to overview]	Percentage of Participants With Diastolic Blood Pressure Control at 8 Week Endpoint
NCT01001572 (5) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to Week 8 Endpoint
NCT01004614 (7) [back to overview]	Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast), Area Under the Plasma Concentration-Time Curve to Infinity (AUCinf)
NCT01004614 (7) [back to overview]	Time to Reach Maximum Observed Plasma Concentration (Tmax)
NCT01004614 (7) [back to overview]	Mean Residence Time (MRT)
NCT01004614 (7) [back to overview]	Maximum Observed Plasma Concentration (Cmax)
NCT01004614 (7) [back to overview]	Apparent Terminal Elimination Half-Life (T-half)
NCT01004614 (7) [back to overview]	Apparent Terminal Elimination Phase Rate Constant (Kel)
NCT01004614 (7) [back to overview]	Area Under the Concentration-Time Curve From Zero Time Until the Last Sampling Time (AUCt)
NCT01030458 (4) [back to overview]	Proportion of Patients Reaching Blood Pressure Control at the End of Follow-up
NCT01030458 (4) [back to overview]	Time to Blood Pressure Control
NCT01030458 (4) [back to overview]	Sitting Systolic Blood Pressure on Automated Measurement
NCT01030458 (4) [back to overview]	Side-effects to Study Medications
NCT01070043 (5) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) From Office Blood Pressure Measurement
NCT01070043 (5) [back to overview]	Number of Participants With Adverse Events During Double-blind Phase
NCT01070043 (5) [back to overview]	Change From Baseline in Mean Systolic Blood Pressure (mSBP) From Ambulatory Blood Pressure Measurement (ABPM) Over 24 Hours
NCT01070043 (5) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) From Office Blood Pressure Measurement
NCT01070043 (5) [back to overview]	Change From Baseline in Mean Diastolic Blood Pressure (mDBP) From Ambulatory Blood Pressure Measurement (ABPM) Over 24 Hours After 8 Weeks of Treatment During the Double-blind Phase
NCT01103960 (10) [back to overview]	DBP and SBP Control and Response After 8 Weeks of Treatment
NCT01103960 (10) [back to overview]	Number of Patients in Blood Pressure Categories Over Time
NCT01103960 (10) [back to overview]	Number of Patients in Blood Pressure Categories at 4 Weeks
NCT01103960 (10) [back to overview]	Change From Baseline in SBP After 4 Weeks of Treatment
NCT01103960 (10) [back to overview]	DBP and SBP Control and Response After 4 Weeks of Treatment
NCT01103960 (10) [back to overview]	Clinically Relevant Abnormalities for Physical Examination, Pulse Rate, Laboratory Parameters and ECG.
NCT01103960 (10) [back to overview]	Change From Baseline in DBP After 4 Weeks of Treatment
NCT01103960 (10) [back to overview]	Change From Baseline in DBP After 8 Weeks of Treatment
NCT01103960 (10) [back to overview]	Change From Baseline in DBP After 8 Weeks of Treatment in Chinese Patients
NCT01103960 (10) [back to overview]	Change From Baseline in SBP After 8 Weeks of Treatment
NCT01107743 (38) [back to overview]	Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Gender.
NCT01107743 (38) [back to overview]	Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Familial Hypercholesterolemia.
NCT01107743 (38) [back to overview]	Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Concomitant Drugs.
NCT01107743 (38) [back to overview]	Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Complications.
NCT01107743 (38) [back to overview]	Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Angina Pectoris.
NCT01107743 (38) [back to overview]	Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Age.
NCT01107743 (38) [back to overview]	Risk Factors for the Proportion of Responders for Hypertension -Complications.
NCT01107743 (38) [back to overview]	Number of Participants That Responded to Amlodipine/Atorvastatin Treatment With Hypertension.
NCT01107743 (38) [back to overview]	Number of Participants That Responded to Amlodipine/Atorvastatin Treatment With Hypercholesterolemia or Familial Hypercholesterolemia.
NCT01107743 (38) [back to overview]	Number of Participants That Responded to Amlodipine/Atorvastatin Treatment With Angina Pectoris.
NCT01107743 (38) [back to overview]	Risk Factors for the Proportion of Responders for Hypertension -Hypertension Severity.
NCT01107743 (38) [back to overview]	Risk Factors for the Proportion of Responders for Hypertension -Renal Dysfunction.
NCT01107743 (38) [back to overview]	Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hypertension.
NCT01107743 (38) [back to overview]	Risk Factors for the Proportion of Responders for Hypertension -Hepatic Dysfunction.
NCT01107743 (38) [back to overview]	Risk Factors for the Proportion of Responders for Hypertension -Gender.
NCT01107743 (38) [back to overview]	Risk Factors for the Proportion of Responders for Hypertension -Concomitant Drugs.
NCT01107743 (38) [back to overview]	Risk Factors for the Proportion of Responders for Hypertension -Age.
NCT01107743 (38) [back to overview]	Risk Factors for the Proportion of Responders for Hypercholesterolemia or Familial Hypercholesterolemia -Renal Dysfunction.
NCT01107743 (38) [back to overview]	Risk Factors for the Proportion of Responders for Hypercholesterolemia or Familial Hypercholesterolemia -Hepatic Dysfunction.
NCT01107743 (38) [back to overview]	Risk Factors for the Proportion of Responders for Hypercholesterolemia or Familial Hypercholesterolemia -Gender.
NCT01107743 (38) [back to overview]	Risk Factors for the Proportion of Responders for Hypercholesterolemia or Familial Hypercholesterolemia -Complications.
NCT01107743 (38) [back to overview]	Risk Factors for the Proportion of Responders for Hypercholesterolemia or Familial Hypercholesterolemia -Age.
NCT01107743 (38) [back to overview]	Risk Factors for the Proportion of Responders for Angina Pectoris -Renal Dysfunction.
NCT01107743 (38) [back to overview]	Risk Factors for the Proportion of Responders for Angina Pectoris -Hepatic Dysfunction.
NCT01107743 (38) [back to overview]	Risk Factors for the Proportion of Responders for Angina Pectoris -Concomitant Drugs.
NCT01107743 (38) [back to overview]	Risk Factor for the Proportion of Responders of Amlodipine/Atorvastatin Combination Tablets for Hypercholesterolemia or Familial Hypercholesterolemia - Hypercholesterolemia Expression Type.
NCT01107743 (38) [back to overview]	Number of Treatment Related Adverse Events.
NCT01107743 (38) [back to overview]	Risk Factors for the Proportion of Responders for Angina Pectoris -Complications.
NCT01107743 (38) [back to overview]	Risk Factors for the Proportion of Responders for Hypercholesterolemia or Familial Hypercholesterolemia -Concomitant Drugs.
NCT01107743 (38) [back to overview]	Number of Treatment Related Unlisted Adverse Events in Japanese Package Insert.
NCT01107743 (38) [back to overview]	Risk Factors for the Proportion of Responders for Angina Pectoris -Gender.
NCT01107743 (38) [back to overview]	Risk Factors for the Proportion of Responders for Angina Pectoris -Angina Pectoris Severity.
NCT01107743 (38) [back to overview]	Risk Factors for the Proportion of Responders for Angina Pectoris -Age.
NCT01107743 (38) [back to overview]	Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Renal Dysfunction.
NCT01107743 (38) [back to overview]	Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hypertension Severity.
NCT01107743 (38) [back to overview]	Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hypercholesterolemia.
NCT01107743 (38) [back to overview]	Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hypercholesterolemia Expression Type.
NCT01107743 (38) [back to overview]	Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hepatic Dysfunction.
NCT01118520 (2) [back to overview]	Change in the Growth Rate of Abdominal Aortic Aneurysm
NCT01118520 (2) [back to overview]	Number of Participants With Aneurysm Related Death
NCT01130168 (10) [back to overview]	TWA Change From Baseline (0 Hours) to 12 Hours in Peripheral SBP After A Single Dose of Treatment
NCT01130168 (10) [back to overview]	Change From Baseline (0 Hours) to Week 4 in Central DBP After Multiple Doses of Treatment
NCT01130168 (10) [back to overview]	Change From Baseline (0 Hours) to Week 4 in Central SBP After Multiple Doses of Treatment
NCT01130168 (10) [back to overview]	Change From Baseline (0 Hours) to Week 4 in Heart-Rate-Corrected AIx After Multiple Doses of Treatment
NCT01130168 (10) [back to overview]	Change From Baseline (0 Hours) to Week 4 in Peripheral DBP After Multiple Doses of Treatment
NCT01130168 (10) [back to overview]	Change From Baseline (0 Hours) to Week 4 in Peripheral SBP After Multiple Doses of Treatment
NCT01130168 (10) [back to overview]	Time-weighted Average (TWA) Change From Baseline (0 Hours) to 12 Hours in Heart-Rate-Corrected Augmentation Index (AIx) After A Single Dose of Treatment
NCT01130168 (10) [back to overview]	TWA Change From Baseline (0 Hours) to 12 Hours in Central Diastolic Blood Pressure (DBP) After A Single Dose of Treatment
NCT01130168 (10) [back to overview]	TWA Change From Baseline (0 Hours) to 12 Hours in Peripheral DBP After A Single Dose of Treatment
NCT01130168 (10) [back to overview]	TWA Change From Baseline (0 Hours) to 12 Hours in Central Systolic Blood Pressure (SBP) After A Single Dose of Treatment
NCT01134393 (9) [back to overview]	Percentage of Patients Achieving Blood Pressure (BP) Control After 12 Weeks of Treatment Using In-clinic BP Measurements.
NCT01134393 (9) [back to overview]	BP Control (Morning and Evening) After 12 Weeks of Treatment Using Home Blood Pressure Measurement (HBPM).
NCT01134393 (9) [back to overview]	BP Control After 4 and 8 Weeks of Treatment Using In-clinic BP Measurements.
NCT01134393 (9) [back to overview]	Change From Baseline Over Time in In-clinic Measured Mean Pulse Rate
NCT01134393 (9) [back to overview]	Change From Baseline Over Time in In-clinic Measured Mean SBP and Mean DBP
NCT01134393 (9) [back to overview]	DBP and SBP Control and Response Rates Morning and Evening Over Time HBPM Measurements
NCT01134393 (9) [back to overview]	Frequency of Patients Requiring Up-titration to Telmisartan 80mg Plus Amlodipine 10mg Combination (T80/A10) to Achieve Blood Pressure Control Over Time
NCT01134393 (9) [back to overview]	Percentage of Patients in Blood Pressure Categories Over Time
NCT01134393 (9) [back to overview]	DBP and SBP Control and Response Rates After 4, 8 and 12 Weeks of Treatment Using In-clinic BP Measurements
NCT01138826 (5) [back to overview]	Time to Reach Maximum Observed Plasma Concentration (Tmax)
NCT01138826 (5) [back to overview]	Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)]
NCT01138826 (5) [back to overview]	AUC From Time Zero to Last Quantifiable Concentration (AUClast)
NCT01138826 (5) [back to overview]	Maximum Observed Plasma Concentration (Cmax)
NCT01138826 (5) [back to overview]	Plasma Decay Half-Life (t1/2)
NCT01167153 (7) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) at the Study End Point (12 Weeks)
NCT01167153 (7) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at the Study End Point (12 Weeks)
NCT01167153 (7) [back to overview]	Change From Baseline in Sitting Pulse at 12 Weeks
NCT01167153 (7) [back to overview]	Percentage of Patients With Effective Systolic Blood Pressure (SBP) Control Rate and Effective Diastolic Blood Pressure (DBP) Control Rate at the Study End Point (12 Weeks)
NCT01167153 (7) [back to overview]	Change From Baseline in Orthostatic SBP and DBP at 12 Weeks
NCT01167153 (7) [back to overview]	Change From Baseline in Orthostatic Pulse at 12 Weeks
NCT01167153 (7) [back to overview]	Percentage of Patients in Whom Blood Pressure Target Was Achieved at the Study End Point at 12 Weeks
NCT01176032 (20) [back to overview]	Change From Baseline in Left Ventricular (LV) Function, LV Ejection Fraction (Teicholz), and LV Ejection Fraction (Simpson)
NCT01176032 (20) [back to overview]	Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Rate of Use of Added Antihypertensive Rescue Drugs
NCT01176032 (20) [back to overview]	Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Patients With SBP < 140 mmHg and DBP < 90 mmHg Compared to Baseline
NCT01176032 (20) [back to overview]	Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Patients With Satisfactory Response Rate
NCT01176032 (20) [back to overview]	Change From Baseline in Left Ventricular (LV) Function, LV End-diastolic Volume by Simpson's Rule, and LV End-systolic Volume by Simpson's Rule in Combination of Aliskiren With Amlodipine
NCT01176032 (20) [back to overview]	Change From Baseline in Biomarker Such as Aldosterone (Aldo) in Heart Disease
NCT01176032 (20) [back to overview]	Change From Baseline in Left Ventricular (LV) Function, LA (Left Atrium) Diameter
NCT01176032 (20) [back to overview]	Change From Baseline in C-terminal Propeptide of Procollagen Type I (PICP)
NCT01176032 (20) [back to overview]	Change From Baseline in Left Ventricular (LV) Function, LV Ejection Fraction (Teicholz), and LV Ejection Fraction (Simpson) in Combination of Aliskiren With Amlodipine
NCT01176032 (20) [back to overview]	Change From Baseline in Left Ventricular (LV) Function, LA (Left Atrium) Diameter in Combination of Aliskiren With Amlodipine
NCT01176032 (20) [back to overview]	Change From Baseline in Left Ventricular (LV) Function, Left Atrial Volume (Biplane Simpson's Method)
NCT01176032 (20) [back to overview]	Change From Baseline in Reduction of Left Ventricular Mass Index (LVMI)
NCT01176032 (20) [back to overview]	Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Reduction in Diastolic Blood Pressure (DBP)
NCT01176032 (20) [back to overview]	Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Reduction in Systolic Blood Pressure (SBP)
NCT01176032 (20) [back to overview]	Change From Baseline in Left Ventricular (LV) Function, LV End-diastolic Volume by Simpson's Rule, and LV End-systolic Volume by Simpson's Rule
NCT01176032 (20) [back to overview]	Change From Baseline of LVMI in Combination of Aliskiren With Amlodipine
NCT01176032 (20) [back to overview]	Change From Baseline in Left Ventricular (LV) Function, Left Atrial Volume (Biplane Simpson's Method) in Combination of Aliskiren With Amlodipine
NCT01176032 (20) [back to overview]	Change From Baseline in Biomarkers in Heart Disease
NCT01176032 (20) [back to overview]	Change From Baseline in Combination of Aliskiren With Amlodipine in Biomarkers of Heart Disease.
NCT01176032 (20) [back to overview]	Change From Baseline in Biomarker Such as Aldosterone (Aldo) in Heart Disease in Combination of Aliskiren With Amlodipine
NCT01177293 (5) [back to overview]	Plasma Decay Half-life (t1/2)
NCT01177293 (5) [back to overview]	Time to Reach Maximum Observed Plasma Concentration (Tmax)
NCT01177293 (5) [back to overview]	Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)]
NCT01177293 (5) [back to overview]	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
NCT01177293 (5) [back to overview]	Maximum Observed Plasma Concentration (Cmax)
NCT01181011 (20) [back to overview]	AUC_0-∞ of Amlodipine
NCT01181011 (20) [back to overview]	The Maximum Observed Plasma Concentration (Cmax) of Telmisartan
NCT01181011 (20) [back to overview]	V_z/F of Amlodipine
NCT01181011 (20) [back to overview]	Apparent Clearance of Telmisartan in Plasma Following Extravascular Administration (CL/F)
NCT01181011 (20) [back to overview]	Apparent Volume of Distribution During the Terminal Phase λz Following an Extravascular Administration (V_z/F) of Telmisartan
NCT01181011 (20) [back to overview]	Area Under the Concentration-time Curve of Telmisartan in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point (AUC_0-tz)
NCT01181011 (20) [back to overview]	Time to Attain Cmax (Tmax) of Telmisartan
NCT01181011 (20) [back to overview]	Tmax of Amlodipine
NCT01181011 (20) [back to overview]	λz of Amlodipine
NCT01181011 (20) [back to overview]	Area Under the Plasma Concentration-time Curve From the Time of Dosing to Infinity (AUC_0-∞) of Telmisartan
NCT01181011 (20) [back to overview]	Number of Participants With Clinically Relevant Findings in Electrocardiogram (ECG), Vital Signs, Physical Finding or Laboratory Finding Abnormalities
NCT01181011 (20) [back to overview]	Terminal Rate Constant in Plasma (λz) of Telmisartan
NCT01181011 (20) [back to overview]	t_½ of Amlodipine
NCT01181011 (20) [back to overview]	Number of Participants With at Least One Treatment Emergent Adverse Event
NCT01181011 (20) [back to overview]	MRT_po of Amlodipine
NCT01181011 (20) [back to overview]	Mean Residence Time of Telmisartan in the Body After Oral Administration (MRT_po)
NCT01181011 (20) [back to overview]	Elimination Half-life (t_½) of Telmisartan
NCT01181011 (20) [back to overview]	Cmax of Amlodipine
NCT01181011 (20) [back to overview]	CL/F of Amlodipine
NCT01181011 (20) [back to overview]	AUC_0-tz of Amlodipine
NCT01200407 (4) [back to overview]	Change From Baseline in SBP and DBP at Week 12 With Last Observation Carried Forward (LOCF)
NCT01200407 (4) [back to overview]	Percentage of Participants Achieving JNC VII Recommended Blood Pressure Goal at Week 12 With LOCF
NCT01200407 (4) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT01200407 (4) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Weeks 4, 8 and 12 Without (w/o) LOCF
NCT01204398 (7) [back to overview]	Treatment Emergent Adverse Events
NCT01204398 (7) [back to overview]	Trough to Peak (T/P) Ratio for DBP and SBP After 8 Weeks of Treatment
NCT01204398 (7) [back to overview]	Change From Baseline to End of Study in In-clinic Pulse Rate
NCT01204398 (7) [back to overview]	ABPM Hourly Mean DBP and SBP at Baseline and the End of the Study, Starting 1 Hour After Dosing
NCT01204398 (7) [back to overview]	Change From Baseline to End of Study in DBP and SBP
NCT01204398 (7) [back to overview]	Change From Baseline in ABPM Hourly Mean DBP and SBP, Starting 1 Hour After Dosing
NCT01204398 (7) [back to overview]	DBP and SBP Change From Baseline in Mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Mean
NCT01222520 (7) [back to overview]	Reduction From the Reference Baseline in Mean Seated Diastolic Blood Pressure (DBP) at Trough
NCT01222520 (7) [back to overview]	Reduction From the Reference Baseline in Mean Seated Systolic Blood Pressure (SBP) at Trough
NCT01222520 (7) [back to overview]	Seated Blood Pressure (BP) Normalisation at Trough
NCT01222520 (7) [back to overview]	Seated DBP Control Rate at Trough
NCT01222520 (7) [back to overview]	Seated DBP Response Rate at Trough
NCT01222520 (7) [back to overview]	Seated SBP Control Rate at Trough
NCT01222520 (7) [back to overview]	Seated SBP Response Rate at Trough
NCT01237223 (5) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) to End of Study (Week 8)
NCT01237223 (5) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) to End of Study (Week 8)
NCT01237223 (5) [back to overview]	Percentage of Participants Achieving a Successful Response Rate
NCT01237223 (5) [back to overview]	Percentage of Participants Achieving Blood Pressure Control at Endpoint
NCT01237223 (5) [back to overview]	Number of Participants With Adverse Events, Serious Adverse Events and Death
NCT01252238 (3) [back to overview]	Pulse Wave Velocity
NCT01252238 (3) [back to overview]	Change in Insulin Sensitivity by HOMA at 12 Weeks
NCT01252238 (3) [back to overview]	Aortic Compliance
NCT01252563 (20) [back to overview]	Number of Participants With Adverse Events Listed in Japanese Package Insert
NCT01252563 (20) [back to overview]	Number of Participants With Treatment Related Adverse Events
NCT01252563 (20) [back to overview]	Number of Participants With Treatment-Related Adverse Events: Male vs. Female
NCT01252563 (20) [back to overview]	Number of Participants With Treatment-Related Adverse Events: With/Without Complication (Angina Pectoris)
NCT01252563 (20) [back to overview]	Number of Participants With Treatment-Related Adverse Events: With/Without Complication (Dyslipidaemia)
NCT01252563 (20) [back to overview]	Number of Participants With Treatment-Related Adverse Events: With/Without Complication(s)
NCT01252563 (20) [back to overview]	Number of Participants With Treatment-Related Adverse Events: With/Without Concomitant Drug (Antihypertensive)
NCT01252563 (20) [back to overview]	Number of Participants With Treatment-Related Adverse Events: With/Without Concomitant Drug (ARB)
NCT01252563 (20) [back to overview]	Number of Treatment Related Adverse Events Unlisted in Japanese Package Insert
NCT01252563 (20) [back to overview]	Changes in Ambulatory Diastolic Blood Pressure From Baseline
NCT01252563 (20) [back to overview]	Changes in Ambulatory Systolic Blood Pressure From Baseline
NCT01252563 (20) [back to overview]	Changes in Home Diastolic Blood Pressure From Baseline
NCT01252563 (20) [back to overview]	Changes in Home Systolic Blood Pressure From Baseline
NCT01252563 (20) [back to overview]	The Achievement Rate to Ambulatory Blood Pressure Goal
NCT01252563 (20) [back to overview]	The Achievement Rate to Home Blood Pressure Goal
NCT01252563 (20) [back to overview]	Number of Participants Who Achieved the Target Blood Pressure: With/Without Complication (Metabolic Syndrome)
NCT01252563 (20) [back to overview]	Number of Participants Who Achieved the Target Blood Pressure: Ambulatory Systolic Blood Pressure
NCT01252563 (20) [back to overview]	Number of Participants Who Achieved the Target Blood Pressure: With/Without Complication (Chronic Kidney Disease)
NCT01252563 (20) [back to overview]	Number of Participants Who Achieved the Target Blood Pressure: With/Without Complication (Diabetes Mellitus)
NCT01252563 (20) [back to overview]	Number of Participants Who Achieved the Target Blood Pressure: With/Without Complication (Myocardial Infarction)
NCT01256411 (5) [back to overview]	Number of Participants With Blood Pressure Control Rate of <140/90 mmHg (Analysis by Maximum Treatment)
NCT01256411 (5) [back to overview]	Number of Participants With Adverse Events, Serious Adverse Events, and Deaths (Analysis by Actual Treatment)
NCT01256411 (5) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) (Analysis by Mono or Combination Therapy)
NCT01256411 (5) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) (Analysis by Maximum Treatment)
NCT01256411 (5) [back to overview]	Number of Participants With Blood Pressure Control Rate of <140/90 mmHg (Analysis by Mono or Combination Therapy)
NCT01259297 (8) [back to overview]	Number of Participants With Renal Dysfunction in Aliskiren Based Regimen Versus Non-Aliskiren Based Regimen
NCT01259297 (8) [back to overview]	Percentage of Participants With Standard Assessment of Global Activities in the Elderly (SAGE) Dimensions (Part II)
NCT01259297 (8) [back to overview]	Number of Participants With Composite Cardiovascular Endpoints in Aliskiren Based Regimen Versus Non-Aliskiren Based Regimen
NCT01259297 (8) [back to overview]	Number of Participants With Composite Cardiovascular Endpoints in Aliskiren+Amlodipine/HCTZ Group Versus All Placebo Group
NCT01259297 (8) [back to overview]	Number of Participants With Total Mortality in Aliskiren Based Regimen Versus Non-aliskiren Based Regimen
NCT01259297 (8) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)
NCT01259297 (8) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)
NCT01259297 (8) [back to overview]	Change From Baseline to End of Study in Standard Assessment of Global Activities in the Elderly (SAGE) Dimensions (Part I)
NCT01277822 (8) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8
NCT01277822 (8) [back to overview]	Percentage of Participants Who Achieve Target Blood Pressure at Week 8
NCT01277822 (8) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 4
NCT01277822 (8) [back to overview]	Change From Baseline in Ankle Circumference at Week 8
NCT01277822 (8) [back to overview]	Percentage of Participants Who Had Peripheral Edema During the Study
NCT01277822 (8) [back to overview]	Percentage of Participants Who Achieve Target Blood Pressure at Week 4
NCT01277822 (8) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8
NCT01277822 (8) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 4
NCT01278797 (3) [back to overview]	Area Under the Concentration-time Curve of Plasma Amlodipine From 0 to 72 Hours (AUC72)
NCT01278797 (3) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Amlodipine
NCT01278797 (3) [back to overview]	Time of Maximum Concentration of Amlodipine (TMAX)
NCT01280266 (9) [back to overview]	Change in Digital Ulcer Number
NCT01280266 (9) [back to overview]	Change in Health Assessment Questionnaire (HAQ)
NCT01280266 (9) [back to overview]	RP Attacks Per Day
NCT01280266 (9) [back to overview]	Dorsal-digital-difference.
NCT01280266 (9) [back to overview]	Change in the RP Duration
NCT01280266 (9) [back to overview]	Change in Physician's Global Assessment on Visual Analogue Scale (VAS)
NCT01280266 (9) [back to overview]	Change in Peak Systolic Flow (cm/Sec)
NCT01280266 (9) [back to overview]	Time-averaged Peak Velocity (cm/Sec)
NCT01280266 (9) [back to overview]	Change in Raynaud's Condition Score (RCS)
NCT01286558 (13) [back to overview]	Changes From the Reference Baseline in the 24-hour ABPM Mean (Relative to Dose Time) for SBP
NCT01286558 (13) [back to overview]	Seated DBP Response Rate at Trough
NCT01286558 (13) [back to overview]	Seated SBP Control Rate at Trough
NCT01286558 (13) [back to overview]	Seated SBP Response Rate at Trough
NCT01286558 (13) [back to overview]	Changes From the Reference Baseline in DBP Hourly Mean Over the 24-hour Dosing Interval as Measured by ABPM
NCT01286558 (13) [back to overview]	Seated DBP Control Rate at Trough
NCT01286558 (13) [back to overview]	Changes From the Pseudo-baseline in the 24-hour ABPM Mean (Relative to Dose Time) for SBP
NCT01286558 (13) [back to overview]	Changes From the Pseudo-baseline in the 24-hour ABPM Mean (Relative to Dose Time) for DBP
NCT01286558 (13) [back to overview]	Changes From the Reference Baseline in SBP Hourly Mean Over the 24-hour Dosing Interval as Measured by ABPM
NCT01286558 (13) [back to overview]	Seated Blood Pressure (BP) Normalisation at Trough
NCT01286558 (13) [back to overview]	Reduction From the Reference Baseline in Mean Seated Systolic Blood Pressure (SBP) at Trough
NCT01286558 (13) [back to overview]	Reduction From the Reference Baseline in Mean Seated Diastolic Blood Pressure (DBP) at Trough
NCT01286558 (13) [back to overview]	Changes From the Reference Baseline in the 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Mean (Relative to Dose Time) for DBP
NCT01302691 (7) [back to overview]	Percentage of Participants Who Had Study Drug Stopped Due to an AE
NCT01302691 (7) [back to overview]	Percentage of Participants Who Experience ≥1 Serious Adverse Event (SAE)
NCT01302691 (7) [back to overview]	Percentage of Participants Who Experience ≥1 Drug-related SAE
NCT01302691 (7) [back to overview]	Percentage of Participants Who Experience ≥1 Drug-related AE
NCT01302691 (7) [back to overview]	Percentage of Participants Who Experience ≥1 Adverse Event (AE)
NCT01302691 (7) [back to overview]	Change in Mean Trough Sitting Systolic Blood Pressure (SiSBP)
NCT01302691 (7) [back to overview]	Change in Mean Trough Sitting Diastolic Blood Pressure (SiDBP)
NCT01316419 (20) [back to overview]	Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Overall
NCT01316419 (20) [back to overview]	Percentage of Patients Achieving Target Blood Pressure SBP/DBP <140/90 mmHg.
NCT01316419 (20) [back to overview]	Percentage of Patients Who Complied With Each Category of Lifestyle Modification Recommendations at 24±2 Weeks
NCT01316419 (20) [back to overview]	Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Environment Domain
NCT01316419 (20) [back to overview]	Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Physical Health Domain
NCT01316419 (20) [back to overview]	Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Psychological Domain
NCT01316419 (20) [back to overview]	Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Social Relationships Domain
NCT01316419 (20) [back to overview]	EuroQol (EQ) Visual Analogue Scale (VAS)
NCT01316419 (20) [back to overview]	Mean Blood Lipid Change - High Density Lipoprotein (HDL)-Cholesterol
NCT01316419 (20) [back to overview]	Mean Blood Lipid Change - Low Density Lipoprotein (LDL)-Cholesterol
NCT01316419 (20) [back to overview]	Mean Blood Lipid Change - Total Cholesterol
NCT01316419 (20) [back to overview]	Mean Blood Lipid Change - Triglyceride
NCT01316419 (20) [back to overview]	Mean Blood Pressure Change Diastolic Blood Pressure (DBP) From Baseline After 24±2 Weeks of Treatment or at the Last Observation in Case of Early Withdrawal.
NCT01316419 (20) [back to overview]	Mean Blood Pressure Change Systolic Blood Pressure (SBP) From Baseline After 24±2 Weeks of Treatment or at the Last Observation in Case of Early Withdrawal.
NCT01316419 (20) [back to overview]	Percentage of Patients Achieving DBP Response
NCT01316419 (20) [back to overview]	Percentage of Patients Achieving Normal Body Mass Index (BMI)
NCT01316419 (20) [back to overview]	Percentage of Patients Achieving SBP Response
NCT01316419 (20) [back to overview]	Incidence and Severity of Reported Adverse Events.
NCT01316419 (20) [back to overview]	Percentage of Patients Achieving SBP/DBP < 130/80 mmHg Among Patients With Diabetes or Kidney Disease
NCT01316419 (20) [back to overview]	Percentage of Patients Who Complied With Each Category of Lifestyle Modification Recommendations at 12±2 Weeks
NCT01337674 (4) [back to overview]	Steady-state Area Under the Plasma Concentration Versus Time Curve (AUC0-24hr) for MK-4618
NCT01337674 (4) [back to overview]	Maximum Change From Baseline in Semi-recumbent and Standing Systolic Blood Pressure: Panel A
NCT01337674 (4) [back to overview]	Maximum Change From Baseline in Semi-recumbent and Standing Systolic Blood Pressure: Panel B
NCT01337674 (4) [back to overview]	Percentage of Participants With a Clinical or Laboratory Adverse Experience
NCT01365481 (5) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (MsDBP) at End Point (Week 78 or Last Observation Carried Forward (LOCF)
NCT01365481 (5) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at End Point (Week 78 or Last Observation Carried Forward (LOCF)
NCT01365481 (5) [back to overview]	Percentage of Chronic Kidney Disease (CKD) Patients Who Had >=50% Reduction in Urine Albumin/Creatinine Ratio (UACR) From Baseline to End Point
NCT01365481 (5) [back to overview]	Percentage of Chronic Kidney Disease (CKD) Patients Who Had Estimated Glomerular Filtration Rate (eGFR) Decrease > 25 % From Baselinefrom Baseline to End Point
NCT01365481 (5) [back to overview]	Number of Participants With MSSBP, MSDBP and (MSSBP and MSDBP Combined) < 95th Percentile for Gender, Age, and Height
NCT01368536 (1) [back to overview]	Number of Patients With Adverse Events, Serious Adverse Events and Death to Assess Safety and Tolerability of Treatment With Valturna and Chlorthalidone or Valturna and Amlodipine Versus Valturna Alone
NCT01556997 (2) [back to overview]	Change From Baseline to End of Treatment in the Mean Seated Trough Cuff Systolic Blood Pressure (SBP).
NCT01556997 (2) [back to overview]	Change From Baseline to End of Treatment in the Mean Seated Trough Cuff Diastolic Blood Pressure (DBP).
NCT01631864 (4) [back to overview]	Number of Participants With Adverse Events, Serious Adverse Events and Deaths
NCT01631864 (4) [back to overview]	Change From Baseline in Insulin Sensitivity Index
NCT01631864 (4) [back to overview]	Oxidative Metabolism
NCT01631864 (4) [back to overview]	Local Adipose Tissue Lipolysis, Glycerol Concentrations
NCT01658657 (1) [back to overview]	Blood Pressure Control, as Defined as Office BP Measurement of <140 mmHg Systolic and <90 mmHg Diastolic
NCT01663233 (9) [back to overview]	Number of Participants Achieving Successful Response in msDBP (< 90 mmHg or a Reduction ≥ 10 mmHg From Baseline)
NCT01663233 (9) [back to overview]	Number of Participants Achieving Successful Response in msSBP (< 140 mmHg or a Reduction ≥ 20 mmHg From Baseline)
NCT01663233 (9) [back to overview]	Number of Participants Achieving Systolic and Diastolic Blood Pressure Control (< 140/90 mmHg)
NCT01663233 (9) [back to overview]	Number of Participants With Adverse Event
NCT01663233 (9) [back to overview]	Change in Mean 24-hour ABPM Diastolic Blood Pressure (maDBP)
NCT01663233 (9) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP)
NCT01663233 (9) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (msSBP)
NCT01663233 (9) [back to overview]	Change in Mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Systolic Blood Pressure (maSBP)
NCT01663233 (9) [back to overview]	Change in Sitting Pulse Pressure (PP)
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Central Aortic Systolic Pressure (CASP) at 12 Weeks
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Central Aortic Systolic Pressure (CASP) at 52 Weeks
NCT01692301 (11) [back to overview]	Change From Baseline in Mean 24-hour Ambulatory Pulse Pressure (maPP)
NCT01692301 (11) [back to overview]	Change From Baseline in Mean 24-hour Diastolic Blood Pressure (maDBP)
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Arterial Pressure (MAP)
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Central Pulse (CPP) Pressure
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Pulse Wave Velocity (PWV)
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Sitting Pulse Pressure (msPP)
NCT01692301 (11) [back to overview]	Change From Baseline in Mean 24-hour Systolic Blood Pressure (maSBP)
NCT01762501 (5) [back to overview]	Change in Nocturnal Diastolic Blood Pressure Level
NCT01762501 (5) [back to overview]	Change in the Absolute Value in Difference With Targeted Value* (15 Percent) of Nocturnal Systolic Blood Pressure Fall**
NCT01762501 (5) [back to overview]	Change in Nocturnal Systolic Blood Pressure Level
NCT01762501 (5) [back to overview]	Change in 24-hour Mean Systolic Blood Pressure Level
NCT01762501 (5) [back to overview]	Change in 24-hour Mean Diastolic Blood Pressure Level
NCT01841593 (5) [back to overview]	Maximum Observed Concentration (Cmax) of Raltegravir and Amlodipine Without and With Co-administration of the Other Studied Drug.
NCT01841593 (5) [back to overview]	Raltegravir AUC(0-12h )
NCT01841593 (5) [back to overview]	Raltegravir C12h
NCT01841593 (5) [back to overview]	Amlodipine AUC(0-24h)
NCT01841593 (5) [back to overview]	Amlodipine C24h
NCT01870739 (10) [back to overview]	Change From Baseline in Local Aortic Strain at 52 Weeks
NCT01870739 (10) [back to overview]	Change From Baseline in Augmentation Index at 52 Weeks
NCT01870739 (10) [back to overview]	Change From Baseline in Augmentation Pressure at 52 Weeks
NCT01870739 (10) [back to overview]	Change From Baseline in Carotid-femoral Pulse Wave Velocity at 52 Weeks
NCT01870739 (10) [back to overview]	Change From Baseline in Distal Descending Aorta Distensibility at 52 Weeks
NCT01870739 (10) [back to overview]	Change From Baseline in Proximal Descending Aorta Distensibility at 52 Weeks
NCT01870739 (10) [back to overview]	Change From Baseline in Regional Aortic Pulse Wave Velocity at 52 Weeks
NCT01870739 (10) [back to overview]	Change From Baseline in Central Blood Pressure at 52 Weeks
NCT01870739 (10) [back to overview]	Change From Baseline in Ascending Aorta Distensibility at 52 Week
NCT01870739 (10) [back to overview]	Number of Patients With Reported Adverse Events, Serious Adverse Events and Death
NCT01911780 (6) [back to overview]	The Number of Patients With DBP<90 mmHg and SBP<140 mmHg Blood Pressure at Trough After 52 Weeks of Extension Period.
NCT01911780 (6) [back to overview]	The Percentage of Patients With DBP<90 mmHg and SBP<140 mmHg Blood Pressure at Trough After 8 Weeks of Double-blind Period.
NCT01911780 (6) [back to overview]	Change From Baseline in Mean DBP Pressure at Trough After 52 Weeks of the Extension Period.
NCT01911780 (6) [back to overview]	Change From Baseline in Mean Seated DBP at Trough After 8 Weeks of the Double-blind Period.
NCT01911780 (6) [back to overview]	Change From Baseline in Mean Seated SBP at Trough After 8 Weeks of the Double-blind Period.
NCT01911780 (6) [back to overview]	Change From Baseline in Mean Seated SBP at Trough After 52 Weeks of the Extension Period.
NCT01975246 (3) [back to overview]	Change From Baseline in Mean Seated DBP at Trough After 8 Weeks of the Double-blind Period.
NCT01975246 (3) [back to overview]	The Proportion of Patients With DBP<90 mmHg and SBP<140 mmHg as Seated Blood Pressure at Trough After 8 Weeks of the Double-blind Period
NCT01975246 (3) [back to overview]	Change From Baseline in Mean Seated SBP at Trough After 8 Weeks of the Double-blind Period.
NCT01977794 (5) [back to overview]	Mean Reduction In Systolic Blood Pressure (SBP) After 18 Weeks of Treatment From Baseline
NCT01977794 (5) [back to overview]	Percentage of Subjects With Controlled Blood Pressure
NCT01977794 (5) [back to overview]	Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, AEs Leading to Discontinuation and AEs Leading to Death
NCT01977794 (5) [back to overview]	Change From Baseline in Heart Rate (HR) After 18 Weeks of Treatment
NCT01977794 (5) [back to overview]	Change From Baseline in Diastolic Blood Pressure (DBP) After 18 Weeks of Treatment
NCT01996449 (2) [back to overview]	Muscle Sympathetic Nerve Activity During Exercise
NCT01996449 (2) [back to overview]	Muscle Sympathetic Nerve Activity at Rest
NCT02034435 (2) [back to overview]	Insulin Secretion
NCT02034435 (2) [back to overview]	Insulin Sensitivity
NCT02046395 (2) [back to overview]	Change in Urine Microalbumin Creatinine Ratio
NCT02046395 (2) [back to overview]	Change in the Level of Urinary Free Light Chains
NCT02062645 (5) [back to overview]	Systolic Blood Pressure (SBP) at Baseline, Week 4 and 8
NCT02062645 (5) [back to overview]	SBP and DBP in Patients With High Sodium Intake at Week 4 and 8
NCT02062645 (5) [back to overview]	Percentage of Participants With High Sodium Intake and Blood Pressure (BP) <140/90 mmHg at Week 4 and 8
NCT02062645 (5) [back to overview]	Percentage of Participants With Blood Pressure (BP) <140/90 mmHg at Week 4 and 8
NCT02062645 (5) [back to overview]	Diastolic Blood Pressure (DBP) at Baseline, Week 4 and 8
NCT02068495 (6) [back to overview]	Number of Participants Who Experience at Least One Adverse Drug Reactions (ADRs)
NCT02068495 (6) [back to overview]	Changes From Baseline in Diastolic Blood Pressure (DBP) at Final Assessment
NCT02068495 (6) [back to overview]	Changes From Baseline in Pulse Rate at Final Assessment
NCT02068495 (6) [back to overview]	Changes From Baseline in Systolic Blood Pressure (SBP) at Final Assessment
NCT02068495 (6) [back to overview]	Number of Participants Who Experience at Least One Adverse Events
NCT02068495 (6) [back to overview]	Percentage of Participants Who Meet Targeted Blood Pressure Level at Baseline and Final Assessment
NCT02121041 (1) [back to overview]	24 Hour Blood Pressure Average at the End of 4 Month Participation.
NCT02129192 (6) [back to overview]	Area Under the Concentration-time Curve (AUC 0-tz) of the Analytes in Plasma Over the Time Interval From 0 to the Last Quantifiable Plasma Concentration After Single Administration of T80/A5/H12.5 mg FDC Tablet
NCT02129192 (6) [back to overview]	Area Under the Concentration-time Curve (AUC 0-tz) of the Analytes in Plasma Over the Time Interval From 0 to the Last Quantifiable Plasma Concentration
NCT02129192 (6) [back to overview]	Maximum Measured Concentration (Cmax) of the Analytes in Plasma
NCT02129192 (6) [back to overview]	Area Under the Concentration-time Curve (AUC 0-infinity) of the Analytes in Plasma Over the Time Interval From 0 to Extrapolated Infinity After Single Administration of T80/A5/H12.5 mg FDC Tablet
NCT02129192 (6) [back to overview]	Area Under the Concentration-time Curve (AUC 0-infinity) of the Analytes in Plasma Over the Time Interval From 0 to Extrapolated Infinity
NCT02129192 (6) [back to overview]	Maximum Measured Concentration (Cmax) of the Analytes in Plasma After Single Administration of T80/A5/H12.5 mg FDC Tablet
NCT02172040 (12) [back to overview]	Mean Change in Average 24-hour Ambulatory Systolic Blood Pressure (SBP24h)
NCT02172040 (12) [back to overview]	Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Diastolic Blood Pressure (DBPday)
NCT02172040 (12) [back to overview]	Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Systolic Blood Pressure (SBPday) - Primary Endpoint
NCT02172040 (12) [back to overview]	Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Systolic Blood Pressure (SBPday) - Secondary Endpoint
NCT02172040 (12) [back to overview]	Mean Change in Average Night-time (01:00 to 06:00) Ambulatory Diastolic Blood Pressure (DBPnight)
NCT02172040 (12) [back to overview]	Mean Change in Average Night-time (01:00 to 06:00) Ambulatory Systolic Blood Pressure (SBPnight)
NCT02172040 (12) [back to overview]	Mean Log-transformed Amlodipine Plasma Concentration
NCT02172040 (12) [back to overview]	Mean Log-transformed Celecoxib Plasma Concentration
NCT02172040 (12) [back to overview]	Mean Non-transformed Amlodipine Plasma Concentration
NCT02172040 (12) [back to overview]	Mean Non-transformed Celecoxib Plasma Concentration
NCT02172040 (12) [back to overview]	Frequency of Adverse Events (Number of Participants Affected/Number of Participants at Risk)
NCT02172040 (12) [back to overview]	Mean Change in Average 24-hour Ambulatory Diastolic Blood Pressure (DBP24h)
NCT02181816 (3) [back to overview]	Percentage of Participants Who Had One or More Adverse Events
NCT02181816 (3) [back to overview]	Diastolic Office Blood Pressure
NCT02181816 (3) [back to overview]	Systolic Office Blood Pressure
NCT02183675 (7) [back to overview]	Amount of HCTZ Excreted in Urine at Steady State From 0 to 24 Hours
NCT02183675 (7) [back to overview]	Maximum Measured Concentration (Cmax) at Steady State for Telmisartan
NCT02183675 (7) [back to overview]	Maximum Measured Concentration (Cmax) at Steady State for HCTZ
NCT02183675 (7) [back to overview]	Maximum Measured Concentration (Cmax) at Steady State for Amlodipine
NCT02183675 (7) [back to overview]	Area Under the Plasma Concentration Curve at Steady State for Telmisartan
NCT02183675 (7) [back to overview]	Area Under the Plasma Concentration Curve at Steady State for HCTZ
NCT02183675 (7) [back to overview]	Area Under the Plasma Concentration Curve at Steady State for Amlodipine
NCT02278471 (6) [back to overview]	LDL Cholesterol
NCT02278471 (6) [back to overview]	LDL Cholesterol
NCT02278471 (6) [back to overview]	Medication Adherence-Percentage of Pills Taken
NCT02278471 (6) [back to overview]	Systolic Blood Pressure
NCT02278471 (6) [back to overview]	Systolic Blood Pressure
NCT02278471 (6) [back to overview]	Medication Adherence
NCT02353806 (12) [back to overview]	Drug Level/Concentration in Infant Blood (Amlodipine Level/Concentration)
NCT02353806 (12) [back to overview]	Neonatal Birth Weight
NCT02353806 (12) [back to overview]	Amlodipine Concentration in Breastmilk
NCT02353806 (12) [back to overview]	Area Under the Curve for Amlodipine in the Maternal Serum
NCT02353806 (12) [back to overview]	Clearance Rate of Plasma Amlodipine
NCT02353806 (12) [back to overview]	Half-life of Amlodipine in Maternal Plasma
NCT02353806 (12) [back to overview]	Infant Gestational Age at Delivery.
NCT02353806 (12) [back to overview]	Infant Length of Stay.
NCT02353806 (12) [back to overview]	Maximal Amlodipine Maternal Serum Concentration
NCT02353806 (12) [back to overview]	Time to Maximal Concentration in the Maternal Serum.
NCT02353806 (12) [back to overview]	Drug Levels/Concentration in Cord Blood (Amlodipine Levels/Concentrations)
NCT02353806 (12) [back to overview]	Major Infant Complications
NCT02387554 (1) [back to overview]	AUClast
NCT02412761 (1) [back to overview]	The Number of Patients for Whom Each Drug is Selected as the Preferred Therapy
NCT02734355 (13) [back to overview]	Passive Emptying of Left Atrium
NCT02734355 (13) [back to overview]	Diastolic Function
NCT02734355 (13) [back to overview]	Left Atrial Reservoir Function
NCT02734355 (13) [back to overview]	Quality of Life
NCT02734355 (13) [back to overview]	Active Emptying of Left Atrium
NCT02734355 (13) [back to overview]	Pulmonary Vein Flow Emptying
NCT02734355 (13) [back to overview]	Left Atrial Pressure Load
NCT02734355 (13) [back to overview]	Left Atrial Dimensions
NCT02734355 (13) [back to overview]	Left Atrial Contractility
NCT02734355 (13) [back to overview]	Isovolumic Relaxation
NCT02734355 (13) [back to overview]	Pulmonary Circulation Pressure Load
NCT02734355 (13) [back to overview]	Exercise Tolerance
NCT02734355 (13) [back to overview]	Retrograde Flow in Pulmonary Veins
NCT02834403 (7) [back to overview]	Recommended Phase 2 Dose (RP2D) of the L-NMMA and Docetaxel Combination
NCT02834403 (7) [back to overview]	Dose Limiting Toxicities (DLTs) and Other Adverse Events
NCT02834403 (7) [back to overview]	Time to Maximum Plasma Concentration of L-NMMA and Docetaxel
NCT02834403 (7) [back to overview]	Clinical Benefit Rate
NCT02834403 (7) [back to overview]	Recommended Phase 2 Dose (RP2D) of the L-NMMA and Docetaxel Combination
NCT02834403 (7) [back to overview]	Asses the Maximum Tolerated Dose (MTD) of L-NMMA When Combined With Docetaxel/Amlodipine in the Treatment of Refractory Locally Advanced or Metastatic TNBC Patients, Based on the Number of Dose Limiting Toxicities (DLTs) Per Dose Level.
NCT02834403 (7) [back to overview]	Asses the Maximum Tolerated Dose (MTD) of Docetaxel When Combined With L-NMMA/Amlodipine in the Treatment of Refractory Locally Advanced or Metastatic TNBC Patients, Based on the Number of Dose Limiting Toxicities (DLTs) Per Dose Level.
NCT02979197 (9) [back to overview]	Change in Average Daytime (9:00 to 21:00) Ambulatory Systolic Blood Pressure (SBPday)
NCT02979197 (9) [back to overview]	Occurrence of Treatment Emergent Adverse Events
NCT02979197 (9) [back to overview]	Non-transformed Plasma Concentration of Amlodipine
NCT02979197 (9) [back to overview]	Log-transformed Plasma Concentration of Amlodipine
NCT02979197 (9) [back to overview]	Change in Serum Creatinine
NCT02979197 (9) [back to overview]	Change in Creatinine Clearance
NCT02979197 (9) [back to overview]	Change in Average 24-hour Ambulatory Diastolic Blood Pressure (DBP24h)
NCT02979197 (9) [back to overview]	Change in Body Weight
NCT02979197 (9) [back to overview]	Change in Average 24-hour Ambulatory Systolic Blood Pressure (SBP24h)
NCT03226275 (10) [back to overview]	Extrapolated Part of Area Under the Plasma Concentration Curve From Time Zero to Infinity (AUCextra%) of Bisoprolol and Amlodipine
NCT03226275 (10) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Bisoprolol and Amlodipine
NCT03226275 (10) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, AEs Leading to Death, and AEs Leading to Discontinuation
NCT03226275 (10) [back to overview]	Time to Reach Maximum Plasma Concentration (Tmax) of Bisoprolol and Amlodipine
NCT03226275 (10) [back to overview]	Apparent Total Body Clearance From Plasma (CL/f) of Bisoprolol and Amlodipine
NCT03226275 (10) [back to overview]	Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/f) of Bisoprolol and Amlodipine
NCT03226275 (10) [back to overview]	Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC 0-inf) of Bisoprolol and Amlodipine
NCT03226275 (10) [back to overview]	Area Under the Plasma Concentration-Time Curve From Time Zero to Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of Bisoprolol and Amlodipine
NCT03226275 (10) [back to overview]	Apparent Terminal Half-life (t1/2) of Bisoprolol and Amlodipine
NCT03226275 (10) [back to overview]	Apparent Terminal Elimination Rate Constant (λz) of Bisoprolol and Amlodipine
NCT03461003 (5) [back to overview]	Change in Mean Wake Ambulatory Systolic Blood Pressure
NCT03461003 (5) [back to overview]	Patient Satisfaction With Intervention as Assessed by a Survey
NCT03461003 (5) [back to overview]	Change in Mean 24-hour Ambulatory Systolic Blood Pressure
NCT03461003 (5) [back to overview]	Number of Participants Who Reported That Side Effects From Medication Led Them to Discontinue Medication
NCT03461003 (5) [back to overview]	Number of Participants Who Self-reported Adherence to Intervention
NCT03722524 (5) [back to overview]	The Mean Standardized Score of the Physical Component of the Quality of Life Questionnaire The Short Form (36) Health Survey at Visit 4 vs Baseline
NCT03722524 (5) [back to overview]	The Mean Systolic BP Changes (mm Hg) at the Visit 4 vs. Baseline
NCT03722524 (5) [back to overview]	The Mean Diastolic BP Changes (mm Hg) at the Visit 4 vs Baseline.
NCT03722524 (5) [back to overview]	Percentage of Patients Who Achieved the Target Office BP Levels (SBP <140 mm Hg and DBP <90 mm Hg) at Visit 4 vs Baseline
NCT03722524 (5) [back to overview]	The Mean Standardized Score of the Mental Component of the Quality of Life Questionnaire The Short Form (36) Health Survey at Visit 4 vs Baseline

Death From Any Cause in the Glycemia Trial.

"Time to death from any cause. Secondary measure for Glycemia Trial.~A finding of higher mortality in the intensive-therapy group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid)." (NCT00000620)
Timeframe: 4.9 years

Intervention	participants (Number)
Glycemia Trial: Intensive Control	391
Glycemia Trial: Standard Control	327

Intervention	mm Hg (Least Squares Mean)
	Week 12	Week 36
Amlodipine 10 mg	-14.2	-13.9
Valsartan 320 mg	-9.1	-11.1

Intervention	mmHg (Mean)
Placebo (Pl)	-5.5
Telmisartan 20 mg (T20)	-13.9
Telmisartan 40 mg (T40)	-13.8
Telmisartan 80 mg (T80)	-13.9
Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5)	-18.4
Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5)	-15.8
Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10)	-19.5
Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5)	-18.7
Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)	-16.8
Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)	-19.6
Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5)	-16.3
Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)	-18.8
Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)	-20.4
Amlodipine 2.5 mg (A2.5)	-11.4
Amlodipine 5 mg (A5)	-13.1
Amlodipine 10 mg (A10)	-17.1

Intervention	mmHg (Least Squares Mean)
Placebo (Pl)	-1.9
Telmisartan 20 mg (T20)	-15.6
Telmisartan 40 mg (T40)	-15.4
Telmisartan 80 mg (T80)	-15.4
Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5)	-19
Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5)	-22.1
Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10)	-25.2
Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5)	-23.2
Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)	-22.2
Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)	-25.3
Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5)	-17.4
Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)	-22.5
Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)	-26.5
Amlodipine 2.5 mg (A2.5)	-12.4
Amlodipine 5 mg (A5)	-14.8
Amlodipine 10 mg (A10)	-21

Intervention	mmHg (Least Squares Mean)
Placebo (Pl)	-4.2
Telmisartan 20 mg (T20)	-11.7
Telmisartan 40 mg (T40)	-10.9
Telmisartan 80 mg (T80)	-11.3
Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5)	-15.1
Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5)	-13.3
Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10)	-17.6
Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5)	-17.5
Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)	-14.2
Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)	-18
Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5)	-14.5
Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)	-17.3
Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)	-19.2
Amlodipine 2.5 mg (A2.5)	-8
Amlodipine 5 mg (A5)	-11
Amlodipine 10 mg (A10)	-15.5

Intervention	mmHg (Least Squares Mean)
Placebo (Pl)	1
Telmisartan 20 mg (T20)	-13.7
Telmisartan 40 mg (T40)	-13.6
Telmisartan 80 mg (T80)	-14
Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5)	-16.2
Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5)	-19.4
Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10)	-23.2
Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5)	-21.8
Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)	-20.4
Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)	-22.8
Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5)	-16.3
Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)	-21.9
Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)	-24.3
Amlodipine 2.5 mg (A2.5)	-10.1
Amlodipine 5 mg (A5)	-13.2
Amlodipine 10 mg (A10)	-19.3

Intervention	mmHg (Least Squares Mean)
Placebo (Pl)	-12.2
Amlodipine 2.5 mg (A2.5)	-15.3
Amlodipine 5 mg (A5)	-16.2
Amlodipine 10 mg (A10)	-19.3

Intervention	percentage of participants (Number)
Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)	53.7
Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)	70.8
Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)	58.5
Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)	77

Intervention	percentage of participants (Number)
Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)	71.6
Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)	82.1
Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)	74.8
Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)	85.3

Intervention	percentage of participants (Number)
Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)	69.4
Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)	77.1
Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)	68.9
Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)	85

Intervention	percentage of participants (Number)
Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)	80.9
Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)	91.9
Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)	88.8
Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)	91.2

Intervention	percentage of participants (Number)
Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)	81.5
Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)	89.6
Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)	87.7
Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)	93

Intervention	percentage of participants (Number)
Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)	88.9
Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)	96.9
Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)	84.9
Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)	95

Intervention	percentage of participants (Number)
	No (SBP>=140 and/or DBP>=90)	High Normal (140>SBP>=130 and 90>DBP>=85)	Normal (130>SBP>=120 and 85>DBP>=80)	Optimal (SBP<120 and DBP<80)
Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)	24.4	30.1	32.5	13
Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)	41.1	28.4	21.3	9.2
Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)	23.5	22.1	39.7	14.7
Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)	34.3	30.1	25.9	9.8

Intervention	mmHg (Mean)
	Week 2	Week 4 (N=133, 115, 135, 129)	Week 6 (N=134, 118, 131, 124)	Week 8 (N=133, 112, 132, 121)
Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)	-14.4	-18.1	-19.0	-19.5
Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)	-14.5	-16.0	-17.1	-16.3
Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)	-14.6	-18.8	-20.0	-20.0
Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)	-15.3	-17.2	-18.0	-18.3

Intervention	mmHg (Least Squares Mean)
Telmisartan 0 mg (T0)	-12.5
Telmisartan 20 mg (T20)	-16.8
Telmisartan 40 mg (T40)	-16.6
Telmisartan 80 mg (T80)	-17.2

Intervention	mmHg (Mean)
	Hour 1	Hour 2	Hour 3	Hour 4	Hour 5	Hour 6	Hour 7	Hour 8	Hour 9	Hour 10	Hour 11	Hour 12	Hour 13	Hour 14	Hour 15	Hour 16	Hour 17	Hour 18	Hour 19	Hour 20	Hour 21	Hour 22	Hour 23	Hour 24
Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)	-15.4	-15	-14.1	-16.5	-14.1	-14.5	-15.6	-17.4	-15.7	-13.8	-14.4	-13.3	-14.7	-14.8	-11.5	-10.3	-10.4	-9.9	-10.5	-9.9	-8.9	-9.8	-13.3	-12.6
Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)	-10.7	-9.8	-11.2	-11.3	-13.1	-10.9	-12.8	-12.1	-13.1	-11.8	-11.2	-12	-10.3	-8.9	-10.3	-10.1	-9.8	-11.9	-9.1	-11	-10.4	-11.1	-9.8	-11.1
Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)	-13.4	-14.6	-15.4	-15.8	-15.7	-16.4	-15.7	-17.1	-17.2	-18.5	-16.1	-15.7	-15.1	-11	-10	-12.2	-11.5	-12.2	-13.2	-15.9	-14.8	-15.4	-14.6	-13.1
Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)	-12.7	-13.4	-14.8	-15.6	-16.3	-14.6	-12.9	-12.7	-14.3	-14.7	-15.1	-12.5	-14.1	-13.4	-11.9	-11.3	-11.2	-10.3	-11.9	-12.6	-8.5	-9.7	-9.9	-12

Intervention	mmHg (Mean)
	Week 2	Week 4 (N=102, 90, 102, 96)	Week 6 (N=102, 92, 98, 96)	Week 8 (N=102, 87, 99, 88)
Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)	-14.7	-18.2	-19.7	-19.4
Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)	-14.7	-16.5	-17.9	-17.1
Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)	-14.9	-19.2	-19.5	-21.1
Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)	-16.1	-17.8	-18.9	-19.3

Intervention	percentage of participants (Number)
	Alanine aminotransferase increased	Aspartate aminotransferase increased	Blood potassium increased	Electrocardiogram QT shortened	Electrocardiogram T wave abnormal	Electrocardiogram repolarisation abnormality	Heart rate irregular	QRS axis abnormal	Atrioventricular block first degree	Left atrial dilatation	Myocardial ischaemia	Palpitation	Sinus bradycardia
Amlodipine Monotherapy	0.0	0.0	0.0	0.3	0.3	0.0	0.3	0.3	0.0	0.0	0.0	0.6	0.0
Combination Therapy	0.1	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.3	0.1	0.0	0.1	0.1
Placebo (Pl)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Telmisartan Monotherapy	0.3	0.3	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0

Intervention	mmHg (Least Squares Mean)
Placebo (Pl)	-6.2
Telmisartan 20 mg (T20)	-13.8
Telmisartan 40 mg (T40)	-13.4
Telmisartan 80 mg (T80)	-14
Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5)	-18.3
Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5)	-15.9
Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10)	-19.3
Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5)	-16.9
Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)	-16.5
Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)	-20.2
Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5)	-15.7
Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)	-18.2
Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)	-20.1
Amlodipine 2.5 mg (A2.5)	-10.6
Amlodipine 5 mg (A5)	-13.4
Amlodipine 10 mg (A10)	-17.11

Intervention	mmHg (Mean)
Placebo (Pl)	-12.3
Amlodipine 2.5 mg (A2.5)	-14.9
Amlodipine 5 mg (A5)	-15.6
Amlodipine 10 mg (A10)	-18.6

amlodipine

Description

Cross-References

Synonyms (148)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (5)

Pathways (1)

Protein Targets (39)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (230)

Molecular Functions (83)

Ceullar Components (63)

Bioassays (230)

Research

Studies (3,938)

Market Indicators

Research Demand Index: 140.75

Study Types

Clinical Trials (541)

Trial Overview

Trial Outcomes

Death From Any Cause in the Glycemia Trial.

First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.

First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.

First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.

First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.

Stroke in the Blood Pressure Trial.

Duration of Response to Botulinum Toxin Injection With Amlodipine and With Placebo

Toronto Western Spasmodic Torticollis Rating Scale (TWSTR) Sum Score

Time-to-event Analysis of Percentage of Patients With a Cardiovascular (CV) Mortality Event, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke

Time-to-event Analysis of Percentage of Patients With a Composite Cardiovascular (CV) Morbidity or Mortality Event

Time-to-event Analysis of Percentage of Patients With a Composite Cardiovascular (CV) Morbidity Event

Change From Baseline in Post-ischemic Forearm Skin Reactive Hyperemia at Week 12

Change in Left Ventricular Mass Index (LVMI) and Diastolic Function Using Echocardiography From Baseline to Week 38

Changes in Baroreflex Sensitivity as it Relates to Changes in Carotid Distensibility From Baseline to Week 12

Change From Baseline in Post-ischemic Forearm Skin Reactive Hyperemia at Endpoint (Week 38)

Changes in Central Blood Pressure, Evaluated by Applanation Tonometry From Baseline at Weeks 12 and 38

Change From Baseline for Endothelial Function Measured by Brachial Artery Flow-mediated Vasodilatation (FMD) Using the Brachial Artery Reactivity Test (BART) at Week 12

Changes in Baroreflex Sensitivity as it Relates to Changes in Carotid Distensibility From Baseline to Week 38

Changes in Mean Left Carotid Distensibility at Week 12

Changes in Mean Left Carotid Distensibility at Week 38

Changes in Mean Right Carotid Distensibility at Week 12

Changes in Mean Right Carotid Distensibility at Week 38

Change From Baseline for Endothelial Function Measured by Brachial Artery Flow-mediated Vasodilatation (FMD) Using the Brachial Artery Reactivity Test (BART) at End-point (Week 38)

Change From Baseline to Week 38 in the Carotid-femoral Pulse Wave Velocity (PWV)

Change From Baseline in Seated Trough Cuff Mean DBP (Observed Treatment Effects)

Change From Baseline in Seated Trough Cuff Mean SBP

Change From Baseline in Seated Trough Pulse Rate

Change From Baseline in Standing Trough Cuff Mean DBP

Change From Baseline in Standing Trough Cuff Mean SBP

Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Amlodipine Effects)

BP Control

DBP Control

DBP Control

DBP Response

DBP Response

Orthostatic Change in Trough Cuff Mean DBP

Orthostatic Change in Trough Cuff Mean DBP

Orthostatic Change in Trough Cuff Mean SBP

Orthostatic Change in Trough Cuff Mean SBP

SBP Response

BP Normality

BP Normality

Change From Baseline at 2,4,6,and 8 Weeks in Seated Trough Cuff DBP

Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Telmisartan Effects)

Change From Baseline in ABPM Hourly Mean (Relative to Dosing) DBP

Change From Baseline in ABPM Hourly Mean (Relative to Dosing) DBP

Change From Baseline in ABPM Hourly Mean (Relative to Dosing) SBP

Intervention	percentage of participants (Number)
Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)	58.9
Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)	75.6
Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)	65.7
Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)	76.5

Intervention	mmHg (Mean)
Placebo (Pl)	-5.9
Telmisartan 20 mg (T20)	-13.2
Telmisartan 40 mg (T40)	-13.1
Telmisartan 80 mg (T80)	-13.6
Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5)	-18
Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5)	-15.7
Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10)	-18.7
Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5)	-16.2
Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)	-16
Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)	-19.6
Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5)	-15.3
Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)	-17.8
Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)	-19.6
Amlodipine 2.5 mg (A2.5)	-10.4
Amlodipine 5 mg (A5)	-13
Amlodipine 10 mg (A10)	-16.5

Intervention	mmHg (Least Squares Mean)
Placebo (Pl)	-2.5
Telmisartan 20 mg (T20)	-15.1
Telmisartan 40 mg (T40)	-14.6
Telmisartan 80 mg (T80)	-14.3
Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5)	-18.8
Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5)	-21
Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10)	-24.4
Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5)	-21.9
Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)	-21.8
Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)	-24.7
Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5)	-17.4
Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)	-22.1
Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)	-26.4
Amlodipine 2.5 mg (A2.5)	-11.4
Amlodipine 5 mg (A5)	-15.4
Amlodipine 10 mg (A10)	-20.7

Intervention	mmHg (Least Squares Mean)
Placebo (Pl)	-4.9
Telmisartan 20 mg (T20)	-10.4
Telmisartan 40 mg (T40)	-10
Telmisartan 80 mg (T80)	-11.1
Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5)	-14.9
Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5)	-13.1
Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10)	-16.9
Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5)	-15.8
Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)	-13.6
Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)	-18.4
Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5)	-13.4
Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)	-16.2
Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)	-19
Amlodipine 2.5 mg (A2.5)	-8.1
Amlodipine 5 mg (A5)	-11.3
Amlodipine 10 mg (A10)	-14.6

Intervention	percentage of participants (Number)
Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)	91.5
Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)	96.7
Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)	87.4
Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)	94.9

Intervention	mmHg (Least Squares Mean)
Placebo (Pl)	-0.5
Telmisartan 20 mg (T20)	-13.2
Telmisartan 40 mg (T40)	-13.2
Telmisartan 80 mg (T80)	-12.9
Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5)	-17.4
Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5)	-18.9
Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10)	-22.3
Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5)	-20.3
Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)	-20
Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)	-22.8
Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5)	-17.4
Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)	-21.2
Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)	-24.9
Amlodipine 2.5 mg (A2.5)	-9.1
Amlodipine 5 mg (A5)	-14.7
Amlodipine 10 mg (A10)	-19.1

Intervention	mmHg (Mean)
Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)	-16.7
Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)	-20.8
Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)	-20.9
Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)	-22.7

Intervention	mmHg (Least Squares Mean)
Amlodipine 0 mg (A0) - Overall	-12.5
Amlodipine 2.5 mg (A2.5) - Overall	-16.4
Amlodipine 5 mg (A5) - Overall	-16.7
Amlodipine 10 mg (A10) - Overall	-19.7

Intervention	mmHg (Least Squares Mean)
Placebo (Pl)	-5.8
Telmisartan 20 mg (T20)	-14.4
Telmisartan 40 mg (T40)	-14.2
Telmisartan 80 mg (T80)	-14.1
Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5)	-18.9
Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5)	-15.9
Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10)	-19.7
Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5)	-18.8
Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)	-17.2
Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)	-20.1
Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5)	-16.6
Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)	-19.1
Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)	-21
Amlodipine 2.5 mg (A2.5)	-11.7
Amlodipine 5 mg (A5)	-13.3
Amlodipine 10 mg (A10)	-17.6

Intervention	Percentage of participants (Number)
	Overall N=691	OLM 20 mg N=688	OLM 20 mg+HCTZ 12.5 mg N=580	OLM 20 mg+HCTZ 25 mg N=446	OLM 20 mg+HCTZ 25 mg+AML 5 mg N=296	OLM 20 mg+HCTZ 25 mg+AML 10 mg N=176
Olmesartan+Hydrochlorothiazide,if Needed+Amlodipine, if Needed	71.8	12.3	16.4	19.2	14.9	8.5